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Abstract 
Introduction. Rotavirus vaccine has been introduced into over 80 countries with 
substantial impact on rotavirus disease. However vaccine effectiveness is reduced in low-
income countries. Patterns of rotavirus transmission could explain some of the observed 
reduced vaccine effectiveness, and vaccine-mediated reductions in rotavirus transmission 
may increase overall vaccine impact. A detailed understanding of rotavirus transmission 
in low income countries (LIC) is required to inform policy decisions to improve vaccine 
performance, however such data are currently lacking.   
Methods. Mixture models were used as a novel method to estimate population level 
incidence of rotavirus in young children from serology data and describe transmission 
patterns in India and Malawi. Surveillance data from Queen Elizabeth Central Hospital, 
Malawi, were used to describe the ongoing burden of rotavirus disease after vaccine 
introduction and investigate for vaccine indirect effects. To investigate whether rotavirus 
vaccine could reduce the infectiousness of a child with rotavirus disease a household 
transmission study was conducted in Blantyre, Malawi to describe rates of rotavirus 
transmission from a symptomatic index child to household contacts, investigate 
predictors of viral shedding density in the index child and identify risk factors for 
transmission. In a final study transmission of vaccine virus from vaccinated infants to 
unvaccinated contacts was evaluated to investigate for horizontal transmission of vaccine 
virus.  
Results. Mixture models described clear differences in patterns of rotavirus incidence in 
young children from India and Malawi. Analysis of surveillance data showed that rotavirus 
remains an important cause of hospitalised diarrhoeal disease in Blantyre despite high 
vaccine coverage, and identified some evidence of an indirect effect in unvaccinated 
infants. Household studies found a high rate of transmission of infection to household 
contacts (434/665, 65%) but a lower rate of transmission for disease (37/698, 5.3%). 
Disease severity in the index child was associated with an increased risk of transmission 
to household contacts, independent of viral shedding density. Rates of transmission of 
vaccine virus to household contacts were very low (2/151, 1.3%).  
Conclusions. These studies demonstrate that rotavirus remains a significant cause of 
admitted diarrhoeal disease in Blantyre, Malawi and describe some evidence of a vaccine 
indirect effect. Transmission rates of rotavirus infection to household contacts are 
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associated with disease severity in the index child. As vaccine provides incremental 
protection against severe disease, vaccination therefore has potential to reduce the 
infectiousness of a vaccinated index child. Horizontal transmission of vaccine virus is 
infrequent and unlikely to make a substantial contribution to rotavirus vaccine indirect 
effects in this setting. In view of high vaccine coverage future studies should consider 
mathematical models to make inferences on the impact of vaccine and inform ongoing 
vaccine strategy.  
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Introduction 
1.1 Virology 
Rotaviruses are the major causative agent of childhood diarrhoeal disease world-wide. 
They were first identified in humans in the early 1970s, when the virus was visualised in 
duodenal biopsies of children with acute gastroenteritis (AGE) using electron 
microscopy(1). Rotaviruses make up one genus of the family Reoviridae. They consist of 
11 segments of double-stranded RNA surrounded by a triple-layered protein shell; an 
outer capsid, inner capsid and internal core. There are 6 structural proteins (VPs) which 
make up the virion and a further 6 non-structural proteins (NSPs). One segment of RNA 
codes for at least one protein. In terms of the structural proteins, the inner layer (core) 
surrounding the RNA segments is formed from VP1, VP2, and VP3,  and the middle layer 
(inner capsid) is formed by VP6. There are 7 serogroups of rotavirus (A to G) defined based 
on antigens expressed on the surface of this inner capsid (Fig 1.1) of which group A are 
the most clinically significant in humans(2–4). The serotype of the virus (G or P type) is 
defined by the neutralisation antigens (VP7 or VP4, respectively), which together make up 
the outer capsid. Rotavirus genomes can re-assort in the event of co-infection within a 
single cell, resulting in a wide diversity of rotavirus strains. G and P types can segregate 
independently of each other and the typing system therefore includes both G and P types 
(5).  
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Figure 1.1 Architectural features of rotavirus. (A) PAGE gel showing 11 dsRNA segments 
comprising the rotavirus genome. (B) Cryo-EM reconstruction of the rotavirus triple-
layered particle. VP4 is colored in orange and VP7 in yellow. (C) A cutaway view of the 
rotavirus TLP showing the inner VP6 (blue) and VP2 (green) layers. (D) Schematic 
depiction of genome organization in rotavirus. The genome segments are represented as 
inverted conical spirals inside the VP2 layer in green. (E and F) Model from Cryo-EM 
reconstruction of transcribing double layered particles (DLP), essential for rotavirus 
replication and assembly. Reproduced and adapted from H Jayaram, M.K Estes, B.V.V 
Prasad, Emerging themes in rotavirus cell entry, genome organization, transcription and 
replication, Virus Research, Volume 101, Issue 1, 2004, 67–81(6), with permission from 
Elsevier. 
1.2 Methods of rotavirus detection and characterisation 
1.2.1 Electron microscopy 
Electron microscopy (EM) is the historic gold standard for rotavirus detection and was the 
method by which rotavirus was first discovered in duodenal cells of children with 
gastroenteritis(1). However it requires expensive equipment and sufficient expertise to 
use and interpret findings, making it impractical for remote areas or for low income 
countries (LIC). It also cannot differentiate rotavirus groups, and is therefore unsuitable 
for routine rotavirus strain surveillance(7–10).  
1.2.2 Antigen detection  
Antigen detection methods target the VP6 protein. Examples include enzyme 
immunoassays (EIA), latex agglutination (LA) and immune-chromatograpic (ICT) tests. EIA 
typically uses 96 well plates pre-coated with an anti-rotavirus antibody to bind rotavirus 
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antigen. A second rotavirus-specific antibody coupled to a detector enzyme detects bound 
antigen, and an enzyme substrate is used to generate a colorimetric reaction(9). EIA is the 
currently recommended diagnostic technique for surveillance programmes due to its 
sensitivity, specificity, low cost and simplicity. Several commercial kits are available; the 
WHO currently recommends either PremierTM Rotaclone (Meridian Biosciences; 
Cincinnati, Ohio) or IDEIATM Rotavirus (Oxoid (Ely) Limited Thermo Fisher Scientific, 
Cambridgeshire, United Kingdom)(10).  
LA methods involve the reaction of rotavirus antigen with specific antibody coated onto 
latex particles. Agglutination can be seen visually. LA is less sensitive and specific than EIA 
but is faster, and does not require expensive equipment such as plate washers or 
spectrophotometers(11).  
ICT tests are lateral flow assays, in which diluted sample migrates along a nitrocellulose 
membrane impregnated with gold particles via capture antibody. A control line confirms 
the sample has migrated a sufficient distance along the membrane and a test line contains 
rotavirus specific antibody which forms a complex with any rotavirus antigen present in 
the sample. These tests are rapid, and can be performed at point-of-care without formal 
laboratory facilities. ICT sensitivity compared with EIA is  >90%(12–14).  
1.2.3 Nucleic acid detection 
Polyacrylamide gels electrophoresis (PAGE) followed by staining with silver nitrate or 
ethidium bromide allows direct visualisation of viral dsRNA following extraction from viral 
particles. Group A, B and C rotaviruses are distinguishable by their distinct migration 
patterns following electrophoresis. PAGE is simple enough to be used in basic 
laboratories, but it is reasonably time consuming. PAGE has been used in some settings 
for routine rotavirus detection and surveillance, differentiating Group A rotaviruses into 
“short” and “long” electropherotypes(10,15–17).  
Molecular amplification methods (e.g. Polymerase-Chain Reaction [PCR]), where DNA is 
amplified following viral RNA extraction and reverse transcription (RT) (RT-PCR), are much 
more sensitive than antigen detection, and will detect lower viral loads, including those 
typically associated with asymptomatic infection. Asymptomatic infection is common in 
young children, and therefore these methods are not necessarily suitable for routine 
diagnosis of clinical disease, or for disease surveillance. In surveillance systems they are 
typically used for characterisation of rotavirus strains in samples which have already 
tested positive for rotavirus using a less sensitive technique such as EIA(5,15,18–20). Real-
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time RT-PCR methods allow quantification of viral loads in clinical samples (see Chapter 2, 
section 2.3.4.4, page 89). 
1.2.4 Rotavirus Characterisation   
Because of the relevance to rotavirus vaccine design most historic surveillance 
programmes were primarily concerned with monitoring G types of rotavirus, however in 
view of the potential for separate re-assortment of G and P types and because vaccines 
may also target the VP4 antigen, surveillance for P types has become increasingly 
important(21). According to their nucleotide sequences there are at least 27 G types and 
37 P types(4). Because serotypes and genotypes are equivalent for G types, G serotype 
types have been traditionally identified using enzyme immunoassays (EIA) with 
monoclonal antibodies targeting serotype specific antigens on the VP7 protein, although 
they can also be determined using molecular methods such as reverse-transcription 
polymerase chain reaction (RT-PCR). P serotypes are more challenging to predict using 
neutralization methods, because there are substantially more genotypes than there are 
reference sera determining serotype. Instead P genotypes are typically used, defined 
based on comparing amino acid sequences to strains with known P serotype(4)(22). 
Because of the challenges and investment of setting up individual assays the World Health 
Organisation (WHO) surveillance platform (see section 1.4.2) recommends that only one 
method is used for rotavirus strain characterisation, and RT-PCR genotyping is typically 
chosen due to its ability to determine both G and P types(10).  
Non-typeable (NT) strains are not uncommonly identified when using RT-PCR methods for 
strain surveillance.  This can arise due to variation in the VP4 and VP7 genes of common 
strains, such that amplification with the original primers is unsuccessful. In this case 
alternative primers may be required(23,24). Novel rotavirus strains can also result in 
failure to type. Other technical explanations include RNA degradation, low viral loads, or 
false positive EIA results. Sequencing can be used to identify NT strains if the presence of 
rotavirus RNA is confirmed. International protocols have been developed to facilitate 
consistent strategies of rotavirus surveillance and characterisation across countries 
(Section 1.4.2)(10,15,21).  
1.3 Clinical features of rotavirus 
Rotavirus causes a substantial spectrum of disease severity, from asymptomatic infection 
identified by the detection of virus in stool samples, through mild vomiting and diarrhoea 
which can be managed at home or the outpatient level, to severe gastroenteritis resulting 
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in circulatory collapse, shock, and death. Typically, rotavirus presents with fever and 
vomiting, then diarrhoea begins 1-2 days later. Symptoms usually resolve within 7 days. 
Additional clinical symptoms are usually a result of dehydration and electrolyte 
imbalance, and can consist of decreased urine output, lethargy, irritability, and 
obtundation(25).  
Extra-gastrointestinal manifestations of rotavirus have been reported, most commonly 
seizures, which can be febrile or afebrile, and usually resolve without consequence on 
resolution of the rotavirus infection(26). Other reported neurological manifestation 
include encephalitis and cerebritis, and rotavirus has been isolated from CSF(27). 
Rotavirus has also been isolated from respiratory secretions(28–30), and has been 
associated with respiratory symptoms. Antigenaemia and viraemia is relatively common 
in children with rotavirus gastroenteritis(31–33) and may be associated with increased 
disease severity.  
1.3.1 Age distribution 
Almost all children will be infected with rotavirus by the age of 5 years. The peak age of 
clinical illness is between 4-23 months, with children from LIC typically presenting at a 
younger age(25,34). In preliminary data from the WHO African Rotavirus Surveillance 
Network over 90% of children hospitalised with rotavirus AGE were under 12 months of 
age(35). Neonatal infection is relatively common, but typically asymptomatic, probably 
due to protection arising from maternal antibodies(36). Reinfection with rotavirus is 
common, with disease typically reducing in severity with each subsequent episode, so that 
most infections in adulthood are asymptomatic(37,38) (see section 1.3.5). Asymptomatic 
infection also appears to decrease in frequency with increasing age; up to one third of 
children under two years have detectable rotavirus in their stool at any one time, 
compared to less than 10% in older adults(19,20). The majority of rotavirus associated 
death occurs in children under 5 years of age, as these are the population most at risk of 
significant dehydration.  
1.3.2 Pathology 
Rotavirus is transmitted through the faecal-oral route, requiring only a small amount of 
virus to cause infection(39). The stability of the triple protein coat permits transmission 
and passage into the proximal small intestine, where rotavirus infects the absorptive 
differentiated enterocytes found at the end of the villi. Rotavirus causes malabsorptive 
diarrhoea by a combination of mechanisms. Firstly, it destroys absorptive enterocytes, 
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which reduces uptake of fluid by the intestine and subsequently causes fluid loss. Secondly 
it leads to down-regulation of certain digestive enzymes, resulting in a higher osmotic load 
in the lumen contents of the small intestine and increased loss of fluid into the lumen. 
Thirdly, it alters the tight junctions between enterocytes resulting in fluid loss between 
cells. Rotavirus also causes a secretory diarrhoea via two main mechanisms; the 
production of an enterotoxin (NSP4) which activates chloride channels, and activation of 
the enteric nervous system(25,36,40,41). 
1.3.3 Treatment and prevention 
Once clinical rotavirus disease is established, supportive care is the mainstay of treatment. 
Low osmolarity Oral Rehydration Solution (ORS) should be given to all children with 
ongoing losses, and additional fluid given to correct dehydration and hypovolaemic shock. 
ORS reduces the need for intravenous (IV) fluid by up to one third, and reduces the 
severity and volume of vomiting and diarrhoea(42). In LIC, the degree of dehydration 
should be assessed and treated using WHO guidelines(43,44). These give clear criteria for 
the assessment of hydration status, and specific management plans depending on the 
presence and degree of dehydration. Children who cannot drink may require nasogastric 
tube rehydration and those with profuse vomiting or who are very dehydrated may 
require IV fluids. Where possible electrolytes should be measured and corrected, either 
enterally or parenterally. Oral zinc should be given to all children from LIC with acute 
gastroenteritis as it reduces the severity and duration of symptoms, and reduces the 
incidence of subsequent diarrhoea for two to three months(45). Feeding should continue, 
with normal feeds established as soon as the child will tolerate this. This is particularly 
crucial in LIC to prevent malnutrition. To the most part clinicians are not aware what the 
causative agent of gastroenteritis is at the time of treatment. In the absence of an 
aetiological diagnosis antimicrobials should only be given to children in LIC with bloody 
diarrhoea, with suspected cholera and severe dehydration or those with other, non-
gastrointestinal, foci of infection. Large scale clinical trials examining the role of antibiotics 
in moderate to severe gastroenteritis disease are underway. 
Strategies to reduce rotavirus disease consist of measures to reduce transmission (water, 
sanitation and hygiene measures), and vaccination, which will be covered in detail later in 
this chapter (section 1.5, page 49). It should also be noted that in LIC where access to 
clean water is limited, breast feeding is a crucial part of preventing diarrhoeal morbidity 
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and mortality. This should be exclusive (i.e. no other food or fluid) for the first 6 months 
of life(46).   
1.3.4 Mechanisms of transmission 
Human challenge studies have shown that Rotavirus is extremely infectious, with 
ingestion of only a few infectious particles (~10) of rotavirus sufficient to cause 
disease(39). Infection with rotavirus is typically via the faecal-oral route(47), but there is 
some evidence from a mouse model to suggest that respiratory transmission is 
possible(48). This has been reinforced recently by the finding that air pollution increases 
rotavirus force of infection(49). Rotavirus has also been detected on fomites(50,51) and 
on hands of care givers(51,52). It has been shown to survive for several hours on human 
hands, and some commonly used detergents, including soap, are inadequate in 
eradication of rotavirus(53–55). Outbreaks connected to water sources have been 
reported, and rotavirus can maintain its infectivity for several days whilst in both raw and 
treated fresh water(56). Furthermore, chlorine concentrations typically used for 
disinfecting drinking water may be inadequate against rotavirus(57). 
In general, access to clean, uncontaminated water is crucial in reducing diarrhoeal 
disease. Adequate volumes of water are very important to maintain hygiene, as is access 
to appropriate toilet facilities. The extremely infectious nature of rotavirus, however, 
combined with its ability to survive in water and on fomites and its resistance to 
disinfectants means that rotavirus is not as amenable to reduction through improvements 
in water and sanitation as other causes of diarrhoeal disease. This is reflected by the 
increase in proportion of hospitalised diarrhoeal disease due to rotavirus in the last 20 
years as sanitation and public health measures have generally improved(58–60), and by 
the fact that rotavirus remains a major problem even in countries with optimal hygiene 
and sanitation. Rotavirus vaccination is therefore vital in reducing transmission, 
preventing infection, and reducing the burden of rotavirus attributable AGE and deaths in 
children.  
1.3.5 Acquisition of immunity to rotavirus 
Several birth cohorts from different populations have monitored rotavirus infection in 
infants (aged under 12 months of life) and young children, and have demonstrated 
incremental acquisition of immunity to rotavirus disease with episodes of natural 
infection. Severe rotavirus disease, which is typically defined using one of two multipoint 
scoring systems(61), usually occurs as the first infection outside the neonatal period. In a 
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birth cohort in Mexico, two previous infections were sufficient to provide complete 
protection against subsequent severe episodes(62), however a birth cohort of 452 infants 
based in an urban slum in Vellore, Southern India, demonstrated that even after 3 
previous infections, protection against severe disease was incomplete at 79%(38). This 
observation suggests that generation of robust immunity to rotavirus may require more 
repeated exposure in some low-income settings compared to high and middle-income 
settings, and is particularly relevant because rotavirus vaccine efficacy and 
immunogenicity is lower in low income vs high income countries (see section 1.5.3 ). In 
Vellore and Mexico anti-rotavirus IgA titres rose incrementally with age and previous 
infection, and demonstrated a negative relationship with infection risk, though it has not 
yet been possible to identify an absolute threshold in anti-rotavirus IgA titres which 
correlates with protection(63,64).  
The mechanisms of immune protection against natural rotavirus infection are not fully 
understood. It is known from the cohort studies described above that natural infection 
provides protection against further episodes of disease, however this immunity is not 
sterilising, with episodes of infection continuing to occur into adulthood(19,38). 
Humoral immunity is thought to be most crucial to generating this protection. Serotype 
specific neutralising (NT) antibodies (IgA and IgG) against VP4 and VP6  have been 
identified following rotavirus infection, and the presence of anti-rotavirus antibodies has 
been shown to correlate with clinical protection against disease. Heterotypic NT 
antibodies have also been demonstrated, suggesting the presence of broadly reactive 
epitopes on the rotavirus cell surface. Rotavirus specific non-neutralizing antibodies 
against the RV capsid proteins VP2 and VP6 have also been identified, and these are not 
type specific. Anti-rotavirus IgA seems to be important in clearing rotavirus infection, 
however IgA deficient mice and individuals are able to eliminate rotavirus – potentially 
as a result of a compensatory increase in IgG(4).  Rotavirus specific B cells have been 
identified following rotavirus infection and express gut-homing receptors (α4β7) 
suggesting that they act locally in the intestine(65). In mice, the humoral response is at 
both the systemic and mucosal levels, B cells are necessary for long term protection 
against rotavirus(66), and IgA deficient mice show delayed clearance and no protection 
against reinfection with rotavirus(67). In terms of cellular immunity, rotavirus specific 
CD8+ cells are found in most adults, although rotavirus does not induce a very strong 
CD8 response(4). Rotavirus specific T-helper cells have been found in blood samples 
from children with a recent rotavirus infection and T cells are important in mice to help 
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remove rotavirus following an initial infection(4). The role of the cellular immune system 
in clinical protection against rotavirus is not yet clear. Little is known regarding the role 
of the innate immune system in protection against rotavirus, although upregulation of 
natural killer cells and increase in expression of 5 toll-like receptors (TLRs) has been 
observed in children following rotavirus infection(4).  
1.4 Global Epidemiology of Rotavirus 
1.4.1 Overview 
Rotavirus is an ubiquitous pathogen causing infection and disease across the globe, 
however there is considerable variation in the epidemiology and impact of rotavirus in 
different regions of the world as a result of differences in population dynamics, economic 
situation, and climate. To describe this, regions are broken down by income state, using 
the world bank classification of low income country (LIC), Lower middle-income country 
(LMIC), upper middle-income country (UMIC) and high-income country (HIC). The 
classification of countries into these groups is reproduced in Table 1.1 The work in this 
thesis focuses on the epidemiology of rotavirus in a low-income, sub-Saharan African 
setting, but to put this in context the global epidemiology of rotavirus is outlined below. 
This is a narrative review. The search terms used can be seen in Table A1 (appendix, page 
259). After searching, papers were manually listed, screened and reviewed by myself, and 
manually categorised where necessary into sub-groups. The decision to include was based 
on assessment of relevance and importance by myself.    
1.4.2 Rotavirus surveillance systems and policy  
The need to accelerate the development of effective new vaccines against rotavirus in 
order to reduce diarrhoeal mortality in children worldwide was highlighted in 2000, at a 
WHO meeting in Geneva(68). The goal of this meeting was to develop a plan of activities 
to expedite the development and implementation of rotavirus vaccines into LIC. Four key 
areas were outlined; the need for data on rotavirus disease burden and molecular 
epidemiology, the need for trials addressing safety, immunogenicity and efficacy of 
candidate vaccines specifically in LICs, strategies to address inclusion of vaccines into the 
WHO Expanded Programme on Immunization (EPI), and plans for issues relating to the 
regulation and supply requirements for vaccine introduction. Following on from this 
meeting the Global Alliance for Vaccines and Immunisation (GAVI) agreed to fund the 
Rotavirus Vaccine Programme (the RVP) and the Accelerated Development and 
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Introduction Plan (ADIP). The RVP was a partnership between the Programme for 
Appropriate Technology in Health (PATH), the Centers for Communicable Disease Control 
and Prevention (CDC) and the WHO, designed to facilitate data collection and 
communication between partner organisations and key stakeholders in industry, 
government and international organisations in order to support rotavirus vaccine 
implementation(69).  
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Table 1.1. Development Assist Committee list of Official Development Assistance 
recipients.  
Least Developed 
Countries 
 
Other Low-Income 
Countries (per capita 
GNI <= $1 045 in 2013) 
Lower Middle-Income 
Countries (per capita GNI 
$1 046-$4 125 in 2013) 
Upper Middle-Income 
Countries 
(per capita GNI $4 126-$12 745 
in 2013) 
Afghanistan Democratic People's 
Republic of Korea 
Armenia Albania 
Angola Kenya Bolivia Algeria 
Bangladesh Tajikistan Cabo Verde Antigua and Barbuda2 
Benin Zimbabwe Cameroon Argentina 
Bhutan 
 
Congo Azerbaijan 
Burkina Faso 
 
Côte d'Ivoire Belarus 
Burundi 
 
Egypt Belize 
Cambodia 
 
El Salvador Bosnia and Herzegovina 
Central African Republic 
 
Georgia Botswana 
Chad 
 
Ghana Brazil 
Comoros 
 
Guatemala Chile2 
Democratic Republic of 
the Congo 
 
Guyana China (People's Republic of) 
Djibouti 
 
Honduras Colombia 
Equatorial Guinea1 
 
India Cook Islands 
Eritrea 
 
Indonesia Costa Rica 
Ethiopia 
 
Kosovo Cuba 
Gambia 
 
Kyrgyzstan Dominica 
Guinea 
 
Micronesia Dominican Republic 
Guinea-Bissau 
 
Moldova Ecuador 
Haiti 
 
Mongolia Fiji 
Kiribati 
 
Morocco Former Yugoslav Republic of 
Macedonia 
Lao People's 
Democratic Republic 
 
Nicaragua Gabon 
Lesotho 
 
Nigeria Grenada 
Liberia 
 
Pakistan Iran 
Madagascar 
 
Papua New Guinea Iraq 
Malawi 
 
Paraguay Jamaica 
Mali 
 
Philippines Jordan 
Mauritania 
 
Samoa Kazakhstan 
Mozambique 
 
Sri Lanka Lebanon 
Myanmar 
 
Swaziland Libya 
Nepal 
 
Syrian Arab Republic Malaysia 
Niger 
 
Tokelau Maldives 
Rwanda 
 
Ukraine Marshall Islands 
Sao Tome and Principe 
 
Uzbekistan Mauritius 
Senegal 
 
Viet Nam Mexico 
Sierra Leone 
 
West Bank and Gaza Strip Montenegro 
Solomon Islands 
  
Montserrat 
Somalia 
  
Namibia 
South Sudan 
  
Nauru 
Sudan 
  
Niue 
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Tanzania 
  
Palau 
Timor-Leste 
  
Panama 
Togo 
  
Peru 
Tuvalu 
  
Saint Helena 
Uganda 
  
Saint Lucia 
Vanuatu1 
  
Saint Vincent and the 
Grenadines 
Yemen 
  
Serbia 
Zambia 
  
Seychelles 
   
South Africa 
   
Suriname 
   
Thailand 
   
Tonga 
   
Tunisia 
   
Turkey 
   
Turkmenistan 
   
Uruguay2 
   
Venezuela 
   
Wallis and Futuna 
Reproduced from http://www.oecd.org/dac/stats/daclist.htm 
(1) The United Nations General Assembly resolution 68/L.20 adopted on 4 December 2013 decided that Equatorial Guinea 
will graduate from  
the least developed country category three and a half years after the adoption of the resolution and that Vanuatu will 
graduate four years after 
the adoption of the resolution. 
(2) Antigua and Barbuda, Chile and Uruguay exceeded the high income country threshold in 2012 and 2013. In accordance 
with the DAC rules  
for revision of this List, all three will graduate from the List in 2017 if they remain high income countries until 2016. 
 
In 2002 the WHO and CDC published a generic protocol for standardised surveillance for 
rotavirus disease in children under 5 years(70). With RVP support this was implemented 
across Asia, North and Latin America, parts of Europe and sub-Saharan Africa, with 
additional support from a regional WHO office to collate and disseminate data. In 2008 
the WHO brought together existing surveillance networks to form the Global Rotavirus 
Sentinel Hospital Surveillance Network. This surveillance platform is used by countries 
from all 6 WHO regions. In 2012 169 sites from 55 countries submitted data, just under 
50% of which met criteria for inclusion in analysis and reports(71).  
1.4.3 Epidemiology of rotavirus in high income settings prior to vaccine 
introduction 
In the pre-vaccine era almost all children from high income countries were infected with 
rotavirus by the age of 5 years. The majority of data on rotavirus incidence is derived from 
health care attendances and admissions, but it should be appreciated that this represents 
the tip of the iceberg for the enormous burden of rotavirus gastroenteritis, as illustrated 
41 
 
in Fig. 1.2. For community level disease and for disease requiring hospital attendance prior 
to the introduction of the WHO surveillance network comparisons between populations 
can be challenging in view of considerable heterogeneities in study design and methods 
used to diagnose rotavirus infection.  
1.4.3.1 Frequency of rotavirus infection and disease at the community level 
Prospective monitoring of an urban population in Michigan, USA from 1976 to 1981 used 
complement fixation to determine serological response to rotavirus and identified a 13% 
annual infection rate in children under 10 years of life(72). A similar study from the same 
population found evidence of serological infection in 21% of those under than two years 
of age per annum(73). In a prospective study which used EIA to examine weekly stool 
samples from children in day care settings over one rotavirus season in Australia, 52% of 
infants had at least one episode of rotavirus positivity, and 82% of these episodes were 
associated with symptomatic gastroenteritis(74). Similarly a study in day cares in Houston, 
USA, found a rate of rotavirus infection of 0.55 episodes per child year, 40% of which were 
associated with symptoms(75). A community study in Northern Virginia, USA, found an 
annual incidence of rotavirus gastroenteritis of 11/100 child years in infants, and 40/100 
child years in those aged 12-23 months, where rotavirus infection was defined as rotavirus 
detection in stool using EM/immunoelectron microscopy and EIA, or rise in rotavirus 
group specific antibody in serum within 3 weeks of illness(76).  
Anti-rotavirus IgA seroconversion rates from the control arms of clinical vaccine studies 
also give some insight into background rotavirus exposure patterns in different 
populations. In Europe and North America between 0 and 21% of unvaccinated infants 
had sero-converted following the second dose of placebo, with time post- last dose of 
placebo ranging from 4-12 weeks(77). It should be acknowledged however that use of 
anti-rotavirus IgA titres to define infection can be problematic as there is no clear 
evidence on how to define infection based on seroconversion, and rise in IgA titres do not 
necessarily correspond clearly with clinical disease(64).  
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Figure 1.2 Rotavirus disease burden and risk by setting Reproduced from Rotavirus 
vaccines: current prospects and future challenges. Glass et al. The Lancet 2006 368, 323-
332, with permission from Elsevier 
1.4.3.2 Frequency of rotavirus disease requiring healthcare attendance 
Europe 
Prior to the introduction of rotavirus vaccine, rotavirus was the commonest pathogen 
responsible for diarrhoeal disease requiring hospital admission or outpatient clinic 
attendance. In 2006, the Pediatric ROTavirus European CommitTee (PROTECT study) 
estimated that there were 72-77,000 annual hospitalisations for community acquired 
rotavirus disease in those under 5 years old in the Europe Union (EU), resulting in an 
annual incidence of hospitalisation of 0.3-11.9/1000 (78). Williams et al in 2009 estimated 
the burden of rotavirus hospitalisation in the WHO European region. This region includes 
some countries outside of the EU, some of which are classified as low income. This study 
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estimated 146,287 hospital admissions, and 6500 deaths annually attributable to 
rotavirus, and an incidence of rotavirus hospitalisation of 1.9-4.2 per 1000 children per 
year, with an estimated 21.3 to 39.5% of acute gastroenteritis (AGE) admissions caused 
by rotavirus(79). The REVEAL study, a prospective multi-site observational study across 7 
high income European countries conducted between 2004 and 2005 included outpatient 
attendances as well as hospitalisations, and estimated a rotavirus incidence for all health 
care attendances of 2.07-4.96/100 children per year(80). The REVEAL study also 
demonstrated a substantial impact of rotavirus disease on family life, including days off 
work and increased stress levels(81,82).  
United States 
In the United States (US) in 1996, prior to the roll out of the now withdrawn RotaShield 
vaccine, Glass et all reported between 54 and 186,000 annual admissions for rotavirus 
AGE. Between 2000 and 2006, before the introduction of the currently licensed vaccines 
Desai et all reported an average of 15 rotavirus hospitalisation episodes annually per 
10,000 children, and estimated that vaccine introduction would lead to a reduction in 
hospital costs of approximately $242 million(83,84). The estimates of Glass et al were 
corroborated by Fischer et al, who reported approximately 60,000 rotavirus 
hospitalisations annually in the USA between 1993 and 2003. They also reported 37 
rotavirus attributable deaths per year(85).  
Australasia 
In the Australian state of New South Wales, annual hospitalisation rates were estimated 
to be 1800 per 100,000, and Australia-wide, an estimated 10 000 children were 
hospitalised annually between 1998 and 2003(86,87). In New Zealand between 1998 and 
2000 43% of hospitalized gastroenteritis cases were positive for rotavirus, and an 
estimated 634 children per 100,000 were hospitalised annually with rotavirus attributable 
AGE(88).  
1.4.3.3 Asymptomatic infection 
Asymptomatic infection with rotavirus is common in high income settings, with an age-
adjusted prevalence of detectable rotavirus in stool in the United Kingdom (UK) of 
11%(19) across all age ranges, and frequent asymptomatic infections detected in 
prospective studies in day care centres(89). 
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1.4.3.4 Molecular epidemiology 
Prior to vaccine introduction in Europe, rotavirus genotypes G1-4 and G9 were the 
commonest circulating strains, with some seasonal variation and regional differences in 
distribution of strains between different countries in Europe – for example G1 
predominated in the UK, Spain, Belgium and Sweden and G9 in Italy and France (90). 
EuroRotaNet, a pan- Europe surveillance system established to determine the diversity of 
circulating rotavirus strains in Europe included 19,140 rotavirus positive samples between 
2006 and 2009 and identified substantial strain diversity, with 141 different combinations 
of G and P types, including both single and multiple infections. G1P[8] strains were the 
commonest across all three years or surveillance, followed by G4P[8], G9P[8], G2P[4], and 
G3P[8](91). 
Similarly in the USA from 1996 to 2005, prior to vaccine introduction, G1P[8] was the 
commonest circulating strain at 78.5%, followed by G2P[4}, G9P[8], G3P[8], and G4P[8]. 
While G1P[8] was consistently the commonest detected genotype over time, prevalence 
of other genotypes varied(92). In Australia, G1P[8] was also the commonest strain for the 
majority of the pre-vaccine surveillance period, but for 2 years G9P[8] was the 
predominant strain and for one year G3P[8] was the dominant strain. There was also 
substantial year on year regional variation in the distribution of genotypes. A systematic 
review of global rotavirus genotype distribution from 1996 to 2007 confirmed the global 
predominance of G1P[8], but also noted a global declining trend in G1P[8] from the year 
2000 onwards, prior to vaccine introduction(93).  
1.4.4 Epidemiology of rotavirus in low income and middle income settings 
1.4.4.1 Frequency of rotavirus infection and disease at the community level 
Middle income settings  
A birth cohort of 200 infants conducted in Mexico, an UMIC, between October 1987 and 
October 1988 collected weekly stool samples and 4 monthly blood samples for anti-
rotavirus IgA and IgG titres for 2 years from birth. Rotavirus infection in stool was defined 
using EIA, and serological evidence of infection defined as a four-fold increase in IgA or 
IgG titres. This study found an incidence of rotavirus infection of 1 episodes per child year, 
and of rotavirus diarrhoea of 0.3 episodes per child year(62). 49 families of newborn 
infants were recruited in another UMIC, Argentina, and had serum and stool samples 
collected at six monthly intervals, plus stool samples collected from any household 
45 
 
member with diarrhoeal disease. Rotavirus was detected in stool samples using EIA, and 
serological infection defined as a 30% increase in anti-rotavirus IgG titres. Families were 
followed between May 1983 and July 1986. Incidence of rotavirus diarrhoea was 0.25 
episodes per child-year for infants, and 0.04 episodes per person-year across all 
household members and ages. Serological evidence of rotavirus infection was estimated 
at 0.63 episodes per person year across all age groups(94).  
A birth cohort of 452 newborns were recruited from an urban slum in Vellore, Southern 
India, a LMIC. Recruits were followed for 3 years between 2002 and 2006. Stool samples 
were collected fortnightly and serum samples every 6 months. Stool samples were 
screened for rotavirus antigen using EIA. Rotavirus infection in stool was defined as either 
rotavirus positive on two EIAs, or on RT-PCR and serological evidence of infection was 
defined as a 3 fold increase in anti-rotavirus IgA or 4 fold increase in IgG. Overall incidence 
of rotavirus infection was 0.99 episodes per child year (95% CI 0.94-1.05), and of rotavirus 
diarrhoea was 0.25 (95% CI 0.22-0.29) episodes per child year. This was higher in the first 
year of life (1.20 [95% CI 1.14-1.37] episodes of infection and 0.49 [95% CI 0.42-0.58] 
episodes of rotavirus diarrhoea per child year)(38). 
Low income countries 
A birth cohort of 200 newborns from Guinea-Bissau, a LIC, were recruited between 1996 
and 1997 and followed for 2 years. Follow-up for 46 of the recruits was discontinued due 
to a military conflict. Stool samples were collected weekly and screened for rotavirus using 
EIA. No serum samples were collected. Overall incidence of rotavirus infection over the 
study period was 0.6 episodes per child year(95).  
As in high income countries, sero-conversion rates in the control arms of vaccine trials can 
provide a useful insight into the prevalence of rotavirus infection in early life and allow 
comparison across populations. In general, sero-conversion rates in trials conducted in 
lower income settings in Africa and Asia were higher than those observed in high income 
settings, at 6-35%(77,96). 
1.4.4.2 Frequency of rotavirus disease requiring hospital/clinic attendance 
In low and middle income countries, the burden of rotavirus AGE is high, with higher 
mortality rates than seen in high income countries. In the Middle East and North Africa 
(Bahrain, Iran, Iraq, Israel, Jordan, Kuwait, Oman, Qatar, Saudi Arabia, Algeria, Egypt, 
Libya, Morocco, Tunisia and Turkey) 16-61% of all cases of AGE, and 112 deaths per 
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100,000 were found to be attributable to rotavirus. Mortality for this region was highest 
in Iraq (4723 rotavirus attributable child deaths annually)(97). Limited data are available 
from central Europe, which contains some high income countries such as Bulgaria, 
Croatia, Czech Republic, Hungary, Poland, Romania, Russia, Slovakia and Slovenia, but also 
some middle income countries such as the Ukraine, Georgia, Moldova, Bosnia-
Herzegovina, Belarus and Albania. In a review of the data from this region from 1999 to 
2009, community incidence of rotavirus diarrhoea was reported to be between 0.11-12.3 
per 1000 children under 5 years annually, with the proportion of AGE cases attributable 
to rotavirus ranging from 22-55% per year(98).  
In Latin America and the Caribbean (including Bolivia, El Salvador, Guatemala, Honduras, 
St Vincent, Venezuela, Chile, Nicaragua, Paraguay and Suriname) between 2005 and 2007 
rotavirus was responsible for 24-47% of hospitalised AGE(99).  
In Asia, the Asian Rotavirus Surveillance Network was established in the early 2000s to 
generate regional data on the burden of rotavirus disease in light of emerging rotavirus 
vaccines. This initially included China, Hong Kong, Indonesia, Malaysia, Myanmar, South 
Korea, Taiwan, Thailand and Vietnam. The majority of these are high or middle income 
countries, with the exception of Myanmar, which is a LIC. Initial data, prior to vaccine 
introduction, showed high levels of rotavirus in children with admitted with AGE; with an 
average of 45% of stool samples positive for rotavirus, ranging from 28% in Hong Kong, to 
59% in Vietnam(100). A systematic review published in 2011, which included 113 studies 
from 2000 to 2011 from all countries in Asia, found a pooled prevalence of rotavirus in 
hospitalised GE samples of 37.5%, and incidence rates of hospitalisation from 2 to 20 cases 
per 1000 children per year(101).  
Africa 
A review of rotavirus disease burden in Africa between 1975 and 1992 by Cunliffe et al 
found between 13-55% (median 24%) of hospitalised AGE cases in children under 15 years 
were attributable to rotavirus and 7-40% (median 23%) of outpatient children with 
diarrhoeal disease. These studies used a combination of EIA, LA, EM, viral culture and 
Immunoelectro-osmophoresis (IEOP) to diagnose rotavirus(102). A subsequent 
systematic review by Sanchez-Padilla et al included studies in sub-Saharan Africa from Jan 
1990 to April 2009 and performed a meta-analysis to obtain a point estimate for disease 
burden for different groups. Overall, almost 40% of hospitalised AGE in infants was 
attributable to rotavirus, dropping to 35% in children under 5 years and rotavirus 
47 
 
prevalence was lower in outpatient AGE compared to hospitalised AGE (33% in infants, 
and 22% in under 5 year olds). Rotavirus was diagnosed using EIA in the majority of 
studies, with a small number using LA, PAGE and EM(103).  
The WHO African Regional Office Rotavirus Surveillance Network was established as part 
of the WHO global sentinel surveillance platform for rotavirus. Preliminary data from this 
network for 2006-2008, which included data from Uganda, Ghana, Kenya, Zambia, 
Zimbabwe, Cameroon, Ethiopia, Tanzania, Togo and Mauritius, showed findings similar to 
those described in the above meta-analysis, with between 29-52% of children testing 
positive for rotavirus(35). A review of rotavirus studies from 1976 to 2006 found a 
somewhat lower fraction of AGE attributable to rotavirus; between 16 (outpatient) and 
32% (combined inpatient and outpatient) of children presenting with AGE were found to 
be rotavirus positive. In these studies Rotavirus was diagnosed using a combination of EIA, 
LA and EM. Despite the variation in results it is clear that prior to the introduction of 
rotavirus vaccine, rotavirus was a major cause of diarrhoeal disease and morbidity in 
Africa(104).  
1.4.4.3 Asymptomatic rotavirus infection 
As observed in high income settings, a proportion of reportedly asymptomatic individuals 
in low and middle income countries can be found to have detectable rotavirus in their 
stool. In Latin America, 30% of asymptomatic children from a Mexico day centre, and 21% 
of their adult contacts were EIA positive for rotavirus(105). In Ecuador, Lopman et al 
described real-time reverse transcription quantitative PCR (qRT-PCR) detectable rotavirus 
in 2% of household contacts of asymptomatic community control children (106). In Asia, 
rotavirus was detected in 13% of asymptomatic Chinese children recruited from hospital 
settings.  
In Africa, in Burkina Faso 18% of asymptomatic community control children aged under 5 
years had rotavirus in their stool on TaqMan qRT-PCR(107), and similarly approximately 
20% of controls were qRT-PCR positive for rotavirus in a case control study of diarrhoeal 
aetiology from Tanzania(108). In a case control study from Malawi, 31% of asymptomatic 
control children aged under 2 years of life were rotavirus positive using qRT-PCR(20). In 
Zanzibar much lower levels of rotavirus (~2%) were found in asymptomatic control 
children(109). In a study of asymptomatic infants in Zimbabwe, 7% of children aged under 
24 months were positive for rotavirus antigen in stool on EIA(110), and in 17 % of children 
from Nigerian day centres were EIA positive(111). Omoigberale et al described high levels 
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(30%) of EIA positive rotavirus infection in 821 adults and children in an urban setting in 
Nigeria in 1996(112).  
1.4.4.4 Molecular Epidemiology 
In North Africa and the Middle East G1P[8] predominated in most countries, apart from 
Egypt, Israel, Iraq and Kuwait, where G2P[4] was dominant. From a review of data from 
central Europe, in 2005/6 G1P[8] was commonest in 3 countries (Croatia, Czech Republic 
and Slovenia, 22-67%), but considerably less common in others (Albania and Bulgaria (7.1 
and 9.1%)(98). In Latin America and the Caribbean, the pan-American surveillance 
network described a predominance of the globally common G1P[8], G9P[8] and G2P[4] 
between 2005 and 2007, with several less common strains also detected(99). A systematic 
review published in 2004 of studies from 1995 reporting rotavirus strain characterisation 
in Latin America also found a predominance of G1P[8], and G2P[4], and also G3P[8] and 
G4P[8](113). In Asia, a systematic review of data from 2000 to 2011 found that the 
commonest circulating strains were the globally common G1P[8], G2P[4], G3P[8] and 
G4P[8], with again significant numbers of less common strains(101).  
A review of published data on rotavirus strain types circulating in Africa prior to vaccine 
introduction from 1997 to 2006 noted increasing diversity of rotavirus strain types. 
G1P[8] was the commonest G/P combination, making up 17.4% of typed samples, though 
this proportion was substantially lower than observed in other surveillance platforms 
where G1P[8] made up over 50% of strains . Also common were G2P[6] (9.6%), G8P[6] 
(9.4%), and G3P[8] (7%). Mixed infections, consisting of more than one G or P type were 
also common. Overall, circulating strains were noted to be more diverse than 
documented in other continents. G9, G3 and G8 were noted to have increased in 
prevalence in comparison to data before 2007(114). From 2007 to 2011 a high diversity 
of G and P combinations continued to be observed, with G1P[8] still commonest at 18.4%, 
followed by G9P[8] (11.7%), G2P[4] (8.6%), and G2P[6] (6.2%). G12 strains were noted to 
have emerged in several African countries and made up the 6th commonest G strain, at 
6.2%(115). Data on rotavirus strains following programmatic vaccine introduction are 
only just beginning to emerge. In Malawi, following introduction of RV1 in October 2012, 
G1P[8] prevalence was noted to be at its lowest since any time in the historical period of 
surveillance (from 1997-2012), and a possible trend towards an increase in G2P[4] was 
noted(116).  
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1.4.5 Seasonality of rotavirus 
Generally, seasonality of rotavirus is more pronounced in high income countries in 
Europe, the United States and Australasia than in LICs, where rotavirus detection is more 
consistent through-out the year, although endemic rotavirus circulation has also been 
described from several high income countries(117). Peak season for rotavirus is typically 
winter -  November to April in the Northern Hemisphere and May to October in the 
Southern Hemisphere. Prior to vaccine introduction in the USA the rotavirus season 
would typically start in the southwest and end in the northeast of the country after an 
interval of some months. This has been shown to relate to annual variation in birth-rates 
across the country(118). A systematic review of rotavirus seasonality in tropical countries 
found a significant negative association between rotavirus incidence and temperature, 
rainfall and humidity(119). This has also been described in more temperate climates (120) 
(121). However a review of the global seasonality of rotavirus found that level of 
development was a stronger indicator of seasonality than climate or geography(117). This 
is corroborated by findings of a modelling study by Pitzer et al which found that the lack 
of seasonality in LICs could be explained by the high force of infection and high birth rates 
observed in such settings(122).  
1.4.6 Mortality  
Rotavirus remains the commonest cause of diarrhoeal mortality in children under 5 years, 
responsible for 37% of diarrhoea associated deaths. The most recent estimates of 
rotavirus mortality are for 2013 and estimated that annual global attributable rotavirus 
mortality in children under five years was 215,000 (range 197,000-233,000), a decline 
from 528,000 (range 465,000-591,000) estimated in 2000, although direct comparisons 
between time periods are difficult because of variation in data used and analytical 
methods. Consistent with previous estimates of rotavirus mortality, the vast majority of 
rotavirus deaths occurred in the poorest countries of the world, with most occurring in 
sub-Saharan Africa (an estimated 121,000 in 2013 [range 111,000-131,000], reduced 
from 250,000 [range 217,000-282,000] in 2000) (58,123). Rotavirus deaths in sub-
Saharan Africa demonstrated a less substantial reduction than in other parts of the globe, 
thus the proportion of all rotavirus deaths occurring in Africa has increased from 47.3% 
to 56.3% in the same time period. 4 countries contribute 49% of rotavirus deaths; India, 
Pakistan, Nigeria and the Democratic Republic of Congo (DRC)), with India alone 
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responsible for 22% of all rotavirus mortality in 2013. Angola has the highest annual 
incidence of rotavirus deaths at 240/100,000 children under five years(58).  
1.4.7 Neonatal rotavirus infection 
Neonatal rotavirus infection is worthy of particular comment. Neonatal rotavirus 
infection has been observed world-wide(124–127), and differs clinically and 
epidemiologically from infection in older infants and children. Infection is usually, but 
not always, asymptomatic and occurs in early life, typically within the first 7 days (127). 
Neonatal infection occurs year round(128), and neonatal infections are often due to 
different genotypes of rotavirus than those circulating in the rest of the population. In 
neonatal nurseries a single strain will  often circulate for some time(125). Most rotavirus 
strains infecting neonates have a P-type of P[6], although in India G9P[11] and G10P[11] 
have also been observed. In one study G10P[11] infections in neonates were associated 
with a high frequency of clinical symptoms(125). Neonatal rotavirus infections are 
common, with up to 44% of neonates infected in some units(125).    
Neonatal infections have been of interest for several years because of their 
asymptomatic nature and potential to induce protective immunity and thus inform 
vaccine development. A cohort study conducted in Australia followed 81 babies at birth 
and found that 44 (54%) shed rotavirus as neonates. The cohort were followed for 3 
years. Infants with a history of neonatal rotavirus infection were not protected from 
rotavirus infection in later life, however they did have significantly less frequent and less 
severe symptoms than those babies who had not been infected as neonates(124). 
However a study in India which followed 33 infants infected with rotavirus at birth and 
300 who were not infected at birth found no difference in the frequency of rotavirus 
positive diarrhoea of any severity(129). A rotavirus vaccine derived from a neonatal 
strain (116E) was shown to have vaccine efficacy of 56%(130) and has now been 
introduced into the Indian vaccine schedule, and a candidate vaccine based on a 
neonatal strain identified in Australia is currently undergoing clinical trials(131).   
1.4.8 Summary 
Rotavirus is an extremely common pathogen world-wide. At the community level, up to 
50% of infants and young children from high-income settings are infected with rotavirus 
annually. Incidence rates for community infection are even higher in low and middle 
income countries, with documented incidence rates for infection as high as 1.2 episodes 
per child-year and higher rates of sero-conversion observed in the control arm of vaccine 
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trials.  Interpreting these observations should take into account heterogeneities in study 
design and uncertainty in interpretation of serological data.  
In recent years data on rotavirus hospitalisation has become more standardised with the 
introduction of WHO surveillance protocols facilitating comparisons between 
populations. Prior to vaccine introduction rotavirus was responsible for hundreds of 
thousands of hospital admissions per year in high income settings, with considerable 
associated financial and social strain on families. In low and middle income countries 
rotavirus was responsible for up to 60% of hospital admissions for gastroenteritis, 
resulting in potentially catastrophic costs for families in poverty(132,133). Other key 
differences in rotavirus epidemiology between high and low-income settings are the 
greater rotavirus strain diversity observed in lower income settings, and the less 
pronounced seasonality in low income compared to high income settings. The most 
striking, however, is the huge difference in mortality. Although rotavirus is extremely 
common across the world, the vast majority of the mortality burden for rotavirus is 
concentrated in the poorest countries in the world.   
1.5 Rotavirus Vaccines 
1.5.1 Overview 
Research to develop rotavirus vaccines began in the mid 1970’s following the discovery of 
rotavirus, and with increasing understanding of its contribution to the global burden of 
diarrhoeal disease in children. The first candidate rotavirus vaccine, a tetravalent human-
rhesus re-assortment live oral vaccine (RotaShield) was licensed for use in the USA in 1998 
after proving highly efficacious in clinical trials in high and middle income countries. 
Unfortunately following routine introduction of RotaShield it was associated with the rare 
but potentially life-threatening condition of intussusception and was withdrawn from the 
market(2).  
There are currently two globally licenced live oral vaccines, a monovalent live-attenuated 
human rotavirus vaccine (Rotarix [RV1], GlaxoSmithKline), and a pentavalent human-
bovine (WC3) assortment vaccine (Rotateq [RV5] Merck and Com, Inc.). RV1 is derived 
from a single G1P[8] strain of human rotavirus that was attenuated by multiple passage. 
RV5 consists of 5 reassortants which represent the commonest human G types (G1-4) and 
P type ([8])(2,134–136). In addition to these vaccines, India has developed and licensed a 
locally produced vaccine (ROTAVAC, Bharat Biotech International) based on a single 
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neonatal strain of rotavirus (G9P[11])(137), and China and Vietnam have also developed 
and licensed local vaccines; the Lanzhou lamb rotavirus vaccine (LLR) and Rotavin-M1, 
respectively. LLR is produced by Lanzhou Institute of Biological Products and Rotavin-M1 
by POLYVAC. There are several additional candidate vaccines currently in development or 
undergoing clinical trial, none of which is yet licensed for use(134).  
1.5.2 Mechanisms of vaccine medicated immunity  
Initially vaccine development focussed on generating multivalent vaccines (e.g. RV5) 
with the principle of developing strong homotypic NT antibodies against a range of the 
commonest circulating strains. Following observation of immunity following natural 
infection  - where repeated infection can generate heterotypic  protection- the 
monovalent (RV1) vaccine was developed. Clinical trials of vaccine efficacy showed that 
the level of clinical protection generated by vaccines did not correlate with NT type 
specific antibody responses, which were considerably lower than the observed level of 
protection(65,96). Currently serum anti-rotavirus IgA titres are thought to provide the 
best correlate of protection at the population level, though a protective threshold at an 
individual level has not been identified(64). As with clinical disease, the mechanism of 
heterotypic protection not fully understood, but possibilities include generation of 
antibodies against common antigens (e.g. VP6), or to heterotypic epitopes, or 
generation of an heterotypic T cell response(96).  Rotavirus specific B cells have also 
been shown to be a weak correlate of protection following vaccination. There is 
currently a paucity of data on cell mediated immune response to vaccine. Understanding 
correlates of protection against rotavirus remains an active research topic.   
 
1.5.3 Measuring vaccine effects 
Evaluations of vaccine effects should be explicit regarding what they are measuring. 
Vaccine efficacy typically refers to pre-licensure evaluations of a vaccine’s ability to 
prevent clinical disease in clinical trial conditions. Vaccine effectiveness refers to the 
ability of a vaccine to protect individuals from disease once implemented into a routine 
vaccine schedule, outside the closely controlled confines of a clinical trial, and is typically 
evaluated using observational studies following programmatic vaccine implementation. 
Vaccine impact refers to effects of a vaccine at a population level, without necessarily 
requiring specific information on vaccine status of individual recruits. Measuring vaccine 
effectiveness involves comparing vaccinated and unvaccinated individuals within one 
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population, measuring vaccine impact involves comparing two populations, typically the 
same population before and after vaccine introduction. Vaccine impact incorporates total, 
indirect and overall effects of vaccination (see Chapter 4, section 4.1, page 126 for a 
detailed overview)(138).  
1.5.4 Efficacy studies for current globally licensed vaccines  
RV1 and RV5 both underwent extensive pre-licensure safety and efficacy trials in high and 
middle income countries of over 60,000 infants each(139,140). No increase in 
intussusception rates of a similar magnitude to that observed with RotaShield was seen 
with either candidate vaccine, and nested efficacy studies demonstrated efficacy of 85% 
for RV1 and 98% for RV5 against severe rotavirus gastroenteritis in the first year of life. 
For RV1 disease severity was defined using the 20 point Vesikari score, and for RV5 it was 
defined using the 24 point Clark scoring system. It should be noted that there are 
substantial differences in the two scoring systems, with the Clark system tending to 
underscore disease severity in comparison to the Vesikari score(61). Importantly the 
monovalent RV1 provided heterotypic protection against a broad range of circulating 
genotypes. RV1 was first licensed in Mexico and the Dominican Republic in 2004. RV5 was 
licensed for use in the United States in 2006(2). As a result of the impressive efficacy 
demonstrated in the above trials the WHO ratified inclusion of rotavirus vaccine into the 
immunisation schedule of any country where it could be expected to make a substantial 
public health impact, but did not initially recommend its inclusion into global 
immunisation schedules until further data were available from lower income settings in 
Africa and Asia(141).  
Subsequent clinical trials for both vaccines were conducted in low, middle and high 
income countries in Africa, Asia and South America. Overall, rotavirus vaccine efficacy was 
observed to be lower in low-income settings compared to high income countries. Reasons 
for this difference in vaccine efficacy  are not known, although there are several 
hypotheses under consideration. These include sub-optimal immune responses in the 
infant as a result of HIV, malnutrition or enteropathy, interference with vaccine virus 
replication by oral polio vaccine or enteric co-infection, inhibition by transplacental 
maternal antibody, or epidemiological phenomenon such as greater force of rotavirus 
infection(96,142–145). A pivotal efficacy study for RV1 conducted in South Africa (UMIC) 
and Malawi (LIC) demonstrated vaccine efficacy against severe disease of 77% in South 
Africa and 50% in Malawi. Crucially, despite this lower vaccine efficacy in Malawi the 
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number of episodes of severe gastroenteritis prevented by vaccine was higher than that 
observed in south Africa, at 3.9/100 vaccinees compared to 2.5 per 100 vaccinees, 
because of the extremely high burden of rotavirus attributable disease in Malawi(146).  
In view of this, plus additional efficacy data from Hong Kong, Taiwan and 
Singapore(147,148) and effectiveness data from the USA, El Salvador and Nicaragua(149) 
in 2009 the immunization Strategic Advisory Group of Experts (SAGE) for the WHO 
recommended that rotavirus vaccine be included in all national immunisation schedules. 
SAGE acknowledged that vaccine efficacy estimates correlated inversely with under 5 
mortality and disease incidence data(139,140,146,147,150–155), but also that in 
countries with higher background rates of rotavirus disease and attributable mortality the 
potential public health benefit of rotavirus vaccines maybe greater than in other regions, 
because of the potential to prevent more cases. WHO-SAGE therefore strongly 
recommended rotavirus vaccine introduction in those countries where diarrhoeal deaths 
were responsible for over 10% of under 5 mortality(156,157). They recommended that 
RV1 be given as two doses at 6 and 10 weeks of life alongside the first two doses of DTP 
to ensure maximum vaccine coverage and reduce the risk of late administration beyond 
the approved age window of 32 weeks. A summary of the results of rotavirus vaccine 
efficacy trials and their relationship to income status of the country can be seen in Table 
1.2.  
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Table 1.2 Summary of major global trials of rotavirus vaccine 1 
Author Date Vaccine Country Economic Control Number Schedule Efficacy* Duration of 
follow up 
Li 2014 RV1 China UMIC Placebo 3333 0,1 month  75% 12m 
Kawamura 2011 RV1 Japan HIC Placebo 765 0, 1 month 92% 24m 
Phua 2009 RV1 Hong Kong & Taiwan HIC Placebo 10519 0, 1-2 month 96.1% 24m 
Ruiz-Palacios 2006 RV1 Latin America & Finland HIC, UMIC, LMIC Placebo 20169 2 doses 1-2 months 
apart in 6-13wk infant 
84.7% 12m 
Linares 2008 RV1 Latin America UMIC & LMIC Placebo 14286 2, 4 months 83.1% 12m 
Madhi 2010 RV1 South Africa UMIC Placebo 973 6,10,14 weeks 81.5% 12m 
      971 10,14 weeks 72.2% 12m 
   Malawi LIC Placebo 505 6,10,14 weeks 49.7% 12m 
      525 10,14 weeks 49.2% 12m 
Lwata 2013 RV5 Japan HIC Placebo 762 3 doses before 32 
weeks, first dose 6-12 
weeks 
100% 12m 
Vesikari 2006 RV5 USA, Latin America, Europe, 
South East Asia 
HIC/UMIC 
1 x LMIC 
(Guatemala) 
Placebo 4512 3 doses 4-10 weeks 
apart in 6-12 week old 
infants 
98%*** 12m 
Zaman 2010 RV5 Bangladesh LIC Placebo 1136 6,10,14 weeks 45.7 % 12m 
   Vietnam LMIC  900 6,10,14 weeks 73.2 % 12m 
Armah 2010 RV5 Ghana LMIC Placebo 2162 6,10,14 weeks 65.0 % 12m 
   Kenya ULIC  1221 6,10,14 weeks 83.4 % 12m 
   Mali LIC  1842 6,10,14 weeks 1.0 % 12m 
*severe disease (>11 on Vesikari score) **severe disease defined using score defined by Duffy et al ***severe disease defined as 24 point severity 2 
score 3 
 4 
 5 
 6 
56 
 
1.5.5 Rotavirus vaccine introduction.  
Following WHO ratification, a GAVI alliance supported programme for accelerated 
introduction of rotavirus vaccine into eligible countries was established, initially for GAVI 
eligible countries in Latin America and Europe, followed by African and Asian countries. 
GAVI is a public-private partnership which supports and subsidizes vaccine purchase, but 
also supports the logistical, strategic and technical systems essential to successful 
implementation of a vaccine, and which are particularly challenging in LIC. As of May 2016, 
81 countries had introduced rotavirus vaccine into their national immunisation 
programmes, nearly half of which are LIC (Fig 1.3) In addition to this Pakistan introduced 
rotavirus vaccine into its schedule at the start of 2017, which promises to make a 
substantial impact on reducing rotavirus morbidity and mortality.  
 
Figure. 1.3 Countries which have introduced rotavirus vaccine, reproduced from the WHO; 
http://www.who.int/immunization/monitoring_surveillance/en/.  
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1.5.6 Post implementation vaccine effectiveness and impact 
1.5.6.1 High income countries 
Following WHO ratification several high income countries introduced rotavirus vaccine 
into their immunisation schedules, with post- introduction vaccine effectiveness (VE) 
close to the impressive efficacy observed in clinical trials. In Europe, vaccine effectiveness 
and impact from 2006 to 2014 has been summarised in a systematic review by Karafillakis 
et al(158). Vaccine effectiveness against hospitalisation for at least one dose of vaccine in 
children from Austria, Belgium, Finland, Germany, Israel and Spain ranged from 89 to 96%, 
and for fully vaccinated children from 80% to 98%. Most studies included RV1 and RV5; 
one Spanish study provided separate estimates for RV1 and RV5 but found little difference 
between the two (RV1 98%, RV5 93% for at least one dose of vaccine). A systematic review 
of VE of RV5 in industrialised countries reported VE against hospitalisation of up to 
100%(159).  
In the USA, case-control studies of hospitalisation and emergency department visits 
conducted between 2006 and 2011 demonstrated vaccine effectiveness of 85-100% for 
RV5, 94-97% for RV1 or RV5, and 85-91% for RV1. These studies are summarised in a 
review by Rha et al(160). In Australia in 2007-2009 effectiveness of RV1 in indigenous 
children was 83-85% against severe disease, hospitalisation, or disease in under 12 month 
olds complicated by acidosis(161–163).  
Substantial population level impact of rotavirus has also been observed following 
widespread introduction of rotavirus vaccine. Karafillakis et al identified and reviewed 
studies from Europe published between 2006 and 2014. They included 15 studies, 4 from 
Austria, 4 from Belgium, 3 from Finland, 1 from France, 1 from Germany and 2 from Spain. 
In vaccine age eligible children reductions in hospitalised rotavirus AGE ranged from 65%-
84% in countries with universal vaccine introduction, and were lower but still substantial 
in countries with sub-national rotavirus vaccine introduction(158). 
 In the USA, in data from 62 paediatric hospitals, reductions in rotavirus specific 
hospitalisations of up to 85% were seen in 2007-2008, immediately following rotavirus 
introduction(164), and reductions in all diarrhoeal admissions of up to 50% noted. Desai 
et all estimated that for the 2008 and 2009 seasons across the US 77,000 diarrhoeal 
admissions were averted, equivalent to approximately $242 million in health care 
costs(84). A review of data from the National Respiratory and Enteric Virus Surveillance 
System (NREVSS) in the USA from 2000 to 2012 confirmed sustained impact of rotavirus 
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vaccine on the prevalence of rotavirus gastroenteritis in the 2010-2011 and 2011-2012 
seasons, with a decline of up to 90% in the frequency of rotavirus positive stool samples 
compared to pre-vaccine data(165). Impact of vaccine introduction on the seasonality of 
rotavirus infection in the USA, with a shorter, blunted season, was noted soon after 
vaccine introduction in 2006(166), and more recently the prevalence of rotavirus has 
failed to meet the trigger level required to define a rotavirus season(165).  
In Australia, reductions in rotavirus notifications in Queensland declined by up to 65% by 
2008, following rotavirus vaccine introduction in 2007(167). Davey et al studied the rate 
of all-cause and rotavirus attributable non-admitted AGE presentations at Accident 
Emergency departments in New South Wales from 2003 to 2011 and noted a 18.3% 
reduction in all cause and 55.4% reduction in rotavirus presentations following RV1 
introduction in 2007(168). Substantial reductions in rotavirus attributable and all-cause 
AGE hospitalisation rates were also observed in three Australian states (New South Wales, 
Australian Capital Territory and the Northern Territory) following RV1 introduction(169), 
and in Queensland following RV5 introduction(170).  
1.5.6.2 Low and Middle income countries 
Vaccine effectiveness in low and middle income countries 
Comparison between studies is not straight forward as there is considerable 
heterogeneity in study design and analysis particularly in relation to control groups used 
and sub-groups used for vaccine-effectiveness estimates. Variation in sub-groups for 
effectiveness estimates most commonly occurred in relation to disease severity, with 
some studies presenting vaccine effectiveness for all rotavirus gastroenteritis, others 
focussing on severe disease (typically defined as a Vesikari score >= 11), and others using 
hospitalised gastroenteritis as an end point. There was also some variation in age groups 
used, with some studies describing vaccine effectiveness by age group, and others 
grouping all vaccine age eligible children together. Most commonly cases were vaccine 
age eligible children with AGE presenting or admitted to health centres. Controls usually 
comprised one or more of children with AGE who tested negative for rotavirus (test 
negative controls), asymptomatic controls from the community or children hospitalised 
with a condition other than AGE, for example children admitted with acute respiratory 
infections (ARI) Major vaccine effectiveness studies in low and middle income countries 
are summarised in Table 1.3 .  
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The first data on real world vaccine performance in low and middle income countries 
arose from Latin America. VE in children in the HMICs Colombia and Brazil varied 
considerably depending on the age group studied and the control group used. For children 
under one year of life VE estimates ranged from 56 to 96%(171–174) with the estimate of 
56% obtained in Brazil using hospital controls, although the same population and age-
group were reported to have an estimated VE of 96% using community controls. With the 
exception of this, all point estimates for VE from Colombia and Brazil were 78% or greater, 
including one study which specifically looked at the completely heterotypic G2P[4](174). 
All studies reported VE for RV1, and one study reported VE for RV1 and RV5 
combined(172).  
Findings were variable in the lower middle income countries of Nicaragua, Guatemala, 
Bolivia and El Salvador. VE for RV5 for infants in Nicaragua varied from 71 to 
96%(149,175), but was considerably lower when all vaccine age eligible children were 
included (43-49%)(176). In Guatemala, Bolivia and El Salvador, VE was reported for RV1, 
with the exception of Guatemala which reported data on RV1 and RV5. VE in infants varied 
from 73-83%, and again was consistently lower (52-77%) when older age groups were 
included(177–180).  
Recently data has been published from lower middle income countries in Europe; Armenia 
and Moldovia. Both of these reported data on RV1 using test negative controls, with VE 
estimates of 68-84% in infants, and 62-79% when all vaccine age eligible children were 
included(181,182).  
In Africa, VE estimates appear to be lower across all income strata than those reported 
from Latin America and Europe. In the UMICs of Botswana and South Africa VE for RV1 
ranged from 54-57%, regardless of age group(183,184). In Ghana, a LMIC, VE was 78% for 
infants and 60% for all vaccine age eligible children(185). The only effectiveness data 
available to date from LIC is from sub-Saharan Africa, with VE estimates from Malawi, 
Rwanda and Zambia(116,186–188). VE estimates from these countries vary from 56-75%, 
depending on the age category used. Malawi and Zambia report data on RV1, Rwanda on 
RV5. All African countries used test negative controls. Key vaccine effectiveness studies 
are summarised in Table 1.3  
Vaccine impact in low and middle income countries 
Despite the lower VE observed in low and middle income countries, programmatic 
rotavirus vaccine introduction has had a substantial impact on the burden of disease. In 4 
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countries in Latin America (Bolivia, El Salvador, Honduras, Venezuela), following 
introduction of rotavirus vaccine, diarrhoeal admissions in under 5 were estimated to 
have declined by 8%, and 12% in infants. Diarrhoeal deaths in children under 5 were also 
estimated to have declined by up to 58%(189). In 2008 and 2009, following vaccine 
introduction in 2007, rotavirus hospitalisation rates declined by 81% in El Salvador (78-
84%) and diarrhoeal related hospital visits declined by 48% (47-48%)(190). In Nicaragua a 
decrease in watery diarrhoea in community based children under 5 years of age was 
observed (rate ratio 0.60, 95% CI 0.40-0.91)(191). In Mexico, all cause diarrhoeal 
hospitalisations declined by 40% in children under 5 years 2 years after vaccine 
introduction(192). At 2 years following vaccine introduction in Panama, diarrhoeal 
hospitalisations had declined by 37% and diarrhoeal mortality had declined by up to 54% 
(95% CI 48%-60%)(193,194). In Brazil, 3 years after rotavirus vaccine introduction in 
children under one, all cause diarrhoeal hospitalisations had reduced by 36% and 
mortality had halved(195). Latin America was the first region to demonstrate evidence of 
a substantial reduction in diarrhoeal mortality in children under 5 years following 
programmatic rotavirus vaccine introduction(196–199).  
In LMICs in Europe population level impact of rotavirus vaccine was also observed, with a 
rate ratio for rotavirus admissions following vaccine introduction of 0.64(95% CI 0.56-
0.74) in children under 5 years in Moldovia, and a 69% reduction in the number of 
rotavirus positive admissions in children under 5 years 3 years following rotavirus vaccine 
introduction in Armenia(181,182).  
In Africa, evidence of substantial impact is beginning to emerge. In Togo, early evidence 
showed a decline in the proportion of children with AGE testing positive for rotavirus from 
53% to 36% in the first year following vaccine introduction(200). In South Africa a 45-65% 
reduction in all cause diarrhoeal admissions was observed in the 4 years following RV1 
introduction(201). In Rwanda, declines of almost 50% were observed in admissions for all 
cause AGE in the three years following rotavirus vaccine (RV5) introduction(202). In 
Zambia, seasonal peaks in rotavirus activity were noted to be blunted, and a decrease in 
diarrhoeal hospitalisation(18-29%) were observed(203). Declines in all cause and 
rotavirus specific hospitalisations at a population level have also been reported from 
Ghana(204). More recently reductions in rotavirus hospitalisations of up to 64% in 
children under 5 years have been observed in Zanzibar, Tanzania and declines of up to 
43% have been observed in in infants presenting to Accident and Emergency departments 
at 3 hospitals in Zimbabwe(205,206).  
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1.5.6.3 Vaccine impact on mortality 
Rotavirus vaccine introduction into regions with high mortality is still too recent to make 
substantial impacts on global rotavirus deaths, but studies from Latin America and recent 
data emerging sub-Saharan Africa(197,198,207,208) have shown country level declines in 
rotavirus attributable mortality, and as such one would expect to see this reflected in 
updated mortality estimates over the next ten years. Comprehensive data on impact on 
mortality in low income African settings are still awaited, but there is some initial data 
from Zambia, a LIC, and Botswana, an UMIC, to show a reduction in diarrhoeal deaths in 
vaccine age eligible children. In Zambia a 27-33% reduction in inpatient diarrhoeal deaths 
was noted, and in Botswana a 22% decline(203,207). While the global impact of rotavirus 
vaccine on rotavirus mortality is not yet known, modelling studies have predicted the 
potential for significant reductions(209).  
1.5.6.4 Impact of vaccine on seasonality 
Modelling studies from Pitzer et al have shown that intrinsic factors such as birth rate 
and transmission rates can influence seasonality, with higher birth rates and transmission 
rates, such as seen in low income settings, leading to a blunting of seasonal 
effect(117,210). If true, this could mean vaccine introduction could alter patterns of 
seasonality, and that more pronounced seasonality may be seen in LICs following 
introduction of vaccine(210). Initial data from the US following vaccine introduction 
demonstrated a delayed and blunted season(166). Data from LICs is not yet available due 
to the relatively recent introduction of vaccine, but has the potential to provide valuable 
data to validate models and to improve our understanding of the factors which 
contribute to rotavirus transmission.  
1.5.7 Summary 
Vaccine efficacy estimates in pre-licensure clinical trials in high-income settings 
demonstrated very high efficacy against severe rotavirus disease(98-100%), but vaccine 
efficacy estimates were substantially lower in lower income settings, with an inverse 
correlation with under-5 mortality rates. Despite this, because of the high burden of 
rotavirus attributable morbidity and mortality in such settings in 2008 the WHO 
recommended that rotavirus vaccine be introduced into low-income countries as a 
priority.  
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Post-implementation vaccine effectiveness studies from high-income settings have 
demonstrated vaccine effectiveness in line with pre-licensure efficacy estimates (85-
100%), and substantial population level impact has also been described. Data from low-
income countries are still emerging, but data published to date has demonstrated 
effectiveness estimates which typically been higher than anticipated based on efficacy 
studies and substantial population impact has been observed including early evidence of 
an impact on mortality, confirming the enormous public health potential of global 
rotavirus vaccination. Despite this however, effectiveness estimates remain sub-optimal 
compared to high-income settings and appear lowest in the poorest countries. There is 
also some evidence of a reduced effect in older children which does not seem apparent 
in high income settings. As such, there remain many important unanswered questions 
regarding the mechanisms of reduced vaccine effectiveness in low-income countries, the 
duration of protection afforded by vaccine, and true extent of population impact.  
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Table 1.3 Summary of major studies reporting RV1 or RV5 vaccine effectiveness estimates from low and middle income settings 1 
Author Year Country Vaccine Severity Age group VE  (%) 95% CI Control type Notes 
Africa 
 Upper middle income 
Enane 2016 Botswana RV1 Hospitalisation All ≥4 months 54 23, 73 Test neg  
    Hospitalisation 4-11 months 52 8, 75 Test neg  
Groome 2014 South Africa RV1 Hospitalisation 4-23 months 57 40, 68 Test neg  
    Hospitalisation 4-11 months 54 32, 68 Test neg  
 Lower middle income  
Armah 2016 Ghana RV1 Hospitalisation All VAE 60 -2, 84 Test neg Any dose 
    Hospitalisation 6-11 months 78 2, 96 Test neg  
 Low income 
Bar-Zeev 2016 Malawi RV1 Hospitalisation All VAE 58 20, 78 Test neg  
    Hospitalisation <12 months 71 34, 87 Test neg  
Tate 2016 Rwanda RV5 All All VAE 75 31, 91 Test neg  
    All 6-11 months 65 -80, 93 Test neg  
Beres 2016 Zambia RV1 Hospitalisation ≥6 months 56 -34,86 Test neg  
          
Europe 
 Lower middle income 
Sahakyan 2016 Armenia RV1 Hospitalisation 6-23 months 62 36,77 Test neg  
    Hospitalisation 6-11 months 68 24,88 Test neg  
Gheorgita 2016 Moldovia RV1 Hospitalisation VAE 79 62 88 Test neg  
    Hospitalisation 6-11 months 84 67, 92 Test neg  
          
Latin America 
 Upper middle income 
Cotes-cantillo 2014 Colombia RV1 Hospitalisation VAE -2 -182, 62 Test neg  
    Hospitalisation 6-11 months 84 23, 97 Test neg  
Ichihara 2014 Brazil RV1 &RV5 Hospitalisation 4-23 months 74 58, 84 Hospital  
    Hospitalisation 4-11 months 78 54, 90 Hospital  
Justino 2011 Brazil RV1 Hospitalisation VAE≥3 months 76 58, 86 Community  
    Hospitalisation VAE≥3 months 40 14, 58 Hospital  
    Hospitalisation 3-11months 96 68, 99 Community  
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VE is for all doses vaccine unless otherwise specified. VAE= vaccine age eligible, controls: test neg = rotavirus negative gastroenteritis control, community= 2 
asymptomatic community control, hospital= non-gastroenteritis hospital control (e.g. acute respiratory infection) 3 
 4 
    Hospitalisation 3-11 months 56 12, 78 Hospital  
Correia 2010 Brazil RV1 Hospitalisation VAE≥12 months 5 -187,69 Test neg  
    Hospitalisation VAE≥12months 41 -79,81 Hospital G2P[4] only 
    Hospitalisation 6-11 months 85 54, 95 Test neg  
    Hospitalisation 6-11 months 83 51, 94 Hospital  
 Lower middle income  
Patel 2016 Nicaragua RV5 Hospitalisation VAE 42 6, 64 Test neg G1P[8] only 
    Hospitalisation 6-11months 71 31, 88 Test neg  
Mast 2011 Nicaragua RV5 Severe AGE VAE 58 38, 72 Hospital  
    Severe AGE VAE 87 78, 93 Community  
    Severe AGE <12 months 82 60, 92 Hospital  
    Severe AGE <12 months 96 82, 99 Community  
Patel 2009 Nicaragua RV5 Hospitalisation VAE 49 17, 68 Hospital  
    Hospitalisation VAE 43 9, 64 Community  
Gastanaduy 2016 Guatemala RV1 & RV5 Hospitalisation VAE 52 26, 69 Test neg  
    Hospitalisation 6-11 months 73 35, 89 Test neg  
Pringle 2013 Bolivia RV1 Hospitalisation VAE 59 37, 73 Test neg  
    Hospitalisation 2-12 months 76 50, 89 Test neg  
Patel 2013 Bolivia RV1 Hospitalisation VAE 69 54, 79 Test neg  
    Hospitalisation VAE 77 65, 84 Community  
    Hospitalisation 6-11 months 64 43, 80 Test neg  
    Hospitalisation 6-11 months 77 51, 89 Community  
De Palma 2010 El Salvador RV1 Hospitalisation VAE 76 64, 84 Community  
    Hospitalisation 6-11 months 83 68, 91 Community  
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1.6 Indirect effects of rotavirus vaccine 
1.6.1 Overview 
In the context of the high disease burden and reduced rotavirus vaccine effectiveness in 
LIC, any additional benefits of the vaccine may be particularly important to the overall 
population level impact and cost-effectiveness of a vaccine programme. The protective 
effect of a vaccine on a community can be divided into two categories; the direct effect, 
which describes protection afforded directly by the vaccine to the vaccinated individual, 
and the indirect effect of the vaccine. Vaccine indirect effects describe reduction in 
disease burden mediated by effects on rotavirus transmission as a result of 
vaccination(211); they can occur both in unvaccinated individuals, and can provide 
additional protection on top of direct effects in vaccinated individuals(212).  
Indirect effects can be broadly divided into two categories. Firstly herd immunity, which 
is immunity generated in unvaccinated individuals as a result of transmission of vaccine 
virus within the community, and secondly herd protection, which results from a reduction 
in transmission of wild type infection(213). Herd protection can arise as a result of two 
phenomenon; a reduction in the infectiousness of a vaccinated index case if they do 
acquire disease, such that they infect fewer susceptible individuals than if they were 
unvaccinated, and/or an overall reduction in the number of infected and therefore 
infectious cases, with subsequent reduced likelihood that susceptible community 
members will come into contact with an infectious individual(214). As a general rule 
parenteral, killed vaccines provide herd protection only, while live, oral vaccines such as 
oral poliovirus vaccine (OPV) and rotavirus vaccine can provide both herd protection and 
herd immunity(213,215).  
1.6.2 Evidence of indirect effects from HIC 
Strong evidence of rotavirus vaccine indirect effects from HIC have been observed 
following routine use of RV1 and RV5. Although there is considerable heterogeneity 
among studies, and the majority of studies are based on observational, population level 
data, indirect effects have been observed to varying extents across a range of different 
high income countries, encompassing inpatient and outpatient health care settings and 
laboratory level data, and have been consistently detected despite a variety of different 
study methods. 
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In the USA, RV5 was recommended for inclusion in the routine national schedule in 2006, 
and RV1 in 2008, and studies from the USA have demonstrated clear evidence of rotavirus 
vaccine indirect effects across a variety of age groups using both prospective and 
retrospective approaches. National level health insurance data reviewed from 2002 to 
2011 revealed a decline in incidence of rotavirus gastroenteritis requiring health-care 
attendance in non-rotavirus vaccinated Diphtheria Tetanus Pertussis (DTP) recipients 
from 151 per 100,000 infants pre- rotavirus vaccine introduction, to 110 per 100,000 
infants post- vaccine introduction, and greater than expected according to vaccine 
coverage declines in laboratory detection of rotavirus was observed at national 
surveillance laboratories(216,217). Comparisons of the burden of rotavirus disease in 
unvaccinated children under 5 years of age following vaccine introduction demonstrated 
substantial reductions in rotavirus disease(25-77%) (218–220) and a review of the first 3 
years of published data from the USA reported declines in rotavirus disease in inpatient, 
outpatient clinic and emergency department attendances for all children <5 years of age, 
and not just those eligible for vaccination(221). Payne et al investigated the presence of 
indirect effects by estimating an expected rate reduction based on vaccine coverage and 
efficacy estimates and used this to quantify indirect effects on rate of rotavirus 
hospitalisations in under 5 year olds; the observed decline(89%) was substantially greater 
than that expected (49%) (219). Notably, reductions have been observed in all age groups 
from young children through to older children and adults(222,223))(224). 
For the most part, indirect effects in the USA have been measured by utilising data from 
surveillance platforms and comparing observed vaccine effectiveness to that expected 
based on local efficacy data, or by documenting reductions in disease burden in age 
groups which have not been covered by vaccination programmes. However one study 
from the USA compared the risk of diarrhoeal disease in households where a child had 
received rotavirus vaccine, to those whose child did not receive rotavirus vaccine, and 
found a statistically significant reduction in rotavirus specific and all-cause gastroenteritis 
hospitalisation rates in older siblings and parents of vaccinated infants(225). A further 
prospective cohort study was conducted by Panozzo et al in young children (<20 months) 
at the time of vaccine implementation to estimate direct VE, indirect VE, total VE and 
overall VE (see Chapter 4, section 4.1, page 126 for a detailed overview of these terms), 
using children from the pre-vaccine time period as the unvaccinated population. They 
estimated that in addition to direct VE, indirect effects conferred an additional 3-8% 
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protection to vaccinated infants to form the total VE, and estimated an indirect VE of 14-
82%, depending on the year under consideration(226).   
In Australia, programmatic rotavirus vaccine (RV5) was introduced into Queensland in 
2007, and Lambert et al described a reduction in the proportion of stool tests positive for 
rotavirus in older, vaccine age ineligible children from Queensland in 2008(167). Clarke et 
al also reported declines in rotavirus gastroenteritis in vaccine age-ineligible children aged 
under 6 years in South Australia following introduction of RV5 and Buttery reported some 
evidence of indirect effects for rotavirus hospitalisation in children too old for vaccine 
from New South Wales, which introduced RV1(227,228). Importantly, taking into account 
indirect effects and all cause gastroenteritis over the first 6 years following vaccine 
introduction, Reyes et al estimated that the rotavirus vaccine programme in Australia was 
likely to be cost-saving(229).  
Austria was the first country in Europe to implement programmatic rotavirus vaccine in 
2007, and they subsequently reported a 22% decline in rotavirus gastroenteritis 
hospitalisations in children under 5 years who were too old to be eligible for 
vaccination(230). Following RV1 introduction in the UK, surveillance at a major hospital 
children’s hospital noted an up to 70% decline in rotavirus gastroenteritis presentations 
in vaccine age-ineligible children aged under 5 years(231) and declines were also observed 
in rates of AGE presentations in children too old to be vaccinated at the primary care 
setting(232). Similar reductions were also observed in Belgium where both RV1 and RV5 
are used(233). Overall, reductions in rotavirus disease among unvaccinated children 
under age 5 years of between 15 and 77%(230,232,234,235) have been observed in 
Europe. As in the US, indirect effects have been observed across a range of ages including 
older children and adults(12-16%)(232) and very young infants and neonates(236). 
Substantial indirect effect has been predicted by modelling studies informed by empirical 
data, with some suggestion that a strong initial indirect effect may be off-set some time 
after vaccine introduction by an increase in the burden of disease in older age 
groups(237–239).  By way of summary, Pollard et al conducted a systematic review of 
vaccine effectiveness from several high and middle income countries, and estimated a 
median indirect effect for rotavirus attributable AGE in infants of 22%(240). 
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1.6.3 Evidence of indirect effect from low and middle income settings 
1.6.3.1 Evidence of indirect effects from middle income settings 
Evidence of rotavirus vaccine indirect effects is beginning to emerge from some UMIC and 
LMIC. In Latin America, in Mexico a 17% reduction in diarrhoea related hospital 
admissions was observed in unvaccinated children under five years following 
programmatic rotavirus vaccine introduction(199), and a nearly 30% decline in diarrhoeal 
mortality was observed in children between one and two years of age, few of whom were 
eligible for vaccination. In Brazil, greater than expected decreases in diarrhoeal related 
hospitalisations following rotavirus vaccine introduction were observed in children under 
five, suggesting an element of indirect protection in this age group(241). 
In central Europe, there is some evidence of an indirect effect of rotavirus vaccine 
reported from Armenia(182), where reductions in hospitalisations of up to 30% in children 
too old to be vaccinated have been described, and from Moldovia where reductions in 
rotavirus hospitalisations following vaccine introduction exceeded expectations for all age 
groups under 5 years(181). In South-East Asia in data from Thailand, an up to 69% 
reduction in vaccine age-ineligible children aged under 5 years has been observed 
following vaccine introduction(242). Data from sub-Saharan Africa have, however, been 
less clear, with no significant reduction in rotavirus disease in unvaccinated children 
observed in studies from the middle income countries of Ghana or South Africa, although 
the data to date are limited(184,185).  
1.6.3.2 Evidence of indirect effects in low income settings 
Currently the only published data on indirect effects of rotavirus vaccine from LICs is 
observational data from Rwanda, where reductions in admissions secondary to rotavirus 
gastroenteritis in children under five years were observed even in those children too old 
to have been vaccinated(202).  
1.6.4 Mechanisms of rotavirus vaccine indirect effects 
The mechanisms underlying observed rotavirus indirect effects are not yet fully 
understood, but as explained above may include both herd protection and herd immunity. 
In terms of herd immunity, It is known that rotavirus vaccine virus is shed in the stool of 
infants to varying degrees following vaccination(243), and transmission of vaccine virus to 
close contacts has been documented(244), but how extensive this is and to what extent 
this contributes to population level protection against rotavirus is as yet unknown.  
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Regarding herd-protection, transmission of wild-type rotavirus seems to be strongly 
associated with symptomatic disease, and introduction of rotavirus infection into 
households seems largely dependent on the presence of a symptomatic infant (section 
1.7.4)(106,245). In addition the quantity of rotavirus shed in the stool of a symptomatic 
child has been shown to correlate with disease severity, and rotavirus vaccine mimics 
natural immunity which provides incremental protection against severe disease(38,62). It 
follows therefore that vaccine-induced reduction in frequency or severity of clinical 
rotavirus disease in infants and young children may lead to a reduction of wild-type 
rotavirus in the community, even in the event of clinical vaccine failure. This could be 
particularly valuable in settings with sub-optimal vaccine performance.  
1.6.5 Summary  
Rotavirus vaccine indirect effects potentially have a very important role to play in the 
impact of programmatic vaccine introduction in low income settings where disease 
burden is high and vaccine effectiveness is reduced compared to that observed in higher 
income settings. The presence of indirect effects may determine whether a vaccine 
programme is cost saving, not just cost-effective. This is crucial for countries currently 
relying on GAVI purchase support to implement vaccine programmes(246,247). There are 
good observational data to support the presence of rotavirus vaccine indirect effects in 
high income countries, but to date there are a paucity of data from LICs. There is also a 
lack of data on the mechanisms which may underlie rotavirus vaccine indirect effects. 
There are fundamental differences between LICs and high and middle income countries 
in terms of disease burden, presence of co-morbidities, population structures, and living 
environments which mean that data from higher income settings cannot be generalised 
to LICs. More data on the presence and extent of indirect effects in LICs are therefore 
urgently needed.  
1.7 Wild-type rotavirus transmission 
1.7.1 Overview 
Given the sub-optimal vaccine effectiveness observed in LIC, understanding rotavirus 
transmission is crucial. Differences in rotavirus transmission between populations may 
provide some explanation for the observed reduced vaccine effectiveness, and 
understanding drivers of transmission is key for unravelling mechanisms of rotavirus 
indirect effects and in evaluating the potential extent of indirect effects.  
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1.7.2 Important parameters in rotavirus transmission  
Several key parameters describe rotavirus transmission. The secondary attack rate (SAR) 
describes the number of new cases derived from contact with one infectious case, and 
varies across populations(248). SAR allows comparison of transmission rates between 
populations and evaluation of risk factors for transmission. A summary of current data on 
rotavirus SAR can be seen in section 1.7.5. The SAR forms the basis of estimating the basic 
reproductive number (R0), which is defined as the number of cases derived from a single 
case in a fully susceptible population(212). R0 is important for modelling of transmission, 
but is almost impossible to measure directly for rotavirus because of the challenge of 
identifying unexposed and therefore non-immune, fully susceptible individuals. Estimates 
of R0 (derived from modelling studies) range from 17.6 in the UK to 191 in 
Malawi(210,237,249). In general, estimates of R0 are higher in low-income countries than 
high income countries, and higher estimates of R0 are associated with settings with higher 
birth rates and a higher proportion of rotavirus occurring at a young age(210,237,249). 
The incubation period is defined as time from infection to onset of symptoms. For 
rotavirus this has been estimated to be a median of 2.0 days (95% confidence interval (CI) 
1.4-2.4 days)(250). The duration of infectiousness, defined as the period of time during 
which an individual can transmit infection to another susceptible individual, is typically 
taken to be duration of symptoms (approximately 4-6 days). The serial interval (SI), 
defined as the number of days from the onset of symptoms in one individual to the onset 
of symptoms in the next individual, can therefore range from 1-9 days, and has been 
reported to be between 4 and 7 days in two prospective studies(76,251). In at least one 
study SI appeared to be longer for adults (mean 6.4 days), than children (mean 4.9 
days).The rate at which susceptible individuals acquire infection is termed the force of 
infection(252).  
1.7.3 Faecal shedding of rotavirus 
Symptomatic children with rotavirus diarrhoea secrete up to 100x109 virus particles per 
gram of stool. Pre-symptomatic shedding (before onset of diarrhoea) is common, and can 
precede symptoms by up to 5 days(253). Two studies from India and Australia have used 
molecular detection methods to investigate shedding patterns over time in children with 
rotavirus gastroenteritis and found that viral shedding peaks soon after symptom 
onset(254,255), with a rapid decline over the following 10 days. Low level shedding 
continues for some time after resolution of symptoms, with a median duration of 
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shedding of 24 days, and a range of 4-57 days in symptomatic children when viral shedding 
is detected using PCR(254,255). Older studies using EIA to detect viral shedding 
demonstrated maximum shedding rates around days 2-5 of illness, with cessation 2-3 days 
after symptom resolution or 7-8 days after symptom onset(256). A shorter duration of 
shedding was observed in asymptomatic children (median duration of shedding of 18 
days, range 8-25)(255). The contribution of this extended low level shedding to 
transmission and propagation of infection is unclear.  
It is not known if viral loads vary substantially among symptomatic children, or whether 
viral shedding density is associated with risk of transmission. There are also very few data 
on determinants of viral shedding density. However, studies from India, Malawi and the 
UK show that children with symptomatic disease do have substantially greater viral loads 
compared to those with asymptomatic infection(20,255,257), and one study from India 
found a significant positive association between viral shedding density and symptom 
severity in children with clinical disease, although this pattern was less clear in neonatal 
infection(258,259). There is also some evidence from Malawi that shedding post rotavirus 
infection detected using RT-PCR may be prolonged in children with HIV infection(260). 
1.7.4 Role of infants in introducing rotavirus infection into communities 
A small number of studies have attempted to investigate the route of introduction of 
rotavirus into closed communities. In Tecumseh from 1977-1981, Koopman et al collected 
paired serum samples from age stratified household members and demonstrated that 
older ages acquired increasing proportions of rotavirus infections within the household, 
with young infants seeming to acquire the majority of their infections in the 
community(245). Galil et al report a rotavirus outbreak in a kibbutz in 1983 which 
appeared to start in young children before spreading to other members of the 
community(261). In a study conducted between 1977-1979 Englebert et al found that the 
presence of an additional child under two years of life in a household was a risk factor for 
rotavirus infection in children presenting to an outpatient clinic with diarrhoea(262).  
These studies suggest that rotavirus is mostly likely to be introduced into closed 
environments by infants. The only exception to this is a serological study conducted in a 
small community in New Zealand in 1985, where Holdaway et al proposed a model where 
young infants acquire infection from a reservoir in older adults in the community, and 
then in turn infect young adults. This hypothesis was based on identifying higher than 
expected IgG levels in adults over 50 years(263). Understanding which groups are 
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primarily responsible for driving infection is important to ensure vaccine strategy is 
targeting appropriate sections of the population.  
1.7.5 Attack rates and risk factors for rotavirus transmission  
The majority of studies of transmission are from high income settings and are household 
based studies. Attack rates for both rotavirus infection and disease in household contacts 
of children with rotavirus disease are extremely high, with child contacts typically infected 
more commonly than adults. A study from New Zealand recruited 47 households of 
children under 5 years presenting to primary health care with vomiting or diarrhoea, in 28 
of which the index child was positive for rotavirus. 48% of household contacts of a 
rotavirus index case had stool samples which tested positive for rotavirus using EIA(251) 
with 75% of children showing evidence of rotavirus infection compared to 33% of adults. 
A significant proportion of the family contacts with detectable rotavirus had symptomatic 
disease (14/18 [78%] adults and 16/18 [89%] children), corresponding to disease attack 
rates of 67% for children and 26% for adults, respectively. The similarity in attack rates for 
infection and disease may at least in part reflect the fact that EIA was used to detect 
rotavirus as EIA typically detects rotavirus viral shedding density that correlate well with 
symptomatic disease(20).  
In a study from the UK, Wyn-Jones et al collected stool samples and symptom information 
from household contacts of 5 children under 5 years admitted with gastroenteritis in the 
UK(264). At least one family member in all of the households was found to have 
detectable rotavirus in their stool, where electron microscopy was used to diagnose 
rotavirus. Those infected included adults and children, at least 2 of whom were 
symptomatic. Similar findings were observed in a family study from Denmark(265). In a 
prospective cohort study in Washington conducted from 1977-1980, Rodriguez et al 
demonstrated rotavirus in 33% of children and 12% of adults exposed to an index rotavirus 
case, the majority of whom developed symptoms. RV was defined using a combination of 
electron microscopy, immunoelectron microscopy and EIA(76). The same group also 
reported high attack rates from an outbreak of rotavirus in a playgroup, with 18/21 
contacts (86%) developing symptoms and of 10/11(91%) of those tested having evidence 
of rotavirus infection on EM/ELISA or serology. These included both children in the 
playgroup, and adult contacts(266).  
In a study from Canada published in 1979 Wenman et al prospectively followed 98 
households of newborn infants for a mean follow-up period of 16.4 months, and identified 
73 
 
43 rotavirus infections in adults, 17 of which were symptomatic(267). Rotavirus infection 
in adults was associated significantly with rotavirus infection in a child in the household 
(36/102 [35%] of adults whose children had rotavirus infection vs 4/86 [5%] of adults 
whose children did not have rotavirus infection [p<0.001]). All studies from high income 
settings were conducted in unvaccinated populations 
In comparison, there are very few studies of rotavirus transmission from middle income 
countries, and to our knowledge none from LICs. Lopman et al’s study of household 
transmission of rotavirus in 40 households from Ecuador between 2011 and 2012 is the 
only study to have used molecular methods to detect rotavirus in the stool of household 
contacts, which is substantially more sensitive than non-molecular techniques to identify 
rotavirus. It is also the only study to be conducted after introduction of routine rotavirus 
vaccine into the immunisation schedule, with 85% of rotavirus positive index children 
vaccinated. The study identified 55% of household contacts as infected with rotavirus. 
They reported a statistically non-significantly higher point estimate for attack rate for 
infection in children under 10 years (67%) than among adults over 30 years (53%)(106). 
Disease attack rates were substantially lower than infection rates, and were significantly 
reduced in adults over 30 (9%) compared to children under 10 years (31%).  
The only other study of rotavirus transmission conducted in a middle income country is 
from India. Banerjee et al conducted a study of household transmission of rotavirus as 
part of a birth cohort recruited in Vellore, Southern India between 2002 and 2003. 
Interestingly Banerjee et al identified markedly lower attack rates for household members 
of children with symptomatic and asymptomatic rotavirus infection, with only 6/560 
samples positive for rotavirus, only 3 of which could be genotyped, giving a definitive 
attack rate of 0.54%(268). EIA was used to screen for rotavirus, before nucleic acid 
extraction and RT-PCR for G and P typing to confirm transmission. It is not clear why attack 
rates were so much lower in this population. One possibility is that they included both 
symptomatic and asymptomatic rotavirus infections as index cases and transmission of 
rotavirus seems to be related to the presence of symptoms in an index child(106). A 
second potential explanation is that they screened contacts using the less sensitive 
method of EIA before using molecular methods. This is however the only study to confirm 
transmission of virus using sequencing to compare the nucleotide sequences of rotavirus 
strains within households.  
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1.7.6 Known risk factors for transmission 
Few studies have investigated risk factors for transmission, and only Lopman et al in 
Ecuador conducted multivariate analysis of predictive factors for transmission. They 
found that transmission was associated with symptomatic disease in the index child, with 
an increased risk of infection with a greater degree of symptoms(106), young age of the 
index child, younger age of the household contact and sharing a room with the index 
child(106). Other identified risk factors for transmission are crowding, both within the 
house and on a population level and environmental considerations such as flooding(269–
271). 
1.7.7 Summary of data on transmission and key questions 
Following introduction of rotavirus vaccines into immunisation schedules of many low-
income countries and emergence of vaccine effectiveness estimates, the focus must now 
shift to optimising vaccine performance and reducing the residual burden of disease. In 
this context understanding community level rotavirus transmission in LIC is crucial. High 
force of infection may be a contributing factor to observed reduced vaccine effectiveness. 
Reduction in rotavirus transmission is key to both the existence of any indirect effects of 
the vaccine and to exploring mechanisms of any such effects. An increased understanding 
of all of the above is necessary to fully evaluate the potential population level impact of 
rotavirus vaccine.  
It is known that children shed large quantities of rotavirus in their stool once they have 
developed symptomatic gastroenteritis, and may shed for extended periods of time. What 
predicts viral shedding density and duration in LICs, and how density and duration relate 
to transmission and whether vaccine can impact on these factors and thereby interrupt 
transmission remains unknown. It seems likely that infants play a major role in the 
introduction of rotavirus infection into households in high income settings, and as such 
programmatic vaccination of young infants has potential to substantially reduce infection 
in close contacts, however data from LICs where contact patterns and social behaviour 
differs considerably from more developed settings are lacking.  
High rates of rotavirus transmission have been described from index children to their close 
contacts, and child-contacts appear to be more susceptible to infection than adult-
contacts. There is however considerable heterogeneity in study design and in laboratory 
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methods used to detect rotavirus and define infection and the majority of studies are from 
high income settings, with only two from middle income countries. Only one study to date 
has used PCR as the primary method to detect rotavirus infection in contacts of index 
children, and only one study has conducted multivariate analysis for risk factors for 
transmission. There are no data from LICs where contact patterns, potential co-
morbidities and living environment differ profoundly from higher income settings, and as 
a result risk factors for rotavirus transmission could be very different.  
1.8 Work to be presented in this thesis 
This thesis aims to address some of the unanswered questions outlined above. In order to 
do this it is divided into two sections.  
Section A: 
Section A consists of two chapters both of which utilise pre-existing population level data 
to address broader questions around patterns of rotavirus transmission and vaccine 
effects. The first chapter describes patterns of force of infection in 2 different populations 
using a novel technique to estimate rotavirus incidence from serological data. The second 
uses hospital surveillance data to describe the residual burden of hospitalised rotavirus 
disease 4 years after programmatic rotavirus vaccine introduction in Malawi, update 
previously published estimates of vaccine effectiveness and to evaluate rotavirus vaccine 
indirect effects.   
Section B: 
Section B utilises primary data collected by the RotaRITE Transmission Epidemiology study 
(described in detail in Chapter 2) and focusses in on rotavirus transmission at a household 
level to investigate mechanisms of rotavirus vaccine indirect effects in a low income sub-
Saharan African setting. It is made up of 4 chapters. The first 3 of these describe SAR for 
rotavirus infection and disease at a household level, investigate predictors of shedding 
density in a symptomatic index child and evaluate risk factors for rotavirus transmission 
from an index child to a household contact. These data are used to evaluate whether 
rotavirus vaccine has the potential to reduce the infectiousness of a vaccinated index 
child, in the event of clinical vaccine failure. The fourth chapter investigates horizontal 
transmission of rotavirus vaccine virus to household contacts of vaccinated infants to 
explore the potential for rotavirus vaccine to generate herd immunity.  
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The broad objectives of each of these chapters is given in the next section, and specific 
aims and objectives are included in each chapter.  
1.9 Aims and Objectives 
This thesis aims to explore rotavirus transmission in a low income country, Malawi, and 
to relate this to vaccine performance. These data are key to informing public health 
strategy to address reduced vaccine effectiveness in low income settings. Specific 
research questions and their corresponding objectives were: 
Section A:  
Research questions 
1. Can existing methods to estimate population level rotavirus incidence be 
improved? 
2. What is the residual burden of rotavirus disease in Blantyre, Malawi four years 
after vaccine introduction? 
3. What are the current rotavirus vaccine effectiveness estimates for hospitalised 
rotavirus disease in Blantyre, Malawi? 
4. Are indirect effects of rotavirus vaccine observed in hospitalised children from 
Blantyre, Malawi? 
Corresponding objectives were to investigate 
1. Patterns of incidence of rotavirus in different low income settings using novel 
methods to estimate incidence from serological data  (Chapter 3) 
2. Whether the prevalence of rotavirus in hospitalised gastroenteritis changes over 
time since vaccine introduction (Chapter 4) 
3. Age stratified effectiveness estimates for rotavirus vaccine in children 
hospitalised with diarrhoeal disease (Chapter 4) 
4. The presence of rotavirus vaccine indirect effects in hospitalised children from 
Blantyre, Malawi (Chapter 4) 
Section B:  
Research questions 
1. Could rotavirus vaccine reduce the infectiousness of a vaccinated child with 
rotavirus disease? 
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2. Could programmatic rotavirus vaccine introduction with monovalent rotavirus 
vaccine lead to herd immunity through horizontal transmission of rotavirus 
vaccine virus?   
Corresponding objectives were to investigate: 
1. SAR for rotavirus infection and disease in household contacts of children with 
rotavirus disease (Chapter 5) 
2. Predictors of viral shedding density in children with rotavirus disease (Chapter 6) 
3. Risk factors for transmission of rotavirus infection and disease to household 
contacts of children with rotavirus disease (Chapter 7) 
4. The proportion of household contacts exposed to a vaccinated infant who 
subsequently shed rotavirus vaccine virus (Chapter 8) 
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Chapter 2. General Methods 
2.1 Overview of studies and study design 
The work presented in this thesis utilises data from several different studies. These are 
outlined in Table 2.1 
Table 2.1 Overview of studies contributing data to this thesis 
This chapter describes the clinical and epidemiological methods which are common to all 
analyses presented in the results chapters 3 to 8, and methods for the laboratory work 
conducted in chapters 4 to 8.  Individual results chapters additionally contain detailed 
methods describing study procedures and statistical analyses relevant to the section.  
With the exception of chapter 3, all analyses utilise data collected in Blantyre, Southern 
Malawi. Primary data collection for this thesis was derived primarily from the 
Transmission Epidemiology arm of the Rotavirus: Response to Immunisation and 
Transmission Epidemiology (RotaRITE) study, and is described throughout the text as the 
RotaRITE: Transmission Epidemiology study (RRTE). The RotaRITE study was jointly 
established by Dr. Louisa Pollock (WT Clinical PhD fellow) and myself to address distinct 
but complimentary questions relating to rotavirus vaccination in Malawi. The RotaRITE: 
Response to Immunisation arm formed the basis of a clinical PhD for Dr. Pollock and was 
designed to investigate mechanisms underpinning rotavirus vaccine failure.  
Chapter Chapter title Study location 
3 Estimating the incidence of 
rotavirus infection in children from 
India and Malawi using serial anti-
rotavirus IgA titres 
Archived samples from birth 
cohorts from Vellore, India and 
Karonga, Malawi 
Vellore, 
India 
Karonga, 
Malawi 
4 Direct and indirect effects of 
rotavirus vaccination on rotavirus 
hospitalizations among children in 
Malawi four years after 
programmatic introduction 
VacSurv diarrhoeal surveillance 
platform 
Blantyre, 
Malawi 
5 Household transmission of rotavirus 
in Blantyre, Malawi 
RotaRITE: Transmission 
epidemiology 
Blantyre, 
Malawi 
6 Duration and density of rotavirus 
shedding in children with rotavirus 
disease and their household 
contacts 
RotaRITE: Transmission 
epidemiology                     
Blantyre, 
Malawi 
7  Risk factors for rotavirus 
transmission in household contacts 
of children with rotavirus disease in 
Blantyre, Malawi 
RotaRITE: Transmission 
epidemiology 
Blantyre, 
Malawi 
8  Horizontal transmission of rotavirus 
vaccine virus to household contacts 
RotaRITE: Horizontal 
Transmission study         
RotaRITE: Response to 
immunisation  
Blantyre, 
Malawi 
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Screening and recruitment processes for both arms of the RotaRITE study were integrated 
across all the study sites. The RotaRITE study recruited from four sites in total; Queen 
Elizabeth Central Hospital (QECH), Blantyre and three government Health Centres, namely 
Gateway, Zingwangwa and Madziabango. At the Health Centres participants were 
screened and recruited directly.  At QECH the RotaRITE study was nested within an 
existing diarrhoeal surveillance platform which has been in place since 1997. Enhanced 
surveillance at QECH was introduced on 1st January 2012 prior to programmatic 
introduction of rotavirus vaccine on the 29th October 2012 with the aim of monitoring 
vaccine effectiveness . This formed part of a Wellcome Trust Programme Grant “New 
Childhood Vaccines for Malawi” [VacSurv] NHSRC #867). Children recruited by the 
VacSurv platform were assessed for eligibility to participate in the RotaRITE study. 
Dependent on vaccination status and results of rotavirus diagnostic tests, children were 
eligible for one or both of the study arms (Fig 2.1). This is described in detail in the 
methods section of chapter 5 (section 5.2, page 154).  
 
 
Figure. 2.1. Structure of study recruitment at QECH. Eligibility criteria for the RotaRITE 
Transmission epidemiology arm are outlined in chapter 5, section 5.2.7.4, page 157.  IC 
test refers to immunochromatograpic rapid test for rotavirus.  
The RotaRITE transmission epidemiology study was a cohort study that recruited eligible 
children presenting to any of the study sites with rotavirus positive gastroenteritis (index 
child). Following consent of the index child, their household contacts were recruited and 
followed up for 12 days after the onset of symptoms in the index child in order to 
determine SAR for rotavirus within households. Data were collected from household 
contacts on symptoms of gastroenteritis and two stool samples were collected and tested 
for the presence of rotavirus. A smaller nested cohort of households had more intensive 
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and prolonged follow up to study viral shedding in more detail. The Horizontal 
Transmission study was a subset of the RotaRITE Transmission Epidemiology study which 
recruited household members of vaccinated infants to investigate for horizontal 
transmission of vaccine virus.   
2.2 Study site and population 
2.2.1 Blantyre, Southern Malawi 
Malawi is a small, land-locked country in sub-Saharan Africa with an estimated  population 
of 16.7 million people(272). It has a sub-tropical climate, with an annual rainy season 
typically from November through to March. According to the 2015 Human Development 
report of the United Nations Development Programme (UNDP), Malawi ranks 173 out of 
188 countries and territories in the Human Development Index, with 66.7% of the 
population defined as living in poverty and 24.5 near poverty, where poverty is defined 
using a multidimensional poverty index(273). The Gross Domestic Product (GDP) per 
capita, based on purchasing-power-parity (PPP) and international United States dollars 
(USD) for 2015 was 1183.6, an increase from 482.5 in 1990 (274). Under 5 mortality per 
1000 live births for 2015 was 64 (90% CI 47, 91)(275), representing a dramatic reduction 
from 247 (234-262 90% CI) in 1990.  
Notably Malawi was one of only 32% of countries to meet Millennium Development Goal 
(MDG) 4; to reduce by 2015 under 5 mortality rate by two thirds since 1990 levels(276). 
This was achieved through a combination of nutritional programmes, vaccine 
programmes, roll out of malaria prevention and treatment strategies and programmatic 
initiation of Anti-Retroviral Treatment (ART). Despite this,  there are still many 
improvements to be made(272). Paucity of clinicians, lack of ongoing training and lack of 
resources mean that available medical care remains substandard compared to high 
income settings, and children still routinely die of preventable medical conditions such as 
diarrhoeal disease, pneumonia, and malaria.  
Blantyre is the commercial capital of Malawi, located in the southern region (Fig. 2.2), 
with an estimated population of 956 898 of whom approximately 154 792 are aged under 
5 years(277). 
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Figure 2.2 Map of Malawi. Blantyre highlighted in red.  
Map data ©2017 Google  
2.2.2 Malawi-Liverpool-Wellcome Trust Clinical Research Programme 
The Malawi-Liverpool-Wellcome Trust Clinical Research Programme (MLW) was founded 
in 1995 with the aims of pursuing scientific excellence, improving the health of people in 
sub-Saharan Africa, and maintaining partnership between the Liverpool School of Tropical 
Medicine, University of Liverpool and the College of Medicine, Blantyre, Malawi. Its major 
funder is the Wellcome Trust, and its major research themes are preventing death from 
severe infections; transmission reduction in HIV, TB and Malaria; and origins and 
intervention in chronic disease. MLW has a strong history of collaborative research within 
the Malawian community and provides extensive logistical infrastructure including 
research laboratories and clinical research facilities. The research institute consists of local 
and international scientists across a multitude of disciplines and a range of seniority.  MLW 
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is an affiliate of the University of Malawi College of Medicine as well as the University of 
Liverpool and Liverpool School of Tropical Medicine.  
 
Photograph 2.1 Malawi Liverpool Wellcome Trust Clinical Research Programme 
2.2.3 Queen Elizabeth Central Hospital 
Queen Elizabeth Central Hospital (QECH) is the major referral hospital for Southern 
Malawi, with an estimated catchment area of approximately 1.3 million for Blantyre 
district(277). The paediatric department includes an Accident and Emergency department 
(A&E), neonatal unit, general paediatric wards, oncology, orthopaedics, surgery, and a 
nutritional rehabilitation unit. On a typical day there are between 200 and 300 inpatient 
children, and almost 25,000 admissions per year. Children with gastroenteritis are triaged 
and have treatment initiated in the A&E department. If admission is required they are 
usually admitted in Paediatric Special Care ward (over 6 months of age), Paediatric 
Nursery (previously discharged neonates to infants 6 months of age), and Moyo House 
(nutritional rehabilitation for children over 6 months with WHO defined Severe Acute 
Malnutrition (SAM)).  
Children are cared for by government appointed nursing staff and patient attendants. 
Paediatric consultant rounds occur on a daily basis, with all critically unwell children 
receiving twice daily consultant review. Health care provider initiated HIV testing of both 
patients and their guardians at any contact with health care provision is part of routine 
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clinical care in Malawi, and this is undertaken at QECH by government trained HIV testers 
and counsellors(278). Health care is free at the point of delivery. Paediatric medical care 
in Malawi remains basic, with medicines limited to a few antimicrobials and anti-malarials, 
and very limited intensive care facilities available in the country. Drug stock-outs are 
frequent. Access to health care often poses a challenge with blockades at social, financial 
and logistical levels.  
 
Photograph 2.2 Queen Elizabeth Central Hospital Adult Accident and Emergency 
Department 
 
Photograph 2.3 Queen Elizabeth Central Hospital – Paediatric Special Care ward 
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2.2.4 Health Centres 
In Malawi, health centres provide primary, and sometimes secondary referral level 
medical care. Children are brought to health centres for routine vaccinations and 
nutritional assessments, and for treatment when clinically unwell. Health centres are 
typically staffed by clinical officers who are healthcare providers with a qualification in 
clinical care, but who are not qualified as physicians. Children are seen and treated at 
these health centres on an outpatient basis; if a child requires admission he or she will 
usually be referred to the nearest district hospital. Antenatal and post-natal care of 
pregnant women typically occurs at the health centre level.  
2.2.4.1 Gateway Health Centre 
Gateway health centre is located adjacent to QECH (Fig 2.3). It acts as a primary health 
centre to reduce the burden on QECH, and as such it has no formal catchment area. It 
mostly provides treatment for acutely unwell adults and children. There are no antenatal 
or inpatient facilities. It typically sees around 6000 to 10,000 outpatients per month, and 
reports up to 250 cases of diarrhoea in children aged under five per month.  There is a 
laboratory which can perform Malaria Rapid Diagnostic Tests (MRDT) and a dispensary. 
Recruitment to the RotaRITE study from Gateway commenced in September 2015.  
2.2.4.2 Zingwangwa Health Centre 
Zingwangwa Health Centre is the primary health centre for Zingwangwa district, with a 
catchment area of 145,821 people (Fig 2.3). It offers maternity services including 
antenatal and post-natal care, and runs a vaccination clinic. It also provides an HIV testing 
service, and has a laboratory which can perform basic tests such as Malaria Rapid 
Diagnostic Tests (MRDT)  and a small pharmacy. The health centre has 2000 to 3500 
outpatient attendances per month, reports 100-250 diarrhoeal cases per month in 
children under five, and vaccinates between 300-550 infants per month with rotavirus 
vaccine. Recruitment to the RotaRITE study commenced here in March 2015. 
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Photograph 2.4 Zingwangwa Health Centre 
2.2.4.3 Madziabango Health Centre 
Madziabango Health Centre provides primary health care to Madziabango district with a 
catchment area of 10,503 individuals. It is situated on the border of Blantyre district, on 
the main road from Blantyre to Chikwawa (Fig. 2.4). It runs antiretroviral treatment (ART) 
clinics for patients with HIV, general medical clinics, provides maternity care and vaccine 
clinics and also has a small diagnostic laboratory and pharmacy. It typically treats 2000-
5000 outpatients per month. It has no electricity supply, and there was a vaccine stock 
out in the last six months of 2015 resulting from breakdown of a gas fridge. This included 
rotavirus vaccine. The RotaRITE study recruited here from August 2016.  
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Figure 2.3. Map of  recruitment sites: Gateway, Zingwangwa and QECH.   
Map data ©2017 Google  
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Figure 2.4 Map of recruitment sites: Madziabango Map data ©2017 Google  
2.2.5 Field Work 
The RotaRITE: Transmission Epidemiology study involved substantial amounts of field work to recruit 
and follow up households. This required travel across the whole of Blantyre district using a 
combination of 4X4 vehicles and public transport, and often walking for long distances when houses 
were particularly inaccessible. Recruiting household members often required several home visits and 
intense follow up from the field work team. 
 
 Photograph 2.5 A study vehicle tracing a recruit 
 
Madziabango 
Health Centre 
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Photograph 2.6 The field team collecting assent from a recruit to the RotaRITE:TE study. *Written 
consent for photograph obtained from participant and guardian.  
2.2.6 Study Team 
The RotaRITE study team was responsible for study activities for RotaRITE Transmission Epidemiology, 
RotaRITE: Response to Immunisation and the RotaRITE Horizontal Transmission study. They consisted 
of: 
Two laboratory technicians: Responsible for sample processing and storage, RNA extraction and cDNA 
synthesis, qRT-PCR, qualitative PCR and EIA testing of stool 
Senior research nurse: Responsible for recruitment and clinical procedures required as part of the 
RotaRITE studies across study sites, and co-ordination of other nursing staff and activities 
Five research nurses: Responsible for screening and consenting study participants and collection of 
data and clinical samples from children recruited into the diarrhoeal surveillance programme and 
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RotaRITE studies. Also responsible for bed side stool testing with immunochromatographic tests for 
rotavirus.   
Seven field workers: Field workers were responsible for follow up and recruitment of household 
contacts, and collection of data and stool samples from household members.  
Data manager (part time): A data manager was shared between the RotaRITE studies, diarrhoeal 
surveillance and a pneumonia surveillance platform. He was responsible for the flow of Case Record 
Forms (CRFs) for the diarrhoeal surveillance platform, scanning in of CRFs for the RotaRITE studies, 
and assisting with data cleaning for the diarrhoeal surveillance and RotaRITE studies.  
2.3 Laboratory Methods 
2.3.1 Overview of laboratory methods 
All laboratory samples were processed, stored and analysed at the Malawi-Liverpool-Wellcome Trust 
Research laboratories. Assays were conducted by laboratory technicians line managed by myself and 
Dr Louisa Pollock, in conjunction with the molecular laboratory manager and core senior technicians. 
SOPs were written, reviewed and approved by a combination of Professor Miren Iturriza-Gomara 
(MIG), Dr Louisa Pollock (LP), Dr Khuzwayo Jere (KJ) and myself (AB). 
2.3.2 Laboratory Processing  
All samples were identified using individual bar codes attached to the sample vial. These were 
attached at the point of sample collection, and matching barcodes attached to corresponding data 
collection forms. Samples were tracked through the lab using their barcodes. On arrival into the 
laboratory samples were entered into the electronic “LIMS” system, which tracks samples and records 
selected test results.  
2.3.2.1 Stool samples 
On arrival stool samples were stored at 4oC. A small portion of each whole stool was used to make 
stool suspensions. 10-20% stool suspensions were generated by adding 200ul of liquid sample (or 1 
bacteriological loop if more solid) to 2ml of PBS solution and vortexing to generate a homogenous 
solution. The remainder of the sample was stored as whole stool. Whole stool and stool suspensions 
were both stored in 2ml polypropylene tubes at -80oC until batch testing.  
2.3.2.2 Blood samples 
Blood samples were collected in 1.3ml EDTA bottles. On arrival in the laboratory blood was centrifuged 
at 3000rpm at 40C for 10 minutes. Following separation plasma was pipetted into 2ml screw-top 
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polypropylene tubes and stored at -800C until further testing. These samples are planned for testing 
for anti-rotavirus IgA antibodies at a later date and these data are not included in this thesis.  
2.3.3 Laboratory data management 
All samples were entered into the generic Laboratory Information Management System (LIMS). 
Sample storage plans, laboratory work flow and laboratory results were initially generated in excel 
spreadsheets. Approximately 12 months into the study these were transferred into an access database 
with a SQL server backend, specifically designed for the RotaRITE studies, and built by the MLW data 
department. This database now serves as a template for all new studies commencing laboratory work 
at MLW.  Sample IDs were entered into the database using a barcode reader to read the barcode on 
the sample, and a work plan generated depending on the sample type. Samples were batch tested 
using qRT-PCR each time a box of samples was full. Input for the PCR machines was generated 
automatically from the work flow plan. Output from the RT-PCR machine was in the form of excel 
spreadsheets which were directly uploaded into the results database and linked back to the sample 
ID. The system was designed to facilitate flow of large volumes of data in an automated fashion and 
to avoid manual entry of data wherever feasible.  
2.3.4 Molecular methods 
2.3.4.1 Summary 
RNA was extracted from stool samples, and converted to complimentary DNA (cDNA) via reverse 
transcription. Semi-quantitative RT-PCR (qRT-PCR) was used to detect and quantify rotavirus 
(Rotavirus VP6 qRT-PCR), confirm rotavirus detection (Rotavirus NSP3 qRT-PCR)), and detect Rotavirus 
vaccine virus (Rotavirus NSP2 qRT-PCR). Qualitative PCRs were used for strain characterisation. Details 
of the assays are given below.  
2.3.4.2 RNA Extraction from stool suspension 
Viral RNA was manually extracted from 10% stool suspension using Qiagen Viral RNA Mini-kits. 
Internal controls (Primer design RNA internal extraction control kit) were added to each sample for 
quality control purposes and tested with a separate qRT-PCR. Positive and negative controls were 
included in each extraction run. The positive control was a known rotavirus positive sample. The 
procedure was conducted in a designated clean room and surfaces were cleaned with RNAse-away 
spray prior to each extraction to minimise risk of contamination. Internal control (IC) RNA was 
prepared according to manufacturer’s instructions and added to the extraction buffers. Extraction was 
then conducted according to protocol. 
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2.3.4.3 Reverse Transcription 
Viral RNA was converted to complimentary DNA(cDNA) to allow amplification of RNA targets via 
reverse transcription. cDNA was generated using random primers (Invitrogen, ThermoFisher, 
Waltham, Massachusetts, USA) and reverse transcriptase enzyme (M-MLV). Random primers were 
used to generate cDNA which could be used for amplification of a range of targets. The cDNA 
generated was then archived to allow further testing at a later date if required. Reaction mix for the 
reverse transcription (RT) reaction was prepared as outlined in Table 2.2. 
Table 2.2 Reaction mix for reverse transcription  
  µl /reaction µl /94 reactions 
10X PCR buffer (without MgCl2; AB) 7 658 
25 mM MgCl2  (AB) 14 1316 
Random Primers @50 M (Invitrogen/AB ) 1 94 
dNTPs (10 mM; AB) 1 94 
M-MLV (200U/ul) 2 188 
Nuclease free Water 5 470 
TOTAL 30 2820 
 
Following preparation of the master mix the following steps were performed:  
1. 40 µl of total nucleic acid was added to each well of 96 well plate and denatured at 97oC for 
2-5 minutes before transferring to a cool box/ice 
2. 30 µl of RT master-mix was added to each well 
3. Incubation step 1.  – room temperature (23± 5oC) for 5 minutes 
4. Incubation step 2 – 37oC for 60 minutes (RT isothermal reaction) 
5. Inactivation step  - heat at 95oC for 2-5 mins 
2.3.4.4 Rotavirus VP6 qRT-PCR 
This semi-quantitative real time PCR (qRT-PCR) assay was used to amplify a 379 base-pair (bp) 
fragment of the rotavirus inner capsid protein (VP6) encoding gene from nucleic acids converted into 
cDNA. qRT-PCR detects amplification of target DNA as the reaction progresses, in contrast to 
conventional PCR which detects the product at the end of the reaction. This allows quantitation of the 
product under investigation, beyond a threshold level of DNA. The number of PCR cycles needed to 
raise copy numbers of the target sequence in a sample above a pre-defined threshold is termed the 
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cycle threshold (Ct), and is inversely proportional to the amount of virus present, such that lower Ct 
values represent a higher viral load. All qRT-PCR assays in this study were run for 40 cycles.  
A standard curve (serial dilution of amplification target for which the concentration is known) was 
included in each run to allow estimation of the rotavirus viral load (copy numbers). Assays were 
conducted on the ABI 7500 PCR machine. A separate PCR was conducted for the internal extraction 
control (IC). Composition of primers and probes are listed in Table 2.5 
Master mix was prepared and stored at -20oC. Master mix for VP6 and IC reactions were prepared as 
listed in tables 2.3 and 2.4 
Table 2.3 Reaction mix for VP6 PCR 
 Reagents µl /reaction ul /94 reactions ul /37 reactions 
Master Mix (with low Rox) 12.5 1175 462.5 
VP6 Fi (@20 pmol/ul) 0.5 47 18.5 
VP6 R (@20pmol/ul) 0.5 47 18.5 
VP6 probe (FAM_MGB @ 20uM) 0.25 23.5 9.25 
Nuclease free Water 8.75 822.5 323.75 
TOTAL 22.5 2115 832.5 
 
Table 2.4 Reaction mix for IC reaction . 
 Reagents µl /reaction ul /94 reaction ul /37reactions 
Master Mix 10 940 370 
IC Primer/probe mix (Vic_none) 1 94 37 
Nuclease free Water 7 658 259 
TOTAL 18 1692 666 
 
Following preparation of the reaction mix the procedure was as follows. A separate plate was used for 
VP6 and IC reactions: 
1. 22.5 µl (VP6) or 18 µl (IC) of reaction mix added to each well of a 96 well plate.  
2. 2.5 µl cDNA (VP6) or 2 µl cDNA (IC) added to the plate 
3. Plate sealed with adhesive cover 
4. Plate spun for 5 seconds in plate centrifuge 
5. Plate transferred to the ABI 7500 machine 
6. Plate cycled at the following temperatures for each reaction: 
93 
 
Denaturation     95oC 2 minutes 
40 cycles 95oC 15 seconds 
  60oC 1 minute 
For each run method, positive and negative controls (a positive sample and a negative sample that 
had undergone extraction and RT steps), a PCR positive control (cDNA containing the target) and RT 
and PCR negative controls (no template controls) were included. Results were analysed by reviewing 
positive and negative controls, adjusting the threshold above any background noise, and by reviewing 
the standard curve. The threshold was set at the beginning of the exponential curve in the linear graph, 
and the middle of the linear phase in the log graph. For the standard curve typically a correlation 
coefficient (R2) of >0.9 and amplification efficiency of >80% and a minimum of 5 points within the 
assay linear range was considered adequate. Ct values of the standard curve were also checked against 
typical/expected values.  
For the run to be accepted all negative controls had to be below the threshold, with no amplification, 
and positive controls had to demonstrate a  Ct value<40 and a sigmoidal curve. Analysis was 
performed by laboratory technicians, reviewed and approved by the study PI (AB), and finally 
reviewed with MIG/KJ prior to accepting result as authorised. Assays were repeated when samples 
failed quality control (QC).  
Table 2.5 Primer and probe composition for VP6 qRT-PCR 
 
 
 
 
 
2.3.4.5 Rotavirus NSP3  qRT-PCR  
This qRT-PCR used primers designed to amplify an 87 bp fragment of the non-structural protein 3 
(NSP3) gene of group A rotaviruses. This assay was used for confirmatory purposes for samples which 
had Ct values >35<40 on VP6 PCR.  The reaction mix was prepared at -20oC in the quantities described 
in Table 2.6. Primer and probe composition is described in Table 2.7 
 
 
Primer/Probe Sequence (5’-3’) 
Nucleotide 
position  
VP6F  GAC GGV GCR ACT ACA TGG T          
747-766(279) 
VP6R GTC CAA TTC ATN CCT GGT G           
1126-1106 
(279) 
VP6P FAM CCA CCR AAY ATG ACR CCA GCN GTA MGB 
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Table 2.6. Reaction mix for NSP3 PCR 
 Reagents µl /reaction 
Master Mix (with low Rox) 12.5 
NSP3F  (@20 pmol/ul) 0.4 
NSP3R (@20pmol/ul) 0.4 
NSP3 probe (FAM_MGB @ 20uM) 0.15 
Nuclease free Water 9.05 
TOTAL 
22.5 
Following preparation of the master mix, the following steps were followed 
1.  22.5µl of NSP3 reaction mix was added to a  96 well plate 
2. 2.5 µl of cDNA was added 
3. The plate was sealed 
4. Plate was spun in a plate centrifuge for 5 seconds 
5. The plate was transferred to the ABI 7500 machine 
6. The same cycling conditions as for VP6 PCR were used 
Each run contained negative controls and low and medium concentration positive controls. Low and 
medium controls were made from stock generated from serial dilutions of a very concentrated 
sample. Medium controls had a target Ct value between 26 and 30, low controls were a 100x dilution 
of the medium control (Ct 34-37).  
Table 2.7 Primer and probe composition for NSP3 
Primer/Probe Sequence (5’-3’) 
Nucleotide 
position 
NSP3-F ACC ATC TWC ACR TRA CCC TCT ATG AG     
963-982 
NSP3-R GGT CAC ATA ACG CCC CTA TAG C 1,034-1049(280) 
NSP3-Probe FAM-AGTTAAAAGCTAACACTGTCAAA MGB 995-1017(281) 
95 
 
2.3.4.6 Rotavirus NSP2 qRT-PCR 
This qRT-PCR used primers designed to amplify a 281 bp fragment of the non-structural protein 2 
(NSP2) gene of RotarixTM vaccine rotavirus strain and as before included a target specific hydrolysis 
probe. The reaction mix was prepared at -20oC according to the quantities outlined in Table 2.8. 
Composition of primers and probes can be found in Table 2.9.  
Table 2.8 Reaction mix for NSP2 PCR 
 Reagents µl /reaction ul /98 reactions 
Master Mix (with low Rox) 12.5 1,225 
NSP2F  (@20 pmol/ul) 0.5 49 
NSP2 R (@20pmol/ul) 0.5 49 
NSP2 probe (FAM_MGB @ 20uM) 0.25 24.5 
Nuclease free Water 9.25 906.5 
TOTAL 23 2,254 
Following preparation of the NSP2 reaction mix the following steps were followed: 
1. 22.5 µl NSP2 reaction mix added to a 96 well plate  
2. 2.5 µl cDNA added 
3. Plate sealed. 
4. Plate spun in plate centrifuge for 5 seconds 
5. Plate transferred to the ABI 7500 machine. 
6. Cycling conditions as for the VP6 PCR.  
PCR negative controls, a RotarixTM cDNA control, and a non-vaccine rotavirus positive cDNA control 
were included on each plate.  
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Table 2.9 Primer and probe composition for NSP2  
 
2.3.4.7 Quality Control for RT-PCR 
A series of quality control steps were incorporated at each stage of the extraction, RT and PCR process 
to ensure results were reliable.  
Internal control (IC) 
The internal control acted as a positive control for the extraction procedure. The IC is an RNA template 
of known quantity extracted along-side sample RNA and then detected on PCR. The IC PCR was run 
separately to the VP6 RT-PCR to avoid inhibition. Ct values of 26+/- 3 from the IC were considered 
acceptable. Analysis of IC plates followed the rules outlined above for VP6 PCR.  
Positive control (PC) 
One positive control was included per extraction batch. This was a known rotavirus positive stool 
sample with Ct value 30-37. Samples selected as controls were prepared as aliquots and used for as 
many extractions as possible to allow comparison of Ct values between batches. Ct values for positive 
controls were plotted to allow inspection for trends over time, and Ct values deviating >+/-3 Ct values 
from previous assays were considered unacceptable. The purpose of the positive control was to 
ensure that extraction, RT and amplification steps all occurred adequately.   
Negative control (NC)  
 One negative control of sterile water was included per extraction batch in order to identify 
contamination in any of the steps.  
cDNA control (cDNA) 
This was added at the PCR stage to confirm that PCR master mix and reagents were prepared correctly. 
This was typically an aliquot of standard plasma.  
 
Primer/Probe Sequence (5’-3’) 
 
RV1NSP2-F GAA CTT CCT TGA ATA TAA GAT CAC ACT GA 
546-574 (282) 
RV1NSP2-R  TTG AAG ACG TAA ATG CAT ACC AAT TC 826-801 (282) 
RV1NSP2-Probe  FAM TCC AAT AGA TTG AAG TCA GTA ACG TTT CCABHQ1 782-753 (282) 
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PCR no template control (PCR NT) 
This was a negative control included at the PCR stage to ensure no contamination occurred at the PCR 
stage.  
2.3.4.8 Rotavirus Genotyping 
G and P typing for rotavirus was conducted according to the method described by  the European 
Rotavirus Network (EuroRotaNet, http://www.eurorota.net), a network of European laboratories 
collaborating to provide comprehensive rotavirus strain surveillance pre- and post- vaccine 
introduction, develop methods for rotavirus typing and respond to changes in molecular epidemiology 
associated with genetic drift(91). Genotyping was conducted on cDNA synthesised using random 
primers, as described above. It utilises a two-stage PCR with consensus and type-specific primers. 
Genotyping was performed through the diarrhoeal surveillance platform. Primary supervision and 
interpretation of results was conducted by MIG and KJ with support from LP and myself.  
G-typing consensus PCR 
First round PCR mix was prepared as described in table 2.10 
Table 2.10 Reaction mix for G-type consensus PCR  
 
 
 
 
 
 
 
Following preparation of the reaction mix 45 µl of mix was added to each PCR tube, and 5 µl cDNA 
added. PCR tubes were added to the thermocycler and cycled at the following temperatures: 
 
 
 
 Reagents  
10 x buffer II (Invitrogen) 4.5 ul 
50mM MgCl2 2.0 µl 
dNTPs (10mM) 1.0 µl 
Taq Polymerase (5U/ul) (Invitrogen) 0.2 µl 
Primer VP7-F (20pmoles/ul) 1.0 µl 
Primer VP7-R (20pmoles/ul) 1.0 µl 
RNase-free H20 35.3 µl 
TOTAL 45.0 µl 
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94 oC 2 min X1 
94 oC 1 min 
X35 52 oC 1 min 
72 oC 1 min 
72 oC 7 min X1 
15 oC hold  
  
G-typing multiplex PCR 
Second round PCR mix was prepared as outlined in Table 2.11 
Table 2.11 Reaction mix for G-typing multiplex PCR 
 
 
 
 
 
 
 
 
 
 
 
 
Following preparation of the reaction mix 48 µl of reaction mix was added to each PCR tube followed 
by 2 µl of first round product. PCR tubes were added to the thermocycler and cycled at the following 
temperatures: 
 
 Reagents  
10 x buffer II (Invitrogen) 4.8 ul 
50mM MgCl2 2.5 µl 
dNTPs (10mM) 1.0 µl 
Taq Polymerase (5U/ul) (Invitrogen) 0.2 µl 
Primer VP7-R (20pmoles/ul) 1.0 µl 
Primer G1 (20pmoles/ul) 1.0 µl 
Primer G2 (20pmoles/ul) 1.0 µl 
Primer G3 (20pmoles/ul) 1.0 µl 
Primer G4 (20pmoles/ul) 1.0 µl 
Primer G8 (20pmoles/ul) 1.0 µl 
Primer G9 (20pmoles/ul) 1.0 µl 
Primer G10 (20pmoles/ul) 1.0 µl 
Primer G12 (20pmoles/ul) 1.0 µl 
RNase-free H20  30.5 µl 
TOTAL 48.0 µl 
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94 oC 4 min X1 
94 oC 1 min 
X30 42 oC 2 min 
72 oC 1 min 
72 oC 7 min X1 
15 oC hold  
 
P-typing consensus PCR 
 First round PCR mix was prepared as outlined in Table 2.12 
Table 2.12 Reaction mix for P-typing consensus PCR 
 
 
 
 
 
 
 
Following preparation of the reaction mix, 45 µl of mix was added to each PCR tube, and 5 µl cDNA 
added. PCR tubes were added to the thermocycler and cycled at the following temperatures: 
94 oC 2 min X1 
94 oC 1 min 
X35 50 oC 1 min 
72 oC 1 min 
72 oC 7 min X1 
15 oC hold  
 
 
 
 Reagents  
10 x buffer II (Invitrogen) 4.5 ul 
50mM MgCl2 2.0 µl 
dNTPs (10mM) 1.0 µl 
Taq Polymerase (5U/ul) (Invitrogen) 0.2 µl 
Primer VP4-F (20pmoles/ul) 1.0 µl 
Primer VP4-R (20pmoles/ul) 1.0 µl 
RNase-free H20 35.8 µl 
TOTAL 45.0 µl 
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P-typing multiplex PCR 
Second round PCR mix was prepared as outlined in Table 2.13 
Table 2.13 Reaction mix for P-typing multiplex PCR 
 
 
 
 
 
 
 
 
 
 
 
48 µl of round mix was added to a 0.2ml tube, followed by 2 µl of first round product. PCR tubes were 
added to the thermocycler and cycled at the following 
94 oC 4 min X1 
94 oC 1 min 
X30 42 oC 2 min 
72 oC 1 min 
72 oC 7 min X1 
15 oC hold  
 
Primer composition for G and P types are listed in Table 2.14 
 
 
 
 Reagents  
10 x buffer II (Invitrogen) 4.8 ul 
50mM MgCl2 2.5 µl 
dNTPs (10mM) 1.0 µl 
Taq Polymerase (5U/ul) (Invitrogen) 0.2 µl 
Primer VP4-F (20pmoles/ul) 1.0 µl 
Primer P[4] (20pmoles/ul) 1.0 µl 
Primer P[6] (20pmoles/ul) 1.0 µl 
Primer P[8] (20pmoles/ul) 1.0 µl 
Primer P[9] (20pmoles/ul) 1.0 µl 
Primer P[10] (20pmoles/ul) 1.0 µl 
Primer P[11] (20pmoles/ul) 1.0 µl 
RNase-free H20  30.5 µl 
TOTAL 48.0 µl 
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Agrose-gel electrophoresis 
1.5g of UltraPureTM Agarose 100 was added to 100ml 1X Tris/Borate/EDTA (TBE) buffer to make 1.5% 
gel and melted in a microwave. Once melted, the gel was cooled to 45oC, and ethidium bromide added 
(at a concentration of 3.5g/L). The cooled gel was poured into a gel plate and fitted with two 22-28 
slot combs. 10 µl of PCR product was added to 10 µl sample buffer in a micro-titre plate. Once set, the 
combs were removed. Samples were mixed with loading dye and 20 µl of either size marker (100bp 
ladder) or diluted sample added to each well. The gel plate was added to the gel tank, and TBE buffer 
added level with the gel. After running the products into the gel for 5 minutes using a voltage of 150V, 
the gel was flooded with TBE buffer such that it was fully submerged. Electrophoresis was then 
performed at a constant voltage between 5 and 8 V/cm until the samples had run the length of the 
gel. The gel was then placed into a UV transilluminator for visualisation.    
Table 2.14 Primer composition for G and P typing (283) 
Primer  Sequence (5’-3’)* Nucleotide Positions Product Size 
VP7-F  ATG TAT GGT ATT GAA TAT ACC AC 51-71 881bp 
VP7-R AAC TTG CCA CCA TTT TTT CC 914-932 881bp 
G1  CAA GTA CTC AAA TCA ATG ATG G 314-335 618bp 
G2  CAA TGA TAT TAA CAC ATT TTC TGT G 411-435 521bp 
G3  ACG AAC TCA ACA CGA GAG G 250-269 682bp 
G4  CGT TTC TGG TGA GGA GTT G 480-499 452bp 
G8  TTR TCG CAC CAT TTG TGA AAT 176-198 756bp 
G9  CTT GAT GTG ACT AYA AAT AC  757-776 179bp 
G10  ATG TCA GAC TAC ARA TAC TGG  666-687 266bp 
G12  GGT TAT GTA ATC CGA TGG ACG 548-567 396bp 
VP4-F  TAT GCT CCA GTN AAT TGG  132-149 663bp 
VP4-R  ATT GCA TTT CTT TCC ATA ATG 775-795 663bp 
P[4]  CTA TTG TTA GAG GTT AGA GTC 474-494 483bp 
P[6]  TGT TGA TTA GTT GGA TTC AA 259-278 267bp 
P[8]  TCT ACT GGR TTR ACN TGC  339-356 345bp 
P[9]  TGA GAC ATG CAA TTG GAC 385-402 391bp 
P[10]  ATC ATA GTT AGT AGT CGG 575-594 583bp 
P[11]  GTA AAC ATC CAG AAT GTG 305-323 312bp 
* R= A or G, N=A or T or G or C 
2.3.5 Rotavirus Enzyme Immuno-assay (EIA) 
EIA testing was performed on children presenting to QECH, as part of the ongoing diarrhoeal 
surveillance platform and in line with WHO recommendations for rotavirus surveillance(10). Stool 
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samples from children with acute gastroenteritis presenting to QECH were processed on arrival in the 
laboratory, and stored as 10% suspension in PBS at 4-7 degrees Celsius before batch testing weekly 
using a commercial EIA assay (Rotaclone, Meridian Bioscience, Cincinnati, Ohio) as per manufacturer’s 
instructions. 
2.3.6 Rotavirus Immunochromatographic (IC) rapid tests 
IC testing was performed in real-time by nurses screening children for eligibility for the RotaRITE 
studies using Coris Rota-stripTM. (Coris BioConcept, Gembloux, Belgium). Testing was performed 
according to manufacturer’s instructions. All facilities used for recruitment had a small laboratory area 
for Malaria testing and this was used for stool testing for rotavirus. Results of the rapid test were 
recorded in the clinical notes regardless of whether the child was recruited into the RotaRITE study.   
2.3.7 Rotavirus Serology methods 
2.3.7.1 Anti-rotavirus IgA 
Anti-rotavirus IgA titres were measured using a semi-quantitative sandwich ELISA developed by the 
Wellcome Trust Research Laboratory Christian Medical College, Vellore (SOP no W/ASA/25 V3.0 for 
Quantitation of Anti-Rotavirus IgA by ELISA) and based on a method developed by R Ward(284). 
Standards and controls were donated from Wellcome Trust Research Laboratory Christian Medical 
College, Vellore. 96 well plates were coated with rabbit anti-rotavirus hyperimmune serum and 
incubated over night with WC3 rotavirus containing cell culture lysate (MA104). 4x2 serial dilutions of 
sera (4X2) were then added and a biotinylated rabbit anti-human IgA (Jackson ImmunoResearch Lab, 
US), avidin-biotin-peroxidase complex (Vecastain ABC kit; Vector) and a peroxidase substrate (o-
Phenylenediaminedihydrochloride; Sigma) used for anti-rotavirus IgA detection. Each run included a 
standard curve (serial dilutions of control plasma (8x2)) and positive and negative controls.  
Results were calculated on a minimum of two values per sample with a coefficient of variation (CV) < 
20% and were expressed as geometric mean titres (IU/ml IgA). Trimmed geometric means were used 
where a CV of <20% could not be obtained after repeat testing. Results were classified as zero if below 
the lower limit of detection.  
2.4 Statistical Methods 
Statistical methods are described in detail in each section. Analysis was conducted using Stata version 
14.2 (StataCorp, USA), GraphPad Prism 6 (GraphPad Software Inc, USA), and R 3.0.2 (R Foundation for 
Statistical Computing, Austria). Missing data was rare, and unless otherwise specified missing variables 
were managed by exclusion from analysis.  
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2.5 Data Management 
Data were collected and stored in accordance with international Good Clinical Practice (GCP) 
guidelines. At the point of recruitment each subject was given a unique identifier. For the RotaRITE 
studies, and for surveillance data collected from 18th January 2015 onwards, source data were 
captured using pre-coded paper case record forms (CRFs). Intelligent Character Recognition scanning 
software (Teleform) was used to convert data into electronic form. Data were stored in a SQL database 
on the secure MLW server, and extracted directly into Stata. Prior to January 2015 data capture for 
the diarrhoeal surveillance programme was conducted by direct data entry into a redcap database.  
The data management systems were designed by AB, with support from the data department at MLW. 
Data discrepancies and queries were identified and recorded using specifically designed algorithms 
and automated data checks, and were manually checked against the study CRF. Following data 
cleaning data manipulation and database construction was conducted by me using Stata 14.2.  
2.6 Ethical Considerations 
Ethical approval for VacSurv was obtained from the National Health Sciences Research Committee, 
Lilongwe, Malawi (867), and by the University of Liverpool Research Ethics Committee (000490).  
Ethical approval for RotaRITE Transmission Epidemiology was obtained from the Malawi College of 
Medicine Research Ethics Committee (P.09/14/1623) and University of Liverpool Research Ethics 
Committee (RETH000757). Sponsorship for the RotaRITE Transmission Epidemiology was obtained 
from University of Liverpool (UoL001070).  
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RESULTS 
SECTION A 
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Chapter 3. Estimating the incidence of rotavirus infection in children from India 
and Malawi using serial anti-rotavirus IgA titres 
3.1 Introduction 
Rotavirus has been, prior to the introduction of rotavirus vaccines, the commonest cause of AGE in 
children worldwide, responsible for enormous morbidity and substantial mortality(58,285–288). As a 
result of a cohesive international effort to develop and license vaccines against rotavirus, there are 
currently two live, oral vaccines against rotavirus disease which are globally licensed, the monovalent 
RV1 and the pentavalent RV5(2).  Both of these vaccines showed high efficacy in clinical trials in high 
income settings (98-100%(139,140)), but notably lower efficacy in low and middle income settings. 
Despite this, in view of the extent of the disease burden in lower income countries the WHO 
recommended routine introduction of vaccine into such settings as a priority in 2009,  and rotavirus 
vaccine has now been introduced in over 35 GAVI eligible countries(289). Post implementation vaccine 
effectiveness data has begun to emerge from LIC, and while vaccine effectiveness appears to be higher 
than observed efficacy in clinical trials, it remains lower than reported from high income settings. 
Section A of this thesis uses existing datasets to address questions regarding population rotavirus 
transmission in the context of reduced vaccine effectiveness in LIC. This chapter investigates a novel 
approach to estimating force of infection in young infants using serological data, the next chapter will 
use surveillance data to investigate for rotavirus vaccine indirect effects in Malawi, a LIC.   
Accurate descriptions of force of rotavirus infection are important given the sub-optimal vaccine 
effects reported from lower income settings. Firstly, force of infection, or the rate at which susceptible 
individuals acquire infection(252), is one possible contributing factor to reduced vaccine effectiveness. 
Force of infection is typically higher in low income settings, as evidenced by the early onset of rotavirus 
disease in such countries(144). High force of infection may result in high titres of circulating maternal 
antibodies against rotavirus, and trans-placental transfer of maternal IgG may interfere with the 
infant’s ability to develop an immune response to the vaccine. In keeping with this, a negative 
correlation has been demonstrated between high maternal IgG titres and infant response to vaccine 
measured by anti-rotavirus IgA titres(143,290,291). Similarly, anti-rotavirus IgA excreted in breast milk 
from women in LIC has been shown to contain higher titres of IgA, and to demonstrate greater 
neutralising ability against rotavirus, than breast milk from women in HIC(292,293).  
High force of infection may also lead to epidemiological artefact in the measurement of vaccine 
effects. For examples, measurement of vaccine efficacy relies on evaluation of the difference in 
infection rates between vaccinated infants and unvaccinated control infants, and rotavirus vaccine is 
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designed to mimic natural immunity which provides incremental protection against severe disease. In 
settings with a high force of infection natural exposure and subsequent acquisition of immunity in the 
control arm may result in similarities in the rate of infection between case and control groups, and an 
apparent reduction in measured vaccine efficacy(145). Describing differences in patterns of force of 
infection between populations is therefore important to improve understanding of variation in vaccine 
performance. 
Secondly, describing population level changes in incidence before and after vaccine implementation 
is an important means of measuring vaccine impact, particularly for diseases such as rotavirus where 
the spectrum of disease is wide and not all cases will present to sentinel surveillance sites. It can also 
capture rotavirus vaccine indirect effects, or reductions in disease in unvaccinated sections of the 
population. Evaluations of impact of the vaccine on rotavirus transmission at the population level 
contribute to accurate estimations of cost effectiveness, which is important to inform vaccine policy. 
Finally, understanding the timing of peak rotavirus incidence in children could help inform vaccine 
scheduling, which is one potential mechanism to improve vaccine performance(294).  
Obtaining accurate estimates of rotavirus incidence is challenging however, as asymptomatic infection 
is common, and shedding of virus in stool is transient(38). Several cohort studies have provided 
invaluable data on rotavirus incidence in infants and children with intensive monitoring and collection 
of serial stool and serum samples(38,62,295), but such studies are expensive and logistically 
challenging to be conducted on a wide scale. Sero-surveys have the potential to be a pragmatic and 
cost-effective means to provide useful information on population level incidence. Serum anti-rotavirus 
IgA has been shown to reflect intestinal IgA, which is thought to be important in immunity against 
rotavirus(296,297). Serum IgA rises in response to rotavirus infection, and in response to rotavirus 
vaccination(63,64,66). IgA seroconversion rates post vaccination have been shown to correlate with 
vaccine efficacy, and anti-rotavirus IgA titres to correlate with protection against severe wild-type 
disease(63,298).  
Although sero-surveys are an attractive option, making meaningful inferences from changes in 
antibody titre is not straight-forward. Serological assays have considerable internal and external 
heterogeneity, and natural fluctuations in antibody levels within subjects may be physiological and 
not necessarily meaningful. Traditionally, fold increase in titre or antibody levels above a certain 
threshold have been taken to demonstrate seroconversion(38,284), but both of these methods are 
prone to misclassification(299,300). As an alternative approach we used mixture models as a 
quantitative analytical method to evaluate changes in anti-rotavirus IgA titres over time and estimate 
rotavirus incidence in infants and young children from two different low income, unvaccinated 
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populations: an urban slum in Vellore, Southern India, and a rural setting in Karonga, Northern Malawi. 
Mixture models (two component Gaussian mixture distributions) have been used to interpret 
serological data for other pathogens(300), but to our knowledge have not previously been used for 
rotavirus. They have potential advantages over more traditional methods of analysing serological data 
as they evaluate data probabilistically, and offer a visual interpretation of the data. In this study we 
compared results from mixture model to findings from more commonly used techniques of fold 
increase and use of a pre-defined cut-off to evaluate change in antibody titres. Patterns of incidence 
over time were compared between the two settings in order to better understand potential 
differences in rotavirus transmission in different environments.  
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3.2 Methods 
3.2.1 Objectives 
1. To describe incidence of rotavirus infection in young infants from Vellore, India, using 
mixture models 
2. To describe incidence of rotavirus infection in young infants from Karonga, Malawi, using 
mixture models 
3. To compare estimates of rotavirus incidence derived from mixture models to those derived 
using alternative methods of interpreting serological data (fold increase and a pre-defined cut 
off) 
3.2.2 Study design 
This study used serum samples previously collected from infants and children enrolled into birth 
cohorts in two low and middle income different locations. 
3.2.3 Study site 
The birth cohorts were located in an urban slum in Vellore, Southern India, a LMIC; and Karonga, a 
rural setting in Northern Malawi, a LIC (Fig 3.1). Both are tropical countries, with similar altitudes (204 
metres above sea-level for Vellore, 529 metres for Karonga). Average yearly temperature is 30oC in 
Karonga and 28oC for Vellore(119,301). Both have an annual monsoon. Neither population had 
introduced rotavirus vaccine at the time of study.  
3.2.4 Study population  
Both studies recruited newborn infants and followed then up prospectively.  
3.2.5 Study procedures 
3.2.5.1 Indian birth cohort.  
The Vellore cohort was designed to investigate acquisition of natural protective immunity to rotavirus 
and recruited infants from within a Demographic Health Surveillance site located within three 
adjacent slum regions in Vellore, with a population density estimated at 17,000/km2. During follow 
up, households were visited twice weekly to collect symptom information for the enrolled infant and 
other household members. Stool samples were collected fortnightly, and serum samples were 
collected from the recruited infant at birth and then every six months. Stool samples were tested for 
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rotavirus using EIA (Rotavirus IDEIA, Dako), and RT-PCR. A detailed description of this cohort has been 
previously published(38).  
3.2.5.2 Malawi birth cohort.  
The Karonga birth cohort was located within the Karonga Health and Demographic Surveillance 
System (HDSS) in northern Malawi, a rural region, with a population density of approximately 
264/km2. The birth cohort was designed to investigate pneumococcal carriage in HIV exposed mothers 
and their infants(302,303). Infants were recruited between January 2009 and December 2010. Serum 
samples were collected at 6, 26 and 52 weeks of life.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1 Location of study sites. A) Karonga, Malawi B) Vellore, India 
Map data ©2017 Google  
3.2.6 Laboratory methods 
Anti-rotavirus IgA antibodies were measured using a standard sandwich ELISA(304). Standard 
Operating Procedures (SOPs), as well as the IgA standards and control plasma used were the same 
across both sites, the only difference being that the Vellore site used 2 x 10 fold dilution of sera and 
Karonga 
Vellore 
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Karonga used 4 x 2 fold dilutions. The assay methods are described in detail in chapter 2.3.7.1, page 
100. Serology for the India cohort was performed by the study team in Vellore.  
3.2.7 Statistical Analysis 
Statistical analysis comprised five stages, which are outlined in Fig. 3.2.  
 
 
Figure 3.2. Outline of statistical analysis.  
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3.2.7.1 Descriptive analysis 
Descriptive analyses consisted of comparing median titres between time points within and across 
populations. Independent and paired medians were compared using sign-rank and rank-sum tests 
respectively. Chi-squared for independent proportions was used to compare the proportion of 
children demonstrating seroconversion between populations, where seroconversion was defined as 
titre ≥20IU/ml(284). The cut-off of 20IU/ml to define sero-conversion has been used through multiple 
vaccine immunogenicity and efficacy studies, particularly in relation to RV1.  
3.2.7.2 Estimating prevalence of sero-conversion over the first 3 years of life time in Vellore 
Firstly, prevalence of seroconversion was estimated using mixture models. Mixture models refer to 
two component Gaussian mixture distributions, where one component is assumed to correspond to 
uninfected individuals and one, with larger values, to seroconverted (presumed infected) individuals. 
These were used to estimate the prevalence of seroconversion in Vellore at 6 monthly time intervals, 
based on increment in log transformed antibody titres between time points. Prevalence refers to the 
proportion of samples assigned to the positive or “infected” distribution(300,305).  
Antibody titres were log transformed after adding one to the value of each titre to allow log 
transformation of zero values. Increment in log transformed titres was then calculated (i.e. 26-6 weeks 
[d1], 52-26 weeks [d2], 78-52 weeks [d3], 104-78 weeks [d4], 130 and 104 weeks [d5] and 156-132 
weeks [d6]). Histograms of the difference in IgA titres between time points showed a bimodal 
distribution, but also identified large numbers of zero values (representing no change in antibody titre) 
for each time point. These did not fit a Gaussian distribution, and were therefore removed from the 
dataset prior to fitting the models. Examples of these distributions are shown in Fig. 3.3. Mixture 
models were then fit to the increment in log transformed titres between each of the time points. As 
the zero increment values clearly represented no evidence of re-infection, they were added back into 
the uninfected component for calculations of prevalence and incidence. Bootstrap confidence bounds 
were calculated around the model derived parameter estimate for prevalence of seroconversion.  
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Figure 3.3. Example histograms of differences in IgA titres between time points (d1, d2, and d3 for 
titres at 26-6 weeks, 52-26 weeks and 52-6 weeks respectively) showing large numbers of zero values. 
Plots shown for combined Vellore and Karonga data. 
3.2.7.3 Estimating seroconversion using fold increase and a pre-defined cut-off 
To evaluate the use of mixture models, seroconversion was also calculated using two alternative 
definitions of seroconversion which are commonly used in the literature and in clinical trials of vaccine 
immunogenicity; fold increase and a pre-defined cut-off of anti-rotavirus IgA titres ≥ 20IU. For 
calculation of fold increase 0.1 was added to each assay result (to allow calculation of fold increase for 
zero values), and seroconversion was defined as a three-fold or greater rise between time points. For 
the cut-off of ≥20IU, sero-positivity was defined as IgA titres ≥ 20IU and becoming seropositive 
between time points was considered seroconversion. 
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3.2.7.4 Estimating incidence from prevalence estimates 
Rotavirus infection incidence , during the interval  between each time point was calculated based 
on a log-linear fit using the formula below, where p corresponds to the prevalence of sero-
conversion(306). For mixture models this refers to the bootstrap estimate of mean prevalence: 
𝜆 =
−ln⁡(1 − 𝑝)
𝜏
 
3.2.7.5 Estimating prevalence of sero-conversion and incidence in Karonga 
To compare exposure to rotavirus infection in infancy between the Vellore and Karonga populations, 
mixture models were fit to the increment in log transformed titres between 6 and 26 weeks, 26 and 
52 and 6 and 52 weeks in Karonga, and the prevalence of seroconversion and derived incidence for 
each time point compared to that demonstrated in Vellore. Prevalence and incidence of 
seroconversion were also calculated using fold increase and a cut-off value, as outlined above. To 
further validate findings, the difference between increments was calculated for each location (i.e [d2]-
[d1]), and the mean value compared between locations using a two-sample t-test.  
3.2.7.6 Calculation of IgA decay rate 
To evaluate the likelihood of capturing repeated infection episodes using mixture models, a decay rate 
was calculated for anti-rotavirus IgA using a subset of children from the Vellore dataset. Serum 
samples were included if a child had a confirmed rotavirus infection in the first 6 months of life 
(asymptomatic or symptomatic stool infection, or a 3 fold increase in IgA titres). Children who had a 
repeat infection between 26 and 52 weeks (defined using stool or serology) were excluded. 87 children 
were identified who had a stool or serologically confirmed rotavirus infection in the first 26 weeks of 
life, and no evidence of re-infection between 26 and 52 weeks. Antibody decay was then calculated 
based on the log of the fold increase in titres between 26 and 52 weeks. The mean fold increase was 
estimated on log transformed titres, and then exponentiated.    
3.2.7.7 Mixture models for asymptomatic and symptomatic infection 
To gain further understanding of the IgA response to infection, an attempt was made to fit mixture 
models to the Vellore dataset for children between 6 and 26 weeks of life with known asymptomatic 
or symptomatic infections, defined as detectable rotavirus in surveillance or diarrhoeal stool samples. 
Only children with single infections during the time period were included. This analysis was under-
powered as very few children had isolated asymptomatic infections, even in the first 6 months of life.  
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3.2.8 Ethics 
Ethical approval for Vellore was obtained from the institutional review boards of Christian Medical 
College, Vellore; London School of Hygiene and Tropical Medicine, London; and Baylor College of 
Medicine, Houston. Ethical approval Ethical for Karonga was obtained from the National Health 
Sciences Research Committee in Malawi (protocol 490) and the London School of Hygiene and Tropical 
Medicine ethics committee (protocol 5345). 
3.3 Results 
A total of 452 newborns were enrolled into the Vellore birth cohort between 2002 and 2006 and follow 
up was completed in 373 infants. Households had a median size of five (range 2-11). Samples were 
available from the 373 infants who completed follow up(64). The Karonga birth cohort recruited 190 
infants between November 2008 and November 2010, 28% of whom (54) were exposed to HIV. 112 
infants had complete sets of three serum samples. Samples were chosen for anti-rotavirus IgA analysis 
if they contained more than 100µl of serum. After this selection process, 198 samples were available 
from 66 children(303).  
3.3.1 Descriptive analysis 
Serum IgA titres rose incrementally in both Vellore and Karonga, with significant rises in median IgA 
titres between time points (Fig. 3.4). 
 
Figure 3.4. Serum IgA titres over time in Vellore (A) and Karonga (B). Error bars represent median and 
IQR. P values represent sign-rank tests for paired medians. Panel (B) modified from a figure submitted 
as part of an MRes report for A Bennett 
115 
 
The proportion of children with anti-rotavirus IgA titres ≥20IU/ml was greater in Vellore than Karonga 
at 6 (15.43% vs 1.52%, chi-squared test p=0.002) and 26 (37.78% vs 13.64 %, chi-squared p<0.001) 
weeks of life, but there was no significant difference between the two populations at 52 weeks of life 
(61.13% vs 60.61%, chi squared p=0.937) (Fig. 3.5) 
 
Figure. 3.5. Proportion of infants with anti-rotavirus IgA titres ≥20IU/ml in Vellore and Karonga. P 
values represent chi-squared tests for difference in independent proportions.  
3.3.2 Patterns of rotavirus infection in first 3 years of life 
Mixture models fit to the Vellore data over 3 years showed an initial high frequency of rotavirus 
infection, with a prevalence of seroconversion of 0.41 (95% CI 0.27 – 0.56) between birth and 6 
months, which declined within each subsequent time interval (Fig 3.6 and Table 3.1). 
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Table 3.1. Parameter estimates from mixture models for rotavirus infection in Vellore and Karonga. 
 Mean 1* 
(‘uninfected’) 
SD* 1 Mean 2 
(‘infected’) 
SD 2 Mean prevalence of 
seroconversion** 
(95% CI) 
Incidence rate of 
rotavirus infectionϮ 
(95% CI) 
6 monthly time intervals 
Vellore 
0-26 weeks -2.44 2.68 3.97 1.86 0.41 (0.27-0.56) 1.05 (0.64-1.64) 
26-52 weeks 0.11 2.08 5.02 1.42 0.20 (0.08-0.40) 0.44 (0.17-1.02) 
52-78 weeks 0.26 1.84 4.69 1.77 0.18 (0.02-0.72) 0.39 (0.04-2.57) 
78-104 weeks -0.08 1.36 4.52 1.43 0.13 (0.02-0.54) 0.29 (0.04-1.57) 
104-130weeks -0.12 1.31 3.84 1.41 0.11 (0.02-0.47) 0.24 (0.04-1.29) 
130-156 weeks -0.17 1.69 5.14 1.36 0.05 (0.00-0.78) 0.10 (0.00-3.04) 
Karonga 
6-26 weeks 0.40 1.45 4.87 1.22 0.15 (0.04-0.44) 0.34 (0.08-1.17) 
26-52 weeks 0.08 1.31 4.48 1.35 0.50 (0.33-0.68) 1.41 (0.79-2.29) 
12 monthly time intervals 
Vellore       
0-52 weeks -0.35 2.62 4.62 1.53 0.55 (0.48-0.62) 0.80 (0.65-0.97) 
Karonga       
6-52 weeks -0.22 0.59 4.26 1.82 0.71 (0.42-0.90) 1.25 (0.54-2.28) 
Data from Vellore for 156 weeks, from Karonga for 52 weeks. *Where mean 1 and SD1 refer to mean and standard deviation 
(SD) for distribution 1 (uninfected), and mean 2 and SD2 to mean and standard deviation for distribution 2 (“infected”). 
**Mean prevalence and confidence intervals (CI) derived from bootstrap estimates Ϯ Incidence rate derived from mean 
prevalence using formula stated previously. Incidence rate in episodes per child year.  
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Figure 3.6 Mixture models showing positive (“infected”) and negative (“uninfected”) distributions for 
increment in log transformed anti-rotavirus IgA titres between 6 month time points in Vellore. Red 
lines indicate positive distributions and blue lines negative distributions. 
3.3.3 Comparison of patterns of rotavirus infection in first year of life between Vellore and Karonga 
Fitting mixture models to the Karonga data demonstrated that the incidence of rotavirus infection 
varied by time and between the two populations. Between 6 weeks and 26 weeks, the incidence of 
infection in Karonga was lower than that observed in Vellore with 0.34 episodes/child year (95% CI 
0.08-1.17) compared to 1.05 episodes/child year (95% CI 0.64-1.64) (Fig 3.7 and Table 3.1). In 
comparison, incidence was considerably higher in Karonga between 26 and 52 weeks than in Vellore 
(1.41 episodes/child year [0.79-2.29] vs 0.44 episodes/child year [0.17-1.02]) (Fig 3.7 and Table 3.1). 
There was no clear difference between the two populations when incidence was calculated between 
6 and 52 weeks (1.25 episodes per child year [0.54-2.28] in Karonga, versus 0.80 [0.65-0.97] in Vellore).  
Consequent to the high level of antibodies in the first six months of life, and a lower relative increase 
in titres in the second six months of life in Vellore, the mean difference between change in titres ([d2]-
[d1]) was significantly smaller in Vellore compared to Karonga (-0.35 in Vellore and 1.45 in Karonga, 
two sample t-test p=0.004).  
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Figure 3.7. Mixture models showing positive (“infected”) and negative (“uninfected”) distributions for 
increment in log transformed anti-rotavirus IgA titres for the first year of life in Karonga and Vellore. 
Red lines indicate positive distributions and blue lines negative distributions. 
Overall, estimates of incidence were comparable using the mixture models and the two alternative 
definitions of sero-conversion (Table 3.2). The notable exception was for estimating incidence 
between 6 and 26 weeks, when using fold increase resulted in a substantially higher estimate in 
Karonga (1.10 episodes/child year [95% CI 0.72-1.58]) than using mixture models or IgA titres >= 20 IU 
(0.34 episodes/child year [95% CI 0.08-1.17] and 0.29 episodes/child year [95% CI 0.11-0.50], 
respectively). Apart from this, all three methods showed higher incidence of seroconversion in Vellore 
compared to Karonga in the first 6 months of life, and higher incidence in Karonga compared to Vellore 
between 26 and 52 weeks. 
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Table 3.2. Prevalence of and incidence of rotavirus seroconversion between 0/6 and 26 weeks, 26 and 
52 and 0/6 and 52 weeks for Vellore and Karonga using mixture models, fold increase and IgA 
titres>=20IU.  
 Mixture model Fold increase IgA titres>=20IU 
 Prevalence* Incidence Ϯ Prevalence Incidence Ϯ Prevalence Incidence Ϯ 
0/6 weeks to 26 weeks 
Vellore 0.41              
(0.27-0.56) 
1.05           
(0.64-1.64) 
0.44            
(0.39-0.49) 
1.16     
(0.98-1.36) 
0.31             
(0.26-0.36) 
0.73         
(0.60-0.88) 
Karonga 0.15                     
(0.04-0.44) 
0.34          
(0.08-1.17) 
0.42             
(0.30-0.55) 
1.10     
(0.72-1.58) 
0.14            
(0.05-0.22) 
0.29        
(0.11-0.50) 
26 to 52 weeks 
Vellore 0.20              
(0.08-0.40) 
0.44             
(0.17-1.02) 
0.35             
(0.30-0.40) 
0.87        
(0.72-1.04) 
0.28           
(0.23-0.33) 
0.66         
(0.53-0.80) 
Karonga 0.50                     
(0.33-0.68) 
1.41           
(0.79-2.29) 
0.61            
(0.49-0.73) 
1.86        
(1.33-2.60) 
0.50             
(0.38-0.62) 
1.39           
(0.94-1.96) 
0/6 weeks to 52 weeks 
Vellore  0.55                      
(0.48-0.62) 
0.80           
(0.65-0.97) 
0.60            
(0.54-0.65) 
0.91        
(0.79-1.05) 
0.50             
(0.45-0.56) 
0.70          
(0.60-0.82) 
Karonga 0.71                     
(0.42-0.90) 
1.25              
(0.54-2.28) 
0.74            
(0.63-0.85) 
1.36      
(1.01-1.90) 
0.59             
(0.47-0.71) 
0.89          
(0.63-1.25) 
*Mean prevalence and confidence intervals (CI) derived from bootstrap estimates Ϯ Incidence rate derived from prevalence 
estimate using formula stated previously. Incidence rate in episodes per child year. 
 
 
 
 
 
 
 
 
 
 
 
120 
 
3.3.4 Anti-rotavirus IgA antibody decay 
Based on the log of fold increase in titre, anti-rotavirus IgA titres showed a relatively rapid decay with 
a mean fold increase of 0.09 fold/year (i.e. > 10X reduction in antibody titres) following an initial 
infection (Fig 3.8).  
 
Figure 3.8. Anti-rotavirus IgA decay rates. A) Log transformed titres at 0, 26 and 52 weeks for 87 
children included in IgA decay analysis. B) Fold increase in titres per year for the same children. Titres 
log transformed then exponentiated.  
 
3.3.5 Mixture models for asymptomatic and symptomatic infection 
Fitting mixture models to the Vellore dataset for children who had symptomatic compared to 
asymptomatic infection was limited by the sparse data for children with single asymptomatic 
infections. Despite this, prevalence of seroconversion appeared higher in children with symptomatic 
disease compared to asymptomatic infection (Fig. 3.9) 
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a)                                                                      b)  
 
Figure 3.9 Mixture models for children who had a) a single asymptomatic infection and b) a single 
symptomatic infection between 6 and 26 weeks of life.  
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3.4. Discussion 
It is crucial that we increase our understanding of patterns in force of infection for rotavirus in 
different populations as heterogeneity in incidence rates is one potential explanatory factor in the 
disparity in vaccine effects observed between HIC and low and middle income countries. These data 
presented demonstrate intriguing differences in the pattern of exposure to rotavirus infection in early 
life between populations in two distinct low and middle income countries, with children from Vellore 
infected with rotavirus at a younger age than children from Karonga, Malawi. Although the confidence 
limits for these estimates of prevalence and incidence are wide, the validity of these findings is 
corroborated in several ways including the consistency of the findings regardless of the definition of 
seroconversion; the estimate of annual incidence in the first year of life which is consistent with 
incidence estimates in other populations for the same age period(38); and a significant difference in 
mean titre increment from the first six to the second six months of life between populations.  
The incidence patterns described were broadly comparable for all 3 methods used to define 
seroconversion. The major exception was for prevalence of seroconversion defined by fold increase 
in the first six months of life in Karonga. Here, substantially more children were identified as having 
seroconverted using fold increase (42%) than either mixture models (15%) or a pre-defined cut-off 
(14%). One possible explanation for this is mathematic artefact, as a very small proportion of children 
had IgA titres ≥20 IU at the time of first sample in Karonga, making it easier to achieve a significant 
fold increase(299). This is corroborated by a sensitivity analysis where the value of two was added to 
each value (results not shown). The value of two was selected as it is half the lower limit of detection 
in the original assay(284). When the higher value was added to zeros there was a reduction in the rate 
of sero-conversion as defined by fold increase, and in the subsequent incidence estimate. It is 
reassuring that the use of a cut-off of 20IU provides similar estimates of the prevalence of 
seroconversion to the mixture models, and argues against any major misclassification of sero-status 
in previous rotavirus sero-response studies.   
The timing of peak incidence of seroconversion between populations, with an earlier peak in Vellore, 
suggests that force of rotavirus infection is greater in Vellore compared to Karonga. This is particularly 
intriguing because both are low income settings. LIC are typically associated with high force of 
rotavirus infection compared to HIC(144,210), which is likely to be a function of several different 
variables associated with poverty. These may include such factors as a high birth rate and 
consequently a larger pool of young children, thought to be crucial for introduction of rotavirus 
infection, in the community(245). Similarly over-crowding, with multiple people living and sleeping in 
the same space, is likely to play a role in propagating transmission(269), particularly if combined with 
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lack of reliable access to clean water and poor sanitation(307). Host factors may also play a role as it 
has been shown that repeated episodes of symptomatic rotavirus gastroenteritis may be required to 
provide protection in LIC, and given that symptomatic disease is thought to be the primary mediator 
of transmission, this could also contribute to high force of infection(38). Aside from factors relating to 
poverty, differences in climate or weather patterns such as humidity, differences in temperature, or 
flooding may also contribute(210,270,271,308).  
Variation in any of the factors listed above could potentially explain why the force of rotavirus 
infection in young children is greater in Vellore compared to Karonga, but it seems likely that the 
striking differences in population density plays a significant role, with Vellore an urban slum region 
with a population density of 17000/km2, in contrast to the rural Karonga district, which has a 
population density of approximately 264/km2(302,309). The potential role of population density is 
substantiated by a recent study from Dhaka, Bangladesh which reported rotavirus incidence rates in 
the densely populated core of the city of almost 3 times those observed in the less densely populated 
peripheries, or a rural region of Bangladesh(270). In terms of other potential contributing factors, the 
observed difference is unlikely to be explained by birth rate, which is higher in Karonga compared to 
Vellore (47/1000 person years in 2005 vs 18/1000 person years between 1995 and 2003 ), or by 
household size, the median of which is 5 for both populations. Climate is also similar between the 
populations and it thus seems unlikely to be a major contributor, whilst acknowledging that there may 
be subtle differences that we do not have capacity to account for in this analysis. It is intriguing that 
there is a significant proportion of children who have detectable IgA at birth in Vellore, with 
approximately 15% having IgA titres ≥20 IU. Transplacental antibodies are typically IgG, so would not 
explain the presence of significant levels of IgA. This may reflect early exposure to rotavirus. A study 
from a neonatal unit in Vellore reported that approximately 44% of neonates were infected with 
rotavirus, which could be sufficient to account for the antibody response(125). It is also possible that 
it could reflect non-specificity of the assay, though it seems unlikely that that would result in a 
differential result between Vellore and Karonga  
Historically, comparing anti-rotavirus IgA titres between populations and between studies has been 
problematic because of variation in sampling times, assays used and interpretation of results. 
However over the last decade anti-rotavirus IgA assays have been conducted in a more standardised 
manner as part of vaccine efficacy and immunogenicity studies, meaning that comparisons of results 
between populations are now much easier(298). The banks of data describing IgA titres in young 
infants from different settings resulting from these studies offer a potentially valuable data source to 
increase our understanding of patterns of exposure in different regions. However, traditional methods 
of defining seroconversion such as fold increase or the use of cut-offs can be problematic. Fold 
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increase can under-estimate new infections in those with high levels of pre-existing antibody titre, or 
over-estimate infections in those with very low level titres at the time of initial sampling(299). The use 
of cut-offs is also prone to misclassification bias, particularly when the antibody titres of potentially 
sero-positive or sero-negative individuals overlap. To maintain specificity, cut-offs are often set at a 
relatively high level, and as a result some truly sero-positive individuals will be misclassified as sero-
negative, potentially underestimating the true sero-prevalence of an infection(300).  
Mixture models offer potential advantages over these methods as they provide a visually intuitive 
interpretation of the data, and evaluate the data probabilistically, (i.e. estimate the probability of each 
sample falling into the positive or negative distribution), thus avoiding the major assumption of an 
absolute cut off. Boot-strapping can be used to generate confidence limits and estimate uncertainty. 
With our models, the mean of the two distributions is reasonably constant across models for Vellore 
and Karonga respectively, increasing confidence that these models would be reproducible and 
consistent across different datasets.  
Improved understanding of patterns of force of infection in LIC could inform evaluations of vaccine 
effects, and strategies to improve vaccine immunogenicity and performance. In terms of evaluation 
of vaccine effects, sero-surveys could be used to estimate population level incidence pre and post 
vaccine introduction in unvaccinated groups. This would contribute to measurement of total vaccine 
impact, and identification of indirect effects in age groups not eligible for vaccination. In terms of 
strategies to improve vaccine immunogenicity, if high force of infection leading to high maternal 
antibodies lowers immunogenicity, an additional dose of vaccine or delayed vaccine schedule may 
improve vaccine immune response(290). A recent randomised controlled trial (RCT) in Ghana 
compared the immunogenicity of three doses of RV1 at 6, 10 and 14 weeks to two doses at either 6 
and 10 or 10 and 14 weeks, and found that a significantly greater proportion of infants seroconverted 
(IgA titres≥20 IU) in the three dose group compared to two doses at 6 and 10 weeks(310). In terms of 
improving vaccine performance, identifying settings such as Vellore with a high burden of very early 
disease could identify populations where a neonatal dose of vaccine may improve overall vaccine 
effectiveness. A clinical trial of two doses of RotaShield in Ghana, the first dose given in the neonatal 
period, demonstrated encouraging vaccine efficacy against rotavirus disease of all severity of 
63.1%(311). In addition, the candidate vaccine RV3-BB, currently undergoing immunogenicity trials, is 
based on a neonatal strain and incorporates a neonatal dose(131).  
3.4.1 Limitations 
Serum IgA is probably the best marker of recent rotavirus infection currently available, but it is not a 
perfect correlate of protection(66). While IgA has been shown to increase in response to rotavirus 
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infection and to correlate with protection against severe disease in several settings(63,64), there is 
some evidence that it is a less good correlate of vaccine take in low income settings(96), and it has not 
been possible to define an absolute cut-off to define protection against rotavirus disease(64). In 
addition, using serology alone to estimate rotavirus incidence will undoubtedly provide an under-
estimate, as it is known from cohort studies in infants that around one quarter of infections in children 
occur without a corresponding rise in IgA titre(38,62). The overall patterns of infection across 
populations should be comparable, but given that IgA response to rotavirus vaccine is reduced in LIC 
compared to HIC(298), and that complete protection against severe rotavirus disease seems to require 
more repeated episodes of infection in some LIC compared to HIC(38), there may be population level 
differences in immune response to natural rotavirus infection that are not yet fully understood. 
Furthermore, given the limited evidence derived from this study when comparing IgA responses to 
symptomatic vs asymptomatic infection, it appears that a substantial proportion of those with 
asymptomatic infection may not seroconvert. It is therefore possible that use of sero-response could 
underestimate the rate of asymptomatic infection.  
It is also possible that sero-response only captures first infection; thus subsequent infections may not 
boost IgA levels sufficiently beyond baseline for re-infection to be identified. We however observed a 
rapid decay in IgA titres (~10 fold per year) following an initial infection, which should allow detection 
of some episodes of reinfection, particularly those with a wider time interval between infections. This 
is consistent with findings described by Bernstein et al, where IgA titres in serum declined by 30% 
within a month of infection, and to a small fraction of their maximal response by a year(312). There 
are also some logistical challenges to the use of serological data, in that multiple serum samples from 
young children are required. While there are several existing datasets which could be utilised to 
explore force of infection using IgA titres prior to vaccine introduction, prospective studies on vaccine 
impact would likely require large scale sero-surveys which can be difficult to implement, and 
particularly difficult to implement in LIC where there can be social and cultural barriers to blood 
collection.  
This analysis was based on existing data, and included a small number of children, particularly from 
Karonga, and it is likely that this contributes to wide confidence bounds around prevalence and 
incidence estimates, although the differences in exposure patterns remain striking. We do not possess 
any data on symptoms or viral shedding in stool from the Karonga cohort, should we have wished to 
investigate the link between IgA response and clinical disease more closely. In addition the timing of 
collection of the first serum sample differed by site (6 weeks in Karonga vs birth in Vellore). This could 
be important given the frequency of neonatal infection in some populations(125) and the variation in 
timings could potentially underestimate the difference in proportion of children with detectable IgA 
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at the time of first sample in each setting, and potentially influence incidence estimates. A further 
difference between the two cohorts is the prevalence of HIV exposure in Karonga, which was 28% of 
infants. Data on HIV exposure in Vellore were not available, but is likely to be much lower. However, 
as HIV infected infants have comparable IgA responses to those of HIV uninfected infants following 
rotavirus vaccine and rotavirus does not appear to be more frequent in HIV infected 
children(260,313,314), it seems unlikely that HIV exposure status should substantially influence IgA 
responses to natural rotavirus infection.  
3.4.2 Implications, conclusions and further work  
Whilst this study does not definitively answer any questions, it utilises existing data to act as a “proof 
of concept”, and to offer an improvement on existing traditional methods to interpret rotavirus 
serology data in order to define incidence. In doing so, it highlights the remarkable heterogeneities in 
rotavirus transmission which can occur in two different populations, even with relatively similar 
socioeconomic situations.  
This work identifies several areas for further study. Detailed examination of host factors in Vellore and 
Karonga may offer some insight into the discrepancies in force of infection, particularly if this is at 
least partly related to immune response in infants. More data on climate and any effect of climate on 
force of infection in the two populations would also be useful. In addition it would be helpful to 
understand the relationship between asymptomatic infection and IgA response in more detail, as this 
would contribute to understanding the role of asymptomatic infection in maintaining protection 
against rotavirus, and the ability of sero-surveys to account for asymptomatic infection in estimations 
of incidence.  
Unfortunately data on globally licensed rotavirus vaccine performance in these two specific 
populations are lacking; vaccine trials in Vellore have tended to focus on locally developed or novel 
candidate vaccines(130), and the vaccine trials in Malawi were conducted in Blanytre, an urban setting 
with very different population characteristics compared to rural Karonga. Future studies could 
develop our understanding of the interplay between force of infection and vaccine performance by 
relating pre-vaccine incidence data to vaccine efficacy and effectiveness at a local level. This should 
be possible in some sites where vaccine trials have been embedded within on-going surveillance 
systems, particularly if historic data could be used. For the most part, these data are only available for 
infants in the first 6 months of life, but it would still offer an opportunity to compare incidence rates 
and vaccine efficacy between locations. If force of infection plays a role in reduced vaccine 
effectiveness, it is possible that effectiveness will improve over time, as force of infection declines 
with vaccine introduction. The methods outlined in this study then could potentially provide a 
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mechanism to monitor changes in population incidence and relate this to vaccine performance, 
though this would need to be planned at or near to the time of vaccine implementation.  
Understanding rotavirus transmission patterns in different populations is extremely important in both 
understanding disparities in vaccine performance in different settings, and in considering strategies 
to address this. Accurate estimates of population level incidence are challenging to obtain, because a 
large proportion of rotavirus infection and disease occurs at the community level, and the intensive 
studies required to delineate these are costly, logistically challenging, and place a considerable burden 
on families. In light of this, using sero-prevalence to estimate incidence, particularly when existing 
data can be utilised, is potentially both efficient and cost effective. The mixture models developed and 
applied in this study may offer an improvement on standard methods of analysing serological data in 
order to define incidence.  
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Chapter 4. Direct and indirect effects of rotavirus vaccination on 
rotavirus hospitalisations among children in Malawi four years after 
programmatic introduction 
 
4.1 Introduction 
There is now good evidence of rotavirus vaccine effectiveness and impact from high and 
middle income countries, which demonstrate vaccine effectiveness similar to pre-
licensure clinical trial efficacy (>85%)(315). Early data on vaccine effectiveness from LIC 
are encouraging compared to efficacy estimates, with vaccine effectiveness estimates 
ranging from 56% to 75%(186–188), but are sub-optimal compared to high income 
settings. In this context characterising the ongoing burden of disease and evaluation of 
the overall population level impact of vaccination programmes in LICs is essential. The 
previous chapter explored techniques for estimating population level incidence, which is 
important for understanding discrepancies in vaccine performance between populations, 
evaluating vaccine impact, and informing interventions. This chapter will focus on 
describing the residual burden of rotavirus disease in a low-income, Malawian population 
4 years after vaccine introduction, and investigating for evidence of rotavirus vaccine 
indirect effects. 
Halloran, Longini and Struchiner(212,316,317) describe how vaccine effects can be 
divided into 4 components or categories based on different combinations of direct and 
indirect effects, and define study designs which allow the evaluation of each of these. The 
four components are defined as firstly the direct effect of the vaccine on the vaccinated 
individual; secondly the indirect effect of programmatic vaccine introduction on 
unvaccinated members of the community; thirdly the total effect of the vaccine on a 
vaccinated individual which is a combination of both direct and community level indirect 
effect; and finally the overall effect of the vaccination programme which is a population 
level weighted average of indirect effects in unvaccinated individuals and total effects in 
vaccinated individuals(317) (Fig 4.1), where indirect effects are defined as reduction in 
disease burden due to changes in transmission resulting from vaccination.  
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Figure 4.1 Types of vaccine effectiveness as described by Halloran et al(212). A vaccinated 
population will still have some individuals within the population who are unvaccinated 
because 100% vaccination coverage is generally never achieved. VE, vaccine effectiveness. 
Reproduced from Panozzo et al. Direct, Indirect, Total, and Overall Effectiveness of the 
Rotavirus Vaccines for the Prevention of Gastroenteritis Hospitalizations in Privately 
Insured US Children, 2007–2010. Am J Epidemiol. 2014;179(7):895-909(226), by 
permission of Oxford University Press.  
 
Evaluation of rotavirus vaccine indirect effects is important, as infants are often reservoirs 
of infection within a community, and crucial for propagating transmission to other 
vulnerable members of a population. Infant vaccination programmes against other 
infectious diseases such as that caused by Haemophilus influenzae and Streptococcus 
pneumoniae(318,319) have generated substantial indirect effects which have had a 
significant, and sometimes unexpected, impact on the overall burden of disease in a 
population. Incorporating indirect effects of vaccination into cost effectiveness models 
and considering them when evaluating overall vaccine impact can tip the balance in terms 
of cost-effectiveness, and can help determine whether vaccines are effective enough to 
reduce transmission and eliminate disease. In a modelling study of the cost effectiveness 
of rotavirus vaccine in European settings, it was predicted that 59% of cost savings would 
be attributable to indirect effects of rotavirus vaccine(320), and a post-implementation 
cost-effectiveness study in Australia found that the national rotavirus vaccination 
programme was likely to be cost-saving, at least in part due to unanticipated indirect 
effects to unvaccinated individuals(229). This is a particularly crucial issue in LIC, as 
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although GAVI Alliance support has allowed many LIC to successfully introduce rotavirus 
vaccination, in the long-term immunisation programmes must be locally funded. Using an 
example from a LIC for a different enteric pathogen, consideration of indirect effects in 
the evaluation of cholera vaccine led to a conclusion that programmatic cholera 
vaccination was cost effective, and also confirmed vaccination as a valuable public health 
measure in the reduction of the cholera burden in endemic settings(246,247).  
In view of this, consideration of vaccine indirect effects is gaining increasing prominence 
as an important component of evaluation of overall vaccine impact(321). Ideally, such 
studies would be planned and implemented as part of clinical trials prior to vaccine 
introduction, for example cluster randomised trials which compare risk of disease 
between unvaccinated individuals in vaccinated clusters and unvaccinated individuals in 
control clusters unexposed to vaccine(322), or stepped-wedge designs where vaccine is 
sequentially introduced into different regions with the as-yet unvaccinated region acting 
as a control arm(323). Randomised prospective studies can minimise the bias and 
confounding which is challenging to control for in observational studies, and allow 
evaluation of separate components of vaccine effects through comparisons between 
different groups within and across clusters(212) (Fig 7.1). However such studies are 
expensive and logistically challenging to conduct, and for already licensed vaccines with a 
documented public health benefit such as rotavirus, difficult to justify both ethically and 
financially. For the most part, we must therefore rely on observational studies to evaluate 
rotavirus vaccine indirect effects.  
The majority of studies which have described rotavirus vaccine indirect effects to date 
have used surveillance or ecological level data to compare the frequency of rotavirus in 
unvaccinated groups following vaccine introduction with that observed at baseline (prior 
to vaccine introduction)(234,235). In addition some studies have estimated the expected 
reduction in rotavirus infection or disease based on vaccine trial efficacy and vaccine 
coverage and compared this to observed declines following vaccine implementation, with 
any additional reduction assumed to be attributable to the indirect effect of the 
vaccine(219). One study compared the risk of rotavirus disease in household contacts of 
vaccinated children with the risk of disease in household contacts of unvaccinated 
children(225), and there are a small number of prospective studies specifically designed 
to evaluate indirect effects in individual groups(224,226).  
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There is increasing evidence of rotavirus vaccine indirect effects in infants, children and 
adults from a variety of high income settings including Europe, Australia, and the USA. 
Data from middle income countries are also beginning to emerge with evidence of greater 
than expected reductions in rotavirus disease burden, or reductions in unvaccinated 
groups described in studies from central Europe, Latin America and Thailand, although 
intriguingly no evidence of a significant indirect effect was observed in Ghana or South 
Africa(185,201), middle income countries in sub-Saharan Africa. Currently the only data 
on rotavirus indirect effects from a LIC is Rwanda, where reductions in rotavirus 
hospitalisations were seen in all children under 5 years, including those age groups not 
age-eligible for vaccination(202). These findings are summarised in detail in Chapter 1, 
section 1.6.2, page 63.  
Obtaining direct data from low income settings is crucial both because these are the 
settings where indirect effects could make a substantial contribution to overall vaccine 
effects and therefore the economic viability of long term vaccination programmes, and 
because differences in the population between low and high income settings mean that 
data cannot be extrapolated from one to the other. LICs differ from HIC and MIC in terms 
of population structures and density, water and sanitation provision, and prevalence of 
underlying co-morbidities such as malnutrition and HIV. These factors may influence the 
incidence and transmission epidemiology of rotavirus infection and disease, and may 
mean that indirect protection differs from that documented from HIC(215).  
This study aimed to describe rotavirus epidemiology and investigate the presence and 
extent of rotavirus vaccine indirect effects 4 years after programmatic vaccine 
introduction in Blantyre, Malawi utilising a cohort of children recruited into an existing 
surveillance platform. Firstly, the overall change in prevalence of rotavirus in all children 
hospitalised with AGE since vaccine introduction, regardless of vaccine status, was 
described. Direct VE estimates were then updated using a case-control design nested 
within the surveillance platform. Following this rotavirus prevalence in unvaccinated 
children pre- and post- vaccine introduction was compared, and finally the observed 
reduction in incidence of rotavirus hospitalisation was compared to that expected based 
on vaccine coverage and trial efficacy estimates to obtain an estimated magnitude of 
rotavirus vaccine indirect effects in this setting.  
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4.2 Methods 
4.2.1 Objectives 
1. Describe change in rotavirus prevalence in admitted children with AGE since 
vaccine introduction 
2. Estimate age stratified vaccine effectiveness for rotavirus gastroenteritis 
3. Describe change in rotavirus prevalence in unvaccinated children with AGE 
since vaccine introduction 
4. Compare observed with expected reductions in admitted rotavirus AGE 
incidence following vaccine introduction 
4.2.2 Study design 
Data for this study arose from a prospective diarrhoeal surveillance platform with a nested 
case control study for evaluation of rotavirus vaccine effectiveness. 
4.2.3 Study site  
This study was conducted at QECH, Blantyre, Malawi. Surveillance for rotavirus 
gastroenteritis has been conducted at QECH since 1997, but enhanced surveillance was 
commenced in January 2012 in advance of planned national introduction of rotavirus 
vaccine. This analysis includes data from this period until the end of June 2016.  
4.2.4 Study population 
This study recruited rotavirus vaccine age eligible children presenting to QECH with a 
diagnosis of acute gastroenteritis, defined as ≥3 loose stools in a 24 time period.  
4.2.5 Study procedures  
The surveillance platform has been described in detail in the literature(116,186). Children 
who present to QECH with acute gastroenteritis (AGE) during routine clinical hours were 
identified by research nurses, and enrolled following informed consent. Surveillance 
included children admitted to the main paediatric ward (special care), the nursery 
(children under 6 months of age), and the malnutrition unit, as well as children treated as 
outpatients in the accident and emergency department. Following enrolment, detailed 
demographic and clinical data were recorded, anthropometric assessment undertaken 
and a bulk stool sample collected. HIV testing was conducted according to Ministry of 
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Health national guidance(278). Vaccine status was obtained from government-issued 
family-held records (Health Passport). Disease severity was defined using the 20-point 
Vesikari score(324), where a score of ≥11 indicates severe disease. HIV infection was 
defined based on a positive rapid test (over 12 months of age), or positive HIV DNA PCR 
(under 12 months of age). HIV exposure was defined as a positive maternal HIV rapid test. 
Nutritional status was assessed using WHO standards, where severe acute malnutrition 
(SAM) was defined as any one of weight for height Z score (WHZ)<-3 SD from WHO 
standard, mid-upper-arm circumference (MUAC)<115mm, or nutritional oedema(325).  
4.2.6 Laboratory methods.  
Stool samples were processed on arrival in the laboratory, and stored as 10% suspension 
in PBS at 4-7 degrees Celsius before batch testing weekly for rotavirus antigen using 
enzyme immunoassay (EIA, Rotaclone, Meridian Bioscience, Cincinnati, Ohio). Following 
testing samples were stored at -80oC . HIV testing of mothers and children was conducted 
using the government programme of two sequential EIA rapid tests (Determine HIV-1/2 
[Abbott Laboratories, USA] and Uni-Gold HIV [Trinity Biotech PLC, Ireland]), or HIV DNA 
PCR for infants under one year of age(278).  
4.2.7 Statistical analysis  
4.2.7.1 Descriptive analysis 
Continuous variables were summarised using mean and standard deviation (SD) for 
normally distributed data, or median and interquartile range otherwise. Differences in 
independent categorical covariates were assessed using Chi squared tests. Student’s t or 
rank sum tests were used to compare independent means or medians respectively. 
Vaccine coverage was described using those children with AGE who tested negative for 
rotavirus.  
4.2.7.2 Prevalence changes over time of EIA positive rotavirus  
As QECH is the only government facility which admits children in the district GE admissions 
for rotavirus were analysed over time as a prospective cohort. Poisson regression models 
were used with robust standard errors(326) to evaluate year-on-year differences in 
rotavirus prevalence in hospitalised gastroenteritis, with the year preceding introduction 
as baseline. Relative risk (RR) was preferred to odds ratios (OR) due to the tendency of OR 
to overestimate effect size when outcomes are not rare. Variables evaluated as potential 
confounders were age, household size, month of admission, HIV infection, HIV exposure 
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and presence of severe acute malnutrition. Univariate analysis of potential confounding 
variables was initially conducted by constructing two by two tables and using chi-squared 
tests for categorical variables, and Mantzel-Haensel odds ratios for continuous variables. 
Potential confounders were then tested in the Poisson model, with comparison between 
models conducted using Akaike Information Criterion (AIC). No significant confounders of 
the relationship between time since vaccine and RR of rotavirus positive gastroenteritis 
were identified, however models were adjusted empirically for age and month of 
presentation, and analysis restricted to the first 6 months (January to June) of each year 
for consistency.  
4.2.7.3 Time series analysis  
Time series analysis was used to describe trend and seasonality in the prevalence of 
rotavirus in hospitalised diarrhoeal cases over time. Mean monthly proportion of rotavirus 
in stools was defined by collapsing the dataset against number of diarrhoeal stools sent 
per month and number of rotavirus positive cases per month. A 5-month locally weighted 
smoother (defined as (1/8)*[1*x(t-2) + 2*x(t-1) + 2*x(t) + 2*x(t+1) + 1*x(t+2)]) was applied 
to this value to define seasonality and a 13-month locally weighted smoother (defined as 
(1/24)*[1*x(t-6) + 2*x(t-5) + 2*x(t-4) + 2*x(t-3) + 2*x(t-2) + 2*x(t-1) + 2*x(t) + 2*x(t+1) + 
2*x(t+2) + 2*x(t+3) +2*x(t+4) + 2*x(t+5) +1*x(t+6)], where x(t)= percentage rotavirus-
positive stools per month) was applied to the same to define secular trend. A linear model 
was then used to assess trend in rotavirus prevalence over time.  
4.2.7.4 Vaccine effectiveness 
Using a nested case-control study design, unconditional logistic regression was used to 
estimate percentage vaccine effectiveness (VE) using (1-OR*100) for rotavirus vaccine 
(using 2 doses of vaccine vs 0 doses) among rotavirus positive gastroenteritis cases vs test-
negative gastroenteritis controls. VE was adjusted for age, and for secular and seasonal 
fluctuations using year and month of admission, consistent with previous VE estimates 
from our group. Only children with documented vaccine status who were age eligible for 
both doses of vaccine (i.e. who were born on or after the 29th September 2012) were 
included. As 15% of children did not have hand held health passports, a sensitivity analysis 
was performed on children with undocumented vaccine status.  
 
 
135 
 
4.2.7.5 Estimating indirect vaccine effects  
Firstly, Poisson regression models with robust standard errors were used to evaluate any 
change in rotavirus prevalence in unvaccinated admitted infants (<12 months of age) and 
children (12-59 months of age) with gastroenteritis pre and post vaccine introduction. All 
available data were included in this. Secondly the observed reduction in incidence of 
hospitalised rotavirus gastroenteritis was calculated year by year following programmatic 
vaccine introduction, and compared to the estimated expected reduction in incidence 
(expected direct effect), making the assumption that any additional reduction in observed 
incidence was due to rotavirus vaccine indirect effects(240). As above, because enhanced 
surveillance data were not available for a full calendar year prior to rotavirus vaccine 
introduction, incidence estimates were calculated for the first 6 months of each year to 
minimise risk of any seasonal bias.  
For this analysis incidence was defined as case numbers of admitted rotavirus 
gastroenteritis per 100,000 age stratified population per 6 month time interval using 
projected population estimates for Blantyre city from the National Statistics Office of 
Malawi. Data on the proportion of infants were not available for Blantyre city, so this was 
assumed to be equivalent to that reported at a national level. The expected direct effect 
was calculated by multiplying vaccine coverage by vaccine efficacy, using a value of 
vaccine efficacy of 49.4% for severe disease in infants, 34.5% for all rotavirus 
gastroenteritis in infants and 17.6% for children with severe disease, and where both 
vaccine coverage and efficacy were expressed as proportions(146,327). There were no 
efficacy estimates published for disease of all severity in children so expected effects were 
not calculated for this group.  
The observed effect was calculated by comparing annual post-vaccination incidence from 
January to June to incidence for January to June 2012 (prior to vaccine introduction) using: 
(Pre-vaccine incidence – post-vaccine incidence)/pre-vaccine incidence*100.  
The indirect effect was then estimated by subtracting the calculated expected effect from 
the observed effect(240).  
To investigate for secular trends in diarrhoeal admissions to QECH, the incidence rate of 
hospitalised test-negative gastroenteritis was estimated. The denominators above were 
used to estimate child years at risk/100,000 population by dividing the total number of 
days at risk by 365, then multiplying this by the population denominator /100,000. For the 
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pre-vaccine period the population estimate for 2012 was used, and for the post vaccine 
period the estimated population at the post-vaccination midpoint was used (September 
2014).  
Throughout, analyses were restricted to children with stool samples collected. With the 
exception of VE estimates, all analyses were restricted to admitted children. For 
assessment of vaccine indirect effects children up to 59 months of age were included 
because of the potential impact of indirect effects in this group, however for the 
remainder of the analysis children were categorised into <12 month or 12-23 month age 
groups.  
4.2.8 Ethics Ethical approval was obtained from the National Health Sciences Research 
Committee, Lilongwe, Malawi (867), and by the University of Liverpool Research Ethics 
Committee (000490).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
137 
 
4.3 Results 
Stool samples were collected from 2320 children (median age 10.68 months, interquartile 
range [IQR] 7.72, 15.29) between 1st January 2012 and 30 June 2016. 1318 infants were 
eligible for both doses of rotavirus vaccine, and 1130 had documented evidence of vaccine 
status. Characteristics of the population are shown in Table 4.1. High levels of vaccine 
coverage were reached within 6 months of vaccine introduction (Fig. 4.2).  
 
Figure 4.2 RV vaccine coverage in vaccine age eligible rotavirus test negative children 
presenting to QECH with AGE.  
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Table 4.1. Characteristics of study population 
 
*Weight corrected by adding 10% to weights for those with severe disease to account for 
dehydration **in those vaccine age-eligible with health record confirmation. ϮHIV infected 
is defined as a positive HIV rapid test over 12 months of age, or a positive HIV DNA PCR 
result. HIV exposed is defined as a positive maternal HIV rapid test.  
4.3.1 Overall decline in rotavirus prevalence 
The relative risk of rotavirus being detected among children admitted to QECH with 
diarrhoeal disease has consistently declined compared to the pre-vaccine baseline (Table 
4.2 and Fig. 4.3A). Despite this, over 25% of all gastroenteritis admissions remain rotavirus 
positive (Table 4.2). This remained true when yearly time intervals following vaccine 
introduction were used, with 61/234 (26%) gastroenteritis stools positive for rotavirus 
from November 2015 to June 2016 (Table A2, Appendix, page 260).  
 
 
 
 
 
 
Characteristic  Denominator 
Male (n, %) 1339 (57.77) 2318 
Age in months (median and IQR) 10.68 (7.72, 15.29) 2320 
Weight for height Z score (WHZ)* 
(mean and SD) 
-0.92 (1.88)         2292 
Severe acute malnutrition (n, %)* 413 (18.05) 2288 
RV coverage** (n, %) 
0 doses 43 (3.81) 1130 
1 dose 60 (5.31) 1130 
2 doses 1027 (90.88) 1130 
HIVϮ 
Infected (n, %) 71 (4.03) 1761 
Exposed (n, %) 426 (18.80) 2266 
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Table 4.2. Relative risk of rotavirus detection in children admitted to QECH with 
gastroenteritis 
 RV** negative RV positive Total  RR (95% CIϮ)* 
Time period     
Pre-vaccine       
(Jan’12- Jun’12) 
110 (56.70) 84 (43.30) 194  1 (Ref) 
Jan’13- Jun’13 185 (58.18) 133 (41.82) 318  0.95 (0.78 -1.16) 
Jan’14- Jun’14 177 (69.96) 76 (30.04) 253  0.77 (0.61 -0.98) 
Jan’15- Jun’15 219 (75.26) 72 (24.74) 291  0.60 (0.46-0.77) 
Jan ’16- Jun’16 132 (72.13) 51 (27.87) 183 0.74 (0.57-0.98) 
Total 823 (66.42) 416 (33.58) 1239  
*adjusted for age in months and month at admission. Relative risk for rotavirus 
gastroenteritis vs test-negative gastroenteritis Ϯ95% confidence interval **Rotavirus (RV) 
 
Following vaccine introduction, the median age of cases has increased significantly from 
9.48 months (IQR 7.00, 13.54) prior to vaccine introduction, to 10.86 months (IQR 7.95, 
15.41) months (rank sum test p<0.001). The adjusted relative risk of rotavirus positivity 
among infants hospitalised with gastroenteritis in the first 6 months of the year has 
decreased from 69/139 [49.64%] to 197/607 [32.45%] since vaccine introduction 
(adjusted RR 0.67 [95% CI 0.55, 0.82] p<0.001).  
This effect is smaller in children aged 12-23 months, where the relative risk pre- and post- 
introduction respectively was 15/37 (40.54%) and 122/352 (34.66%) (adjusted RR 0.85 
[95% CI 0.57, 1.28] p=0.440) (Fig. 4.3A). The proportion of admitted rotavirus positive 
cases aged 12-23 months increased from 15/84 (17.86%) in the January to June period 
prior to vaccine introduction to 122/319 (38.24%) in the same months subsequent to 
vaccine introduction (chi squared p<0.001).  
Five month and 13 month smoothers provided a good fit to the seasonal and secular 
trends in proportion of rotavirus positive stools over time (Fig. 4.3B). Clear seasonality in 
rotavirus prevalence is demonstrated, with some blunting of this seasonal picture 
following vaccine introduction (Fig. 4.3A&B). Linear regression showed a significant 
negative trend in prevalence of rotavirus over time in infants (regression coefficient         -
0.36 [95% CI -0.46, -0.25] P<0.001) and in children aged 12 to 23 months of age (regression 
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coefficient -0.43 [95% CI -0.51, -0.36] p<0.001), where the regression coefficient 
represents the percentage change in rotavirus positivity per month. 
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B.  
 
Figure 4.3 A Monthly diarrhoeal and rotavirus positive admissions to QECH over time, with 
secular and seasonal trends in rotavirus prevalence B. Fit of smoother to raw data for 
monthly rotavirus prevalence 
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4.3.2 Vaccine effectiveness estimates 
The adjusted VE for two doses of vaccine, across all ages and disease severity was 61.89% 
(95% CI 28.04%, 79.82%) (Table.4.3). VE against severe disease among children <12 
months of age was 85.94% (95% CI 58.64%, 95.22%). VE against severe disease in the 12-
23 month age group was 20.40% (95% CI -412.74%, 87.64%). Results were similar when 
analysis was limited to passport confirmed vaccine status or when undocumented vaccine 
status was included. Reported results are for passport confirmed vaccine status.  
Table 4.3. Vaccine effectiveness estimates 
 N (Rotavirus 
positive 2 dose 
RV1 [%])** 
(N Rotavirus 
positive 0 dose 
RV1 [%])** 
Vaccine Effectiveness 
(95% CI) 
P value 
Adjusted*  
2 doses 275/1019 (26.99) 20/43 (46.51) 61.89 (28.04-79.82) 0.003 
Disease severity* (all ages) 
Severe 237/754 (31.43) 15/23 (65.22) 78.95 (48.25-91.44) 0.001 
Mild/mod 36/249 (14.46) 4/19 (21.05) 14.20 (-193.39-74.90) 0.807 
By age* (all severity) 
<12 m 190/696 (27.30) 16/29 (55.17) 74.88 (44.59 -88.61) 0.001 
12-23m 78/285 (27.37) 4/13 (30.77) 31.69 (-139.03-80.48) 0.551 
By age* (severe disease)  
<12m 160/521 (30.71) 13/18 (72.22) 85.94 (58.64-95.22) <0.001 
12-23 71/208 (34.13) 2/5 (40.00) 20.40 (-412.74-87.64) 0.810 
*Adjusted for age, and year and month of presentation. All are two-dose estimates. 
**Number of rotavirus positive cases; the denominator is all gastroenteritis cases with 
stool sample collected. RV1=monovalent rotavirus vaccine 
 
4.3.3 Indirect vaccine effects 
Among unvaccinated infants with gastroenteritis, rotavirus prevalence declined from 
117/221 (52.94%) in the 10 months prior to vaccine introduction to 65/184 (35.33%) in 
the 14 months following vaccine introduction, (adjusted RR 0.70 [95% CI 0.55, 0.88] 
p=0.003) (Fig 4.4A). Linear regression showed a significant negative trend in prevalence 
of rotavirus over time (regression coefficient -0.73 [95% CI -0.86, -0.60] P<0.001). In 
unvaccinated children 12-59 months of age with severe disease, there was no evidence of 
a decline in the prevalence of rotavirus following vaccine introduction, with 26/84 
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(30.95%) rotavirus positive pre-vaccine introduction and 70/193 (36.27%) rotavirus 
positive after introduction, RR 1.14 (95% CI 0.79, 1.63), and no evidence of a significant 
decline on linear regression of trend (regression co-efficient 0.07, 95% confidence interval 
-0.22 to 0.36, p=0.634). This analysis was truncated at 24 months from the start of 
surveillance because the vast majority of infants after this time point were vaccinated. 
This truncation limited the ability to describe rotavirus seasonality in unvaccinated 
children pre- and post-vaccine introduction, but the 5 month (seasonal) and 13 month 
(secular) smoothers provided a good fit to the data (Fig 4.4 B) 
Comparing the observed against expected reduction in incidence showed a difference of 
between 9 and 24% in admitted infants with rotavirus gastroenteritis of any severity 
(Table 4.4). Restricting to infants with severe rotavirus gastroenteritis, no difference was 
seen. There was also no evidence of an indirect effect demonstrated on comparison of 
observed vs expected reductions in incidence in children aged 12-59 months (Table 4.4) 
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Table 4.4. Comparison of expected and observed vaccine effects by year since vaccine 
introduction 
 Incidence* RV coverage** 
(%) 
Expected 
effect (%) 
Observed 
effect (%) 
Difference in 
observed effect (%) 
<12m severe RV GE 
Jan ’12- Jun’12Ϯ 149 - - - - 
Jan ’13- Jun’13 194 29.46 14.56 -30.09 -44.64 
Jan ’14- Jun’14 104 92.31 45.60 30.28 -15.31 
Jan ’15- Jun’15 117 94.12 46.49 21.72 -24.77 
Jan ’16- Jun’16 99 94.29 46.58 33.62 -12.95 
All post vaccine 129 77.48 38.11 13.89 -24.23 
<12m all RV GE      
Jan ’12- Jun’12 Ϯ 234 - - - - 
Jan ’13- Jun’13 256 29.41 10.21 -9.22 -19.43 
Jan ’14- Jun’14 139 90.08 31.26 40.73 9.47 
Jan ’15- Jun’15 123 94.32 32.73 47.45 14.73 
Jan ’16- Jun’16 102 92.31 32.03 56.39 24.13 
All post vaccine 149 73.16 25.39 33.84 08.45 
12-60 m severe RV GE 
Jan ’12- Jun’12 Ϯ 13 - - - - 
Jan ’13- Jun’13 Ϯ Ϯ 58 - - - - 
Jan ’14- Jun’14 25 63.23 11.13 -85.91 -97.04 
Jan ’15- Jun’15 26 90.77 15.96 -94.23 -110.21 
Jan ’16- Jun’16 14 96.43 16.97 -07.46 -24.43 
All post vaccine 22 85.82 15.10 -62.53 -77.64 
*6 month Jan to June, per 100,000 infants (<1 year). **% coverage for 2nd dose of rotavirus 
vaccine Ϯprior to vaccine introduction Ϯ Ϯperiod from Jan ’13 to Jun ’13 excluded for 
children over 12months as these children were not vaccine age eligible.  
In contrast to the incidence rate of rotavirus-positive hospitalisations, the incidence of 
hospitalisation for rotavirus-negative gastroenteritis increased over time. The incidence 
rate of hospitalisation with rotavirus-negative gastroenteritis among infants was 479 per 
100,000 child-years at risk prior to rotavirus vaccine introduction and 655 per 100,000 
child-years at risk subsequently (Incidence rate ratio 1.37 [95% CI 1.06, 1.79]). For 
children, the incidence rate for hospitalisation with rotavirus-negative gastroenteritis was 
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77 per 100,000 child years pre- and 136 per 100,000 child years post-rotavirus-vaccine 
introduction (Incidence rate ratio 1.77 [95% CI 1.27, 2.52]) 
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A. 
 
B. 
 
Figure 4.4A Monthly diarrhoeal and rotavirus positive admissions to QECH over time in (a) 
unvaccinated infants and (b) children 12-59 months, with secular and seasonal trends in 
rotavirus prevalence. Data truncated at 24 months from start of surveillance (14 months 
from vaccine introduction) due high vaccine coverage. Fig 4.4B Fit of smoother to raw data 
for monthly rotavirus prevalence 
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4.4 Discussion 
Four years following programmatic rotavirus vaccine implementation in Malawi,  the 
prevalence of rotavirus in children presenting to hospital with gastroenteritis consistently 
declined. Vaccine effectiveness against all rotavirus disease was 61.89%, (95% CI 28.04-
79.82%). Notably however, a less pronounced reduction in disease and lower VE was 
observed in children 12-23 months of life compared to those under 12 months of age. 
There remains a persistent residual burden of disease, with rotavirus responsible for over 
1 in 4 gastroenteritis admissions despite high levels of rotavirus vaccine coverage. There 
was some evidence of a reduction of all hospitalised rotavirus disease in unvaccinated 
infants, cautiously attributed to indirect vaccine effects, but no evidence of indirect 
effects were identified in older children or those with severe disease.  
In this study high vaccine effectiveness in infants with severe disease was observed 
(85.94% [95% CI 58.64%, 95.22%] , although this should be interpreted with some caution 
in view of the large confidence bounds. This finding is consistent with previously reported 
estimates for Malawi and with estimates from Rwanda(116,187). Our vaccine 
effectiveness estimates, particularly in children under 12 months of age, have been 
consistently greater than vaccine efficacy estimates obtained in the same setting from 
pre-licensure clinical trials, and similar effects have also been seen in other sub-Saharan 
African countries(187). One explanation for this could be the presence of vaccine indirect 
effects increasing the measured VE. By design, the case control study for VE should 
estimate direct VE, as it included only children age-eligible for vaccination and therefore 
part of a vaccinated population (Fig 4.1). However a modelling study demonstrated the 
potential for the presence of indirect effects of vaccination to bias measurement of 
vaccine effectiveness upwards in a situation where vaccine coverage is heterogenous 
within a population – a situation which is likely in real world post-implementation 
studies(328).  
Despite the encouraging VE estimates in infants and high vaccine coverage, there remains 
a substantial burden of rotavirus disease in children attending QECH. This is consistent 
with findings from other LICs(116,185,202,329), and is likely to reflect a combination of 
sub-optimal vaccine effectiveness and high force of infection. Of interest, however, a 
residual burden of disease following vaccine introduction has also been noted in some HIC 
where vaccine effectiveness is high, raising the possibility of population groups other than 
infants contributing to rotavirus transmission(234). The current study has the major 
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advantage of being based in a long-standing surveillance system. This will allow ongoing 
evaluations of trends in rotavirus incidence over time, and will become increasingly 
important as high vaccine coverage will ultimately prohibit further case-control analysis 
of VE. 
The point estimates of VE in children aged 12 to 23 months are considerably lower than 
those observed in infants; and although again this should be interpreted in the light of 
very wide confidence intervals and a significance test which is non-significant at the 5% 
level, the point estimate still reflects the maximum likelihood value, and is worthy of 
cautious consideration. This is particularly true given that this finding is corroborated by 
the relative risk of rotavirus gastroenteritis compared to test-negative controls which has 
not decreased in this older age group, and the proportion of rotavirus cases occurring in 
children 12 to 23 months of age which has increased from 21% to 38% following vaccine 
introduction. Some middle income countries, for example Colombia and Brazil(171,174), 
have also reported non-significant lower point estimates for VE in the second year of life, 
but others, including sub-Saharan African countries such as South Africa and 
Botswana(201,207) have demonstrated protection that is both significant at the 5% level 
and consistent into the second year of life. Rwanda, the only other LIC which has currently 
published data on VE in the second year of life, has reported an adjusted VE in the second 
year of life of 81% (95% CI 25-95)(187).  
The observed decline in VE in the second year of life in Malawi could represent a number 
of phenomena. It could represent evidence of immunological waning, supported by the 
finding of a large randomised controlled trial in Malawi which showed a higher point 
estimate of vaccine efficacy in the second year of life among infants given a three-dose 
RV1 schedule(327), although this study was under-powered to investigate this formally. 
Alternatively, it could represent an epidemiological effect caused by high background 
force of infection in LICs, which could lead to an increase in similarity between cases and 
controls as controls acquire natural immunity through wild-type rotavirus exposure over 
time, and an artificially reduced VE(145). If this is the case it is possible VE estimates in 
the second year of life might improve over time as force of infection decreases as a result 
of vaccination. It may also reflect uncertainty in point estimates or a type two error, 
resulting from small numbers of children in the older age group. Due to high levels of 
vaccine coverage in this population it is not possible to recruit further children into the 
case control study to address this further.  
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There are currently very little data on rotavirus vaccine indirect effects from LICs(187). 
This study describes reductions in the relative risk of rotavirus-positive gastroenteritis in 
unvaccinated infants in the year following vaccine introduction, though this analysis was 
also limited by high vaccine coverage resulting in a short time period for analysis, and the 
findings should be interpreted with caution in light of this. Because of the limited data 
available, data were included for all months of the year for this analysis, acknowledging 
the possibility that this may introduce some seasonal bias. A sensitivity analysis was 
conducted restricting to the first 6 months of the year; this resulted in a similar trend to 
that observed in the full period analysis, although the results were no longer significant at 
the 5% level. When observed reductions in incidence were compared with those 
expected, greater reductions were identified in infants with disease of any severity than 
would be explained by direct effects alone. However this effect was lost when analysis 
was restricted to those infants with severe disease, possibly reflecting the larger value for 
vaccine efficacy in this group.  
There was also no evidence of an indirect effect of vaccine in older children, contrary to 
observations from HIC. One potential explanation for this is patterns in age distribution of 
disease in LIC. Prior to rotavirus vaccine introduction the majority of rotavirus disease in 
Malawi occurred in the first year of life, with very little rotavirus disease presenting in 
children over two years of age(260), possibly as a result of high exposure in infancy and 
subsequent robust immune protection as an older child. On programmatic rotavirus 
vaccine introduction into such settings older children may therefore be less susceptible to 
changes in transmission due to a reduction in disease in infants. If true, there may be an 
increase in identifiable indirect effects in older age groups as force of infection decreases 
with ongoing vaccination. Detection of any indirect effect in older children could also be 
made less likely if there is a shift of the burden of disease into the second year of life. In 
support of this explanation, modelling studies from European settings have predicted that 
early herd protection could be countered by an later increase burden of disease in 
children over 12 months of life(330).  
These estimates of indirect effects are minimum estimates, as they only capture the effect 
on hospitalised cases which represent a small proportion of the community burden of 
rotavirus disease. Additionally if the observed increase in incidence of hospitalisation with 
rotavirus-negative diarrhoeal disease following vaccine introduction reflects secular trend 
towards increased presentation and admission with AGE, this could bias estimation of 
vaccine impact based on hospitalised cases, and estimation of indirect effects derived 
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from this, towards the null. It should also be acknowledged that these methods of 
estimating indirect effects are very sensitive to the assumptions used in the calculations. 
I have used trial vaccine efficacy to estimate the predicted reduction in burden of rotavirus 
disease because vaccine effectiveness estimates from case control studies may be biased 
in the event of uneven vaccine coverage(328), however the vaccine efficacy estimates are 
smaller than the vaccine effectiveness estimates which may bias towards detection of 
indirect effects. Additionally vaccine coverage was calculated as a monthly average from 
children presenting to QECH, which may not be representative of coverage throughout 
the community, although coverage estimated from QECH is consistent with the national 
level coverage reported by the DHS (91% for two doses in the 2015-2016 DHS(331). 
Inaccuracies in vaccine coverage could also bias estimates of indirect effects.  
The reason for the observed increase in incidence of test-negative diarrhoeal cases 
observed following vaccine introduction is unclear, but could represent secular changes 
in health-care seeking behaviour or admission patterns with time. For example, trends in 
improvement in child health in Malawi and increasing maternal education around health 
care seeking could result in increased presentations with diarrhoeal disease, and a lower 
threshold for admission if children do attend. It also may reflect under-ascertainment or 
unusually low frequency of presentation or admission in the year prior to vaccine 
introduction. Unfortunately the relatively short period of enhanced surveillance before 
this point limits assessment of trends in rotavirus prevalence prior to vaccine introduction. 
Secular changes in denominators can affect prevalence estimates, and as such ongoing 
surveillance is required to evaluate the long term impact of vaccine in this setting.  
4.4.1 Implications, conclusions and further work  
In this study a consistent decline in the prevalence of rotavirus in hospitalised GE cases 
was documented following rotavirus vaccine introduction, and alongside encouraging VE 
estimates in young infants, particularly those with severe disease. However a residual 
burden of rotavirus disease was demonstrated, with rotavirus remaining responsible for 
over a quarter of all AGE admissions, and an apparent reduced vaccine effectiveness in 
the second year of life. Evidence of an indirect effect of rotavirus vaccine in infants with 
hospitalised disease was noted, but this was not seen in those with more severe disease 
or children over 12 months of life. Further observational evaluations of vaccine 
effectiveness or indirect effects in unvaccinated groups in this setting are challenging as 
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vaccine coverage is now so high that identifying unvaccinated children is very difficult, and 
any children who remain unvaccinated are likely to be subject to selection bias.  
Several of the phenomena identified in this study, such as apparent reduced vaccine 
effectiveness in the second year of life and the lack of indirect effect in children over 12 
months, may be a result of high force of infection in Malawi, and it is possible that as force 
of infection and ongoing transmission declines with long term wide spread vaccination 
programmes some of these effects will change. To monitor this and evaluate ongoing 
changes in prevalence and incidence, continued surveillance is necessary. In order to gain 
a better understanding of the trends and to investigate the presence and extent of such 
effects in greater depth more complex mathematical modelling may be required, 
particularly in light of the limitations of observational studies in the context of high vaccine 
coverage 
Although tremendous progress has been made over the past decade in reducing the 
global burden of rotavirus disease and protecting children from rotavirus attributable 
morbidity and mortality, rotavirus remains a significant cause of AGE in Malawi. If the 
persistent burden of rotavirus disease continues, interventional studies may be indicated 
to determine methods to improve vaccine effectiveness or reduce immunological waning 
in the second year of life. These have been outlined in previous chapters (Chapter 3, 
section 3.4, page 120) but could include changes or additions to the vaccine schedule such 
as an additional or delayed dose of vaccine, or novel candidate vaccines. To decide if such 
strategies are required, and to inform public health strategy to best protect young infants 
from rotavirus disease, a greater understanding is needed of the overall population level 
impact of rotavirus vaccines in the poorest countries, including indirect effects, and direct 
vaccine effectiveness in sub-groups, and how these evolve over time.  
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Chapter 5. Household transmission of rotavirus in Blantyre, Malawi 
5.1 Introduction 
The two chapters in Section A have outlined the importance of understanding population 
level rotavirus transmission in LIC in the context of reduced vaccine effectiveness and a 
persistent burden of rotavirus disease, and discussed the potential for rotavirus vaccine 
to reduce transmission through an overall reduction in the force of rotavirus infection.  In 
addition to this, rotavirus vaccine has the potential to reduce transmission by reducing 
the infectiousness of an index case, or by horizontal transmission of vaccine virus shed in 
the stool of a vaccinated infant to their household contacts(215). Understanding these 
phenomenon requires study of the transmission of wild-type and vaccine-type rotavirus 
between individuals, and Section B will focus on this. The current chapter will focus on 
defining transmission rates for rotavirus to household contacts exposed to a rotavirus 
positive index case. Subsequent chapters will explore the relationship between viral 
shedding density and symptoms, investigate risk factors for rotavirus transmission and 
investigate horizontal transmission of vaccine type virus within a household.  
There is reasonable evidence that rotavirus vaccine has the potential to reduce the 
infectiousness of an index case. Rotavirus vaccination aims to mimic natural rotavirus 
infection, which is known to protect against severe rotavirus disease to a degree which 
varies by location(38,62). Studies from India and South America have shown that the 
severity of rotavirus diarrhoea correlates with the quantity of virus shed in the stool and 
that the presence of symptoms is related to the risk of transmission(106,255). Rotavirus 
vaccination may therefore both diminish viral shedding following exposure to natural 
rotavirus infection and reduce secondary transmission rates in households, even in the 
event of clinical vaccine failure. Such effects have been demonstrated with other vaccines 
such as pertussis(332), and, given the high disease burden of rotavirus, have the potential 
to contribute substantially to the reduction in the burden of disease in the community, 
and the overall cost effectiveness of the vaccine programme.   
The first step in understanding what may reduce rotavirus transmission is an accurate 
description of rotavirus secondary attack rate (SAR). SAR is defined as the number of new 
cases among contacts of an index case(248).  Describing SAR is important in itself, as it 
allows comparisons of transmission rates between populations, and within populations 
before and after interventions. Persons infected with rotavirus can have symptoms of 
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gastroenteritis (rotavirus disease), or can have detectable rotavirus shedding in their stool 
but remain asymptomatic (rotavirus infection). SAR needs to be estimated separately for 
each of these, as the effect of interventions may differ between them. In addition to this, 
SAR also forms the basis of estimating important parameters such as the basic 
reproductive number (R0), which is the number of secondary cases generated by one 
infectious case in a fully susceptible population(212). Accurate estimates of R0 are crucial 
in infectious disease epidemiology as an R0 below 1 indicates that it is possible for 
transmission to be interrupted. However directly measuring R0 for rotavirus is not 
possible because the ubiquitous nature of rotavirus and the fact that it generates partial 
immunity make it extremely difficult to identify a fully susceptible population.  
Households studies are a well-established method of investigating attack rates for 
infectious diseases(333–337), and provide appropriate sampling frames to measure 
rotavirus SAR as they contain a defined group of individuals within close physical proximity 
to an infectious rotavirus case. Although other small communities have also been used to 
describe rotavirus SAR, including nurseries and closed communities such as 
kibbutz(261,338,339), households are relatively practical and efficient to recruit, which is 
particularly important for studies conducted in low income settings(322). As outlined in 
chapter 1, the majority of data on rotavirus transmission comes from unvaccinated 
populations in high income settings including  Europe, the US and Australasia, where SARs  
have been reported to range widely from 12-91% for infection, and 26-86% for disease, 
depending on the age of the contact and the study design used(76,251,266). All studies 
employed EIA or EM to diagnose rotavirus which have low sensitivity for the low levels of 
viral shedding associated with asymptomatic rotavirus infection, and are therefore likely 
to have under-estimated SAR for infection.  
The only data on household rotavirus transmission from middle income countries comes 
from two studies from Ecuador and India. Both were conducted in household contacts of 
childhood rotavirus cases, and described strikingly different SAR between populations.  
Ecuador reported a SAR for infection of 55%(106), while India reported a SAR for infection 
of 0.54%(268). Whilst both of these studies used qRT-PCR to detect rotavirus in stool 
samples from household contacts, in India samples were screened first using EIA to detect 
rotavirus antigen. EIA will only detect large quantities of virus in the stool, broadly 
corresponding to those amounts typically found in association with clinical disease rather 
than with asymptomatic infection, so this may partly explain the observed discrepancy in 
attack rates.  
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There are no data describing household transmission of rotavirus from LIC or from sub-
Saharan Africa. Findings from low and middle income settings cannot be generalised to 
low income, sub-Saharan countries as factors which may have a major influence on the 
risk of transmission such as living environments, crowding, contact patterns, access to 
sanitation systems and frequency of exposure to rotavirus are fundamentally different 
from those in high income and middle income settings. We therefore aimed to describe 
SAR for rotavirus infection and disease in household members after contact with a 
symptomatic rotavirus case in an urban setting in Malawi.  
5.2 Methods 
5.2.1 Overview 
This chapter, and the following 3 chapters, describe data collected as part of the RotaRITE 
transmission epidemiology study (RRTE), conducted in Blantyre, Malawi. 
5.2.2 Objectives 
 
1. To define SAR for rotavirus infection to household contacts of a symptomatic 
index child. 
2. To define SAR for rotavirus disease to household contacts of a symptomatic index 
child. 
3. To describe rotavirus genotypes in symptomatic index children and relate this to 
rotavirus genotypes identified in household contacts 
 
5.2.3 Study design 
This was a prospective cohort study initially designed to investigate the potential impact 
of rotavirus vaccination of infants on SAR within households. The study identified index 
children with acute rotavirus gastroenteritis and followed up members of their 
households for asymptomatic rotavirus infection and clinical rotavirus disease. 
5.2.4 Study site 
This study was conducted at Queen Elizabeth Central Hospital (QECH), and three 
government health centres in Blantyre: Zingwangwa, Gateway and Madziabango.  
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5.2.5 Study population  
The RRTE study recruited households of vaccine-age eligible children presenting with 
rotavirus positive gastroenteritis (index cases) to four government health facilities in 
Blantyre; QECH, Zingwangwa Health Centre, Gateway Health Centre, and Madziabango 
Health Centre. Eligibility criteria for Index cases and household members are outlined 
below. Recruitment at QECH commenced on the 16th February 2015, and at Zingwangwa 
one month later to allow for training of study staff. Gateway Health Centre, an adjacent 
facility to QECH, was subsequently added as an additional site to ensure adequate 
representation of the mild and moderate cases of rotavirus AGE presenting to QECH. This 
was because on starting the study it became apparent that some children with milder 
diarrhoea were referred from QECH to Gateway Clinic. Madziabango was added as fourth 
site in August 2016 as an attempt to increase recruitment of unvaccinated children, as 
there had been a recent vaccine stock out in the area. Locations of these facilities can be 
seen in the map in Figs 2.3 and 2.4 in Chapter 2 (pages 84 and 85). The monovalent 
rotavirus vaccine (RV1) was incorporated in to the Malawi Expanded Programme on 
Immunisation (EPI) EPI schedule in Malawi on 29th October 2012. Two oral doses are given 
at 6 and 10 weeks.  
 
5.2.6 Integration with other studies 
As described in Chapter 2, section 2.1, page 76, the RotaRITE study was made up of two 
complementary but distinct study arms. This study makes up one arm of the RotaRITE 
study (RotaRITE Transmission Epidemiology, the RRTE study), the second arm (RotaRITE: 
response to immunization, the RRRI study) investigated mechanisms underpinning 
rotavirus vaccine failure and was undertaken by Dr. Louisa Pollock.  
 
At QECH,  RotaRITE was nested within an existing diarrhoeal surveillance platform, 
established to monitor rotavirus vaccine effectiveness (“New Childhood Vaccines for 
Malawi” (VacSurv) NHSRC #867) [PI Professor Nigel Cunliffe]. Children recruited by the 
surveillance platform were assessed for eligibility to participate in the RotaRITE study. 
Dependent on vaccination status and results of rotavirus diagnostic tests, children were 
eligible for one or both of the RotaRITE study arms. Consent and data collection processes 
are described in detail below in section 5.2.7. In the health centres no diarrhoeal 
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surveillance platform was in place. The RotaRITE study therefore identified and recruited 
eligible children directly. 
5.2.7 Study procedures 
5.2.7.1 Identification of participants for diarrhoeal surveillance platform at QECH 
Recruitment took place during the routine working hours of 8am and 4pm Monday to 
Friday from February 16th 2015 to 11th November 2016. Clinicians and nurses working in 
A&E at QECH were asked to refer all children with diarrhoea to the study team and study 
research nurses based in A&E actively screened waiting patients for diarrhoeal cases. 
Admission records and the paediatric wards were also screened on a daily basis to identify 
all cases admitted with gastroenteritis. At the end of each day admission books were 
checked for the number of children with diarrhoea and compared to the number 
screened. The number of children not screened was documented in screening logs. This 
study was originally powered to investigate the difference in proportion of household 
members shedding wild-type rotavirus in households where the index child was 
vaccinated, in comparison to households where the index child was not vaccinated and to 
run over a 24 month period however due to the success of the rotavirus vaccine 
programme in Malawi it was not possible to identify unvaccinated children and 
recruitment was stopped early in November 2016 (Section 5.3.8).    
Cases were eligible for enrolment in the surveillance study if they met the ALL following 
criteria: 
• <5 years of age. 
• Lived in Blantyre district  
• Presented to QECH with diarrhoea 
• Clinical illness not explained by an alternative underlying medical condition 
• Clinical illness commenced within 14 days prior to hospital visit; and 
• Either: 
o Seen at A&E at QECH and treated with rehydration (oral or intravenous) 
for diarrhoea and discharged home; or 
o Admitted to the hospital and treated for diarrhoea  
Cases were not eligible for enrolment in the surveillance study if they met ANY of the 
following criteria: 
• Unable to contact parent or guardian to obtain informed consent 
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• Admitted to another hospital for >24 hours (and subsequently transferred to QECH) 
• Re-presentation within 14 days of previous hospital separation for the same illness 
• Hospital admission >48 hours prior to enrolment 
• Known oncological diagnosis or congenital immunodeficiency (apart from HIV 
infection) 
Families of eligible children were invited to participate, and if in agreement, written 
informed consent obtained. A combined enrolment form was used for all 3 studies, and a 
single bulk stool sample collected.  
5.2.7.2 Identification of potential participants for the RotaRITE studies at QECH 
Vaccine age eligible children (born on or after 17th September 2012) enrolled in the 
surveillance platform had a rotavirus rapid immunochromatographic test (ICT) performed 
on stool samples, and depending on the result of this underwent further eligibility 
screening for the RotaRITE studies.  
5.2.7.3 Initial screening at health centres 
Clinical officers and nurses at participating health centres were asked to refer any child 
who presented with diarrhoea to the study team. The study team also surveyed the clinic 
for children with diarrhoea. At the end of each day the clinic admissions books were 
checked for the number of children with diarrhoea and compared to the number 
screened. The children not screened were documented in the screening log, together with 
the reason for not screening.  
Parents/guardians of vaccine age eligible children presenting with diarrhoea were 
approached by the study team and invited to take part in a screening step for the RotaRITE 
studies. Following informed consent a stool sample was obtained, and an ICT test 
performed. Rotavirus positive children fulfilling eligibility criteria were then enrolled into 
the RRTE study as index cases following informed consent from their parent or guardian.  
5.2.7.4 Eligibility Criteria for Index cases for RR TE Study 
Infants were eligible for enrolment as rotavirus positive index children if they met ALL the 
following criteria: 
• Presented to health care facility with diarrhoea after onset of study 
• Clinical illness commenced within 7 days of hospital visit  
• Age eligible to have received rotavirus vaccine (i.e. born on or after 17th 
September 2012) 
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• Aged 6 weeks old or older 
• Produced a stool sample positive for rotavirus on IC rapid test during the first 72 
hours after presentation  
Infants were excluded from enrolment as a rotavirus positive index children if ANY of the 
following applied: 
• Live outside Blantyre district 
• Re-presentation within 14 days of previous admission for the same illness 
• Admission >72 hours prior to enrolment 
• Had received only a single dose of rotavirus vaccine (RV1) 
• Received RV1 within the last 14 days 
• Lived in an institution 
5.2.7.5 Study procedures at enrolment of index child 
Study procedures at enrolment are summarized in box 1. 
History taking 
Data was collected from the parent/guardian of the index child on presenting symptoms 
and their duration, past medical history including HIV status, vaccine history and the 
number of people in the household. Data were collected using a questionnaire and from 
medical records and health passports. Health passports are hand held government issued 
health records which document vaccination, and attendances to health care facilities. 
Box 1.  
 
 
Clinical assessment 
Children had their weight, height and mid-upper arm circumference measured according 
to a standardized protocol. Disease severity was assessed using the Vesikari score, a 20 
point clinical scoring system for gastroenteritis. This is outlined in Table 5.1. The clinical 
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definition of some and severe dehydration used in the Vesikari score is also outlined in 
Table 5.2.  
Table 5.1. Components of the Vesikari score.  
Category Values 
Maximum number of loose 
stools per day 
1-3 4-5 ≥6 
Diarrhoea duration (days) 1-4 5 ≥6 
Maximum number of 
vomits per day 
1 2-4 ≥5 
Vomiting duration (days) 1 2 ≥3 
Temperature 35.9-37.3 37.4-37.8 ≥37.9 
Dehydration  No dehydration  Some dehydration ≥6% severe dehydration 
Treatment Oral rehydration Hospitalization for >24h or 
IV rehydration 
n/a 
Score awarded 1 2 3 
TOTAL  SCORE 
Severity Category <7 mild 7-10 moderate ≥11 severe 
 
Table 5.2. Defining dehydration for use in Vesikari score 
Where plan B and C are WHO plans for rehydration, plan C involving rapid intravenous 
rehydration and plan B oral rehydration.  
 
 
 
 
 
Signs of Dehydration 
Dehydration Classification 
Treated with Plan C or 
Two signs of:  
• Sunken eyes 
• Lethargic/unconscious 
• Not able to drink/drinking poorly 
• Skin pinch goes back very slowly 
Severe dehydration 
(≥ 6% dehydration) 
 
Vesikari score 3 for dehydration 
Two signs of: 
• Sunken eyes 
• Restless/irritable 
• Thirsty/drinks eagerly 
• Skin pinch goes back slowly 
OR one severe dehydration and one some sign 
Some dehydration 
(1-5% dehydration) 
 
Vesikari score 2 for dehydration 
Does not meet criteria for Plan C or Plan B 
No dehydration 
Vesikari score 1 for dehydration 
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5.2.7.6 Sample collection at recruitment of the index child.  
Stool samples 
Bulk stool samples were collected preferentially. Rectal swabs were also used to collect 
stool samples from index children where it was not possible to obtain a bulk stool sample. 
Rectal swabs were introduced in September 2015 in response to a concern that children 
with milder disease were being under-ascertained because of inability to obtain a bulk 
stool sample.   
Blood samples 
1-2 mls of venous blood was collected from index children at presentation.  
HIV testing 
All children attending health care facilities were offered HIV testing in line with current 
Malawi National Guidelines using ELISA point of care tests with confirmatory HIV-PCR if 
aged under 12 months of age. HIV testing services were those provided by the Ministry of 
Health. Study staff encouraged and facilitated the testing of children and their guardians, 
but did not themselves actively conduct HIV testing.  
 
5.2.7.7 Household visits and follow up 
After initial recruitment of the index child a preliminary home visit took place. The 
household head or their representative was asked for consent for the household to 
participate. All adult household members were then individually consented and assent 
was obtained from age appropriate children. Procedures at household visits are outlined 
in Table 5.3.  
5.2.7.8 Eligibility criteria for household contacts for RRTE Study 
Individuals were eligible for recruitment as household contacts of rotavirus positive index 
children if they met ALL the following criteria: 
• Live in household containing a rotavirus positive index child 
• Identify with same household head as index child 
• Have lived in household for at least 3 weeks prior to enrolment 
• Able to perform household visit within 10 days of onset of symptoms in index 
child 
Individuals were excluded from enrolment as a household contact of a rotavirus positive 
index patient if ANY of the following applied 
• Live outside Blantyre district 
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• Unable to contact household head or their representative to obtain informed 
consent 
5.2.7.9 Procedures at initial household visit 
History taking  
Field workers collected data on past medical history including HIV status, current 
symptoms and contact patterns with the index child for each household member. Vaccine 
history was collected from children under the age of 5 years.  
Clinical assessment 
Any children under 5 years had their weight, height and mid-upper arm circumference 
measured and documented.  
Documentation of household location 
Household location was documented using Global Positioning System (GPS) software. 
Sample collection 
At the end of the initial visit field workers left sample containers for each study participant 
in the household. These were clearly labelled to identify which container should be used 
for each participant.  
 
5.2.9.10 Follow up household visits  
The initial visit was followed by two additional visits to collect stool samples. The first stool 
sample aimed to be 5-7 days after the onset of symptoms in the index child and the second 
stool sample 10-12 days after the onset of symptoms in the index child (Fig 5.1). Brief data 
were collected on symptoms in each household member since the last visit.  
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Table 5.3. Overview of processes to be carried out at each household visit 
 
 
Figure 5.1 Overview of timing of stool samples 
5.2.7.11 Control recruitment  
On interim analysis of stool samples from household contacts of rotavirus positive index 
cases 50% of household contacts were found to have detectable rotavirus in at least one 
stool sample. In light of this high frequency of detectable rotavirus a decision was made 
to recruit 55 control households to describe the frequency of rotavirus shedding in 
household members without history of recent exposure to a rotavirus case. Control 
households were selected to contain a child retrospectively frequency matched to the age 
distribution of rotavirus positive index children already recruited into RRTE. Random GPS 
locations within the Blantyre Municipality were generated using R software (Version 
3.3.2). Households at each random location were visited, moving outwards in a systematic 
 Initial visit Visit 1 Visit 2 
Recruitment of household members ✓   
Nutritional assessment of household 
members aged under 5 years 
✓   
HIV status of mothers and other children 
(from health-care records) 
✓   
Confirmation of vaccine status (children) ✓   
Demographic Questionnaire ✓   
Symptom Questionnaire  ✓  ✓ 
Containers left for stool sample ✓ ✓  
Collection of stool sample  ✓ ✓ 
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manner until suitable control patients were found and recruited. Household members of 
control households were asked to complete a CRF covering symptom and demographic 
data, and to produce a single stool sample. Control households were recruited between 
July 2016 and January 2017.  
 
5.2.7.12 Eligibility criteria for control households 
Households were eligible for enrolment as control households if ALL of the following 
applied 
a) Household contained a child whose age was frequency matched to a RRTE index 
case child 
b) No one resident in the household  had gastroenteritis symptoms at the time of 
recruitment or in the 2 weeks preceding  
Households were excluded from enrolment as control households if 
a) Household contained a known rotavirus case 
5.2.7.13 Consent procedures 
Informed consent was obtained for each stage of the recruitment process, with parental 
consent obtained for children. In addition to parental consent, assent was sought from 
children aged 8 years and above. Initially written assent was obtained from all children, 
but these procedures were revised part way through the study following feedback from 
the field team in order to minimize the burden to the family. From December 2015 
onwards children aged 8-11 underwent a verbal assent process, while children aged 12 
years and over continued to provide written assent. For illiterate participants a thumb 
print witnessed by an independent party was used to confirm consent.  
5.2.8 Sample size calculations 
5.2.8.1 Primary study 
This study was powered to compare the proportion of household members shedding 
rotavirus in households were the index child was vaccinated, compared to households 
were the index child was unvaccinated. The sample size was inflated to account for 
clustering at the household level based on an estimate of the intra-class correlation co-
efficient (ICC) of 0.5, derived from a study of household rotavirus transmission in Ecuador. 
Under the following assumptions an initial sample size of 306 was selected 
• Precision of 0.05% 
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• Power of 80% 
• ICC 0.5 
• Household size of 5 
• Baseline transmission rate 50% in unvaccinated households,  
• Transmission rate of 37.5% (25% reduction) in vaccinated households 
 An interim analysis by an independent statistician after 6 months of recruitment revised 
the estimate of the  ICC based on interim RRTE data to 0.13 (95% CI 0.03, 0.42) and 
prevalence of shedding in vaccinated household contacts to 55%. The target sample size 
was subsequently revised to 182 households; 146 households containing  a vaccinated 
child, and 36 containing an unvaccinated child.  
5.2.8.2 Control households 
55 control households was selected to allow detection of a significant difference in the 
proportion of household members shedding rotavirus in control households, compared 
to households exposed to an index case given the following assumptions:  
• Precision of 0.05 
• Power of 80% 
• ICC of 0.3 
• Household size of 5 
• Rotavirus shedding in 31 % of unexposed household members (ie asymptomatic 
control households) 
• Rotavirus shedding in 49% of exposed household members (ie household contacts 
of a rotavirus case. 
The proportion of asymptomatic household members expected to be shedding was based 
on the proportion of asymptomatic control children found to be shedding rotavirus on 
qRT-PCR from a case-control study in Malawi(20). The proportion of exposed household 
members shedding was based on interim analysis of RRTE data. 
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5.2.9 Laboratory procedures 
Laboratory procedures are described in detail in chapter 2, section 2.3, page 87. With the 
exception of ICT rapid tests for rotavirus in stool, all laboratory procedures were 
conducted in the research laboratories at the Malawi-Liverpool-Wellcome Trust clinical 
research programme.  
5.2.9.1 Laboratory tests at recruitment for index children 
Stool samples 
ICT rapid tests. Stool samples were tested for rotavirus antigen in real time using ICT rapid 
tests to determine eligibility for the RRTE study.  This was undertaken at the clinical site 
of recruitment by the study nurses.  
Enzyme-immunoassay (EIA) tests. Children recruited into the Vacsurv surveillance 
platform had stool samples tested with EIA in addition to qRT-PCR and IC tests. This was 
for with historical surveillance, and in line with WHO guidance for rotavirus surveillance. 
EIA results were not used in the RRTE study except as a quality control to compare the 
sensitivity and specificity of IC tests for rotavirus.  
Molecular tests: Stool samples from all index children recruited into the RRTE study were 
tested using real-time qRT-PCR (RT qRT-PCR) to assess stool viral load and by qualitative 
RT-PCR to determine genotype.  
Blood samples 
Anti-rotavirus IgA titres: Serum was stored for testing for anti-rotavirus IgA titres to 
assess pre-existing immunity to rotavirus at a later date.  
 
5.2.9.2 Laboratory procedures for household follow up visits 
Stool samples 
Molecular tests: Stools collected from household visits were tested for rotavirus using 
real-time qRT-PCR. Rotavirus positive samples with a Ct value of <=35 underwent 
qualitative RT-PCR to determine genotype. Only one sample from any one individual 
underwent genotyping. Any samples positive for rotavirus but where the Ct value was >35 
underwent a confirmatory PCR for a second target (NSP3).  
 
5.2.10 Statistical methods 
Distributions of continuous variables were examined and categorical variables were 
tabulated to generate descriptive statistics. Missing observations were excluded from 
analysis. Two-sided t-tests were used to compare independent means of normally 
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distributed data and rank sum tests were used to compare non-normally distributed data. 
Chi squared or Fischers exact tests were used to compare categorical variables, depending 
on the number of observations present.  
 
5.2.11 Managing specific variables 
The question of whether or not the household contact was responsible for changing the 
index child’s nappy was only asked to adults in the household. To enable inclusion of this 
variable in multi-variable models without problems of sparse data, a dummy variable was 
created for “child” where the response for nappy changing was “unknown”. Similarly 
children under 16 were not asked if they were the primary care giver for the child. For this 
variable, it was assumed that children under 16 were not primary care givers, given that 
there was an additional adult in the household and in all but one of our recruited 
households a mother was present.   
 
Wealth 
Individual proxy variables for poverty were compared between groups. In addition, a 
composite variable was generated to rank participants against each other in terms of 
relative wealth using a modified version of model developed by Payongyong et a using 
the 1998 Malawi DHS data(340). The coefficients for this model are given in Table 5.4 
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Table 5.4. Coefficients for proxy means test model developed by Payongyong et al from 
the Malawi 1998 DHS.  
Preferred urban Malawi proxy means test model 
Dependent variable: log household welfare indicator 
Response variable Co-efficient 
HH owns a fridge 0.518 
Household size -0.306 
Household size squared 0.016 
Age of head of household 0.005 
Education level of household head 0.151 
No. of salaried HH members 0.061 
HH owns a motor vehicle 0.704 
HH get lighting from electricity or gas 0.280 
HH owns a bed 0.247 
Blantyre City -0.037 
Constant 2.347 
Observations 872 
R-squared 0.60 
Reproduced from Payongayong E, Benson T, Ahmed A, Kanyanda C, Mwanza P, Chilopa K, 
Banda N MA. Simple household poverty assesment models for Malawi: Proxy Means Test 
from the 1997–98 Malawi Integrated Household Survey. 2006. The model was modified 
by substituting car or vehicle for mobile phone which was felt to be more relevant to 
current poverty levels. A continuous variable for wealth was generated by multiplying the 
identified variables by their respective co-efficient. This was then split into quintiles.  
 
Nutritional status 
Admission weights in index children were adjusted to account for dehydration by 
multiplying by 110% for children with severe dehydration and 105% for children with 
some dehydration. These weights were used to calculate Z Scores, referred to as adjusted 
Z scores in the text. Nutritional status was defined using WHO standards, as described in 
Chapter 4, section 4.2.5, page 130. Weights were not adjusted for community controls or 
household contacts of index children. 
HIV status 
HIV exposure and infection was defined as described in Chapter 4, section 4.2.5, page 130. 
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5.2.12 Ethics 
The RRTE study was reviewed and approved by the University of Liverpool Research Ethics 
committee (# 000757), and the Malawi College of Medicine Research Ethics Committee 
(P.09/14/1623). Sponsorship was provided by the University of Liverpool. Ethical approval 
for the diarrhoeal surveillance platform was provided by the University of Liverpool 
Research Ethics Committee (# 000490) and by the National Health Sciences Research 
Committee, Lilongwe, Malawi (# 867) 
 
5.2.13 Defining of outcome variables  
Defining rotavirus positivity for infection secondary attack rates 
Results of rotavirus VP6 qRT-PCR are presented as copy numbers or log transformed copy 
numbers. Samples with a Ct value in range 35-40 underwent NSP3 PCR as a confirmatory 
assay. Due to lack of reproducibility in samples with very low viral loads samples were 
defined as rotavirus positive if they had >=100 viral copy numbers and were positive on 
NSP3 assay.   
Defining clinical disease for disease secondary attack rates 
Clinical disease in household contacts was defined as any reported vomiting or diarrhoea 
in individuals who tested rotavirus positive on at least one stool sample. This is a broader 
definition than used to define diarrhoea in index children where >=3 loose stools in 24 
hours was used. This was to increase sensitivity of detection of clinical disease in 
household contacts.  
5.2.14 Other definitions  
Vaccine age eligible: born on or after 17th September 2012. 
Index child: vaccine age-eligible household member with rotavirus positive gastro-
enteritis, presenting to a health facility  
Shedding density: viral copy number, derived from Ct value of real-time PCR. 
Severe rotavirus disease: Rotavirus positive AGE with Vesikari scale ≥ 11  [41] 
Mild to moderate disease: Rotavirus positive AGE with Vesikari scale of 1-10. 
Asymptomatic infection: Rotavirus detected by PCR but no diarrhoea or vomiting reported 
during follow-up, or in the preceding 10 days. 
Household: group of individuals who identify with the same household head, and live 
within the same physical structure as each other. 
Household contact: an individual living in the same household as the index child and 
fulfilling eligibility criteria for the study  
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5.3 Results 
5.3.1 Description of cohort 
Recruitment for the primary study took place from February 16th 2015 to 11th November 
2016. A total of 196 households were recruited into the study.  
Breakdown of screening and recruitment by site can be seen in Fig. 5.2.  
 
Figure 5.2 Overview of RRTE study recruitment 
5.3.2 Description of index children 
Characteristics of the rotavirus positive index children recruited are listed in Table 5.5. 
Median age was 11.5 months (IQR 8.8, 15.2). There was a slight preponderance to male 
sex in rotavirus positive index children. Approximately 13% of children were HIV exposed 
(25/196), and of those with data available 2/58 (3.5%) were HIV infected.  
The majority of children had severe rotavirus gastroenteritis, as defined as a Vesikari score 
≥11 (168/193, 86.5%). Vomiting was a prominent symptom, with 182/196 (92.9%) 
reporting at least one episode. Most had at least some clinical evidence of dehydration 
(124/196, 63.3%), and around one quarter were severely dehydrated (46/196, 23.5%). 
Approximately one third required intravenous (IV) rehydration (58/196, 29.6%), and over 
half were admitted to hospital (111/196, 56.6%). A total of 2/196 (1.02%) children 
recruited as index cases died. Children were typically underweight with a mean adjusted 
weight-for-height (WHZ) Z score of -0.59 (standard deviation [SD] 1.61). Mean height-for 
age Z score (HAZ) was -0.04 (SD 2.46). Prevalence of severe acute malnutrition after 
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adjusting for dehydration was 23/194 (11.9%). Previous history of diarrhoeal disease was 
common, with almost half of the index children having attended a health care facility for 
diarrhoeal disease on a previous occasion (91/196, 46.4%). Breast feeding was almost 
universal (195/196, 99.5%). Rotavirus vaccine coverage was very high at 194/196 (99.0%).  
113 of 196 (57.7%) children were recruited at QECH, and the remainder were recruited 
from health centres. Children recruited at QECH had more severe disease than those 
recruited at health centres (median Vesikari score 15 (IQR 14, 16) vs 12 (IQR 10,14) 
p<0.001) (Table A3, appendix, page 261). Children recruited at QECH also tended to be 
more wasted (mean WHZ -1, SD 1.5) compared to children from health centres (mean 
WHZ -0.34, SD 1.7, p=0.005). Significantly more children recruited from QECH had had a 
previous presentation to a health facility with diarrhoeal disease (69/113 [61.1%] vs 22/83 
[26.5] p<0.001). There were no significant differences in terms of feeding, birth weight, 
age, sex or vaccine status between groups.   
Table 5.5. Description of index children in primary study, and control children 
 Primary study Controls   
 Summary 
statistic 
Missing 
data 
Summary 
statistic 
Missing 
data 
P valueϮ 
Age (median and IQR) 11.5(8.8,15.2) 0/196 11.5(8.2,15.4) 0/55 0.75** 
Sex (male) (%) 108/196 (55.1) 0/196 26/55(47.3) 0/55 0.304 
Diarrhoea (%) 196/196 (100) 0/196 0/55 (0) 0/55 <0.001  
Duration (days)  0/196    
1-3 (%) 173/196 (88.3)  - - - 
5 12/196 (6.1)  - - - 
≥6 11/196 (5.6)  - - - 
Episodes(n)***  0/196    
1-4 (%) 24/196 (12.2)  - - - 
5 86/196 (43.9)  - - - 
≥6 86/196 (43.9)  - - - 
      
Vomiting (%) 182/196 (92.9) 0/196 0/55 (0) 0/55 <0.001 
      
Duration (days)  0/182    
1 (%) 23 (12.6)  - - - 
2 59 (32.4)  - - - 
≥3 100 (55.0)  - - - 
Frequency (n)  0/182    
<5 (%) 123 (67.6)  - - - 
≥5 59 (32.4)  - - - 
      
HIV      
Exposed (%) 25/196 (12.8) 0/196 6/54 (11.1) 1/55 0.75 
Infected (%) 2/58 (3.5) 138/196* 0/11 (0) 44/55 0.53 
Completed rotavirus 
vaccination (%) 
     
 Vaccinated  
(2 doses)  
194/196 (99.0) 0/196 55/55 (100) 0/55 0.45 
172 
 
Unvaccinated  
(0 dose)  
2/196 (1.0) 0/196 0/55 (0) 0/55 0.45 
Admitted (%)      
Yes 111/196 (56.6) 0/196 - - - 
Vesikari score  (IQR) 14 (12, 16) 3/196 - - - 
Temperature (rectal, oC)      
37.1-38.4 (%) 92/193 (47.7)  - - - 
38.5-38.9 48/193 (24.9)  - - - 
≥39.0 53/193 (27.5)  - - - 
Thirst (%)      
No thirst 32/196 (16.3)  - - - 
Thirsty 141/196 (71.9)  - - - 
Drinks poorly 23/196 (11.7)  - - - 
Skin pinch (%)      
Normal 56/196 (28.6)  - - - 
Goes back 
slowly 
104/196 (53.1)  - - - 
Goes back very 
slowly 
36/196 (18.4)  - - - 
General Appearance (%)      
Well, alert 94/196 (48.0)  - - - 
Restless 83/196 (42.4)  - - - 
Unconscious 19/196 (9.7)  - - - 
Dehydration (%)      
None 26/196 (13.3)  - - - 
Some (5%)  124/196 (63.3)  - - - 
Severe (10%)  46/196 (23.5) 0/196 - - - 
IV fluids (%)      
Yes 58/196 (29.6) 0/196 - - - 
Oral fluids (%)      
Yes  185/196 (94.4) 0/196 - - - 
Outcome (%)      
Home 194/196 (99.0)  - - - 
Died 2/196 (1.0) 0/196 - - - 
Anthropometry, mean 
(SD) 
     
Adjusted WHZ -0.59(1.61) 1/196 - - - 
Adjusted WAZ -0.46 (1.6) 1/196 - - - 
Adjusted HAZ -0.04 (2.46) 5/196 - - - 
MUAC 13.48 (1.28) 1/196 - - - 
SAM 23/194 (11.9) 3/196 - - - 
Previous diarrhoeal 
admission (%) 
15/196 (7.7) 0/196 3/55 (5.5) 0/55 0.58 
Previous diarrhoeal 
presentation (%) 
91/196 (46.4) 0/196 26/55(47.3) 0/55 0.912 
Premature (%) 7/196 (3.6) 0/196 2/53 (3.6) 0/55 0.83 
Birth weight, mean (SD) 2.96 (0.63) 12/196 2.95(0.55) 4/55 0.99* 
Ever Breastfed (%) 195/196 (99.5) 0/196 2/55 (3.6) 0/55 0.06 
Diet includes food other 
than breast milk (%) 
190/196 (97.0) 0/196 48/55(87.3) 0/55 0.004 
ϮP values are X2 p values for differences in proportions between case children and control 
children unless otherwise specified. *2 sided independent ttest **rank sum test. Clinical 
data not collected for control children 
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5.3.3 Description of households 
Characteristics of the households of index children are listed in Table 5.6. Median 
household size was 5 (IQR 3, 6). Just under 50% of households had electricity at home 
(89/196 (45.4%), and the majority shared a toilet with at least one other household 
(148/196, 75.5%). Over one third of households took over 30 mins to access water (68/196 
[34.7%]) and most households sourced water from a shared tap to their village or 
compound (115/195 [59.0%]). In most households at least one person had a regular salary 
(127/196 [65.1%]). Nearly one third of households families reported sometimes having 
difficulty getting the food they need (60/196 [30.6]), and almost a quarter 45/196 [23.0%] 
reported an adult missing a meal in the last two weeks to ensure that the other family 
members had enough to eat. Recruitment of households was reasonably equally 
distributed throughout the year. 114/196 (57.9%) were recruited in the rotavirus season, 
where the season was defined as May to October.  
Table 5.6. Description of households in primary study, and control households 
 Primary study Controls  
 Summary 
statistic 
Missing 
data 
Summary 
statistic 
Missing 
data 
P value 
Household size (%)  0/196  0/55  
≤5 136/196(69.4)  44/55 (80.0)   
>5 60/196 (30.6)  11/55 (20.0)  0.123 
Additional child <1 (%)      
0 187/192(97.4)  54/55 (98.2)   
1  5/192 (2.6) 4/196 1/55 (1.8) 0/55 0.739 
Additional children < 5 (%)      
0 126 (65.0)  43/55 (78.2)   
1 62 (32.0)  10/55 (18.2)   
2 5 (2.6)  2/55(3.6)   
4  1 (0.5) 2/196 0/55 (0) 0/55 0.224 
Education level of mother (%)      
Primary or less 108/196(55.1)  24/55 (43.6)   
Secondary 81/196 (41.3)  29/55 (52.7)   
Higher  7/196 (3.6) 0/196 2/55 (3.6) 0/55 0.309 
Education level of household 
head (%) 
     
Primary or less 59/192 (30.7)  14/55 (25.5)   
Secondary 113/192(58.9)  35/55 (63.6)   
Higher 20/192 (10.4) 4/196 6/55 (10.9) 0/55 0.750 
Electricity at home      
Yes (%) 89/196 (45.4) 0/196 27/55 (49.1) 0/55 0.628 
Shared toilet      
Yes(%) 148/196(75.5) 0/196 40/55 (72.7) 0/55 0.674 
How long for household to 
access water (%) 
     
0-5 mins 34/196 (17.4)  22/55 (40.0)   
5-30mins 94/196 (48.0)  30/55 (54.6)   
>30 mins 68/196 (34.7) 0/196 3/55 (5.5) 0/55 <0.001 
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Water source (%)      
Well 16/195 (8.2)  3/55 (5.5)   
Borehole 35/195 (18.0)  11/55 (20.0)   
Shared tap  115/195(59.0)  38/55 (69.1)   
Tap to house 29/195  (15.0) 1/196 3/55 (5.5) 0/55 0.003 
How many people have a 
regular salary (%) 
     
0 68/195 (34.9)  5/55 (9.1)   
≥1 127/195(65.1) 1/196 50/55 (90.9) 0/55 0.001 
Problems getting food in the 
past month (%) 
     
No 136/196(69.4)  26/55 (47.3)   
Sometimes/often 60/196 (30.6) 0/196 29/55 (52.7) 0/55 0.002 
Has an adult skipped a meal in 
the past 2 weeks? 
     
Yes (%) 45/196 (23.0) 0/196 10/55 (18.2) 0/55 0.449 
Wealth indicator  
(mean and SD) 
2.38 (0.57) 5/196 2.55(0.52) 1/55 0.040 
Time of recruitment      
Quarter of year (%)      
Jan-Mar 43/196 (22.0)  3/55 (5.5)   
Apr-Jun 58/196 (29.6)  0/55 (0)   
Jul-Sept 56/196 (28.6)  28/55 (50.9)   
Oct-Dec 39/196 (19.9) 0/196 24/55 (43.6) 0/55 <0.001 
Season (%)      
In season 114/196(57.9)  27/55 (49.1)   
Out of season 82/196 (42.0) 0/196 28/55 (50.9) 0/55 0.337 
ϮP values are X2 p values for differences in proportions between case children and control 
children unless otherwise specified. *2 sided independent ttest **rank sum test 
5.3.4 Description of household members 
705 household members of 196 index children were recruited. Characteristics of these 
household members can be found in Table 5.7. The median age of household recruits was 
19 years, ranging from 4 months to 61 years. Household recruits were slightly more likely 
to be female (386/702 [55.0%]) than male. Half of the household recruits had been tested 
for HIV (345/665 [51.8%)], and of those with available results 29/338 were HIV infected 
(8.6%). The majority of household recruits were children, (312/705 [44.3%], followed by 
mothers (195/705 [27.7%]) and then other adults (198/705 [28.1%]).  
For household contacts aged under 5 years, 8/89 (9.0%) reported a previous hospital 
attendance with diarrhoeal disease. Mean WHZ was lower than the WHO standard at -
0.24 (SD 1.9), and children were stunted, with a mean HAZ of -1.55 (SD 1.5), Prevalence 
of SAM was 6/75 (8.0).  
Most household members slept in the same room as the index child (423/705 [60.0%]), 
with half sharing a bed (359/705 [50.9%]). Just over 40% of contacts spent all day in the 
house (296/705 [41.9%]), and the same number spent all day with the index child. Most 
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people used a simple pit toilet or ventilated improved pit latrine (VIP), (659/705[93.5%]). 
Most people did not share a toilet with the index child (684/705 [97.0%]) – which is likely 
to reflect the fact that most index children were infants who would not yet use a toilet. 
209/705 [29.7%] were identified as the primary carer for the index child, and a third were 
identified as responsible for changing the index child’s nappy (203/705 [28.8%]).   
Table 5.7. Description of house contacts in primary study, and control household contacts 
 Primary study Controls  
Variable Summary 
statistic 
Missing 
data 
Summary 
statistic 
Missing 
data 
P value 
Household member age (%)      
<5 years 92/702 (13.1)  11/153 (7.2)   
5-15 years 198/702 (28.2)  53/153 (34.6)   
15-45 years 394/702 (56.1)  87/153 (56.9)   
45+ years 18/702 (2.6) 3/705 2/153 (1.3) 0/153 0.099 
Sex (male) (%) 316/702 (45.0) 3/705 54/153 (35.3) 0/153 0.028 
Diarrhoea (%) 40/705 (5.7) 0/705 0/153 (0) 0/153 0.003 
Vomiting (%) 17/705 (2.4) 0/705 0/153 (0) 0/153 0.052 
 HIV      
Ever tested (%) 345/665 (51.8) 40/705 86/149 (57.7) 4/153 0.197 
HIV Infected (%) 29/338 (8.6) 7/345 6/86 (7.0) 0/86 0.630 
Relationship to child (%)      
Mother 195/705 (27.7)  55/153 (36.0)   
Other adult relative 198/705 (28.1)  32/153 (20.9)   
Child contact 312/705 (44.3) 0/705 66/153 (43.1) 0/153 0.067 
Contact behaviour 
Sleep in same room as child  (%) 423/705 (60.0) 0/705 88/153 (57.5) 0/153 0.570 
Share a bed with index child  (%) 359/705 (50.9) 0/705 82/153 (53.6) 0/153 0.549 
Time spent in house  (%)      
All day 296/705 (42.0)  74/153 (48.4)   
Half day 244/705 (34.6)  52/153 (34.0)   
Evening only/no time 165/705 (23.4) 0/705 27/153 (17.7) 0/153 0.216 
Time spent with index child  (%)      
All day 296/705 (42.0)  74/153 (48.4)   
Half day 243/705 (34.5)  52/153 (34.0)   
Evening only/no time 166/705 (24.0) 0/705 27/153 (17.7) 0/153 0.208 
Share toilet with index child  (%)      
Never 684/705 (97.0)  130/153 (98.3) 0/153  
Sometimes 16/705 (2.3)  2/153 (1.3) 0/153  
Often 3/705 (0.4)  0/153 (0.0) 0/153  
Always 2/705 (0.3) 0/705 1/153 (0.7) 0/153 0.634 
Toilet type  (%)      
None 13/705 (1.8)  3/153 (2.0)   
Simple pit/VIP 659/705 (93.5)  143/153 (93.5)   
Water toilet 33/705 (5.0) 0/705 7/153 (4.6) 0/153 0.994 
Primary care giver for index child      
Yes (%) 209/705 (29.7) 0/705 56/153 (36.6) 0/153 0.091 
Responsible for changing nappy        
Never/sometimes (%) 190/705 (27.0) 0/705 34/153 (22.2) 0/153  
Always/often 203/705 (28.8) 0/705 53/153 (34.6) 0/153  
N/A 312/705 (44.3) 0/705 66/153 (43.1) 0/153 0.279 
Under 5s only 
RV1 doses  (%)      
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0 doses 36/79 (45.6)  2/10 (20.0)   
1 doses 2/79 (2.5)  0/10 (0.0)   
2 doses   41/79 (51.9) 12/91 8/10 (80.0) 1/11 0.236 
Previous history of clinic visit 
with diarrhoea  (%) 
     
No 80/89 (89.9)  11/11 (100)   
Yes 8/89 (9.0)  0/11 (0)   
Unknown 1/89 (1.1) 2/91 0/11 (0) 0/11 0.543 
Anthropometry. Mean (SD)      
WHZ -0.24 (1.9) 15/91 -0.03(1.26) 3/11 0.760* 
WAZ -1.04 (1.6) 6/91 -0.93 (0.84) 2/11 0.847* 
HAZ -1.55(1.5)  15/91 -1.73(2.17) 3/11 0.757* 
MUAC 15.3 (1.70) 3/91 13.99 (0.70) 1/11 0.017* 
SAM (%) 6/75(8.0) 16/91 0/8 (0) 3/11 0.406 
ϮP values are X2 p values for differences in proportions between case children and control 
children unless otherwise specified. *2 sided independent ttest **rank sum test 
5.3.5 Controls 
55 control households were recruited from randomly generated locations in Blantyre, 
frequency matched on age to index children from the primary RRTE dataset. 
Characteristics of the 55 children frequency matched on age and compared to index 
children from the primary study can be seen in Table 5.5. Median age was 11.5 months 
(IQR 8.2, 15.4). No children had symptoms of gastroenteritis as this was an exclusion 
criteria for control households. All age matched children were vaccinated against 
rotavirus. As with the index children a substantial proportion (26/55(47.3%) had 
previously attended a health care facility with diarrhoea, with 3/55(5.5%) having previous 
hospital admissions due to diarrhoeal disease. There were no significant differences in 
birth weight, prematurity or breastfeeding between control children and index children. 
Household size, presence of electricity at home, and use of a shared toilet also showed no 
significant difference across groups.  
There were however a few differences between control and index child households. 
Fewer control households spent over 30 minutes collecting water compared to index child 
households (3/55 (5.5%), compared to 68/197 (34.5 %) of index children (p<0.001)). In 
50/55 (90.1%)of control households at least one person had a regular salary compared to 
127/196(65.1%) of index households, p<0.001. The wealth index was significantly higher 
in control households (mean 2.55 (SD 0.52), compared to 2.37 (SD 0.57) in index 
households (p=0.04). However half of control households reported problems getting the 
food they needed (29/55, 52.7%), compared to 60/196 (30.6 %) of index households. The 
majority of control households were recruited in the second two quarters of the year, in 
comparison to index children who were fairly evenly distributed throughout the year. 
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There was however no significant difference in the proportion of households recruited in 
rotavirus season between the two groups (Table 5.6).  
5.3.6 Secondary attack rates 
5.3.6.1 Secondary attack rates in household contacts of symptomatic children 
705 household members were recruited from 196 households. If no samples were given 
data were collected on symptoms to define secondary attack rate for disease. 6 household 
contacts were documented as having unknown symptom status at least once during 
follow up, and these are excluded from the denominator for clinical secondary attack. 665 
individuals from 188 households contributed at least one sample, with a total of 1212 
samples collected. Secondary attack rates in household contacts of symptomatic rotavirus 
cases were very high with 434/665 (65.3%) individuals positive for rotavirus. Attack rates 
were even higher when a sensitivity analysis was performed using any detectable 
rotavirus as the definition of a positivity (563/665 (84.7%)) (Table 5.8). Viral loads were 
low, with median copy numbers of 311 (IQR 89, 2298) for sample one and 306 (IQR 80, 
1353) for sample two. There was no clear difference in secondary attack based on age of 
the household contact. 
Clinical secondary attack was much less common with 48/699 (6.9%) household contacts 
reported symptoms of gastroenteritis at any point during follow up. Of these 47 had 
samples available for testing and 37 (77.1%) were positive for rotavirus, resulting in a SAR 
for clinical rotavirus disease of 37/698 (5.3%). Rates of clinical disease were significantly 
higher in children under 5 years (12/91, 13.2% p<0.001).  
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Table 5.8 Secondary attack rates for rotavirus infection and disease in households exposed 
to rotavirus positive index children, compared to shedding rates in asymptomatic control 
households  
  Definition of secondary attack 
 Infection Clinical disease 
 >= 100 copy numbers Any shedding** Rotavirus positive 
clinical disease 
 Study Control  Study Control  Study Control X2 P* 
Overall 434/665 
(65.3%) 
40/144 
(27.8%) 
<0.001 Ϯ 563/665 
(84.7%) 
76/144 
(52.8%) 
<0.001 Ϯ 37/698 
(5.3) 
0/153 
(0.0) 
0.004 Ϯ 
Age stratified  (years) 
0-4 57/88 
(64.8) 
2/10 
(20.0) 
0.006Ϯ 76/88 
(86.4) 
6/10 
(60.0) 
0.033 Ϯ 12/91  
(13.2) 
0/11 
(0.0) 
0.200 Ϯ 
5-14 127/193 
(65.8) 
14/48 
(29.2) 
<0.001 Ϯ 170/193 
(88.1) 
24/48 
(50.0) 
<0.000 Ϯ 4/197  
(2.0) 
0/53 
(0.0) 
0.296 Ϯ 
15-45 240/367 
(65.4) 
5/20 
(27.4) 
<0.001 Ϯ 302/367 
(82.3) 
44/84 
(52.4) 
<0.001 Ϯ 20/390 
(5.1) 
0/87 
(0.0) 
0.031 Ϯ 
45+ 9/16 
(56.3) 
1/2 
(50.0) 
0.867 Ϯ 14/16 
(87.5) 
2/2 
(100.0) 
0.596 Ϯ 1/18 
(5.6) 
0/2 
(0.0) 
0.732 Ϯ 
X2 P* 0.894 0.838  0.583 0.596  0.001   
*p value for difference in proportion across age categories Ϯp value comparing difference in 
proportion between cases and controls **any shedding defined as any rotavirus detected on VP6 
qRT-PCR without confirmatory NSP3 assay 
Of the symptomatic household members 42/48 (87.5%) reported symptoms at their initial 
interview, the remaining 5 developed symptoms subsequently. Of the 42 that reported 
symptoms at baseline 4 had symptoms which started before those of the index child, and 
4 started the same day. The age and stool test results for these individuals are summarised 
in Table 5.9. One household member who was symptomatic at baseline had missing data 
for symptom onset. If these household members are excluded, disease attack rate for 
rotavirus gastroenteritis was 30/690 (4.3%). The serial interval for clinical disease ranged 
from 1-8 days with a mean of 3.2 days. Household contacts where symptoms started on 
or before the onset of symptoms in index children were excluded from estimations of 
serial interval.  
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Table 5.9 Summary of household contacts with symptom onset prior to or same day as 
index child   
 
 
5.3.6.2 Rotavirus shedding in control households 
There was also a high prevalence of rotavirus shedding in the control households, with 
40/144 household members positive for rotavirus (27.8%), significantly less than observed 
in household contacts of a symptomatic case (434/665, (65.3%)) (Table 5.8). No significant 
difference was seen in shedding patterns across age groups. There was no clinical 
gastroenteritis in the control households, as this was an exclusion criterion for 
recruitment. 
5.3.7 Genotyping data 
5.3.7.1 Genotypes in index child 
Out of 195 samples from index children with available genotyping data, almost a third 
were G2P[4] (60/195, 30.8%). The next most frequent was G1P[8], at 48/195 (24.6%), 
followed by G2[P6] (28/195, 14.4%) and G12P[6] (16/195 (8.2%). 16/195 (8.2%) were 
mixed genotypes, and for three samples a G type was not obtained (3/195 [1.5%]) (Fig 
5.3).  
Symptom start date: 
household contact  
Symptom start date: index 
child 
Age of household 
Contact (years) 
Rotavirus 
positive 
15 Aug 2015 15 Aug 2015 37.11 Yes 
29 Aug 2015 29 Aug 2015 1.08 Yes 
25 Mar 2015 26 Mar 2015 39.87 No 
19 Mar 2016 20 Mar 2016 1.03 Yes 
19 Mar 2016 19 Mar 2016 1.19 Yes 
25 Mar 2015 26 Mar 2015 33.22 Yes 
01 Jan 2016 02 Jan 2016 0.91 No sample 
24 Jul 2016 24 Jul 2016 32.14 Yes 
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Figure 5.3 Rotavirus genotypes in index children 
5.3.7.2 Genotyping in household members 
Initially, genotyping was attempted on samples from household members with a Ct value 
of <38, however very few samples with Ct values between 35 and 38 were successfully 
typed, so typing was limited to samples with a Ct of ≤35. Only one sample was typed per 
household contact, if a household member had two samples with Ct values ≤35 the first 
sample was selected for typing. 297 samples were genotyped from contacts in the 195 
households with genotypes available for the index child. Of these, in 94/297 (31.6%) 
samples the same G and P type was identified in the household contact as identified in 
the index child. In a further 27/297 (9.1%) and 15/297 (5.0%) respectively the G type or 
the P type was the same between index child and household contact, but it was not 
possible to type the second component. In 28/297 (9.4%) samples the G type was 
consistent between index child and household contact but the P type was different, and 
in 21/289 (7.1%) the P type was consistent and the G type different.  In 44/297 (14.8%) of 
samples both the G and P types were different between the index child and the household 
contact. This is summarised in Table 5.10.  
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Table 5.10. Summary of genotyping results 
Number of household contacts 705 from 196 households 
Number of samples 1212 
Number of  contacts with at least one sample 665, from 188 households 
Number of samples genotyped  
 195 index children 
 297 samples from household contacts 
Transmission of concordant genotypes from index child to household contact 
Full transmission 94 (31.6%) 
G transmission P type not typed 27 (9.1%) 
P transmission G type not typed 15 (5.0%) 
Neither G or P type typed 22 (7.4%) 
Both G & P type different 44 (14.8%) 
G transmit P type different 28 (9.4%) 
P transmit G type different 21 (7.1%) 
G type different, P type not typed 30 (10.1%) 
P type different, G type not typed 16 (5.4%) 
 
5.3.8 Decision to stop recruiting 
This study was initially powered to investigate differences in secondary attack rates in 
households were in the index child was vaccinated, compared to those where the index 
child was not vaccinated. However due to the overwhelming success of the vaccine 
campaign, extremely rapid uptake of rotavirus vaccine, and higher than anticipated 
vaccine coverage, this was not possible. In August 2016 only 2 unvaccinated children had 
been recruited. In a final attempt to recruit unvaccinated children an additional study site 
was opened where there had been a recent vaccine stock out. After 3 months of 
recruitment at this site, no additional unvaccinated rotavirus positive cases had been 
identified and the decision was taken that any additional attempts to recruit unvaccinated 
children would be futile and recruitment was ceased.  
 
5.3.9 Quality control and validation of cohort 
5.3.9.1 Withdrawals 
There were 61 households which consented at initial recruitment point but then withdrew 
from the study. 59 of these completed the initial consent process and index child 
recruitment form, 2 withdrew before any data collection was conducted. Demographic 
information was compared between index children who completed the study and 
withdrawals to look for evidence of systematic differences between groups and evaluate 
risk of bias. Data for index children and children who withdrew is outlined in Table A4 
(Appendix, page 264). Withdrawal children were similar to index children who completed 
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the study, with no evidence of systematic differences. The only differences observed were 
in sex, where withdrawal children were significantly more likely to be male (41/59 
[69.5%]) compared to index children (108/196 [55.1%], chi squared p 0.049), and in 
previous presentations with diarrhoeal disease, where withdrawals were more likely to 
have presented with diarrhoea to a health centre previously (36/59 [61.02) vs 91/196 
[46.4%], chi squared p value 0.049. Data from withdrawn households is not used in any of 
the subsequent analysis.  
5.3.9.2 Representativeness of RRTE recruits 
Children enrolled into the transmission study were also compared to rotavirus positive, 
vaccine age eligible children from the diarrhoeal surveillance study who were not 
recruited into the RRTE study to look for evidence of selection bias in recruits. For the 
purposes of this analysis, children were defined as rotavirus positive if rotavirus antigen 
was detected on IC rapid test or EIA. EIA was not performed in real time, so children who 
were positive on EIA but negative on ICT would not have been identified as eligible for the 
RRTE study. Sensitivity and specificity of ICT test compared to EIA is described in Table 
5.11. 
From 16th February 2015 to 11th November 2016 inclusive 287 vaccine-age eligible 
children were identified as rotavirus positive across all 4 study sites using  ICT rapid tests. 
A further 44 children from QECH were identified as rotavirus positive using EIA (28 of 
whom had been negative on ICT test, and 16 for whom ICT test was not performed. This 
gave a total of 331 children positive for rotavirus, 196 (59.2%) of whom were recruited 
into and completed follow up for the RRTE study. Children enrolled into the RRTE study 
came from both health centres and QECH, while the surveillance platform only recruited 
at QECH.  
The comparison between groups is outlined in detail in Table A5 (Appendix page 267). 
Rotavirus positive children from the surveillance study were somewhat younger than 
children recruited into RRTE (10.2 months, IQR 7.6, 14.9 vs 11.4 months, IQR 8.7, 15.3). 
Children in the diarrhoeal surveillance platform were less likely to be vaccinated that 
children in RRTE (8/135 [5.9%] unvaccinated vs 2/196 [1.0%]). Children in the diarrhoeal 
surveillance platform were more likely to have had previous attendances for diarrhoeal 
disease (85/135 [62.9%] vs 91/196 [46.4%]. Prevalence of SAM was also higher in the 
diarrhoeal surveillance platform (27/135, [20.0%] vs 23/193 [11.9%]).  Children in the 
diarrhoeal surveillance platform were more likely to be admitted than children in RRTE 
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(110/135 [81.5%] vs 111/196 [56.6%]), which likely reflects the different recruitment sites 
used. There was no significant difference between the two groups in terms of disease 
severity, prevalence of dehydration, need for IV rehydration, or outcome. There were no 
significant difference in household characteristics such as electricity at home, sharing a 
toilet, access to water, water source, challenges obtaining food or in mean wealth 
indicator.  
5.3.9.3 Sensitivity and specificity of IC tests 
A summary of samples from the diarrhoeal surveillance study which were tested with both 
EIA and ICT test can be seen in Table 5.11. 22 samples positive on ICT test were negative 
on EIA. VP6 qRT-PCR was performed on a subset of 10 of these samples (i.e. those children 
recruited into RRTE). All were positive for rotavirus on qRT-PCR, with a median Ct value of 
24.3, ranging from 17.6 to 37.6. As the decision to conduct qRT-PCR was based on a 
positive ICT result it is not possible to report qRT-PCR results on EIA positive ICT negative 
samples. Five index children had no initial bulk stool collected as the initial screening was 
performed on rectal swab and a bulk stool sample was not obtained at the time. Four of 
these had a second sample collected. In all four of these the second sample was qRT-PCR 
positive for rotavirus with Ct values ranging from 15.0 to 26.8. One index child was 
identified purely on rectal swab with no bulk stool sample. Rotavirus was identified in 
household contacts, so this child was assumed to be a true rotavirus positive case and 
included in the analysis.  
Table 5.11. Sensitivity and specificity of rapid test, where EIA is taken as the gold standard  
  IC test  
 Positive Negative Total 
Rotavirus EIA Positive 217 29 246 
Negative 22 450 472 
 Total 239 479 718 
     
 Sensitivity IC test 88.2 (83.5, 92.0)   
 Specificity IC test 95.3 (93.0, 97.1)   
 PPV* 90.8 (86.4, 94.1)   
 NPV** 94.0 (91.4, 95.9)   
*Positive predictive value **Negative predictive value 
5.3.9.4 Representativeness of household contacts.  
Where possible, limited anonymous data were collected on household members who 
were not recruited, to identify any evidence of systematic bias in the household members 
who were recruited, and to ensure that household members successfully recruited were 
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representative.  Out of 983 documented members of the 196 households,  901 (91.7%) 
were recruited, including index children. Data were available for 78 of the 84 refusers. 
54/78 (69%) were male. 49/77(63.6%) declined to take part in the study, 23/77(29.8%) 
were absent from the home during the time frame the study was conducted, and 5/77 
(6.5%) gave another reason (not specified) for not taking part. Despite the higher refusal 
rate in males fathers participated in 137/196 (69.9%) of households. This compares to 
mothers, who took part in 195/196 (99.49) of households. Fathers who did take part were 
less likely to contribute a sample compared to other relatives. 15/137 (11%) of fathers 
contributed no sample, compared to 26/568 (4.4%) of other relatives 
5.4 Discussion 
In this vaccinated population, very high attack rates (65%) were observed for rotavirus 
infection in households following contact with a symptomatic index rotavirus case, but a 
low frequency of rotavirus disease(5%). Frequency of asymptomatic rotavirus shedding 
was lower in household contacts of asymptomatic control children at 28%. These data 
confirm the remarkable transmissibility of rotavirus and although the estimate of SAR for 
rotavirus infection is high, it is consistent with findings from other settings. In New 
Zealand, 48% of household contacts of a rotavirus index case had rotavirus detected in 
their stool using EIA(251) which is likely to represent a minimum estimate as EIA is 
substantially less sensitive than qRT-PCR for detecting rotavirus(341), and in Ecuador SAR 
determined using qRT-PCR was found to be 55%(106).  
In contrast to the high SAR for infection, much lower attack rates were observed for 
clinical disease (5%) than have been previously observed. In Ecuador disease attack rates 
were 15%, and in New Zealand 67% for children and 26% for adults(106,251).  One 
possible explanation for the lower disease rates observed in Malawi could be high 
background force of infection, such that once immunity to clinical disease is obtained it is 
regularly “boosted”, resulting in a lower risk of symptomatic disease on re-infection. This 
theory is supported by the high frequency of detectable rotavirus in asymptomatic control 
household members, suggesting a high frequency of exposure to rotavirus in the 
community. It is also possible that this finding could reflect under-ascertainment of 
symptoms. This could occur if symptoms were underreported perhaps because mild 
symptoms are not considered significant, or because adults or older children may be 
embarrassed to report symptoms of diarrhoeal disease. In our experience however 
community members were felt to have a low threshold for reporting symptoms to the 
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study team because the study team were seen as having the ability to facilitate medical 
assistance or treatment. Another potential reason for under-ascertainment is that for 
practical reasons after the initial household visit, symptom data for each household 
member could be collected from a proxy instead of directly from the household member 
themselves and it is possible that this was less accurate than obtaining data from each 
individual household member directly.  
It is intriguing that there was no difference in the frequency of rotavirus infection in 
household contacts with age, either in households exposed to a rotavirus case, or in 
control households. This is in contrast to findings from the UK, where asymptomatic 
rotavirus shedding occurred with decreasing frequency with increasing age, and from 
Ecuador, where secondary attack for infection was higher in children under 10 years 
compared to those over 10 years(19,106). This finding is particularly interesting given that 
clinical disease attack rate does depend on age, with a significantly higher risk of disease 
attack in  children under 5 years of age. It is possible that in Malawi, exposure to rotavirus 
generates protection against clinical disease, but not against infection. This could reflect 
sub-optimal immune response in Malawi, which would fit with the widespread 
observation that children demonstrate less robust immune response to rotavirus vaccine 
in low income compared to high income settings(298), and  that children from LIC seem 
to require a greater number of severe disease episodes to generate protection compared 
to high income countries(38). It could also reflect differences in contact patterns. 
Households in LIC such as Malawi often live in much closer proximity to one another than 
households in high income countries, and children are often cared for by many different 
family members, so this finding could reflect also a more equal distribution of exposure in 
Malawi. While serial interval range (1-8) reported in this study is consistent with that from 
previous studies, the mean is somewhat shorter (3 vs 4 to 7 days(76,251)). This may reflect 
errors in reporting – literacy levels are low in Malawi and accurate estimations of time can 
be difficult to obtain, but could also reflect differences in contact intensity or water and 
sanitation.  
Although in approximately one third of genotyped samples the genotype identified was 
consistent between index house and household contact, there were considerable 
numbers of households where there were inconsistencies between the genotype in the 
index child and that observed in contacts. This is consistent with findings from 
Ecuador(106), and is perhaps unsurprising given the high levels of asymptomatic shedding 
identified in the community without recent history of exposure to an index child. It does 
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however highlight the complexity of rotavirus transmission in low income settings. The 
high background circulation of rotavirus may provide frequent opportunity for viral re-
assortment, and may provide one explanation for the wide diversity of genotypes 
previously observed in rotavirus surveillance in Malawi(114,342–344).  
This study also demonstrated a high frequency of detectable rotavirus (28%) in household 
contacts of asymptomatic control children. This is substantially greater than observed in 
Ecuador, where 12% of asymptomatic infants had detectable rotavirus in their stool(106), 
and no household contacts of these infants had detectable rotavirus, and also greater 
than reported from the UK, where age adjusted prevalence of detectable rotavirus in 
asymptomatic individuals using qRT-PCR was 11%(19). It is however consistent with  
studies from Burkina Faso, Tanzania and Malawi were prevalence of rotavirus using qRT-
PCR in asymptomatic children ranged from 18-31%(20,107,108). It also corroborates 
findings from historic studies of asymptomatic infants and adults in south America and 
Africa. In Mexico 30% of children and 21% of adult contacts were found to be EIA positive 
for rotavirus, and in Nigeria in 1996 30% of 821 asymptomatic adults and children were 
found to be EIA positive for rotavirus(105,112). Given the higher sensitivity of qRT-PCR for 
rotavirus, this is likely to reflect a similar frequency of low level shedding to that observed 
in this dataset. Although the frequency of rotavirus shedding in the community is high, it 
seems plausible given what is known about the high burden of rotavirus in Malawi, and 
levels of poverty with associated issues of crowding and poor water and sanitation.   
5.4.1 Limitations 
It is possible that the high frequency of rotavirus shedding in households reflects cross 
contamination between samples. This is unlikely at the laboratory level, as negative 
controls were included for each stage of the analysis, and any assays which failed were 
repeated. In addition to this any sample with a Ct value of >35 and or copy numbers of 
<100 had a repeat qRT-PCR performed using a different target (NSP3), and was reclassified 
if negative on NSP3. Cross contamination at the household level is difficult to exclude 
entirely, as samples were, by necessity, collected by the family in the absence of the field 
team. However, every effort was made to counsel families on how to collect samples 
appropriately and it seems unlikely that non-compliance would be systematic. Because of 
unavoidable delays in obtaining relevant permission to recruit control households all 
control samples were collected in a limited time period between July and January 2016, 
so one explanation for the high frequency of detection of rotavirus in household contacts 
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of asymptomatic control children could be seasonal changes in the prevalence of 
rotavirus, although this is perhaps less likely as historically the rotavirus season in Malawi 
has been between approximately May to October.  
While control households were largely comparable to households of index children 
control households, the wealth index was significantly higher in control households than 
in households of index cases.  This could represent a degree of selection bias in 
recruitment of controls – controls were selected using a random walk from a random 
location and it could be that more easily accessible houses are wealthier. This could also 
represent random chance. However given the similarities in the majority of the rest of 
household characteristics this is unlikely to have a substantial impact on rates of 
transmission. It is interesting that despite the fact that control households were wealthier 
a larger proportion of control households reported problems getting the food they 
needed, compared to index households. Again, this may represent random chance, or it 
could reflect time of recruitment. Food supply varies with season in Malawi and the 
majority of control households were recruited in the latter two quarters of the year, which 
is the beginning of what is known at the hungry season. In contrast recruitment of index 
households was reasonably evenly distributed throughout the year.  
Children recruited from health centres were comparable to children recruited from QECH, 
with the exception of disease severity which was greater at the tertiary centre (QECH). 
This is expected, as the sickest children are referred to QECH and recruitment at health 
centres was deliberately expanded to increase recruitment of children with less severe 
disease. Children also tended to be more wasted at QECH. This could reflect a tendency 
of less well-nourished children to develop more severe disease(345), or could reflect 
greater levels of dehydration due to a greater severity of disease. It is interesting that a 
significantly greater proportion of children presenting to QECH had previous attendances 
for diarrhoeal disease compared to those presenting to health centres. This could be 
random error, or reflect recall bias. However it could also reflect a phenomenon observed 
in India, where it was identified that a subset of children develop repeated episodes of 
severe disease without mounting protective immunity(346).  
Despite careful consent processes, post recruitment withdrawal rates were high(24%). 
Most recruits completed an initial data collection form before withdrawing so we were 
able to compare demographics between those who completed the study and those who 
did not, and investigate for any evidence of selection bias. There were significant 
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differences in sex and previous presentation with diarrhoeal disease between 
withdrawals and children completing the study, but this seems likely to be a result of 
chance rather evidence of systematic differences. There were no other significant 
demographic differences between withdrawals and children who completed, and it is 
likely that the children who completed the study are a representative sample of children 
presenting to health care facilities in Blantyre with diarrhoeal disease.  
Although the overall numbers of unvaccinated rotavirus positive children identified were 
very low (10), children who took part in the RRTE study were significantly less likely to be 
vaccinated than vaccine age eligible children in the diarrhoeal surveillance platform only. 
Vaccine coverage in Blantyre is now high enough that unvaccinated children are a biased 
group, and likely not representative of the population as a whole. There also may be a 
reluctance for families to consent to taking part in a study about rotavirus vaccine if a child 
was unvaccinated, and then subsequently required admission for rotavirus disease. There 
were however no other significant differences between the groups suggestive of 
systematic bias. In households which did consent to take part in the RRTE study, 91% of 
eligible household contacts consented to take part in the study. The majority of those who 
declined to take part were male, which is likely to reflect a combination of males being 
absent from the home more, and cultural factors surrounding compliance in males and 
the requirement for stool samples. Despite this, in the majority of households fathers took 
part in the study (70%) and although fathers were underrepresented in comparison to 
other household members, there are sufficient numbers of adult males and fathers in the 
sample that it seems likely that the results for male family members are representative of 
the population.  
ICT rapid tests were used to identify children for recruitment into this study. When 
eligibility is based on the results of a diagnostic test there is always the risk of 
misclassification. In the RRTE study however the sensitivity of the IC rapid test was very 
good compared to an EIA gold standard (88.2%), and there was no false positive case 
recruited. A small number of potentially eligible children were not identified because of 
false negative IC test results, however sensitivity analysis has shown no evidence of  
differences between rotavirus positive children who were recruited and rotavirus positive 
children who were not recruited, so this is unlikely to have affected the results. 
One unavoidable problem with the design of this study is that direction of infection cannot 
be certain. It would be impossible to define direction of infection clearly without a 
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prospective cohort study, which was not feasible given available time and resources. 
Previous studies have shown that in the majority of occasions it is infants which bring 
rotavirus into the house(245), and the low viral loads and low frequency of clinical disease 
in household contacts in this study corroborate this. Considerable care was taken in this 
study to collect symptom data on all household members for the 10 days preceding the 
date of presentation in the index child. In a small number of households (8), other 
household members reported onset of symptoms the same day, or the day before 
symptom onset in the index child. These have been included in the primary analysis given 
that the numbers are small, the time difference between symptom onset is narrow, and 
this small number of cases is unlikely to have a significant impact on results.    
5.4.2 Implications, conclusions and future work 
This study demonstrates a high frequency of rotavirus infection in household contacts of 
rotavirus positive cases in a vaccinated population, but a low frequency of clinical disease. 
Rotavirus shedding in household contacts of asymptomatic control children was lower, 
but still substantial. Programmatic rotavirus vaccination was introduced into Malawi 4 
years ago and vaccine coverage is now over 90% in Blantyre, so this study raises questions 
about the impact of rotavirus vaccine on asymptomatic rotavirus shedding, and the ability 
of rotavirus vaccine to substantially reduce population level transmission. The role of 
asymptomatic rotavirus infection in ongoing transmission in the community is as yet 
unknown, and a topic for future study.  
It is important to note that household contacts in this study appear to be protected 
against rotavirus disease with increasing age, but not against infection, and that 
protection against disease seems to be more substantial than observed in other countries. 
If this protection against disease relies on frequent exposure to rotavirus throughout life, 
then an increase in rotavirus disease in older age groups may be observed as incidence of 
rotavirus gastroenteritis falls following vaccine introduction. In contrast, household 
contacts in this study seem to have less immunity to infection than seen in other 
populations such as the UK, where asymptomatic rotavirus shedding decreases in 
frequency with increasing age. Both of these observations require further study, and 
ongoing monitoring to investigate the long term impact of vaccine on these effects. 
This study was originally designed to investigate the effect of vaccine exposure on the risk 
of rotavirus transmission to household contacts of a symptomatic rotavirus index case. 
Due to the excellent vaccine coverage in Blantyre it is not possible to answer that question 
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directly, but it may be possible to explore using more complex analytical techniques and 
mathematical models. In order to do this, outstanding questions on the relationship 
between disease severity and viral shedding in index children and predictors of rotavirus 
transmission in households must be answered. These questions will be addressed in the 
next two chapters. 
These are the first  data on rotavirus transmission from sub-Saharan Africa, and provide 
important baseline data from which further studies into risk factors for transmission and 
potential strategies to reduce transmission can be built. In particular, because of the 
complex nature of rotavirus epidemiology and immune response to exposure and vaccine, 
mathematical models have increasingly been used to evaluate the effect of different 
vaccine strategies on disease burden, and have provided invaluable insights into the 
presence of indirect effects and other vaccine effects on the epidemiology of 
rotavirus(118,237,330,347).  As observational studies become increasingly difficult to 
conduct in view of high levels of vaccine coverage across growing proportions of the global 
population mathematical models are likely to become increasingly crucial in informing 
global rotavirus vaccine policy. The accuracy of predictions made by mathematical models 
largely depends on correct parameterisation, particularly of key factors such as SAR and 
R0, and providing locally accurate baseline data to inform models is therefore 
essential(348–350).  
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Chapter 6. Duration and density of rotavirus shedding in children 
with rotavirus disease and their household contacts 
6.1 Introduction 
The previous chapter established that rates of rotavirus transmission in households 
exposed to a symptomatic index child are extremely high. The next chapters will focus on 
understanding how viral shedding and other risk factors affect transmission. Rotavirus 
transmission is predominately person to person direct spread through the faecal-oral 
route. The passage of viral particles shed in the stool of infected individuals is a necessary 
step for onward transmission(47), but much remains unknown regarding density and 
duration of shedding in infected individuals and how this relates to disease severity and 
risk of transmission to close contacts, particularly in low income settings.  
Viral particles are shed in the stool when individuals are infected with rotavirus. These 
were first identified in duodenal sections from children with acute gastroenteritis by Ruth 
Bishop in the 1970s using electron microscopy(1), and since then a variety of techniques 
have been used to evaluate the presence of rotavirus in stool samples. These are 
described in detail in chapter 1, section 1.2, page 30. Initial studies using electron 
microscopy or immunoassays revealed that rotavirus was shed in the stool of 50% children 
prior to the onset of symptoms(253), and that shedding continued for several days after 
symptoms had resolved(351,352).  The advent of molecular techniques to detect rotavirus 
in stool increased the sensitivity of detection of rotavirus, allowed lower viral loads to be 
detected and demonstrated that viral shedding in children continued for several days 
longer than had been previously determined using other antigen detection methods(18).  
Using RT-PCR Richardson et al described extended viral secretion of 25-57 days in 11/57 
(30%) children admitted with clinical rotavirus disease in Australia (254).  
Development of a semi-quantitative real-time RT-PCR for rotavirus allowed quantitative 
estimation of viral loads in stool samples(259,353). Using these techniques, Mukhopadhya 
et al demonstrated shedding of rotavirus for a median of 24 days in children from 
southern India with rotavirus gastroenteritis and 18 days in children with asymptomatic 
infection(255). They also demonstrated a rapid decline in viral load after the resolution of 
symptoms in children with disease, and described lower viral loads in children with 
asymptomatic infection compared to symptomatic disease. Kang et al showed a strong 
positive correlation between disease severity defined using the 20 point Vesikari score 
and viral load, and a positive association between the frequency of passage of diarrhoeal 
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stools and viral load(259). Phillips et al were able to identify a cut-off in qRT-PCR cycle 
threshold that correlates with the presence of clinical disease(354) and a similar cut-off 
has also been identified in children from Malawi(20). The use of qRT-PCR has also 
identified a high frequency of asymptomatic infection in community members of all ages, 
but of highest frequency (30%) in young children(19). It is possible that low level 
asymptomatic shedding plays a substantial role in community transmission of rotavirus 
infection, but the degree to which this is the case is not well described. 
Since rotavirus vaccination mimics natural infection, which provides incremental 
protection against severe rotavirus gastroenteritis, then it is possible that prior 
vaccination could mitigate disease severity in the event a vaccinated child develops 
rotavirus disease. If, as found in India(259), disease severity correlates with faecal viral 
shedding density, it follows that vaccination may be able to reduce viral shedding, and 
therefore reduce transmission to close contacts, even in the event of clinical vaccine 
failure. If this hypothesis is correct, this could be particularly important in low-income 
high-burden settings, where vaccine effectiveness against symptomatic disease is lower.  
Most of the available data, excepting India, come from high income settings. Individuals 
from low income settings may differ in intestinal integrity, nutritional state, immune 
response or co-morbidities, and this may lead to different shedding patterns compared to 
high income settings. For example, Cunliffe et al in Malawi identified that HIV-infected 
children with rotavirus gastroenteritis continue to shed for longer following an episode of 
rotavirus gastroenteritis compared to children who were HIV negative(260).  
Improved understanding of vaccine impact on rotavirus transmission requires a better 
defined  relationship between the symptom severity and viral shedding in low income 
settings. This study therefore aimed to describe patterns of rotavirus shedding over time 
in infants with rotavirus gastroenteritis and their household contacts and to investigate 
factors associated with faecal viral load in vaccine age eligible children with symptomatic 
disease in Malawi.  
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6.2 Methods 
6.2.1 Objectives 
1. To describe change in rotavirus viral load over time from symptom onset in 
symptomatic index children and in household contacts 
2. To identify factors associated with viral shedding density in symptomatic 
index children 
3. To describe duration of rotavirus shedding in symptomatic index children and 
in household contacts of index children who are found to be shedding 
rotavirus 
6.2.2 Study design 
These data come from the prospective cohort study of children with clinical rotavirus 
disease and their household contacts, described in detail in Chapters 2 and 5, and from a 
smaller cohort nested within the primary study of 21 index children and their household 
contacts in whom more intensive sampling was carried out for a longer period of time. 
6.2.3 Study site 
Participants for this study were recruited from QECH, Zingwangwa Health Centre, 
Gateway Health Centre and Madziabango Health Centre.  
6.2.4 Study population 
Study population are described in detail in Chapter 5. Additionally, the nested intensive 
cohort comprised 21 children and their household contacts in whom more detailed 28-
day follow up was conducted.  
6.2.5 Study Procedures 
6.2.5.1 Enrolment 
Enrolment into the primary study is described in Chapter 5 (section 5.2.7, page 155). 
Enrolment procedures and data collection for the nested cohort were the same, with the 
exception that recruitment took place from 16th Feb to 14th April 2016 and follow up 
occurred for a longer time period. Eligibility criteria for index children and their household 
contacts were identical to those used in the primary study and described in Chapter 5 
(Sections 5.2.7.4, page 157 and 5.2.7.8, page 160).  
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6.2.5.2 Sample collection 
Primary study: 
Each index child had two bulk stool samples collected (Fig. 6.1): 
• Sample 1: at presentation to health care facility and recruitment into the 
study 
• Sample 2: 5 to 7 days after symptom onset 
Each household contact had two stool samples collected 
• Sample 1:  days 5 to 7 after the onset of symptoms in the index child 
• Sample 2: days 10 to 12 after the onset of symptoms in the index child 
 
Figure 6.1 Sample collection in primary study 
Nested cohort 
Index children had up to 11 stool samples collected (Fig. 6.2): 
• daily from time of presentation for the first 7 days after symptom onset 
• twice weekly from 7 until 14 days after symptom onset 
• weekly from day 14 until day 28 after symptom onset 
Household contacts had up to 4 stool samples collected: 
• days 7, 14, 21 and 28 after symptom onset in the index child 
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Figure 6.2 Sample collection in nested cohort 
6.2.5.3 Household visits and follow up 
Household visits were conducted according to the schedule described above. Procedures 
and data collection were as described in Chapter 5, section 5.2.7, page 155. Data on 
symptoms in both the index child, and their household contacts were collected at the 
same time as each sample was collected.  
6.2.6 Sample size calculation  
No formal sample size calculation was conducted for the exploratory nested cohort. 20 
households were selected as the limit of what was practical and feasible in the contexts 
of the primary study. Because of difficulties in follow up in one of the households an 
additional household was recruited. 
6.2.7 Laboratory procedures 
Laboratory procedures were described in detail in Chapter 2, section 2.3, page 87 and 
chapter 5, section 5.2.7, page 155. Stool samples from all recruits were tested using real-
time qRT-PCR (RT qRT-PCR) to assess stool viral load. 
6.2.8 Statistical analysis 
Rotavirus shedding was defined as the presence of 100 or greater viral copy numbers in 
stool on VP6 qRT-PCR and positive on confirmatory NSP3 assay if Ct value was ≥35, as 
described in chapter 5, section 5.2.13, page 168. The exception to this was for analysis of 
changes in viral load over time in index children and in rotavirus positive household 
contacts where all data were included regardless of viral load. 
Faecal viral load distributions were plotted, and central tendency described using median 
and interquartile range [IQR]. Viral load did not follow a normal distribution so was log-
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transformed for further analysis using the natural logarithm. Change in viral load over 
time and relationship between symptoms and viral load were evaluated using linear 
mixed models with a random intercept to account for the within child clustering resulting 
from repeated measures. To account for the non-linear relationship between faecal viral 
load and time, polynomial terms (quadratic and cubic) were included in the model for viral 
load over time in index children. These were selected based on the best visual fit to the 
data. Polynomial terms did not improve the visual fit in the models for viral load over time 
in household contacts so were not included.  
Relationship between faecal viral shedding load and disease severity was investigated 
using linear regression. The outcome variable was peak log-viral load in index children. 
Variables achieving a Z test p value of ≤0.1 on univariate analysis were selected for 
evaluation in the multivariable model. Age and sex were included a priori. Nested models 
were compared using F tests. Only one variable of a set of collinear variables (such as 
diarrhoeal duration and diarrhoeal frequency) was selected for inclusion in the final 
model. 3 outlying values with high statistical leverage were excluded from the final model. 
Time-to-event analysis was used to describe the duration of shedding in index children 
and in household contacts, where the event of interest was defined as cessation of 
shedding.  Cessation of shedding was defined as the first time point from which no 
rotavirus was subsequently detected until censoring. Thus, an individual with no 
detectable rotavirus at a given analytical timepoint but who was shedding rotavirus in 
subsequent samples, was classified as having ongoing shedding at the timepoint of 
analysis. Sampling duration was limited to 28 days. For those who ceased shedding it was 
assumed that there was no viral shedding beyond truncation. For index children the start 
time for analysis was the onset of symptoms, for household contacts start time was 
defined as the first positive sample. 
6.3 Results 
This analysis was conducted in 4 parts.  
i) Rotavirus positive children with gastroenteritis from the primary study.  
These were children with symptomatic rotavirus disease from the primary database who 
had two stool samples collected in the first week after presentation. This dataset was used 
to analyse associations with viral shedding density 
ii) Rotavirus positive children with gastroenteritis from the nested cohort.  
197 
 
These were the 21 children with up to 11 samples collected over a 28 day period following 
symptom onset. Data were used to investigate trends in faecal shedding over time and 
duration of shedding in symptomatic children  
iii) Household contacts of symptomatic index children from the primary study 
This comprises the primary dataset in which two samples were collected in the 12 day 
time period after the onset of symptoms in the index case and was used to investigate 
temporal relationship between faecal viral load in contacts and symptom onset in index 
children.  
iv) Household contacts of the 21 children recruited into the nested  cohort 
These household members had two additional samples were collected at 21 and 28 days 
after symptom onset.  These data were used to describe duration of shedding in 
household contacts. 
6.3.1 Rotavirus positive children – primary dataset 
374 samples were collected in total; 189 first samples and 185 second samples (5 children 
had rectal swabs alone collected at the time of first testing, and two bulk samples were 
lost during processing).  
Samples 1 and 2  were collected respectively a median of 3 (IQR 2,4) days and 5 (IQR 3,7) 
days after symptom onset. Sample 1 median viral loads were significantly higher, with 
median Ct value of 19.1 (IQR 17.2, 22.2) corresponding to median copy numbers of 1.67 
x 107  (IQR 1.63 x 106, 6.37 x 107 ) in Sample 1, compared with median Ct value of 22.61 
(IQR 19.04, 29.14) corresponding to median copy numbers of 5.5 x 105  (IQR 7.9 x 103, 7.31 
x 106 ) in Sample 2, sign rank p value <0.001.  
6.3.1.1 Predictors of viral load 
On univariate analysis a significant positive association was demonstrated between peak 
viral load and clinical disease severity as measured by the standard 20-point Vesikari score 
(see Chapter 5, section 5.2.7.5, page 158) (Table 6.2, Fig. 6.3, regression coefficient 
0.24[95% CI 0.10, 0.38]).  The presence of vomiting (regression coefficient 1.80 [ 95% CI 
0.32, 3.28] and admission to hospital (regression coefficient 0.98 [95% CI 0.21, 1.76]) were 
also strongly associated with viral load. Weak evidence of a positive association with 
diarrhoeal duration, vomiting duration of at least 3 days, and severe dehydration were 
also identified. In addition peak viral load was significantly positively associated with birth 
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weight and height for age Z score (HAZ) and negatively associated with weight for height 
Z score (WHZ) and there was weak evidence of a negative association with mid-upper arm 
circumference (MUAC) (Table 6.1).  
On multivariable analysis a positive association with Vesikari score (regression coefficient 
0.17 [95% CI 0.04, 0.312]) and a negative association with WHZ (regression co-efficient -
0.26 [95% CI -0.46, -0.02]) were retained. Sex and age were included a priori. There was 
weak evidence that including diarrhoeal duration improved the model (F test p value 
0.0672) in addition to Vesikari score, but this was not included in the final model due to 
concerns around collinearity.   
 
Figure 6.3. Relationship between log peak viral load and Vesikari score. Raw data are 
log(peak viral load), and the fitted line represents the regression line. Confidence bound 
represents the 95% confidence limit either side of the fitted valued. Regression 
coefficients can be seen in Table 6.1 
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Table 6.1. Univariate and multivariate analysis of potential predictive factors for peak 
viral load in index children 
 
 
 
Covariate N Univariate association 
with peak viral load 
P 
value* 
Multivariate association 
with peak viral load 
P 
value* 
Sex (Male) 195 -0.56 (-1.34, 0.22) 0.157 -0.60, (-1.33, 0.14) 0.110 
Age in months 195 -0.04 (-0.10, 0.02) 0.245 0.00 (-0.06, 0.06) 0.964 
HIV exposed 195 0.13 (--1.03, 1.29) 0.823   
HIV infected 58 0.58 (-3.55, 4.71) 0.779   
Premature 195 0.34 (-1.75, 2.43 ) 0.748   
Birth weight (kgs) 195 0.23 (0.01, 0.44) 0.038   
Ever breast fed 195     
Yes  -1.18 (-6.62, 4.25) 0.668   
SAM      
Yes 193 0.17 (-1.04, 1.38)  0.780   
WHZ 194 -0.39 (-0.63, -0.15) 0.001 -0.26 (-0.46, -0.02) 0.032 
WAZ 194 0.10 (-0.24,  0.43)  0.565   
HAZ 190 0.28(0.12, 0.43) 0.001   
MUAC (Cm) 194 -0.26 (-0.56, 0.04) 0.090   
Diarrhoea episodes** 195      
1-3  REF    
4-5  0.60 (-0.67, 1.87) 0.350   
≥6  0.69 (-0.58, 1.96) 0.286   
Diarrhoea duration (days) 195      
1-4  REF    
5  1.60 (-0.00, 3.21) 0.051   
≥6  -0.44 (-2.11,1.23) 0.604   
Vomiting 195     
Yes  1.80 (0.32, 3.28) 0.018   
Vomiting frequency 181     
<5  REF    
≥5  0.06 (-0.78, 0.88) 0.892   
Vomiting duration (days) 181     
1  REF    
2  0.62 (-0.64, 1.88) 0.333   
≥6  1.33 (0.15, 2.52) 0.028   
Dehydration  195     
None  REF    
Some  0.65 (-0.53, 1.83) 0.282   
Severe  1.31 (-0.03, 2.65) 0.055   
IV fluids 195     
Yes  0.57 (-0.28, 1.42) 0.185   
Oral fluids 195     
Yes  0.24 (-1.44,  1.92) 0. 775    
Admission 195     
Yes  0.98 (0.21, 1.76) 0.013   
Outcome  195     
Home  REF    
Died  -2.03 (-5.88, 1.80) 0.297   
Vesikari score 192 0.24 (0.10, 0.38) 0.001 0.17 (0.04, 0.312) 0.013 
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6.3.2 Rotavirus positive index children from nested cohort 
178 samples were collected from 21 children over a period of 29 days from symptom 
onset. Viral load declined significantly over time since symptom onset (Fig 6.4) with a 
regression coefficient for relationship between log copy numbers and time in days since 
symptom onset of -1.60 (-2.44, -0.74, p<0.001) (Table 6.3). Viral load was significantly 
higher when children were symptomatic, regression coefficient  (6.44, 95% CI 4.63, 8.25) 
(Fig 6.5). When adjusted for time since onset of symptoms the trend toward higher viral 
loads persisted but was no longer significant at the 5% level (regression co-efficient 1.45, 
95% CI -0.27, 3.17). 
 
Figure 6.4. Decline in viral load over time in symptomatic children. Raw data is log(viral load), 
and the fitted line represents the regression line including quadratic terms to account for the non-
linear nature of viral decay. Confidence bound represented the 95% confidence limit either side of 
the fitted valued. Regression coefficients can be seen in Table 6.2 
Table 6.2 Regression model for shedding curve 
Log viral load Regression coefficient P value 95% Confidence limits 
Time since symptom 
onset (TS) 
-1.60 <0.001 -2.44, -0.74 
(TS)2 0.06 0.110 -0.01, 0.13 
(TS)3 -0.01 0.403 -0.00, 0.00 
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Figure 6.5 Log viral load by presence or absence of symptoms. Error bars represent mean 
and standard deviation.  
The proportion of children shedding rotavirus declined significantly with each visit, from 
100% at the first visit to 20% at the final visit (Table 6.3, Fig 6.6). 7 children were still 
shedding rotavirus at the time of their last follow up visit. Of those who did stop shedding 
whilst in follow up median duration of shedding was 27 days (IQR 19, 28) 
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Table 6.3. Proportion of children shedding rotavirus at each visit 
 Visit number 
Shedding 1 2 3 4 5 6 7 8 9 10 11 
No 0(0) 3 (14) 4 (14) 2 (10)  3 (15) 6 (32)  7 (41)   3 (23) 6(55)  5(56)  4(80)  
Yes 21(100) 18(86) 16(80) 19(90) 17(85) 13(68) 10(59) 10(77) 5(45) 4(44) 1(20) 
Total 21 21 20 21 20 19 17 13 11 9 5 
Chi squared p value<0.001. Numbers in brackets are percentages 
 
 
Figure 6.6. Kaplan Meier curve of time to cessation of shedding in index children. Analysis 
time is in days since symptom onset 
6.3.3 Household contacts of symptomatic children 
1312 samples were collected from 665 household contacts. 1212 of these were from the 
606 individuals in the “primary study” with 2 samples collected over 2 weeks from onset 
of symptoms in the index case and 100 were from the 59 individuals in the intensive 
cohort with up to 4 samples collected over 28 days. Data from both groups were analysed 
together to examine changes in viral load over time. Viral loads were considerably lower 
than those observed in children presenting with rotavirus disease, with a median Ct value 
across all the samples of  34.8 (IQR 31.8, 36.6), corresponding to a median viral load of 
712 (IQR 256, 3704). Timing of samples in days since symptom onset in index child can be 
seen in Table 6.4.  
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Table 6.4  Timing of sample collection household contacts in relation to symptom onset 
in the index child 
 Median time in days since symptom onset in index child (range).  
Sample 1 5 (1, 18) 
Sample 2 11 (7, 39)  
Sample 3 21 (19, 32) 
Sample 4 28 (26, 40) 
 
Viral load in household contacts declined significantly over time from symptom onset in 
the index child (Fig. 6.7), with a regression coefficient for relationship between log copy 
numbers and time since symptom onset in index child of -0.05 (95% CI -0.02, -0.08) (Table 
6.5).    
 
Figure 6.7 Viral load in household contacts since time of symptom onset in index child. 
Raw data is log(viral load), and the fitted line represents the regression line. Confidence bound 
represented the 95% confidence limit either side of the fitted valued. Regression coefficients can 
be seen in Table 6.5 
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Table 6.5 Regression model for log viral copy numbers in household contacts since 
symptom onset in the index child   
 Coef. P value 95% CI 
Time since symptom onset in index child (TSI) -0.05 0.001 -0.08, -0.02 
 
Log viral load was significantly higher in those household members with symptoms of 
gastroenteritis (Fig 6.8) , with a regression coefficient for relationship between log copy 
numbers and presence of symptoms in the household contact of  3.36 (95% CI 2.33, 4.40, 
p<0.001) 
 
Figure 6.8 Log viral load in household contacts by presence or absence of symptoms. Error 
bars represent mean and standard deviation. 
6.3.4 Household contacts of children in nested cohort 
In the 59 household contacts of children in the nested cohort the proportion of household 
members shedding rotavirus declined significantly over time, from 76.3% at visit 1 to 
31.82% at visit 4, chi squared p value 0.001 (Table 6.6). Time to cessation of shedding can 
be seen in Fig. 6.9. For this analysis the start of shedding was defined as the first positive 
sample. 29/59 (49.2%) individuals stopped shedding rotavirus before follow up was 
completed. For these individuals median time to cessation of shedding was 19 days (IQR 
17, 23), with a range of 9-26 days. 16/59 (27.1%) individuals continued to shed rotavirus 
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throughout follow up, median follow up for these individuals was 23 days (IQR 20.5, 24.5, 
range 20, 36). This compares to 290/606 (47.9%) individuals in the primary cohort who 
were still shedding rotavirus at the time follow up ceased. 14/69 (20.2%) did not shed 
rotavirus at any point during follow up. No new episodes of shedding were identified in 
week 3 or 4 or follow up - all individuals who had a positive sample at visit 3 or 4 had had 
a previous positive sample at visit one or two. Only two contacts in the nested cohort 
developed symptoms, and there was no significant difference in median time to cessation 
of shedding compared to those with asymptomatic infection, so they were included in the 
analysis.  
Table 6.6. Proportion of household members shedding rotavirus by at each visit 
 Visit 
Shedding 1 2 3 4 
No 14  12 34 30 
Yes 45 (76.3) 40 (76.9) 22 (39.3) 14 (31.82) 
Total 59 52 56 44 
Numbers in brackets are percentages 
 
 
Figure 6.9. Kaplan Meier curve of time to cessation of shedding in household contacts. 
Analysis time is in days from first positive sample 
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6.4 Discussion  
This study corroborates findings from other settings regarding the relationship between 
viral shedding density and symptomatic disease. Malawian children with rotavirus 
gastroenteritis shed rotavirus in high density at the time of initial symptom onset, and 
continue to shed rotavirus for an extended period of time after symptoms resolve. Disease 
severity was associated with higher viral shedding density, and symptoms were associated 
with higher viral loads than asymptomatic infection.  
The pattern of rotavirus shedding observed in symptomatic rotavirus cases is similar to 
that observed by Mukhopadya et al in children from India(255). Initial extremely high viral 
titres showed a rapid decline over the first 10 days after symptom onset, and then plateau, 
with a median duration of shedding of approximately 4 weeks (27 days in Malawi, 24 days 
in children from Vellore). This is substantially longer than the median duration of shedding 
of 10 days observed by Richardson et al in Australia(254). This could at least in part reflect 
differences in sensitivity of the assay used; the same assay was used in India and Malawi, 
and a different, less sensitive assay used in Australia. However there is good evidence that 
the immune response to both natural rotavirus infection and to rotavirus vaccine is 
reduced in low income compared to higher income settings(38,62,95)(96,298) and it is 
possible the extended duration of shedding observed in this study and in India represents 
another manifestation of this, reflecting delayed clearance of replicating virus as a result 
of sub-optimal mucosal immunity.  
In household contacts the significant decline of viral load over time since onset of 
symptoms in the index child and the lack of new infections identified beyond the second 
week of follow up in the nested cohort supports the hypothesis that the symptomatic 
index child is the primary source of transmission.  Median duration of shedding in 
household contacts who stopped shedding was similar to that observed in asymptomatic 
Indian children (19 vs 18 days). Notably 27% of household contacts were still shedding 
rotavirus at the cessation of follow up, with a median duration of follow up 23 days. This 
raises the possibility that the true duration of shedding in Malawi is longer than observed 
in this study. Unfortunately this cannot be confirmed because follow up in this study was 
truncated at 28 days.  
The presence of symptoms was significantly associated with higher viral loads in both 
index children and their household contacts. This corroborates data from India, Malawi 
and the UK which found significant differences in viral load between individuals with 
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rotavirus disease compared to those with asymptomatic rotavirus infection(20,255,354). 
Disease severity defined using the Vesikari score showed a significant positive association 
with viral load, in line with findings from Vellore(259). When individual components of  
the Vesikari score were investigated, the presence of vomiting, duration of vomiting, 
duration of diarrhoea, presence of dehydration and need for admission showed some 
evidence of a positive  association with viral load.  Only duration of diarrhoea was retained 
in the model once adjusted for Vesikari score, with weak evidence of an additional 
association with increasing viral load (F test p 0.07). This was not included in the final 
model because of concerns regarding collinearity with Vesikari score. In India, viral 
shedding density was associated with diarrhoea frequency, and it was postulated that 
high viral load could contribute to high diarrhoeal frequency, however we did not find a 
univariate association between diarrhoeal frequency and viral load. This may reflect 
differences in data collection practices; in India data on stool frequency was recorded by 
nurses on the ward but in Malawi we relied on maternal report which could be less 
accurate. Counting diarrhoeal frequency accurately is particularly difficult in Malawi as 
children typically rely on cloth wrappers rather than nappies, and admitted children with 
diarrhoeal disease are often nursed with multiple children in one bed. It may be that more 
absolute variables such as the presence or absence of vomiting or the need for admission 
are more reliable proxies for disease severity in very low-income countries such as 
Malawi. 
Viral shedding is negatively associated with WHZ score in our dataset, implying that 
children shed more virus with increasing levels of malnutrition. As a note of caution in 
interpreting this, accurate measurement of height in young children is challenging and 
more error prone than measuring weight or MUAC. The standard deviation for our 
estimates of all our anthropometrical measures is outside than the range given by the 
WHO for data quality assessment  purposes (Table A6, Appendix page 269 )(355), and the 
point estimate for HAZ for our study is substantially higher than that obtained in the 2010 
DHS for Blantyre district (-0.04 vs -1.6(356)), meaning that children in our cohort are taller 
than expected. This is also reflected in the WHZ measurements which are considerably 
lower in the RRTE cohort than in the 2010 DHS (-0.59 vs 0.4), Table A3. As a result, our 
findings on nutritional status should be interpreted with caution, and, whilst 
acknowledging that children attending healthcare facilities with severe gastroenteritis are 
a different population from children in the community, our estimates of under-nutrition 
based on WHZ are likely to be an over-estimate. This likely goes someway to explaining 
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the counter-intuitive findings between the relationship between WHZ and HAZ on viral 
load in this study, where increasing WHZ is negatively associated with viral shedding 
density but HAZ is positively associated with viral shedding density – this likely reflects the 
relationship between WHZ and HAZ. Despite this, the negative association with WHZ and 
viral load is corroborated by weak evidence of a negative association between MUAC and 
viral load, and it is biologically plausible that children with poorer nutritional states could 
shed more rotavirus due to changes in intestinal mucosal integrity, ability to amount 
mucosal immunity, and intestinal microbiome and an increased tendency to more severe 
disease associated with malnutrition(345,357–359). Given the prevalence of 
undernutrition in LIC, these  findings certainly merit further investigation.  
6.4.1 Limitations 
Unfortunately for logistical reasons our follow up was limited to 2 weeks in the majority 
of household contacts, and to 28 days in a subset of 59 individuals, and so a substantial 
proportion of household contacts were still shedding rotavirus when follow up ceased 
(48% of the 606 of individuals in the main cohort and 27% of the 59 in the extended follow 
up cohort). Low level shedding in infected individuals can be transient(254), so we defined 
cessation of shedding as the absence of shedding in current and subsequent samples. If a 
participant was negative for rotavirus at day 8, but then shed rotavirus again at day 10, 
this would be classified as ongoing shedding until day 10. Individuals who were not 
shedding at the time the last sample was collected were assumed to have stopped 
shedding. This will have resulted in misclassification of some ongoing shedders, and our 
description of the duration of shedding should therefore be considered a minimum 
estimate. We were also only able to collect one sample per week from household 
contacts, limiting the accuracy of the duration of shedding. Whilst the absolute duration 
of shedding should be interpreted with caution, we can be confident that once infected 
with rotavirus individuals in Malawi appear to shed virus for an extended period of time.  
This, combined with the high SAR for rotavirus infections in households, and high rotavirus 
force of infection in Malawi, may provide an explanation for the high frequency of 
asymptomatic shedding in community households described in the previous chapter.  
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6.4.2 Conclusions, implications and further studies 
The positive association of viral shedding density and rotavirus severity is important as it 
suggests that reducing disease severity, for example through vaccination, has potential to 
reduce viral shedding density and therefore rotavirus transmission. The vast majority of 
the children in this study were vaccinated so it is clear that vaccinated children in low 
income settings still develop severe disease, however a reduction in disease severity at 
the population level may still have potential to contribute substantially to an overall 
reduction in community transmission.  
Children in Malawi shed large quantities of rotavirus following an episode of rotavirus 
diarrhoea and shed for an extended period of time. A large proportion of household 
contacts of a symptomatic rotavirus case shed rotavirus, some for several weeks after 
exposure took place. In combination, this is likely to be a major contributor to the large 
burden of asymptomatic rotavirus observed in the community. It remains to be seen what 
effect a sustained rotavirus vaccine programme will have on this substantial pool of 
asymptomatic infection, and indeed the role of this asymptomatic infection in 
propagating ongoing transmission remains unknown.  
This study highlights several questions for further study. In order to accurately define  
duration of shedding, a cohort study with extended follow up is required, both for 
symptomatic children and their asymptomatically infected contacts. Unfortunately such 
studies can be expensive and logistically challenging. Similar studies on duration of 
shedding in high income settings using similar molecular assays to detect rotavirus would 
help identify if there if truly is a difference in shedding duration between high and LIC. The 
intriguing finding of a potential association between WHZ and viral shedding density 
merits further investigation in different datasets. Finally, having identified a positive 
relationship between disease severity and viral shedding density the relationship between 
these two factors and rotavirus transmission needs further study. This will be explored in 
the following chapter.  
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Chapter 7. Risk factors for rotavirus transmission in household 
contacts of children with rotavirus disease in Blantyre, Malawi 
7.1 Introduction 
In the context of lower vaccine effectiveness in high burden low-income settings, any 
vaccine-associated reduction in community transmission of rotavirus may be an 
important factor in overall disease reduction, both for unvaccinated individuals, and as an 
additional benefit to those vaccinated. Such additional transmission-mediated effects are 
collectively termed indirect effects of the vaccine, and have the potential to contribute 
substantially to population level vaccine impact (Chapter 4, section 4.1, page 125)(215). 
Understanding what influences rotavirus transmission is important for understanding 
both the mechanisms underlying and the extent of vaccine mediated indirect effects. 
Possible mechanisms for indirect effects are outlined in Chapter 1 (section 1.6, page 63), 
but may include overall reduction in frequency of rotavirus disease in the community such 
that a susceptible individual is less likely to become exposed; a reduction in the number 
of susceptible contacts infected by one symptomatic individual (reduction in 
infectiousness of an index case); or transmission of vaccine virus from vaccinated infants 
to contacts, such that the contacts also generate immunity (Fig 7.1). The first two 
mechanisms are termed herd protection, the latter herd immunity(360).  
 
Figure 7.1 Possible mechanisms of vaccine indirect effects 
Given that vaccination mimics the incremental protection obtained  from consecutive 
natural rotavirus infections(38,62,95), and that disease severity is positively associated 
with viral shedding density(8, chapter 6, section 3.6.1.1,page 196), it follows that rotavirus 
vaccine may have potential to reduce disease severity, viral shedding density, and 
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therefore transmission to close contacts, even in the event of clinical vaccine failure. Such 
vaccine effectiveness for infectiousness (rather than disease) has been described with 
other pathogens such as pertussis(332), but not specifically with rotavirus. In Malawi, 
where vaccine effectiveness for hospitalised gastroenteritis is approximately 60%, vaccine 
mediated reduction in infectiousness has the potential to contribute substantially to 
overall reduction in burden of disease.   
To determine vaccine effects on infectiousness and household level transmission it  is 
necessary to determine risk factors for transmission of rotavirus infection and disease 
within households. Risk factors for transmission can be broadly divided into susceptibility 
factors or infectiousness factors. Susceptibility factors relate to the relative susceptibility 
of household contacts to becoming infected and can be divided into population level 
factors such as climate, household level factors such as relative poverty, and individual 
factors such as HIV status of the household contact. Infectiousness factors relate to the 
index child, and examples include disease severity or viral shedding density in the index 
child.  
 The existing data on risk factors for rotavirus transmission are limited. There is evidence 
from the USA that transmission of rotavirus within the household is propagated by the 
presence of young children(245).  At a population level high population density in Dhaka, 
Bangladesh(270) and flooding(271) in the Solomon Islands have been associated with 
increased frequency of rotavirus transmission. In terms of household level susceptibility 
factors household crowding was associated with increased transmission in St Lucia(269). 
Individual level susceptibility factors associated with transmission of infection and disease 
were identified in a household study in Ecuador by Lopman et al(106). They identified that 
being younger than 10 years of age and sharing a room with the index child was associated 
with susceptibility to rotavirus disease, and being a sibling of the index child was 
associated with susceptibility to rotavirus infection. The same study investigated 
infectiousness risk factors for transmission and found that younger age of the index child, 
increased frequency of vomiting, severe disease, and higher faecal viral load was 
associated with risk of transmission of disease, and vomiting and disease severity were 
weakly associated with risk of transmission of infection.   
Both Ecuador and St Lucia are upper middle income countries, and to date there are no 
detailed data on rotavirus transmission from LIC where population structures, contact 
patterns, living conditions, comorbidities and rotavirus epidemiology differ substantially 
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from higher income settings. We therefore aimed to investigate risk factors for 
transmission of rotavirus to household contacts in a semi-urban environment in Blantyre, 
Malawi.  
7.2 Methods 
7.2.1 Objectives 
1. To identify independent risk factors for transmission of rotavirus infection to 
household contacts of a symptomatic index child 
2. To identify independent risk factors for transmission of rotavirus disease to 
household contacts of a symptomatic index child 
7.2.2 Study design 
Data for this study were derived from the prospective cohort study of household contacts 
of children with symptomatic rotavirus disease recruited as part of the RotaRITE: 
Transmission Epidemiology Study (RRTE), methods for which are described in detail in 
chapter 5 (section 5.2, page 154). Briefly, vaccine age-eligible children presenting with 
acute gastroenteritis to participating study sites were screened, and recruited into the 
study if eligibility criteria were met. Household contacts were then recruited and followed 
up for laboratory evidence of subsequent rotavirus infection and for symptoms of 
gastroenteritis (rotavirus disease).  
7.2.3 Study site 
Participants for this study were recruited from QECH, Zingwangwa Health Centre, 
Gateway Health Centre and Madziabango Health Centre.  
7.2.4 Study population 
Vaccine age-eligible children with acute gastro-enteritis were screened for eligibility 
criteria,  and if eligible were consented to participate in the study. All household contacts 
of enrolled children who fulfilled eligibility criteria were invited to take part in the study.  
7.2.5 Study Procedures 
7.2.5.1 Enrolment 
Enrolment into the primary study has been described previously (chapter 5, section 5.2, 
page 154).  
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7.2.5.2 Data collection and follow up 
Index children had detailed data collected at the point of enrolment. Household contacts 
had baseline data collected at an initial visit, and were asked to report any gastroenteritis 
symptoms in the preceding 10 days. They then had data on symptoms and a stool sample 
collected at two time points following onset of symptoms in the index child. The first two 
samples collected from household contacts members enrolled into the nested intensive 
cohort (Chapter 6) were also included in this analysis.  
7.2.5.3 Sample collection 
Each household contact had two samples collected 
- Sample 1 at days 5 to 7 after the date of reported onset of symptoms in the index 
child 
- Sample 2 at days 10 to 12 after the date of reported onset of symptoms in the 
index child 
7.2.6 Sample size 
The sample size calculation for this study is described in Chapter 5 (section 5.2, page 154). 
7.2.7 Laboratory procedures 
All stool samples were tested for rotavirus using VP6 qRT-PCR as described in chapters 2 
(section 2.3, page 87)and 5 (section 5.2, page 154). Positive results with Ct values >35 
were confirmed using an additional assay targeting NSP3.  
7.2.8 Statistical methods 
Variables were graphed and tabulated to examine distributions of data and look for 
missing data and inconsistencies. Missing data were excluded from the analysis.  
The model for transmission was built using a hierarchal conceptual framework (Fig 
7.2)(361). Variables were divided into groups, factors relating to the infectiousness of the 
symptomatic index child, and susceptibility factors relating to the susceptibility of 
household contacts to developing rotavirus infection or disease as described above. 
Susceptibility factors were further divided into proximal susceptibility factors (factors 
operating at an individual level), and distal susceptibility factors (factors operating at a 
household level). Individual models were built for each of these 3 groups of co-variates to 
select risk factors of importance, whilst adjusting for potential confounding. A final model 
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was then built incorporating all three groups, starting with distal susceptibility factors and 
then adding in proximal susceptibility factors and finally infectiousness factors. Separate 
models were built for infection and disease. Models were build using logistic regression 
models with a random effect to account for clustering at the household level. Akaike’s 
Information Criterion (AIC) are reported for the constituent and final models for 
infectiousness and disease, respectively.  
Model selection was conducted as follows. First, univariable analysis was conducted 
between the outcome variable and all potential exposure variables in turn. All variables 
with p<0.1 on univariable analysis were then tested for inclusion in the final model. The 
variable with the largest association (i.e. smallest p value) with the outcome on 
univariable analysis was the first variable selected for inclusion, and then regression 
analysis was conducted using this model and each subsequent exposure variable. Nested 
models were compared using likelihood ratio tests. The variable with the smallest p value 
from the regression analysis became the newly selected variable and included in the 
model. This cycle was continued until no more exposure variables were able to be 
included (because p>0.1 when tested). If a variable improved the model it was included, 
and retained in the model even if it subsequently lost significance. 
Co-linearity between co-variates was evaluated based on a-priori knowledge and using 
pair-wise correlation coefficients where relevant. For pairs of co-linear co-variates, only 
one of the pair was included in the final model.  
This analysis presents the effect of potential risk factors on the likelihood of transmission 
using odds ratios (OR). If an outcome is rare the OR approximates to the relative risk (RR) 
(rare disease assumption), however as an outcome becomes more common the OR 
becomes larger in comparison to the RR(326). As a result the effect size of the odds ratio 
can be prone to misinterpretation. A sensitivity analysis was therefore performed to 
estimate the RR of infection and disease in household contacts by fitting a Poisson model 
using generalised estimating equations (GEE) with exchangeable correlation matrix to 
account for the household level clustering(362).  
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Figure 7.2. Hierarchical framework for constructing model of risk factors for transmission 
7.2.9 Definitions 
Definitions of infection, disease, index child, household and contact can be found in 
Chapter 5 (section 5.2, page 154). 
7.3 Results 
705 household contacts were recruited from 196 index children. The characteristics of 
these contacts are outlined in chapter 5 (section 5.3.4, page 174). All 705 household 
members contributed symptom information, and 665 individuals  from 188 households 
had qRT-PCR data. Overall 435/665 (65.4%) of household contacts of infected index 
children were themselves infected with rotavirus, and 173/188 (92%) households had at 
least one episode of transmission. 37/698 (5%) household contacts reported rotavirus 
associated gastroenteritis, which was at least one episode in 33/196 (17%) households.  
7.3.1 Risk factors for rotavirus infection 
7.3.1.1. Distal susceptibility factors for infection 
On univariable analysis, households in which at least one member earned a regular salary 
had lower odds of transmission than households where no-one earned a r-egular salary, 
OR 0.47 (95% CI 0.26, 0.86), and households where the household head had higher 
education showed weak evidence of lower odds of transmission (OR 0.37, 95% CI 0.13, 
1.03). Households that obtained water from a tap or a borehole had decreased odds of 
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transmission compared to households using a well (Table 7.1). Difficulty obtaining 
sufficient foods for the household to eat was associated with reduced odds of 
transmission, OR 0.52 (95% CI 0.28, 0.96). On multivariable analysis presence of a 
household member who earned a salary and difficulty obtaining sufficient foods for the 
household remained in the model (OR 0.45 [95% CI 0.25, 0.82] and OR 0.49 [95% CI 0.27, 
0.90] respectively).   
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Table 7.1 Distal susceptibility risk factors for transmission of rotavirus infection 
 
7.3.1.2 Proximal susceptibility factors for infection 
On univariable analysis, other adult relatives or child household contacts were less likely 
than mothers to become infected with rotavirus (OR 0.28 [95% CI 0.16, 0.49]) and 0.49 
[95% 0.28, 0.81], respectively). Sleeping in the same room as the index child was weakly 
associated with an increased risk of transmission (OR 1.46 [95% CI 0.85, 1.93]). Spending 
increasing amounts of time in the house and with the index child were both associated 
 Univariate analysis Multivariable analysis  
Variable OR 95% CI P  N OR 95% CI  P N 
Household size    665    663 
<5 REF        
>5 0.672 0.37, 1.21 0.186      
Toilet type    665     
None REF        
Simple pit/VIP 0.18 0.02, 1.81 0.146      
Water toilet 0.15 0.01, 2.05 0.154      
Shared toilet    665     
No REF        
Yes 0.54 0.28, 1.06 0.072      
Distance to water    665     
0-5 mins REF        
5-30mins 0.91 0.41, 2.01 0.808      
>30 mins 1.07 0.47, 2.44 0.881      
Water source    663     
Well REF        
Borehole 0.29 0.07, 1.13 0.075      
Shared tap 0.22 0.06, 0.76 0.017      
Tap to house 0.28 0.07, 1.16 0.079      
Maternal education    665     
Primary or less REF        
Secondary 0.03 0.51, 1.69 0.810      
Higher  0.79 0.19, 3.33 0.744      
Household head education    645     
Primary or less REF        
Secondary 1.07 0.56, 2.03 0.839      
Higher  0.37 0.13, 1.03 0.058      
Number of adults with 
salary in household 
   663     
None REF    REF    
≥1 0.47 0.26, 0.86 0.014  0.45 0.25, 0.82 0.009 663 
Has an adult skipped a 
meal in the past 2 weeks? 
   665     
No REF        
Yes 0.65 0.34,1.27 0.213      
Problems getting food in 
the past month  
   665     
No REF    REF    
Sometimes/often 0.52 0.28, 0.96 0.037  0.49 0.27, 0.90 0.022 663 
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with an increased risk of transmission(Table 7.2), as was being the primary care giver (OR 
2.25, 95% CI 1.43, 3.55) and frequently changing  the child’s nappy (OR 3.32, 95% CI 1.92. 
5.75). Rotavirus vaccination status was not associated with risk of infection (OR 1.45 [95% 
CI 0.12, 17.46] and 1.51 [95% CI 0.60, 3.80] for one or two doses respectively. Once 
adjusted for relationship to the child on multivariable analysis no other risk factor 
remained significantly associated with rotavirus of infection.   
Table 7.2. Proximal susceptibility risk factors for transmission 
 Univariate analysis Multivariable analysis 
 
OR 95% CI P  N OR 95% CI P  N 
Relationship to child         
Mother REF   665 REF   665 
Other adult 
relative 
0.28 0.16, 0.49 0.000  0.28 0.16, 0.49 0.000  
Child contact 0.49 0.28, 0.81 0.005  0.49 0.28, 0.81 0.005  
Sleep in same room as 
index child 
   665     
No REF        
Yes 1.46 0.95,2.25 0.083      
Share bed with index child    665     
No REF        
Yes 1.28 0.85, 1.93 0.240      
Share toilet with index 
child 
   665     
Never REF        
Sometimes/often 1.92 0.57,6.57 0.294      
Household member age    664     
<5 years REF        
5-15 years 0.85 0.44,1.65 0.639      
15-45 years 0.87 0.47,1.59 0.644      
45+ years 0.57 0.14,2.31 0.435      
Time spent with index 
child 
   665     
All day REF        
Half day 0.70 0.44, 1.13 0.144      
Evening only/no 
time 
0.52 0.31, 0.87 0.012      
Time spent in house    665     
All day REF        
Half day 0.70 0.44,1.12 0.139      
Evening only/no 
time 
0.48 0.29, 0.80 0.005      
HIV status         
Uninfected REF        
Infected 1.37 0.40,4.67 0.619 325     
Primary care giver for 
child 
   665     
No         
Yes 2.25 1.43, 3.55 0.000      
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Responsible for changing 
nappy 
   665     
Never/sometimes REF        
Always/often 3.32 1.92,5.75 0.000      
Child/NA 1.72 1.06,2.79 0.029      
Children under years 5  only 
RV1 doses    81     
0 REF        
1 1.45 0.12,17.46 0.768      
2 1.51 0.60, 3.80 0.381      
Premature         
No REF        
Yes 0.43 0.14, 1.30 0.135      
Birth weight (Kgs) 1.67 0.62, 4.56 0.313 80     
WAZ 1.16 0.85, 1.58 0.359 82     
WHZ 1.02 0.79, 1.34 0.827 73     
HAZ 1.17 0.85, 1.62 0.346 73     
MUAC 0.90 0.73, 1.11 0.327 87     
 
7.3.1.3 Infectiousness risk factors for infection 
Several clinical features of rotavirus disease in the index child acted were identified as 
univariable risk factors for transmission of rotavirus infection within the home (Table 7.3). 
The presence of vomiting was significantly associated with transmission (OR 3.40, 95% CI 
1.20,9.64), as was requirement for admission (OR 2.29, 95% CI 1.29, 4.06) and increasing 
Vesikari score (OR 1.17, 95% CI 1.05, 1.30). Several other markers of disease severity in 
the index child showed a trend towards increased risk of transmission, but were not 
significant at the 5% level. These included increasing duration of vomiting and frequency 
of vomiting and increasing duration and daily frequency of diarrhoea, the presence of 
dehydration, and death before discharge from hospital. Other factors which showed weak 
evidence of an association with increased risk of transmission were increasing height for 
age Z score (OR 1.12, 95% CI 1.00, 1.27) and increasing MUAC (OR 1.25, 95% CI 1.00, 1.55). 
On multivariable analysis age in months, sex and viral load were included in the 
multivariable model a-priori. Increasing Vesikari score and increasing MUAC were also 
identified as independent risk factors for transmission (OR 1.16 [95% CI 1.04, 1.29] and 
OR 1.32 [95% CI 1.05, 1.68], respectively).   
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Table 7.3. Infectiousness risk factors for rotavirus infection 
 Univariate analysis Multivariable analysis 
Variable OR 95 % CI P 
value 
N OR 95% CI P 
value 
N 
Vesikari score 1.17 1.05, 1.30 0.004 652 1.16 1.04,1.29  0.007 625 
Diarrhoea duration (days)    665     
1-3 REF        
5 1.15 0.34,3.85 0.824      
≥6 2.23 0.63,7.94 0.215      
Diarrhoea episodes*    665     
1-4 REF        
5 1.74 0.70,4.32 0.232      
≥6 2.28 0.92, 5.69 0.077      
Vomiting    665     
No REF        
Yes 3.40 1.20, 9.64 0.021      
Vomiting duration (days)    612     
1 REF        
2 0.84 0.32, 2.15 0.710      
≥3 1.65 0.68, 4.00 0.272      
Vomiting frequency*    612     
<5 REF        
≥5 1.68 0.88, 3.21 0.119      
Temperature (rectal, oC)    655     
37.1-38.4 REF        
38.5-38.9 0.54 0.26, 1.11 0.105      
≥39.0 0.68 0.34, 1.37 0.282      
Skin pinch    665     
Normal REF        
Goes back slowly 1.94 1.01,3.73 0.046      
Goes back very 
slowly 
1.83 0.76,4.39 0.179      
General appearance    665     
Alert REF        
Restless 0.97 0.53,1.78 0.921      
Unconscious 0.91 0.34,2.46 0.850      
Thirst    665     
No REF        
Thirsty 1.87 0.85, 4.11 0.119      
Drinks poorly 2.02 0.66, 6.15 0.215      
Dehydration    665     
None REF        
Some 1.47 0.62,3.51 0.385      
Severe 1.35 0.50, 3.67 0.560      
Admission    665     
No REF        
Yes 2.29 1.29,4.06 0.005      
Outcome    665     
Home REF        
Died 2.45 0.10, 60.06 0.583      
         
Sex         
 REF        
Male 1.00 0.56,1.77 0.988 665 1.00 0.56,1.79 0.980 625 
Age in months 1.00 0.96, 1.04 0.941 665 1.00  0.95,1.04 0.872 625 
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Log viral copy numbers 1.05 0.95, 1.15 0.346 643 1.04 0.95,1.15 0.980 625 
HIV exposed    665     
No REF        
Yes 1.44 0.58,3.57 0.430      
HIV infected* - - -      
Premature    665     
No REF        
Yes 0.71 0.16,3.19 0.660      
Birth weight (Kgs) 1.47 0.95, 2.29 0.086 625     
Ever breastfed         
No REF        
Yes 9.60 0.24,378.8 0.228 665     
         
Completed rotavirus 
vaccination 
   665     
No REF        
Yes 1.71 0.10, 29.64 0.711      
         
Adjusted WHZ 0.89 0.75,1.06 0.206 662     
         
Adjusted WAZ 1.21 0.95, 1.54 0.122 662     
         
Adjusted HAZ 1.12 1.00, 1.27 0.053 648     
         
MUAC 1.25 1.00, 1.57 0.055 660 1.32 1.05,1.68 0.019 625 
         
Genotype    663     
G1P8 REF        
G2P4 0.44 0.20,0.96 0.038      
G2P6 0.50 0.19,1.28 0.148      
G12P6 1.24 0.34, 4.56 0.747      
Other type 0.54 0.24,1.25 0.153      
*maximum number per day **model unable to converge 
7.3.1.4 Final model for risk factors for rotavirus infection 
The fully adjusted model had a lower Akaike’s Information Criterion (AIC) than the 
constituent models (Table 7.4). In the fully adjusted model, the presence of at least one 
adult in the household with a salary continued to be associated with reduced odds of 
rotavirus transmission (OR 0.41, 95% CI 0.22, 0.75)(Table 7.5) Other adult household 
members and children remained significantly less likely to be infected than mothers, and 
increasing Vesikari score in the index child was associated with increasing odds of 
transmission to contacts (OR 1.16, 95% CI 1.04, 1.29). The relative risk of transmission is 
also reported, with an increased risk of transmission of 1.04 (95% CI 1.01, 1.07) per unit 
increase in Vesikari score and 1.08 (95% CI 1.02, 1.14) per unit increase in MUAC. A 
decreased risk of 0.82 (95% CI 0.72, 0.93) is described for households in which at least one 
member had a regular salary, and of 0.75 (95% CI 0.65, 0.86) and 0.83 (95% CI 0.74, 0.92) 
compared to mothers for other adults and children in the household.   
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Table 7.4 Akaike’s Information Criterion for multivariate models for risk factors for 
infection 
 Akaike’s Information Criteria 
Distal susceptibility risk factors for 
infection 
791 
Proximal susceptibility risk factors for 
infection  
784 
Infectiousness risk factors for infection 748 
Final model for infection 721 
   
Table 7.5 Final model for risk factors for rotavirus infection 
Variable  OR  P 
value 
95% CI RR P 
Value 
95% CI N 
       623 
Vesikari 1.16 0.009 1.04, 1.29 1.04 0.008 1.01, 1.07  
Age in months 1.00 0.851 0.95, 1.04 1.00 0.814 1.00, 1.01   
Sex REF       
Male 1.00 0.965 0.55, 1.76 0.98 0.788 0.85, 1.13   
Log viral copy number 1.05 0.282 0.96, 1.16 1.01 0.380 0.99, 1.04   
Number of adults with 
salary in household 
       
None REF       
≥1 0.41 0.004 0.22, 0.75 0.82 0.002 0.72, 0.93  
Problems getting food in 
the past month (%) 
       
No REF       
Sometimes/often 0.69 0.240 0.37, 1.28 0.90 0.213 0.76, 1.06  
Relationship with child        
Mother REF       
Other adult 
relative 
0.28 0.000 0.16, 0.50 0.75 0.000 0.65, 0.86  
Child contact 0.40 0.001 0.24, 0.68 0.83 0.001 0.74, 0.92  
MUAC 1.37 0.009 1.08, 1.76 1.08 0.004 1.02, 1.14   
 
7.3.2 Risk Factors for disease 
7.3.2.1 Distal susceptibility factors for disease 
The only distal susceptibility factor associated with the risk of rotavirus disease was toilet 
type, where using a pit toilet or a water toilet were associated with a reduced odds of 
rotavirus disease compared to having no toilet (OR 0.16 {95% CI 0.04, 0.68] and OR 0.10 
[95% CI 0.01, 1.26], respectively) (Table 7.6).    
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Table 7.6 Distal susceptibility factors for disease 
 
7.3.2.2 Proximal susceptibility factors for disease 
Age of household contact was significantly associated with odds of disease. Odds of 
disease were highest in those aged under 5 years, and all other age groups were at 
significantly reduced odds of disease in comparison (OR 0.12 [95% CI 0.04, 0.42] for 
children aged 5-15 years, 0.34 [95% CI 0.15, 0.75] for contacts aged 15-45 years and 0.36 
[95% CI 0.04, 3.21] for contacts aged 45 years or older (Table 7.7). The model investigating 
 Univariate analysis Multivariable analysis 
Variable OR 95% CI P N OR 95% CI P N 
Household size    698     
<5 REF        
>5 0.75 0.36, 1.54 0.429      
Toilet type    698    698 
None REF        
Simple pit/VIP 0.16 0.04, 0.68 0.014  0.16 0.04, 0.68 0.014  
Water toilet 0.10 0.01, 1.26 0.075  0.10 0.01, 1.26 0.075  
Shared toilet    698     
No REF        
Yes 0.68 0.33, 1.43 0.306      
Distance to water    698     
0-5 mins REF        
5-30mins 2.30 0.74, 7.14 0.150      
>30 mins 1.41 0.43, 4.66 0.557      
Water source    696     
Well REF        
Borehole 5.51 0.68, 44.34 0.109      
Shared tap  2.24 0.29, 17.42 0.440      
Tap to house 2.54 0.28, 22.82 0.406      
Maternal education     698     
Primary or less REF        
Secondary 0.92 0.44, 1.94 0.832      
Higher  0.72 0.09, 6.12 0.765      
Household head education  0.97 0.70, 1.33 0.830 678     
Primary or less REF        
Secondary 1.11 0.49, 2.54 0.800      
Higher  0.62 0.12, 3.17 0.569      
Number of adults with 
salary in household 
   696     
None REF        
≥1 0.65 0.32, 1.31 0.227 
 
    
Has an adult skipped a meal 
in the past 2 weeks? 
   698     
No REF        
Yes 0.91 0.38, 2.15 0.822      
Problems getting food in the 
past month (%) 
   698     
No REF        
Sometimes/often 1.08 0.50, 2.29 0.851      
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the association between vaccination status of children in the households and risk of 
disease did not achieve convergence. On multivariable analysis only age of the household 
contact remained significant. 
Table 7.7. Proximal susceptibility factors for disease 
 Univariate analysis Multivariable analysis 
 OR 95% CI P N OR 95% CI P N 
Relationship to child    698     
Mother REF        
Other adult relative 0.90 0.37, 2.19 0.810      
Child contact 0.91 0.41, 2.03 0.815      
Share bedroom with index child    698     
No REF        
Yes 1.89 0.88, 4.02 0.104      
Share bed with index child    698     
No REF        
Yes 1.65 0.82, 3.31 0.163      
Shared toilet with child    698     
No REF        
Sometimes/always 4.08 1.00, 17.01 0.053      
Household member age    696    696 
<5 years REF    REF    
5-15 years 0.12 0.04, 0.42 0.001  0.12 0.04, 0.42 0.001  
15-45 years 0.34 0.15, 0.75 0.008  0.34 0.15, 0.75 0.008  
45+ years 0.36 0.04, 3.21 0.359  0.36 0.04, 3.21 0.359  
Time spent with index child    698     
All day REF        
Half day 0.60 0.26, 1.41 0.247      
Evening only/no time 1.18 0.53, 2.64 0.689      
Time spent in house    698     
All day REF        
Half day 0.67 0.30, 1.53 0.343      
Evening only/no time 1.07 0.47, 2.45 0.870      
HIV status         
Uninfected REF   335     
Infected 0.91 0.17, 4.99 0.916      
Primary care giver for child         
No REF   698     
Yes 1.13 0.55, 2.33 0.737      
Responsible for changing nappy    698     
Never/sometimes REF        
Always/often 1.02 0.42, 2.49 0.969      
Child/NA 0.97 0.42, 2.21 0.937      
Household contacts under 5 years only 
Rotavirus vaccine doses*         
0 REF        
1 -        
2 -        
Premature         
No REF   105     
Yes 1.13 0.22. 5.71 0.884      
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* model unable to converge 
7.3.2 3 Infectiousness risk factors for rotavirus disease 
Disease severity in the index child was associated with increasing odds of disease in 
household contacts. There was a positive association between Vesikari score and odds of 
disease (1.27 [95% CI 1.08, 1.48]). Vomiting frequency was associated with increased odds 
of disease (OR 2.59, 95% CI 1.25, 5.37), as was admission to hospital (OR 3.27, 95% CI 1.37, 
7.80). Weak evidence of  an association with odds of disease was described for vomiting 
duration of 3 days or more (OR 6.22, 95% CI 0.81, 47.66), severe dehydration (OR 7.53, 
95% CI 0.93, 61.19)and rotavirus strain in the index child. In terms of rotavirus genotype, 
compared to G1P[8] strains G2P[4], G2P[6] and G12P[6] strains in the index child were 
associated with reduced odds of disease transmission (OR 0.38 [95% CI 0.14, 1.04], 0.50 
[95% CI 0.14, 1.84] and 1.26 [0.38, 4.21]), respectively). Age in months and viral load were 
included in the multivariable model a-priori. In addition to these Vesikari score was 
identified as an independent risk factor for disease in household contacts (Table 7.8).   
 
 
 
 
 
 
 
 
 
 
 
 
Birth weight(Kgs) 1.37 0.46, 4.09 0.572 82     
WAZ 0.94 0.63, 1.40 0.745 84     
WHZ 0.98 0.70, 1.36 0.897 75     
HAZ 1.38 0.88, 2.17 0.157 75     
MUAC 0.23 0.06, 1.54 0.900 88     
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Table 7.8 Infectiousness factors for disease 
 Univariate analysis Multivariable analysis 
Variable OR 95 % CI p N OR 95% CI P N 
Vesikari 1.27 1.08, 1.48 0.004 685 1.29 1.08, 1.55  0.005 663 
Diarrhoea duration    698     
1-3 REF        
5 0.41 0.05, 3.30 0.405      
≥6 1.73 0.52, 5.69 0.369      
Diarrhoea episodes    698     
1-4 REF        
5 1.07 0.28, 4.12 0.926      
≥6 1.59 0.43, 5.87 0.485      
Vomiting    698     
No REF        
Yes 3.43 0.43, 27.28 0.244      
Vomiting duration    642     
1 REF        
2 4.56 0.56, 37.13 0.156      
≥3 6.22 0.81, 47.66 0.078      
Vomiting frequency*  
 
 642     
1-4 REF        
≥5 2.59 1.25, 5.37 0.010      
Temperature    689     
37.1-38.4 REF        
38.5-38.9 1.07 0.47, 2.39 0.888      
≥39.0 0.60 0.24, 1.48 0.265      
Skin pinch    698     
Normal REF    REF    
Goes back 
slowly 
1.07 0.44, 2.64 0.880  0.44 0.16, 1.22 0.115  
Goes back 
very slowly 
2.70 0.96, 7.56 0.059  0.95 0.31, 2.93 0.926  
Sunken eyed    698     
No REF        
Yes 3.62 0.47, 27.80 0.217      
General appearance    698     
Alert REF        
Restless 1.44 0.68, 3.08 0.342      
Unconscious 1.13 0.29, 4.37 0.856      
Thirst    698     
No REF        
Thirsty 6.19 0.82, 46.80 0.077      
Drinks poorly 6.19 0.65, 58.69 0.112      
Dehydration    698     
None REF        
Some 4.27 0.55, 32.88 0.163      
Severe 7.53 0.93, 61.19 0.059      
Admission    704     
No REF        
Yes 3.27 1.37, 7.80 0.008      
Outcome    698     
Home REF        
Died 4.78 0.40, 56.49 0.215      
Sex    698     
227 
 
Female REF        
Male 1.69 0.81, 3.56 0.165      
Age in months 1.00 0.95, 1.06 1.00 698 1.00 0.95, 1.05 0.916  
Log copy viral numbers 0.98 0.87, 1.11 0.727 676 0.98 0.86, 1.11 0.718  
HIV exposed    698     
No REF        
Yes 1.85  0.73, 4.69 0.193      
HIV infected    188     
No REF        
Yes 2.93 0.19, 46.14 0.446      
Premature    704     
No REF        
Yes 2.53 0.61, 10.49 0.202      
Birth weight (kgs) 0.76 0.44, 1.29 0.307 651     
Ever breastfed** 
 
       
No REF        
Yes - - -      
Completed rotavirus 
vaccine** 
 
       
No REF        
Yes - - -      
Adjusted WHZ 0.91 0.73, 1.13 0.389 695     
Adjusted WAZ 0.90 0.67, 1.20 0.461 695     
Adjusted HAZ 0.98 0.85, 1.14 0.839 680     
MUAC 0.97 0.74, 1.28 0.857 693     
Genotype    696     
G1P8 REF        
G2P4 0.38 0.14, 1.04 0.060      
G2P6 0.50 0.14, 1.84 0.297      
G12P6 1.26 0.38, 4.21 0.706      
Other type 1.17 0.50, 2.75 0.710      
*maximum number per day **model unable to converge 
7.3.2.4 Final model for risk factors for disease.  
Akaike’s Information Criterion (AIC) for the multivariate models for risk factors for 
infection can be seen in Table 7.9, and as with the model for infection, the fully adjusted 
model had the lowest AIC.  Once fully adjusted, Vesikari score in the index child remained 
positively associated with increased odds of disease in household contacts (OR 1.31, 95% 
CI 1.08, 1.58). Age of household contact was also found to be an independent risk factor 
for disease (Table 7.10). The relative risk for disease is also estimated. In this case the OR 
and RR for disease are similar, as the overall prevalence of rotavirus disease was relatively 
uncommon (5%) (Table 7.10).  
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Table 7.9 Akaike’s Information Criterion for multivariate models for risk factors for disease 
 Akaike’s Information Criteria 
Distal susceptibility risk factors for 
disease 
290 
Proximal susceptibility risk factors for 
disease  
284 
Infectiousness risk factors for disease 280 
Final model for disease 273 
 
Table 7.10 Final model for risk factors for rotavirus disease  
Disease OR P value 95% CI RR  P 
value 
95% CI N 
       661 
Age in months 1.02 0.437 0.97, 1.08 1.02 0.396 0.98, 1.06  
Log viral copy numbers 1.00 0.990 0.88, 1.13 1.00 0.897 0.92, 1.10  
Toilet type        
None REF       
Simple pit/VIP 0.47 0.370 0.09, 2.47 0.62 0.310 0.24, 1.57  
Water toilet 0.27 0.336 0.02, 3.94 0.34 0.341 0.04, 3.12  
Skin pinch        
Normal REF       
Goes back 
slowly 
0.47 0.159 0.16, 1.35 0.51 0.265 0.16, 1.66  
Goes back very 
slowly 
0.95 0.928 0.29, 3.05 0.93 0.907 0.26, 3.14  
Household member age        
<5 years REF       
5-15 years 0.12 0.001 0.03, 0.44 0.15 0.001 0.05, 0.48  
15-45 years 0.34 0.015 0.14, 0.81  0.38 0.005 0.19, 0.75  
45+ years 0.37 0.376 0.04, 3.36  0.42 0.400 0.06, 3.13  
Vesikari score 1.31 0.005 1.08, 1.58 1.27 0.001 1.09, 1.48  
 
7.4 Discussion 
This study found that increasing disease severity in the index child is associated with 
increased odds of both rotavirus infection and clinical disease in household contacts. 
Although the association between SAR and disease severity is modest, this finding could 
be important, as it suggests that reducing symptom severity in an index child may have 
potential to reduce rotavirus transmission. However, interestingly and contrary to what 
was hypothesised, the relationship between disease severity and transmission does not 
appear to be mediated by viral load.  
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Increasing Vesikari score is associated with increased odds of rotavirus transmission. 
Vesikari score is an ordinal score of disease severity which is typically used to define 
severe disease for the purposes of vaccine studies and is a composite end point made up 
of several different markers of disease severity (Chapter 5, section 5.2, page 154). 
Although several component variables of disease severity such as vomiting and admission 
to hospital were associated with odds of transmission at a univariate level, none were 
independently associated with transmission once Vesikari score was included in the 
model, suggesting that Vesikari score is a good marker of disease severity in our setting. 
Interestingly hospital admission was strongly predictive of the risk of transmission for 
both infection and disease. This is somewhat counter-intuitive as once admitted children 
were removed from households and contact with susceptible household members. This 
suggests that most transmission within households is occurring soon after the index case 
develops illness, before presentation to healthcare. This is supported by the significant 
decline in rotavirus viral load in household contacts over time since symptom onset in 
index children observed in chapter 6 (section 6.3.3, page 201). It also suggests that 
admission is an objective measure of disease severity, particularly in a context such as 
Malawi where literacy rates are low and providing accurate estimates of frequency and 
duration of symptoms can be challenging.  
Despite the findings described in chapter 6 (section 6.3.1.1, page 196) that disease 
severity is positively associated with viral load in the index child and the association 
between disease severity and odds of transmission described in this chapter, there was 
no association between viral load and risk of transmission. This is contrary to findings in 
Ecuador, where children with a Ct value of <15 on qRT-PCR were more likely to transmit 
than those with lower viral loads(106). In our setting the mechanism of increased odds of 
transmission with increasing disease severity may reflect increased environmental 
contamination or increased opportunity for contact with infectious material in the 
household, rather than an increased density of viral shedding per-se. Possibly once 
children are symptomatic in this cohort, viral loads are too homogenous to identify any 
difference based on viral load, or differences in living conditions and sanitation result in 
symptoms being the more important driver of transmission.  
In terms of other infectiousness risk factors for transmission, the positive association with 
increasing MUAC in the index child is intriguing. The association between MUAC and 
transmission is corroborated by the finding of reduced odds of transmission in households 
where food is scarce, although this loses significance in the fully adjusted model. A study 
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in Bangladesh by Verkerke et al found that malnutrition was protective against rotavirus 
disease in infants, so it is possible that MUAC in the index child is a proxy for the overall 
nutritional status of the household, and that poor nutrition in the household is protective 
against rotavirus infection(363).  These findings seem contrary however to published 
associations between increased severity of diarrhoeal disease and SAM(345), and the 
negative association between WHZ and viral shedding density observed in chapter 6 
(section 6.3.1.1, page 196). It is possible that there are separate mechanisms at play, and 
that as postulated by Verkerke at al(363), malnutrition is protective against infection with 
rotavirus because of an associated enteropathy, but if infection does occur children 
develop more severe disease due to global immune impairment(364).  
Household level susceptibility factors associated with transmission of infection include the 
lack of a regular salary in the household. This is likely to be a proxy for relative poverty, 
and there are numerous reasons why relative poverty could result in increased 
transmission, including crowding, sanitation, carer education levels, and many other 
unmeasured factors. This finding is supported in the univariate analysis by the reduced 
risk of transmission in households where the household head has higher level education, 
although this association loses significance when adjusted for salary in the multivariable 
model. The absence of a toilet was significantly associated with the risk of disease in 
household contacts in the multivariable disease susceptibility model, but is no longer 
significant in the fully adjusted final model for disease. This is likely to reflect low levels of 
hygiene and sanitation which could increase the risk of transmission, or form another 
proxy for poverty.  
In terms of proximal risk factors for transmission of infection, the main risk factor appears 
to be contact with the index child, with sharing a bedroom with the child, spending time 
with the child or in the house, and changing the nappy all significantly increasing the risk 
of transmission on univariate analysis. Vaccine status of household contacts was not 
associated with risk of infection. This could be a result of lack of power, as vaccine status 
was only asked of children under 5 years of age resulting in large numbers of missing data 
for this variable. However it is also plausible that vaccination does not protect against 
infection with rotavirus. The relatively small number of contacts with data on vaccine 
status, combined with the small number of disease episodes is the most likely explanation 
for the lack of convergence of the model investigating vaccine status and disease. The 
single independent proximal susceptibility risk factor for infection is relationship with the 
child, which incorporates all of the above plus likely several other unmeasured factors. 
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Age of the household contact was not associated with risk of infection, which is in direct 
contrast with the proximal risk factors for disease where age of the household contact is 
strongly associated with odds of disease. This suggests that in Malawi individuals develop 
immune protection against clinical disease with increasing age and repeated exposure, 
but not against infection. This differs from age distributions of asymptomatic rotavirus 
observed in the UK in a case control study of diarrhoea aetiology, where the prevalence 
of asymptomatic infection declined with increasing age(19), but reflects the patterns seen 
in the study of household transmission in Ecuador(106), and in the asymptomatic 
community control households in this study (Chapter 5, section 5.3.6.2, page 178). This 
could be explained by different exposure patterns; household contacts in this study and 
in Ecuador all have a known exposure, and adults in Malawi are more likely to have regular 
contact with children than adults in the UK in general, but it is possible it could also reflect 
differences in immunity between populations. Children under five were at the highest risk 
of rotavirus disease despite the fact that over 50% of this age group had received two 
doses of rotavirus vaccine (41/79, Table 5.7, page 174) and the older age groups were not 
yet vaccine age eligible. It is possible that the association between age and risk of rotavirus 
disease was even stronger prior to rotavirus vaccine introduction.  
7.4.1 Limitations 
Due to very high vaccine coverage it was not possible to investigate whether vaccine 
status in the index child had any effect on risk of transmission to household contacts. 
Although the sample size for this study is large, there were few episodes of rotavirus 
disease. The regression analysis for disease will therefore be underpowered, and should 
be interpreted with some caution in light of this(365). The factors contributing to 
transmission are complex and though this study accounts for this as best as possible with 
a structured approach to the analysis, it is impossible to collect data on all possible 
confounding variables and there is a risk of unmeasured confounding which should be 
considered when interpreting the study findings. Finally the population which accesses 
government health care in Malawi, while representative of the majority of the urban 
population in Malawi, is extremely poor, and possibly too homogenous to identify risk 
factors in transmission which relate to poverty or water or sanitation.  
7.4.2 Conclusions, implications and future study 
The observation that disease severity predicts risk of transmission for both infection and 
disease in this setting is potentially important as it suggests that vaccine mediated 
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reduction in disease severity has potential to reduce rotavirus transmission to household 
contacts of index cases. It is unfortunately not possible to investigate the effect of vaccine 
exposure on transmission in this study because of the high vaccine coverage in Blantyre, 
however future studies could model the potential effect of vaccine on transmission using 
these data to inform model parameterisation. 
As in chapter 5, this analysis highlights the lack of immunity to infection with increasing 
age in household contacts. It is not clear if this reflects sub-optimal immune response to 
repeated exposure, or if it relates to contact patterns or intensity of exposure. Further 
studies could explore this by investigating contact patterns, and incorporating high 
income populations with similar exposure patterns.  
The negative association between MUAC and odds of transmission is not fully understood, 
and although it could simply reflect sampling error, the fact that it is corroborated by the 
association with food scarcity in the household and by observations from Bangladesh 
suggests that further studies are needed to explore the relationship between nutritional 
status and rotavirus disease.  
This study highlights the complex factors contributing to rotavirus transmission in low 
income settings and identifies key risk factors for transmission, including disease severity 
in the index child. It will form the basis for more complex analysis investigating the 
potential effect vaccine could play on rotavirus transmission in our setting.  
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8. Horizontal transmission of rotavirus vaccine virus to household 
contacts 
8.1 Introduction 
Chapter four outlined the potential importance of indirect or transmission-mediated 
vaccine effects in the overall population level impact of rotavirus vaccine, in the context 
of high rotavirus disease burden and reduced vaccine effectiveness in low-income 
countries. Indirect effects have been documented from high income countries, but the 
presence and extent of rotavirus vaccine indirect effects in low-income countries in Africa 
and Asia remain unknown. This chapter focusses on the role that horizontal transmission 
of vaccine virus may play in rotavirus vaccine indirect effects in low-income settings.  
The mechanisms behind observed indirect effects of rotavirus vaccine are not fully 
understood but may include reduction in transmission of wild-type rotavirus as discussed 
in previous chapters, and/or horizontal transmission of vaccine-virus following excretion 
in stool of vaccinated infants(215,360). Horizontal transmission of vaccine virus to 
unvaccinated individuals has been well described with another enterally-administered 
vaccine,  oral polio vaccine(366), but the role of such transmission in the generation of 
rotavirus vaccine indirect effects is not yet  established.  
Both current globally licensed rotavirus vaccines (RV1 and RV5) are live oral vaccines 
which mimic natural infection, and replicate in the gastrointestinal tract before being shed 
in the stool. To date, most data on vaccine virus shedding have come from high income 
countries, and shedding has most commonly been identified using enzyme-linked 
immunosorbent assay (EIA) in combination with virus culture in MA104-cells, both of 
which are less sensitive than molecular methods(341) and likely underestimate the 
frequency of shedding. A review of studies reporting vaccine shedding post vaccination 
(all defined using EIA and cell culture) reported rates of shedding that varied between 0 
to 80% for RV1, with the level of viral shedding typically greater following dose 1 than 
after dose 2; these studies also  described more frequent vaccine virus shedding following 
RV1 compared to RV5. In the same review, eight  studies  investigated transmission of 
vaccine virus to placebo recipients, and five episodes of transmission were described from 
two of these studies. One study reported 3/50 (4%) episodes of transmission and the 
other 2/78 (2.6%)(243). Horizontal transmission of RV5 has also been described in siblings 
exposed to vaccinated infants in the US(367), and of RV1 in twin siblings from a placebo 
randomised controlled trial in the Dominican Republic(244). To my knowledge, there are 
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only two studies which have used PCR to detect vaccine virus shedding. The first study 
from Taiwan described shedding frequency in vaccinated infants and reported shedding 
rates of 80-90% following both RV1 and RV5 vaccine, with shedding of greater viral density 
following RV1 compared to RV5. The second, from Japan, reported horizontal 
transmission of vaccine virus to contacts of RV1 and RV5 vaccinated infants in a foster 
home with only one in 23 unvaccinated infants in a foster home shedding detectable 
vaccine virus(368,369).   
Transmission of rotavirus vaccine virus to close contacts has not previously been 
investigated in low-income settings where differences in disease epidemiology, socio-
economic factors and the underlying burden of co-morbidities mean that the risk of 
transmission of vaccine virus is likely to differ compared to that observed in high and 
middle income countries. Differences among populations has potential to effect both the 
frequency and density of viral shedding in the vaccinated infant and therefore impact on 
their infectiousness to close contacts, and to affect the susceptibility of close contacts to 
infection.  
Frequency and density of vaccine virus shedding is thought to reflect vaccine “take”, or  
strength of vaccine response(131,370,371). There are widespread data to suggest that 
rotavirus vaccine is less immunogenic in low-income compared to high-income 
countries(298), and as a result vaccine virus shedding could be less frequent and occur at 
a lower level than that observed in high income settings. Similarly in countries where oral 
polio vaccine (OPV) is still used, concomitant administration of OPV may inhibit rotavirus 
vaccine replication and reduce shedding(372). Contrary to this, prolonged rotavirus 
shedding has been described in HIV infected children following rotavirus disease, and in 
children with hereditary immunodeficiencies after rotavirus vaccination(260,373), which 
could mean that in countries with a high frequency of lowered immunity due to HIV or 
malnutrition, post vaccine viral shedding may be prolonged. This is supported by the 
finding described in chapter 6 (section 6.4, page 206)that the median duration of rotavirus 
shedding following symptomatic disease in Malawi was considerably longer than 
previously described in Australia(254). Any differences in viral shedding in infants from 
low-income settings could therefore contribute to an increase or a decrease in 
infectiousness, depending on the overriding effect.  
In terms of susceptibility factors, it seems likely that close contacts of vaccinated infants 
in low-income countries may be more susceptible to infection with vaccine virus. 
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Crowding in the household, and poor water and sanitation could increase the risk of 
exposure to rotavirus vaccine virus for unvaccinated contacts, and increased background 
prevalence of co-morbidities such as malnutrition and HIV could increase risk of infection 
once exposed. Risk of transmission is likely to vary based on background immunity to 
rotavirus, which typically increases with age(38), so we might expect the likelihood of 
infection with rotavirus vaccine virus to decline with increasing age. This has not 
previously been explicitly investigated, including in high or middle income settings.     
Understanding the extent of horizontal transmission of vaccine virus is essential for 
understanding any potential contribution to rotavirus vaccine indirect effects. This study 
therefore aimed to investigate the proportion of nearest-aged siblings and other 
household members exposed to an infant vaccinated with RV1 who subsequently shed 
vaccine type virus in Malawi, a very low-income country in sub-Saharan Africa. RV1 was 
introduced to the national immunization programme in Malawi in October 2012.  
8.2 Methods 
8.2.1 Objectives 
1. To establish the proportion of household members exposed to a RV1 vaccinated 
infant who develop shedding of vaccine virus.  
2. To identify risk factors for horizontal transmission of vaccine virus within a 
household 
8.2.2 Study design 
This was a prospective cohort study designed to investigate horizontal transmission of 
rotavirus vaccine virus to household contacts of infants receiving monovalent rotavirus 
vaccine in Blantyre, Malawi 
8.2.3 Study site 
This study was conducted at Zingwangwa Health Centre (HC), Blantyre District, Malawi 
where approximately 80 infants attend for vaccination each month.  
 
8.2.4 Study population 
This study recruited household contacts of infants presenting to Zingwangwa Health 
Centre, Blantyre, Malawi for routine rotavirus vaccine delivered as part of the Expanded 
Programmed on Immunization (EPI). In Malawi the monovalent rotavirus vaccine is used 
(RotarixTM) with two oral doses delivered at 6 and 10 weeks of age.  
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8.2.5 Study procedures 
8.2.5.1 Integration with other studies 
Infants enrolled in the study were already recruited into a study of predictors of vaccine 
response (the RotaRITE response to immunization study (RotaRITE:RI). Infants recruited 
into the RotaRITE:RI study had an initial baseline stool taken pre-vaccine, and then serial 
stool samples were collected and tested for vaccine virus using qRT-PCR at 2,4,6,8 and 10 
days after vaccination. Demographic and clinical data were also collected for each infant 
at each visit. Clinical and laboratory data from the RotaRITE:RI study were shared with the 
Horizontal Transmission study following written parental consent.  
8.2.5.2 Recruitment of households 
Infants were recruited into the RotaRITE:RI study prior to, or on the same day as, their 
first rotavirus vaccination. Infants who were consented to participate in the RotaRITE:RI 
study were then invited to take part in the Horizontal Transmission study. Once consent 
of the parent or guardian was obtained, the household contacts of the infant were 
approached and asked for their consent or assent to take part in the Horizontal 
Transmission study. Consent and assent procedures followed the same guidelines as 
outlined in detail in chapter 5 (section 5.2, page 154) for the primary study.  
8.2.5.3 History taking  
Field workers collected data on past medical history including HIV status, current 
symptoms and contact patterns with the vaccinated infant for each household member. 
Rotavirus vaccine history was collected from children under the age of 5 years. Symptom 
questionnaires were conducted at the time of each sample collection (Table 8.1). 
8.2.5.4 Sample collection 
Once household contacts were consented, household members were given stool 
containers, and mothers were asked to bring baseline stool samples for the household 
when they attended the clinic for the first dose of rotavirus vaccine.  If the infant was 
recruited on the day of administration of the first dose of vaccine, where possible baseline 
stool samples were collected from contacts within 24 hours of vaccine receipt. The 
baseline stool sample was followed by collection of a single stool sample at 8-10 days 
following each dose of RV1 in the infant. Samples were collected from households by the 
study team, or family members brought the samples to the health centre themselves. In 
total 3 stool samples were collected from each household recruit (Fig 8.1). The purpose 
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of the baseline stool sample was to act as a pre-exposure control sample for each study 
participant.  
 
 
Figure 8.1 Sample collection for the horizontal transmission study 
 
Table 8.1. Overview of processes to be carried out at each visit – households of vaccinated 
children 
 
 Visit 1 Visit 2 Visit 3 
Recruitment of household members ✓   
Adult and child questionnaire ✓   
Symptom Questionnaire  ✓  ✓ 
Containers left for stool sample ✓ ✓  
Collection of stool sample ✓ ✓ ✓ 
 
8.2.6 Sample size 
The sample size required for this study was calculated to estimate the proportion of 
nearest-aged siblings with detectable vaccine virus shedding following exposure to a 
vaccinated infant. Sample sizes were calculated to estimate the number of discordant 
pairs required for a two-sided test McNemar’s test of paired proportions. A discordant 
pair refers to a child who was a non-shedder pre-exposure, who subsequently goes on to 
shed vaccine virus, or vice-versa. If 95% of discordant pairs were assumed to arise from 
children who did not shed vaccine type virus pre-exposure, but who subsequently shed 
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post exposure, 9 discordant pairs were estimated to be required to detect a significant 
difference between the proportion of household contacts shedding vaccine virus before 
and after exposure to rotavirus vaccine with 80% power and an alpha of 0.05.  
From recent qRT-PCR data in the same population between 60-80% of infants receiving 
vaccine were expected to shed vaccine type virus (defined as positive for both NSP2 and 
VP6) at any point between 3 and 10 days after either dose 1 or dose 2 of RV1. The 
proportion of nearest aged siblings who would shed vaccine type virus was not known. 
The sample size calculations for a range of possible assumptions are shown in Table 8.2.  
Table 8.2. Estimated sample size inflated for proportion of infants and nearest aged 
siblings shedding vaccine type virus.  
 Proportion of nearest age siblings shedding*  
% infants 
Shedding* 0.10 0.20 0.30 0.40 0.50 
40% 225 113 75 56 45 
50% 180 90 60 45 36 
60% 150 75 50 38 30 
70% 129 64 43 32 26 
80% 113 56 38 28 23 
*where shedding is defined as a sample positive for vaccine type virus (on both NSP2 and VP6 assays) after 
dose 1 or dose 2 of vaccine. Numbers in table refer to number of nearest-aged siblings. Shaded area shows 
achievable targets with a sample size of 60. 
A sample size of 60 nearest aged-siblings was selected. This corresponded with the lower 
limit of expected shedding in the vaccinated infant, and was sufficient to detect a range 
of proportions within the limits of what was pragmatic and feasible. Circumstances which 
would be detected with 80% power and 5% significance level by a sample size of 60 pairs 
are shaded in grey in the above tables. To explore risk factors for transmission each 
household member was invited to participate in the study. Each household was assumed 
to have a median of 5 household members in line with contemporaneous data from the 
diarrhoeal surveillance platform. Assuming a 25% loss to follow-up/drop-out rate, 75 
households were planned to be recruited to achieve 60 completed households. 
8.2.7 Laboratory procedures 
All stool specimens were tested for rotavirus using VP6 qRT-PCR and with a vaccine virus 
specific qRT-PCR (NSP2) using the procedures outlined in Chapter 2 (section 2.3.4.6, page 
93). Samples were considered positive for vaccine type virus if both NSP2 and 
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confirmatory VP6 assays were positive. Samples positive on NSP2 and negative on VP6 
were classified as negative and samples positive on VP6 but negative for NSP2 were 
assumed to represent wild-type rotavirus. Data on HIV status and viral shedding density 
in the vaccinated infant were available from the RotaRITE:RI study.  
8.2.8 Statistical analysis 
To generate descriptive statistics, distributions of continuous variables were examined 
and categorical variables were tabulated. Missing observations were excluded from 
analysis. Chi squared tests were used to compare independent categorical variables and 
McNemar’s tests were used to compare paired proportions. Two-sided t-tests were used 
to compare independent means of normally distributed data and rank sum tests were 
used to compare non-normally distributed data. Sign-rank tests were used to compare 
paired medians.  
8.2.9 Managing specific variables 
Questions regarding whether or not the household contact was responsible for changing 
the index child’s nappy, and whether or not the contact was the primary care giver, were  
asked of  adults or children over 5 years of age. Children under 5 years completed a 
separate form where these questions were not included. For analysis purposes it was 
assumed that children under 5 years were not primary care givers or responsible for 
changing the nappy, and the variables were recoded to reflect this.   
Wealth 
A proxy variable for relative wealth was constructed as described in Chapter 5 (section 
5.2, page 154).  
Shedding 
Shedding in vaccine recipients was defined as vaccine virus shedding at any point between 
3 and 10 days after either dose 1 or dose 2 of RV1, where vaccine virus shedding was 
defined as detectable vaccine type virus on NSP2 and on confirmatory qRT-PCR for VP6. 
Samples collected less than 3 days after vaccine receipt were excluded as any vaccine virus 
present at this time was considered likely to represent gut transit, rather than viral 
replication (131,370).  
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8.2.10 Ethics 
This study was approved as an amendment to the RotaRITE:TE study by the University of 
Liverpool Research Ethics committee (000757), and the Malawi College of Medicine 
Research Ethics Committee (P.09/14/1623).  
8.3 Results 
8.3.1 Description of cohort.  
Horizontal Transmission study recruitment took place between the 25th of April 2016 and 
the 8th of August 2016. Of 72 households who consented to take part in the study, 3 
withdrew, leaving 69 households with follow up data (Fig. 8.2). These 69 households 
consisted of 287 household members, of whom 220 (76.7%) consented to take part in the 
study; 69 vaccinated infants and 151 contacts.  
Figure 8.2. Overview of Horizontal Transmission Study recruitment 
8.3.2 Description of vaccinated infants 
Of the 69 infants who participated in the study, 64 had complete data on shedding post 
vaccination. Characteristics of the 69 recruited infants are summarised in Table 8.3. 
Median age at recruitment was 6.1 weeks (range 5.1 to 8.7 weeks). All were breastfed.  A 
total of 12(17%) infants were born to mothers with HIV infection; 11 of these were 
successfully followed up to obtain HIV DNA PCR results, of which 5 were determined to 
be HIV-uninfected and in 6 infants the family did not yet know the HIV DNA PCR result. 
No infants reported diarrhoea or vomiting at the time of recruitment. Household size was 
a median of 4 (IQR 3,5). Food insecurity was common, with 32% of households reporting 
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difficulties obtaining the food they need in the last month, and 19% of adults skipping a 
meal in the last 2 weeks to ensure there was adequate food for the household. Median 
wealth was 2.5 (IQR 2.1, 2.9), which is consistent with findings of other cohorts in this 
study (Chapter 5, section 5.3, page 169).  
Table 8.3. Characteristics of vaccinated infants 
Co-variate Summary statistic Missing 
Age at recruitment in weeks (IQR) 6.1 (6.0-6.4) 0/69 
Male sex (%) 29/69 (42.0) 0/69 
Diarrhoea (%) 0/69 (0.0) 0/69 
Vomiting (%) 0/69 (0.0) 0/69 
HIV (%)   
Exposed 12/69 (17.4) 0/69 
Infected* 0/5 (0.0) 6/11 
Anthropometry. Mean (SD)   
Weight for height Z score  0.72 (1.24) 2/69 
Weight for age Z score  -0.48 (1.10) 0/69 
Height for age Z score  -1.09 (1.25) 1/68 
Mid upper arm circumference  12.5 (11.5, 13) 0/69 
Household size (IQR) 4 (3,5) 0/69 
Premature (%) 4/68 (5.9) 1/68 
Birth weight (%) 3 (2.7, 3.3) 0/69 
Ever Breastfed (%) 69/69 (100.0) 0/69 
Additional child <1 (%)   
0  69/69  (100.0) 0/69 
Additional children < 5 (%)   
0  46 (66.67)  
1  22 (31.88)  
3  1 (1.45) 0/69 
Electricity at home   
Yes (%) 37/69 (53.6) 0/69 
Shared toilet   
Yes (%) 54/69 (78.3) 0/69 
Typically, how long does it take for household to 
access water? (%) 
  
Instant 9/69 (13.0)  
<5 mins 21/69 (30.4)  
5-30 mins 36/69 (52.2)  
30 mins-1hr 2/69 (2.9)  
>1hr 1/69 (1.5) 0/69 
What is the typical source of domestic water (%)   
Borehole 4/69 (5.8)  
Covered well 1/69 (1.5)  
Open well 0/69 (20.3)  
Tap to house 14/69 (39.1)  
Shared tap compound 27/69 (39.1)  
Shared tap village 23/69(33.3) 0/69 
Number of adults in the house with a regular salary    
0 (%) 18/69 (26.1)  
1 43/69 (62.3)  
2 7/69 (10.1) 
 
3 1/69 (1.5) 0/69 
Problems getting food in the last month? (%)   
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Never 45/69 (65.2)  
Sometimes 22/69 (31.9)  
Often 2/69 (2.9) 0/69 
Has an adult skipped a meal in the past 2 weeks?   
Yes (%) 13/69 (18.8) 
 
Wealth indicator (IQR) 2.5 (2.1, 2.9) ** 1/68 
* Of 12 HIV exposed infants 11 were successfully traced for HIV PCR results. Of those, 5 
were confirmed uninfected and 6 did not know their status/had not received their result.  
**Where wealth is a composite variable compiled as described in chapter 5 (section 5.2, 
page 154). 
 
Of the 64 vaccinated infants with complete shedding data, 45(70%) shed vaccine virus at 
any point (Table 8.4). The proportion of infants shedding was slightly higher post dose two 
than dose one (29/69 [42.0%] vs 34/64 [53.1%]) but this was not significant at the 5% level 
(Mcnemar’s p value 0.150). The proportion of infants shedding was reasonably constant 
across days 4-10 following each dose of vaccine, with a trend towards a greater frequency 
of shedding at days 4-8 (Table 8.5). Shedding was low level, with peak shedding following 
vaccine dose one of median Ct 32.2(IQR 29.9-35.0) and 33.1(IQR 30.5-35.5) following dose 
two. There was no significant difference in median Ct value between doses (sign-rank p  
0.9750) (Table 8.4). Over 20% of infants shed vaccine virus after both doses (14/64, 
21.9%).  
 Table 8.4  Shedding in infants and household contacts 
 % shedding 
NSP2 at baseline 
% shedding 
post d1 
Median peak Ct 
value post d1 
(IQR) 
% shedding 
post d2 
Median peak Ct 
value post d2 
(IQR) 
% with any 
shedding 
Infant 1/34 (2.9) 29/69 (42.0) 32.2(29.9-35.0) 34/64 (53.1) 33.1(30.5-35.5) 45/64(70.3) 
HH 
contact 
0/123 (0.0) 0/138 (0.0) - 2/122 (1.64) - 2/151(1.3) 
 
Table 8.5  Shedding by day post vaccine dose in infants 
 Days post vaccine dose 1 Days post vaccine dose 2 
 4 6 8 10 4 6 8 10 
No 
shedding 
(%) 
15/58 
(25.9) 
18/61 
(29.5) 
15/56 
(26.8) 
12/65 
(18.5) 
20/57 
(35.1) 
21/60 
(35.0) 
20/57  
(35.1) 
17/55 
(30.9) 
 
8.3.3 Description of households 
151 household contacts were recruited. Characteristics of household contacts are shown 
in Table 8.6. 46 (31%) were male. Age of contacts ranged from under 1 year to 41 years 
old (median 20.3, IQR 9.6, 29.35).  70/151 (46%) of recruits were mothers of the 
vaccinated infants and 51/151 (34%) were children who were relatives of the vaccinated 
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infant. Fathers made up 13% (20/151) of recruits. Of the 17 contacts aged under 5 years 
with available data 7 (41%) were completely vaccinated against rotavirus. The majority of 
household contacts were in close contact with the vaccinated infant with 109/151 (72%) 
sharing a bedroom, and 85/151 (56%) typically spending all day in the  company of the 
child. Sanitation facilities were basic, with 93% (140/151) reporting that they typically use 
a simple pit latrine. No contacts reported diarrhoea or vomiting during follow up.  
Pre-vaccine exposure samples were obtained from 123 contacts and none were positive 
for vaccine virus. Post-exposure samples were collected a median of 8 days (IQR 8,8) after 
sample 1 and 8 days after sample 2 (IQR 8,10). A total of 2/151 (1.3%) household contacts 
shed vaccine virus following exposure to a vaccinated infant; one sibling (age 3 years) and 
one mother (age 34 years)(Table 8.4). This was not significantly different from baseline 
(McNemar’s P value 0.500).  Both of the positive samples were collected  after the second 
dose of vaccine administered to the infant. The mother was reported to be HIV negative, 
shared a bedroom with the vaccinated infant, spent the whole day with the child and was 
responsible for changing the infant’s nappy. The sibling contact did not share a bedroom 
and spent an estimated half of the day in the company of the vaccinated infant. The sibling 
contact had not been tested for HIV. Of household members, 9 (6%) had detectable wild-
type rotavirus in at least one stool sample. Wild type shedding was more common in those 
under 10 years (4/40 [10%]) than those aged over 10 years (5/111 [5%]), though this was 
not significant at the 5% level (X2 p value 0.21). Due to the small number (two) of 
transmission episodes it was not possible to formally investigate risk factors for horizontal 
transmission.   
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Table 8.6 Characteristics of household contacts 
Co-variate Summary 
statistic 
Missing 
Age category in years (%)   
0-5 20/151 (13.3)  
5-10 20/151 (13.3)  
10-15 12/151 (8.0)  
15-30 70/151 (46.4)  
30-45 29/151 (19.2)  
45+ 0/151 (0) 0/151 
Male sex (%) 46/151 (30.5) 0/151 
Diarrhoea (%) 0/151 (0) 0/151 
Vomiting (%) 0/151 (0) 0/151 
 HIV   
Ever tested (%) 79/149 (53.0) 0/149 
HIV Infected (%) 13/77 (16.9) 2/79 
Relationship to child (%)   
Mother 70/151 (46.4)  
Father 20/151 (13.3)  
Grandmother 1/151 (0.7)  
Grandfather 0/151 (0)  
Other adult 9/151 (6.0)  
Child relative 51/151 (33.8)  
Child non-relative 0/151 (0) 0/151 
Rotavirus vaccine doses in under 5s (%)   
0 doses 9/17 (52.9)  
1 doses 1/17 (5.9)  
2 doses 7/17 (41.2) 1/18 
Sleeps in same room as vaccinated infant (%) 109/151 (72.2) 0/151 
Sleeps in same bed as vaccinated infant (%) 91/151 (60.3) 0/151 
Time spent in house (%)   
All day 85/151 (56.3)  
Half day 44/151 (29.1)  
Evening only 22/151 (14.6) 0/151 
Time spent with child (%)   
All day 85/151 (56.3)  
Half day 44/151 (29.1)  
Evening only 22/151 (14.6) 0/151 
Toilet type (%)   
Simple pit 140/151 (92.7)  
VIP 4/151 (2.7)  
Water toilet 7/151 (4.6) 0/151 
Primary care giver for vaccinated infant (%)   
Yes 72/151 (47.7) 0/151 
Responsible for changing nappy of vaccinated infant (%)   
Never 76/151 (50.3)  
Sometimes 5/151 (3.3)  
Often 0/151 (0)  
Always 70/151 (46.4) 0/151 
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8.4 Discussion 
This study found a very low frequency of horizontal transmission of vaccine virus to 
household contacts of vaccinated infants in Malawi, a low income country in sub-Saharan 
Africa. In this setting, it seems unlikely that horizontal transmission of vaccine is a major 
contributing factor to rotavirus vaccine indirect effects. This is the first study to investigate 
rotavirus vaccine virus transmission in households in a low income setting, where immune 
response to vaccine, nutritional status, contact patterns and sanitation systems are very 
different to those in higher income countries.  
This study has the major advantage of using qRT-PCR to detect vaccine virus shedding. 
The majority of previous studies have used EIA or cell culture, which is considerably less 
sensitive than qRT-PCR and provides an under-estimate of the degree of transmission. All 
positive results were confirmed with a second (VP6) qRT-PCR to ensure reliability. This is 
also the first study to describe transmission of rotavirus vaccine virus to all household 
contacts, enabling risk factors for transmission to be evaluated, should there have been 
enough events for meaningful analysis.  
These findings corroborate the findings of a study conducted on infants in contact with 
RV1 vaccinated infants in a Japanese foster home which also used qRT-PCR to detect 
vaccine virus, and identified one possible episode of vaccine virus transmission in a 
contact who had previously received rotavirus vaccine. The numbers recruited were 
relatively small (4 vaccinated infants and 23 contact infants) however, and in contrast to 
this study did not include care givers or older children. The low frequency of transmission 
is however in contrast to a study by Rivera et al who conducted a randomised controlled 
trial (RCT) of RV1 transmission in twins in the Dominican republic(244). Transmission was 
defined using EIA,  and the study found transmission rates of almost 20%, a quarter of 
whom sero-converted. Potential explanations for these differences include higher rates 
of shedding in vaccinated infants in the Dominican Republic, perhaps due to more robust 
immune response to vaccination, or differences in contact patterns or the age of the 
contact. Infants in the Japanese study had a median age of 9 months, and median age of 
contacts in our study was 20 years. In comparison twin siblings at the age of vaccination 
(1-3 months) are likely to have little pre-existing immunity to rotavirus, even compared to 
infants 9 months of age, and therefore may be more likely to become infected with 
vaccine virus. It is also possible that twins spend more time in close proximity with each 
other than infants in a foster home, or older relatives. 
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It is also intriguing that vaccine virus transmission differs so substantially from wild-type 
transmission in the same socio-cultural environment. The most likely explanation is a 
combination of presence of symptoms and viral load. Peak viral load was not associated 
with risk of transmission for infection or disease in our setting (Chapter 7), however in 
symptomatic children median cycle thresholds for the first sample after presentation 
were 19.1 (Chapter 6, section 6.3.1, page 195), compared to a cycle threshold of 32 with 
vaccine virus. It may be that differences in viral load are not associated with risk of 
transmission in symptomatic children because they all have very high viral loads, but that 
once viral loads become substantially lower transmission is less likely. This is corroborated 
by the fact that no new episodes of infection were identified in household contacts of 
symptomatic index children beyond the first two weeks after initial exposure, despite the 
fact that the majority of index children were still shedding at low levels (Chapter 6, section 
6.3.4, page 203). The importance of symptoms in transmission is demonstrated by the 
association between symptom severity and transmission identified in this thesis (Chapter 
7, section 7.3, page 214), and also by a study from Ecuador, which identified rotavirus 
infection in 55% of households of symptomatic index cases, 8% of household contacts of 
rotavirus EIA negative children with diarrhoea, and 2% of household contacts of healthy 
control children(106). None of the infants recruited into this horizontal transmission study 
reported symptoms.  
This is the first study of rotavirus vaccine virus transmission conducted in a setting with 
high background HIV prevalence. This is relevant as there is some evidence that HIV 
infected children may shed rotavirus for longer following rotavirus infection, and children 
with severe immunodeficiencies have been shown to shed rotavirus, including vaccine 
virus, for extended periods of time(260,373). In this study prevalence of HIV infection in 
household contacts was 17%, consistent with the background prevalence of HIV in 
Blantyre, Malawi, estimated at 18.5% in 2010(374). None of the vaccinated infants had 
confirmed HIV infection, although 12 were known to be HIV exposed.  The adult contact 
with detectable vaccine strain was reported to be HIV negative when last tested, and the 
child contact who shed vaccine virus had never been tested for HIV. With the caveat that 
this study was not designed or powered to formally investigate the relationship between 
HIV exposure in a household and risk of vaccine virus transmission, there is no evidence 
from this study that vaccine virus transmission is significant with populations with a high 
background prevalence of HIV.  
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8.4.1 Limitations 
 It is notable that males, and particularly fathers, are under-represented in household 
contacts to a greater extent than was observed in the primary household transmission 
study (13% of recruits vs 19% in the primary study, chapter 5, section 5.3, page 169). This 
is likely to represent the method of recruitment for this study, which was predominantly 
based at the health centre with household contacts bringing samples to the health centre, 
in contrast to the primary study where the field team visited and recruited from the home. 
The primary transmission study also often recruited children who were admitted to 
hospital, in which case extended family members including fathers visited, facilitating 
contact. Although fathers are under-represented, this is unlikely to have affected the 
validity of results as we have seen so little transmission in mothers, who typically have 
much more direct contact with the vaccinated infant, or in young children who are likely 
to be more susceptible to rotavirus infection.  
Data for this study were collected from April 2016 through August 2016 which is not a 
complete year. The start of recruitment was delayed due to delays in ethical approval, 
and recruitment had to stop in August because the RotaRITE:RI study completed 
recruitment. Wild-type rotavirus shows some seasonality in Malawi, with the peak of 
disease occurring between May and October(34). Recruiting for only part of a year could 
mean that the prevalence of wild-type rotavirus in household contacts is misleading, but 
would be unlikely to significantly affect rates of transmission of vaccine virus.   
Single stool samples from contacts were collected at either day 8 or day 10 after 
vaccination in the infant and it is possible that some transient shedding episodes were not 
detected by this method. Serial stool samples in contacts would have been a more robust 
way to ensure all episodes were captured, but unfortunately that was not possible due to 
funding and logistics. However shedding of vaccine virus occurred early in vaccinated 
infants, with a similar proportion of infants observed to be shedding at day 4 as at day 10; 
qRT-PCR was used to detect vaccine virus which is highly sensitive even to very low level 
viral shedding and the study findings are corroborated by those from the study in Japan 
which did conduct serial sampling(368). These findings may represent a minimum 
estimate of horizontal transmission, but it seems unlikely that the true frequency should 
differ substantially from this. 
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Conclusions, implications and further studies 
This study identified very little horizontal transmission of vaccine virus to household 
contacts in Malawi, despite high background HIV prevalence, crowded living conditions 
and poor sanitation, and as such horizontal transmission of vaccine virus seems unlikely 
to be a major contributing factor to indirect effects in this setting. This does not however 
preclude the presence of substantial indirect effects through reduction in transmission of 
wild-type rotavirus, and studies which build on the work in this thesis and attempt to 
quantify these effects are  needed.  
In order to understand the implications of horizontal transmission and to detect 
transmission episodes not identified using faecal shedding, testing sero-response in 
household contacts would be very useful. This was not possible in the context of our study 
due to cost and logistics, and because blood collection in the community is subject to 
complex social implications which need negotiating, however future studies should 
consider incorporating this into study design. Any future studies of horizontal 
transmission should also consider collecting serial samples from contacts to minimise the 
risk of under-detecting shedding episodes.   
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9. Discussion and Conclusions 
9.1 Overview 
Global rotavirus vaccine introduction has had an enormous public health impact, and it is 
a remarkable achievement that the trajectory from first discovery of rotavirus in the 
1970s, description of the burden of disease, vaccine development, global vaccine 
introduction and post-implementation evaluation studies have occurred over less than 
half a century. However despite these successes, and even in the context of highly 
successful vaccine campaigns and higher than expected vaccine effectiveness estimates, 
rotavirus remains the commonest cause of admitted gastroenteritis in children from some 
sub-Saharan African settings(329). In order to maximally protect the most vulnerable 
children from rotavirus and inform ongoing vaccine policy, it is necessary to understand 
mechanisms for the reduced vaccine effectiveness in low income settings; to characterise 
the residual burden of disease; to describe rotavirus epidemiology in vaccinated 
populations and to evaluate the total population level impact of the vaccine, including any 
indirect effect(215).  
Very little is known about rotavirus transmission in LICs, yet it is crucial to all of the 
unanswered questions above. High force of infection may contribute to the reduced 
vaccine effectiveness observed in LICs and the age distribution of rotavirus infection and 
disease is likely to relate to transmission dynamics. In terms of evaluating population level 
impact, vaccine mediated reductions in rotavirus transmission via reduced frequency of 
infectious contacts, reduction in infectiousness of symptomatic cases or transmission of 
vaccine virus to unvaccinated contacts have the potential to increase protection afforded 
by vaccine to vaccinated infants and protect members of the population that have not 
themselves been vaccinated. Such vaccine indirect effects can be sufficient to transition a 
vaccine programme from cost effective to cost saving(229), but there are a paucity of data 
from LICs where these effects are most crucial.   
This thesis set out to address some of these questions. The results are divided into two 
sections. Section A consists of two chapters and focuses on rotavirus transmission at a 
population level. The first chapter explores a novel and pragmatic technique to estimate 
rotavirus force of infection in different populations which has the potential to increase 
our understanding of how transmission dynamics may relate to global disparities in 
vaccine performance. The second uses surveillance data to quantify rotavirus vaccine 
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indirect effects for the first time in a LIC, and to describe the changing epidemiology of 
rotavirus in a sentinel surveillance site following vaccine introduction.   
Having identified evidence of rotavirus vaccine indirect effects in a Malawian population, 
and differences in patterns of indirect effects compared to those from in higher income 
settings, Section B of the results focusses on rotavirus transmission at a household level 
to understand mechanisms driving rotavirus vaccine indirect effects in a LIC. Section B is 
further divided into two main questions. Firstly whether rotavirus vaccine has potential 
to reduce the infectiousness of an index case. This is addressed in stages; by defining SAR 
in a LIC in sub-Saharan Africa, investigating whether disease severity is associated with 
viral load in index children, and investigating whether disease severity and viral load are 
associated with risk of transmission at the household level. Secondly, it asks whether 
horizontal transmission of vaccine virus and subsequent generation of herd immunity is 
likely to contribute to rotavirus vaccine indirect effects in a Malawian population.  
This current chapter summarises the findings of the thesis, and outlines implications for 
vaccine policy and future work which may arise.  
9.2 Summary of findings 
Section A 
By utilising a novel method of analysing rotavirus sero-prevalence data, Chapter 3 
demonstrates substantial differences in timing of first exposure to rotavirus in infants 
from two different unvaccinated low-income populations, with infants from Vellore, 
Southern India exposed to rotavirus at an earlier age than children from Karonga, 
Northern Malawi. Reasons for this difference are not known, but may include differences 
in population density, poverty levels, or prevalence of co-morbidities such as malnutrition. 
High force of rotavirus infection has been cited as one possible explanatory factor for low 
rotavirus vaccine effectiveness in LICs because of high maternal antibody levels which 
could interfere with vaccine immunogenicity in infants(142,143), or because high 
frequency of natural exposure in unvaccinated control groups impacts on measurement 
of rotavirus vaccine effects(145). Describing heterogenicity in force of infection between 
populations will increase our understanding of  the relationship between force of 
infection and vaccine response, and mixture models may be a useful and pragmatic 
analytical technique to support this.  
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Using data from 5 years of diarrhoeal surveillance at QECH, Chapter 4 describes a 
consistent decline in the prevalence of rotavirus attributable gastroenteritis requiring 
hospitalisation in Blantyre, Malawi, following programmatic vaccine introduction in 2012. 
It also identifies an additional reduction in incidence of hospitalised rotavirus 
gastroenteritis of any severity of 9-24% in infants beyond that predicted based on vaccine 
efficacy and vaccine coverage. This is the first quantifiable evidence of rotavirus vaccine 
indirect effect from a LIC. However in contrast to findings from higher income settings 
indirect effects were not identified in infants with severe disease or children over 12 
months of age(221). In addition, the observed reduction in the prevalence of rotavirus 
attributable gastroenteritis was less pronounced in children aged 1-2 years of age 
compared to infants under one year; the proportion of rotavirus gastroenteritis occurring 
in children aged 12-24 months increased from 18 to 38% following vaccine introduction 
and the point estimate for vaccine effectiveness was substantially lower in children aged 
12-24 than those under 12 months of life. Despite high vaccine coverage and encouraging 
vaccine effectiveness estimates in infants, rotavirus remains a major cause of hospitalised 
gastroenteritis in Blantyre, responsible for over one quarter of all admissions for 
gastroenteritis. 
Section B 
Could rotavirus vaccine reduce the infectiousness of a vaccinated index case? 
Rates of transmission for rotavirus infection were very high in household members 
exposed to a symptomatic index child, but rates of disease were much lower. Rotavirus 
disease was commoner in household contacts under 5 years, but transmission rates for 
infection did not vary according to the age of the household contact. In this population 
repeated exposure appears to result in immunity to disease but not infection. Rates of 
infection were comparable to those identified by a study in Ecuador which also used qRT-
PCR(106), but disease rates were notably lower. One explanation for this could be high 
background infection rates in Malawi contributing to maintenance of immunity against 
clinical disease. This hypothesis is supported by the high frequency (27%) of asymptomatic 
rotavirus infection described in control households without history of recent exposure to 
a child with diarrhoea.  
Index children with clinical rotavirus gastroenteritis shed large quantities of rotavirus in 
their stool, corroborating previous findings from India. Shedding density declined quickly, 
but in some children ongoing low level shedding persisted for weeks after symptom onset. 
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Children with more severe disease shed more virus than children with milder disease, 
suggesting that interventions to reduce disease severity, for example vaccine, could 
reduce viral shedding density in index children and therefore transmission. Viral load in 
household contacts declined with time from onset of symptoms in the index child, 
supporting the hypothesis that household contacts are infected from a symptomatic 
infant in the house.  
Increasing disease severity in the index child was associated with an increased risk of both 
rotavirus infection and disease in household contacts. Contrary to what was hypothesised 
this did not appear to be mediated through a reduction in viral shedding density, which 
showed no association with transmission of infection or disease at the univariate or 
multivariate level. Transmission of infection showed no relationship with the age of 
household contact, but risk of disease was significantly higher in children under 5 years of 
age. Contact with the index child was a risk factor for infection, with mothers at 
significantly greater risk of infection than any other household relative. The association 
between disease severity in the index child and risk of transmission for both infection and 
disease suggests that vaccination has the potential to reduce the infectiousness of a child 
with rotavirus gastroenteritis even in the event of clinical vaccine failure, as rotavirus 
vaccine provides incremental protection against severe disease. As a result of the 
successful vaccine programme and high vaccine coverage in Blantyre we were unable to 
identify enough unvaccinated children to directly investigate the effect of vaccine on 
rotavirus transmission.  
Could horizontal transmission of monovalent human rotavirus vaccine virus (Rotarix) to 
household contacts contribute to rotavirus vaccine indirect effects in Malawi? 
Very low rates of horizontal transmission of vaccine type virus were observed in 
household in Blantyre, Malawi, with 2/151 (1.3%) of household contacts of vaccinated 
infants found to be shedding vaccine virus. This was despite high frequency of low level 
shedding in vaccinated infants and a high background prevalence of HIV exposure. 
Horizontal transmission of vaccine virus does not appear likely to be a major mechanism 
underpinning the production rotavirus vaccine indirect effects in Malawi.  
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9.3 Implications  
Force of infection in low income countries 
Rotavirus remains a major cause of diarrhoeal disease requiring hospitalisation in Malawi. 
This has ongoing implications for health care provision and resource management, as well 
as substantial social and economic ramifications for the community. It is possible that as 
force of infection drops following vaccine introduction rotavirus disease burden in LIC will 
to decline, but if disease burden remains high with continued surveillance and sustained 
high vaccine coverage, then a change to vaccine strategy either with modification to 
scheduling for current vaccines or with novel candidate vaccines may be required(294). 
Understanding patterns of force of infection in different settings, for example with 
serological data, could inform decisions around optimal vaccine scheduling. For example 
a very high burden of early disease may require  a neonatal dose of vaccine, or 
alternatively a delayed vaccine dose once the influence of maternal immunity has waned.   
High force of infection may also influence the measures of effect currently used for 
vaccine studies, such that studies conducted in high disease burden settings are not 
directly comparable with low income settings. As argued by Gomes at al(145), in settings 
where force of infection is high vaccine efficacy may represent cumulative efficacy against 
several episodes of disease and per-event estimates of efficacy could result in estimates 
which are more comparable with lower burden settings. Similarly, because of high 
frequency of exposure to rotavirus in unvaccinated children and acquisition of natural 
immunity, high force of infection could in part explain the reduced vaccine effectiveness 
in the second year of life observed in Malawi and why indirect effects appear less 
substantial in older children than reported from higher income settings (Chapter 4). If the 
extent of rotavirus vaccine indirect effect described in Chapter 4 is accurate and vaccine 
indirect effects are indeed limited to infants, then indirect effects may play a lesser role 
in population level vaccine impact in a Malawian population than hoped. However, if this 
is in part a function of high force of infection then vaccine indirect effects and indeed 
observed vaccine effectiveness may actually increase over time as population level 
incidence drops. Additional vaccine doses may then become less urgent.  
 
 
 
254 
 
Rotavirus transmission in Malawi 
This thesis provides a first step in understanding the complexity of rotavirus transmission 
in low income settings and considering how vaccine may impact on this. Very high levels 
of rotavirus infection were observed in households following exposure to a symptomatic 
index case, but much lower levels of disease were seen. It may be that regular exposure 
to rotavirus in late child- and adult-hood results in maintenance of immunity against 
disease, and it is possible disease attack rates will increase over time if population level 
transmission drops as a result of vaccine. A high frequency of asymptomatic shedding of 
rotavirus was also observed in households which had not recently been exposed to a 
symptomatic index case. This high frequency of low level rotavirus shedding may at least 
partly explain the great diversity of rotavirus strains observed in Malawi and other low 
income settings. The frequency of asymptomatic shedding and the fact that there was no 
observed reduction in asymptomatic shedding with age calls in to question whether 
individuals in Malawi develop immunity to rotavirus infection. The contribution of this 
asymptomatic shedding to ongoing transmission is as yet unknown.  
Mechanisms of rotavirus vaccine indirect effects 
The positive association between disease severity and household transmission of 
infection and disease provides evidence to support the hypothesis that vaccine mediated 
reductions in disease severity could reduce household transmission in the event of 
vaccine failure. Given a vaccine effectiveness of approximately 60% in Malawi, this could 
have a substantial impact on transmission at the population level. From this study, it 
seems that horizontal transmission of vaccine virus, or generation of herd immunity, is 
not a major contributor to rotavirus vaccine indirect effects in our setting. That horizontal 
transmission of vaccine virus is so infrequent an occurrence, even in a population with 
high HIV and malnutrition prevalence, should reduce any anxiety about the risk of harmful 
transmission to children or adults with immunocompromise   
9.4 Further studies and work building on this thesis 
The work in this thesis expands our knowledge of rotavirus transmission in low income 
settings and how this may influence vaccine effects; however several additional research 
questions arise from the work described here. These are outlined below.  
1. Is pre-existing immunity against rotavirus associated with disease severity, viral 
shedding density and risk of transmission?  
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This thesis has demonstrated a positive association between disease severity and 
transmission, and between viral load and disease severity, but the role of pre-existing 
immunity to rotavirus in these phenomena is not known. If higher titres of anti-rotavirus 
IgA at presentation at baseline are associated with reduced disease severity and reduced 
risk of transmission to household contacts this would add weight to the hypothesis that 
vaccine could reduce infectiousness. In order to address this question serum samples 
were collected from index children at the time of presentation for measurement of anti-
Rotavirus IgA titres. These data are not yet available, but will form the basis of future 
analyses to address the above question.   
2. Is high force of infection associated with reduced vaccine effectiveness?  
This question has two strands. Firstly, could high force of infection have a causative role 
in sub-optimal vaccine effectiveness, either as a result of reduced vaccine immunogenicity 
mediated by high maternal anti-bodies, or because of a high burden of disease before 
infants have been adequately vaccinated(294). If this is the case then interventions such 
as changes to dosing schedules or novel candidate vaccines could have an important role 
to play in maximising protection. A clearer understanding of different patterns of 
transmission epidemiology in the first year of life is then important to understand how to 
target interventions. Sero-prevalence data of rotavirus in infants has the potential to 
improve understanding of incidence patterns in different populations, and if this is 
combined with vaccine efficacy or effectiveness data from the same populations has 
potential to provide insight into the relationship between force of infection and vaccine 
performance. Sero-prevalence data from multiple different counties and socio-economic 
settings exists from vaccine pre-licensure clinical trials. These data have the major 
advantage that the serology was conducted in a standardised way using the same assay, 
and is therefore comparable and suitable for meta-analyses. Mixture models could be a 
pragmatic and effective means of estimating force of infection from such sero-prevalence 
data.  
In terms of potential interventions, immunogenicity trials of different dosing strategies 
have been conducted and describe increased immunogenicity with either a delayed 
additional dose (14 weeks)(310), or a booster dose (9 months)(375), and neonatal dosing 
strategies of a tetravalent rotavirus vaccine have been shown to be immunogenic and 
demonstrate good efficacy against rotavirus gastroenteritis of any severity (60%) (311). A 
Phase 2b trial of a novel candidate vaccine based on a neonatal strain (RV3), which has 
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shown promising results from immunogenicity studies in New Zealand(131), is planned to 
be undertaken in Malawi.  
Secondly, could force of infection effect the measurement  of rotavirus vaccine indirect 
effects and rotavirus vaccine effectiveness: in other words could high levels of natural 
exposure and subsequent immunity in older unvaccinated children explain some of the 
observed disparity between LIC and HIC. A low burden of disease in older children due to 
pre-existing immunity could explain the absence of identifiable indirect effects in children 
over 12 months of age, and natural exposure to wild-type disease in unvaccinated children 
could result in comparison groups becoming too similar, and result in reduced vaccine 
effectiveness estimates. It seems unlikely to be the only explanatory factor explaining 
reduced vaccine performance in LIC given the sub-optimal immunogenicity also observed 
in such settings from clinical trials(298). If, however, such a phenomenon does make a 
contribution it maybe that observed vaccine effectiveness and indirect effects to older 
age groups increase as transmission decreases as a result of vaccine introduction. Careful 
ongoing surveillance is necessary to evaluate this, to identify at-risk groups, and enable 
observation of trends in rotavirus prevalence with time. Given the success of the vaccine 
campaign and the low frequency of unvaccinated children further direct estimates of VE 
are not possible and ongoing evaluation will requires more complex analytical techniques 
and mathematical modelling. Ongoing sentinel surveillance at QECH will inform 
mathematical models of rotavirus vaccine indirect effects. These analyses will be 
invaluable in understanding the effect on changes in transmission on vaccine effects in 
our setting.  
3. What is the role of asymptomatic infection in immunity against rotavirus disease? 
Asymptomatic rotavirus shedding in the community in Blantyre, is extremely common but 
its role in the maintenance of immunity is not clear. The high frequency of asymptomatic 
infection may act as a “booster” to the immune system and provide protection against 
rotavirus disease. This could explain why we see so little disease in household contacts of 
symptomatic index cases. Alternatively the high frequency of asymptomatic rotavirus 
shedding could reflect an inability to mount a complete immune response to rotavirus 
infection. If this is different to patterns in high income settings it may add insight into 
observed reduced vaccine immunogenicity. It will only be possible to evaluate this if 
similar household studies with comparable molecular techniques used to detect rotavirus 
are conducted in higher income settings. There is some evidence that children from low 
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income settings shed rotavirus for longer following a symptomatic episode than children 
from high income settings (254,255)although as a result of heterogenicities between 
studies this requires further validation. To investigate this, cohort studies which follow up 
children with symptomatic rotavirus for an extended period of time are needed in both 
low and high income settings. If differences in clearance of rotavirus infection are 
confirmed this could add information to our growing understanding of the mucosal 
immune response to rotavirus – perhaps delayed clearance of rotavirus reflects 
suboptimal mucosal immunity in low income settings – and further inform understanding 
of reduced vaccine immunogenicity in LIC.  
4. What is the magnitude of rotavirus vaccine indirect effects in Blantyre, Malawi 
This study identified some evidence of indirect effects of rotavirus vaccine in infants 
following rotavirus vaccine introduction, but not in children aged over 12 months of age. 
This is intriguing, as it is contrary to findings in higher income settings(221). There are 
reasonable epidemiological hypotheses which could explain this, for example a low 
burden of symptomatic disease in older children due to frequent re-exposure, but the 
findings are limited by a short duration of pre-vaccine introduction surveillance data, and 
ongoing evaluation is impossible due to high vaccine coverage. Addressing this question 
therefore requires more complex mathematical models, and this is being undertaken with 
collaborators at Yale School of Public Health.   
5. What is the vaccine effectiveness on infectiousness of an index child to household 
contacts? 
It was not possible to directly estimate the effect of vaccine on infectiousness because of 
the high vaccine coverage in Blantyre. However it may be possible to model vaccine 
effectiveness on infectiousness using data on the relationship between disease severity 
and transmission demonstrated in this thesis and existing estimates of vaccine 
effectiveness for different degrees  of disease severity. Strategies to do this are currently 
under discussion. Such an estimate would provide a quantitative value for reduction in 
household rotavirus transmission mediated via reduced infectiousness of an index child 
and contribute to evaluations of population level rotavirus vaccine impact.  
All of the above questions feed into one, over-arching question which extends beyond the 
scope of this thesis: 
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Is additional intervention required to improve protection of Malawian children against 
rotavirus disease? 
The answer to this question is complex, and will require assimilation of data from multiple 
different locations and sources. It is possible that disease burden will continue to decline 
without intervention as a result of vaccine impact on transmission, but it is also possible 
that additional changes to the dosing schedule, or novel vaccines, could play an important 
role in reducing the ongoing burden of morbidity and mortality caused by rotavirus. Any 
policy decision will require careful weighing of further data, including assessment of 
ongoing disease burden informed by surveillance data, accurate assessment of vaccine 
effects  incorporating indirect effects, field evaluations of possible interventions and 
predictive modelling studies.  
9.5 Conclusions 
Rotavirus remains an important cause of hospitalised diarrhoeal disease in children in 
Blantyre, Malawi, despite high vaccine coverage and encouraging vaccine effectiveness 
estimates. An additional, indirect effect of rotavirus vaccine is seen, but to a lesser 
magnitude than described from higher income settings. Rotavirus is remarkably 
transmissible, with SAR for infection within households of over 65%. Reducing disease 
severity in the index child reduces rates of transmission to household contacts, supporting 
the hypothesis that vaccination could reduce infectiousness of index children who fail 
vaccine. Horizontal transmission of vaccine virus to generate herd immunity is unlikely to 
be a major contributor to rotavirus vaccine indirect effects in our setting. A detailed 
understanding of patterns and drivers of rotavirus transmission is essential to 
understanding disparities in vaccine performance between different populations, 
evaluating the total impact of the vaccine and making policy decisions to best protect 
children in the world’s poorest countries from rotavirus disease. 
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10. Appendices 
Table A1. Search terms for literature review of rotavirus epidemiology 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Rotavirus & middle income 
Rotavirus & low & income 
Rotavirus & central & Europe 
Rotavirus & middle & east 
Rotavirus & North Africa 
Rotavirus & South & America 
Rotavirus & Latin & America 
Rotavirus & Cental & America 
Rotavirus & Asia 
Rotavirus & Africa 
Rotavirus & Malawi 
Rotavirus & Africa & asymptomatic 
Rotavirus & asymptomatic 
Rotavirus & mortality 
Rotavirus & efficacy 
Rotavirus & effectiveness 
Rotavirus & vaccine & impact 
Rotavirus & vaccine & effect 
Rotavirus & vaccine & indirect 
Rotavirus & transmission 
Rotavirus & family 
Rotavirus & families 
Rotavirus & household  
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Table A2. Relative risk of rotavirus detection in children admitted to QECH with 
gastroenteritis for annual time periods since vaccine introduction 
 
 RV** 
negative 
RV positive Total  RR (95% CIϮ)* 
Time period     
Pre-vaccine       
(Jan’12- 
Oct’12) 
202 (55.49) 162 (44.51) 364  1 (ref) 
Nov’12- 
Oct’13 
365 (64.49) 201 (35.51) 566  0.81 (0.69, 0.94) 
Nov’13- 
Oct’14 
322 (74.71) 109 (25.29) 431  0.58 (0.48, 0.71) 
Nov’17- 
Oct’15 
382 (72.62) 144 (27.38) 526  0.64 (0.54, 0.77) 
Nov ’15- 
Jun’16 
173 (73.93) 61 (26.07) 234  0.60 (0.47, 0.76) 
Total 1,444 (68.08) 677 (31.92) 2,121   
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Table A3. Comparison of characteristics of index children for children recruited in QECH 
and children recruited from health centres.  
 QECH Health centre   
 Summary 
statistic 
Missing 
data 
Summary 
statistic 
Missing 
data 
P valueϮ 
Age (median and IQR) 11.0(8.7,14.6) 0/113 12.8(9.0,16.0) 0/83 0.35** 
Sex (male) (%) 68/113 (60.2) 0/113 40/83(48.2) 0/83 0.096 
Diarrhoea (%) 113/113 (100) 0/113 83/83 (100) 0/83 -  
Duration (days)  0/113  0/83  
1-3 (%) 96/113 (85.0)  77/38 (92.8)   
5 9/113 (8.0)  3/83 (3.6)   
≥6 8/113 (7.1)  3/83 (3.6)  0.242 
Episodes(n)***  0/113  0/83  
1-4 (%) 12/113 (12.2)  12/83 (14.5)   
5 48/113 (43.9)  36/83 (45.8)   
≥6 53/113 (43.9)  33/83 (39.8)  0.535 
      
Vomiting (%) 105/113 (92.9) 0/113 77/83 (92.8) 0/83 0.968 
      
Duration (days)  0/105  0/77  
1 (%) 8/105 (7.6)  15/77(19.5)   
2 19/105 (18.1)  40/77(52.0)   
≥3 78/105 (74.3)  22/77 (28.6)  <0.001 
Frequency (n)  0/105  0/77  
<5 (%) 67/105 (63.8)  56/77 (72.7)   
≥5 38/105 (36.2)  21/77 (27.3  0.204 
      
HIV      
Exposed (%) 17/113 (15.0) 0/113 8/83 (9.6) 0/83 0.262 
Infected (%) 2/42 (4.8) 71/113* 0/16 (0) 67/83 0.374 
Completed rotavirus 
vaccination (%) 
     
 Vaccinated  
(2 doses)  
111/113 (98.2) 0/113 83/83 (100) 0/83 0.223 
Admitted (%)      
Yes 111/113 (98.2) 0/113 0/83 (0) 0/83 <0.001 
Vesikari score  (IQR) 15 (14, 16) 3/113 12 (10,14) 0/83 <0.001* 
Temperature (rectal, oC)      
37.1-38.4 (%) 46/111 (41.4)  46/82 (56.1)   
38.5-38.9 28/111 (25.2)  20/82 (24.4)   
≥39.0 37/111 (33.3) 2/113 16/82 (19.5) 1/83  
Thirst (%)      
No thirst 8/113 (7.1)  24/83 (28.9)   
Thirsty 86/113 (76.1)  55/83 (66.3)   
Drinks poorly 19/113 (16.8) 0/113 4/83 (4.8) 0/83 <0.001 
Skin pinch (%)      
Normal 8/113 (7.1)  48/83 (57.8)   
Goes back 
slowly 
70/113 (62.0)  34/83 (41.0)   
Goes back very 
slowly 
35/113 (31.0) 0/113 1/83 (1.2) 0/83 <0.001 
General Appearance (%)      
Well, alert 36/113 (31.9)  58/83 (69.9)   
Restless 58/113 (51.3)  25/83 (30.1)   
Unconscious 19/113 (16.8) 0/113 0/83 (0) 0/83 <0.001 
Dehydration (%)      
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None 4/113 (3.5)  22/83 (26.5)   
Some (5%)  68/113 (60.2)  56/83 (67.5)   
Severe (10%)  41/113 (36.3) 0/113 5/83 (6.0) 0/83 <0.001 
IV fluids (%)      
Yes 58/113 (51.3) 0/113 0/83 (100.0) 0/83 <0.001 
Oral fluids (%)      
Yes  112/113 (99.2) 0/113 73/83 (88.0) 0/83 0.001 
Outcome (%)      
Home 111/113 (98.2)  83/83  - 
Died 2/113 (1.8) 0/113 0/83 0/83 0.223 
Anthropometry, mean 
(SD) 
     
Adjusted WHZ -1.00(1.5) 1/113 -0.34 (1.7) 0/83 0.005* 
Adjusted WAZ -0.55(1.2) 1/113 -0.14 (1.1) 0/83 0.061* 
Adjusted HAZ -0.41 (2.5) 5/113 -0.50(2.4) 0/83 0.708* 
MUAC 13.2 (1.3) 0/113 13.5 (1.2) 1/83 0.090* 
SAM 17/113 (15.0) 0/113 6/81(7.4) 2/81 0.105 
Previous diarrhoeal 
admission (%) 
11/113 (9.7) 0/113 4/83 (4.8) 0/83 0.201 
Previous diarrhoeal 
presentation (%) 
69/113 (61.1) 0/113 22/83(26.5) 0/83 <0.001 
Premature (%) 4/113 (3.5) 0/113 3/53 (3.6) 0/83 0.978 
Birth weight, mean (SD) 2.99 (0.64) 12/113 2.92(0.63) 4/83 0.381* 
Ever Breastfed (%) 112/113 (99.1) 0/113 0/83 (0.0) 0/83 0.390 
Diet includes food other 
than breast milk (%) 
109/113 (96.5) 0/113 81/83(97.6) 0/83 0.650 
ϮP values are X2 p values for differences in proportions between case children recruited at 
QECH or health centres unless otherwise specified. *2 sided independent ttest **rank 
sum test 
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Table A4. Comparison of index children who completed study to index children 
withdrawn from study 
 Index children who 
completed 
Index children who 
withdrew 
 
 Summary 
statistic 
Missing 
data 
Summary 
statistic 
Missing 
data 
P 
Age (Median and IQR) 11.5 (8.8, 15.2) 0/196 11.0 (8.3, 
13.9) 
0/59 0.215 
Sex (male) (%) 108/196 (55.1) 0/196 41/59(69.5) 0/59 0.049 
Diarrhoea 196/196 0/197 59/59 (100) 0/59 - 
Duration (days)  0/196    
1-3 173/196 (88.3)  48/59 (82.4) 0/59  
5 12/196 (6.1)  7/59 (11.9) 0/59  
≥6 11/196 (5.6)  4/59 (6.8) 0/59 0.307 
Max per day (n)  0/196    
1-4 24/196 (12.2)  13/59 (22.0) 0/59  
5 86/196 (43.9)  26/59 (44.1) 0/59  
≥6 86/196 (43.9)  20/59 (33.9) 0/59 0.130 
      
Vomiting 182/196 (92.9) 0/196 55/59 (93.2) 0/59 0.924 
      
Duration (days)  0/182    
1 23 (12.6)  6/55 (10.9) 0/55  
2 59 (32.4)  19/55(34.6) 0/55  
≥3 100 (55.0)  30/55 (54.6) 0/55 0.922 
Max per day (n)  0/182    
<5 123 (67.6)  39/55 (70.9) 0/55  
≥5 59 (32.4)  16/55 (29.1) 0/55 0.642 
HIV      
Exposed (%) 25/196 (12.8) 0/196 6/59 (10.17) 0/59 0.594 
Infected (%) 2/58 (3.5) 138/196* 0/14 (0) 45/59 0.547 
RV1      
Vaccinated (2 
doses) (%) 
194/196 (99.0) 0/196 58/59 (98.3) 0/59  
Unvaccinated (0 
dose) (%) 
2/196 (1.0) 0/196 1/59 (1.7) 0/59 0.674 
Admitted (%)      
Yes  111/196 (56.6) 0/196 37/59 (62.7) 0/59 0.407 
Vesikari score  (IQR) 14 (12, 16) 3/196 14 (12, 16) 0/59 0.754** 
Dehydration (%)      
None 26/196 (13.3)  7/59 (11.9)   
Some (5%) 124/196 (63.3)  34/59 (57.6)   
Severe (10%) 46/196 (23.5) 0/196 18/59 (30.5) 0/59 0.550 
IV fluids (%)      
Yes 58/196 (29.6) 0/196 16/59 (27.1) 0/59 0.714 
Oral fluids (%)      
Yes 185/196 (94.4) 0/196 57/59 (96.6) 0/59 0.496 
Outcome  (%)      
Home 194/196 (99.0)  58/59 (98.3)   
Died 2/196 (1.0) 0/196 1/59 (1.7) 0/59 0.677 
Anthropometry 
(mean and SD) 
     
Whz -0.59(1.61) 1/196 -0.92(1.65) 0/59 0.181* 
WAZ -0.46 (1.6) 1/196 -0.50(1.28) 0/59 0.877* 
HAZ -0.04 (2.46) 5/196 0.12(2.46) 4/59 0.688* 
MUAC 13.48 (1.28) 1/196 13.39(1.12) 0/59 0.628* 
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SAM 23/194 (11.9) 3/196 6/59 (10.17) 0/59 0.713 
Household size  0/196    
≤5 136/196 (69.4)  46/59 (78.0) 0/59 0.201 
>5 60/196 (30.6)  13/59 (22.0)   
Previous diarrhoeal 
admission (%) 
15/196 (7.7) 0/196 5/59 (8.47) 0/59 0.829 
Previous diarrhoeal 
presentation (%) 
91/196 (46.4) 0/196 36/59 
(61.02) 
0/59 0.049 
Premature (%) 6/196 (3.1) 0/196 2/59 (3.4) 0/59 0.899 
Birth weight  
(mean and SD) 
2.96 (0.64) 12/196 2.98(0.51) 3/59 0.872* 
Ever Breastfed (%) 195/196 (99.5) 0/196 59/59 (100) 0/59 0.583 
Other food (%) 190/196 (97.0) 0/196 58/59 (98.3) 0/59 0.573 
Additional child <1      
0 (%) 187/192 (97.4)  59/59 
(100.0) 
  
1 (%) 5/192 (2.6) 4/196 0/59 (0.0) 0/59 0.211 
Additional children < 5      
0 (%) 126 (65.0)  40/59 (67.8)   
1 (%) 62 (32.0)  17/59 (28.8)   
2 (%) 5 (2.6)  2/59(3.4)   
4 (%) 1 (0.5) 2/196 0/59 (0) 0/59 0.894 
Electricity at home      
Yes (%) 89/196 (45.4) 0/196 28/59 (47.5) 0/59 0.782 
Shared toilet      
Yes(%) 148/196 (75.5) 0/196 48/59 (81.4) 0/59 0.351 
How long for household to 
access water (%) 
     
How long for household to 
access water (%) 
     
0-5 mins 34/196 (17.4)  12/58 
(20.69) 
  
5-30mins 94/196 (48.0)  21/58 
(36.21) 
  
>30 mins 68/196 (24.7) 0/196 25/58 
(43.10) 
1/59 0.286 
Water source (%)      
Well 16/195 (8.2)  0/58 (0.0)   
Borehole 35/195 (18.0)  8/58 (13.8)   
Shared tap 
village/compound 
115/195 (59.0)  42/58 (72.4)    
Tap to house 29/195  (15.0) 1/196 8/58 (13.8) 1/59 0.088 
How many people have a 
regular salary (%) 
     
0 68/195 (34.9)  22/59 (37.30   
≥1 127/195 (65.1) 1/196 37/59 (62.7) 0/59 0.734 
Problems getting 
food in the past 
month (%) 
     
No 136/196 (69.4)  38/59 (64.4)   
Sometimes/often 60/196 (30.6) 0/196 21/59 (35.6) 0/59 0.471 
Has an adult skipped a 
meal in the past 2 weeks? 
     
Yes 45/197 (22.8) 0/197 14/59 (23.7) 0/59 0.902 
Wealth  
(Mean and SD) 
2.38 (0.57) 5/196 2.38(0.41) 0/59 0.999* 
Time of recruitment      
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Quarter of year (%)       
Jan-Mar 43/196 (22.0)  22/59 (37.3)   
Apr-Jun 58/196 (29.6)  18/59 (30.5)   
Jul-Sept 56/196 (28.6)  10/59 (17.0)   
Oct-Dec 39/196 (19.9) 0/196 9/59 (15.3) 0/59 0.069 
Season (%)       
In season 114/196 (57.9)  28/59 (47.5)   
Out of season 82/196 (42.0) 0/196 31/59 (52.5) 0/59 0.147 
Location (%)       
QECH 113/196 (57.7)  36/59 (61.0)   
HC 83/196 (42.4) 0/196 23/59 (39.0) 0/59 0.646 
ϮP values are X2 p values for differences in proportions between case children and 
control children unless otherwise specified. *2 sided independent ttest **rank sum test.  
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Table A5. Comparing those completing the RRTE study to vaccine age eligible rotavirus 
positive children from the diarrhoeal surveillance study not recruited into the RRTE 
study 
 RRTE study Diarrhoeal surveillance 
study 
P value 
 Summary 
statistic 
Missing 
data 
Summary 
statistic 
Missing 
data 
 
Age (Median and IQR) 11.4 (8.7,15.3) 0/196 10.2 (7.6, 
14.9) 
0/135 0.055** 
Sex (male) (%) 108/196(55.1) 0/196 83/135 (61.5) 0/135 0.248 
Diarrhoea (%) 196/196 (100) 0/196    
Duration (days)  0/196    
1-3 173/196 (88.3)  107/135(79.3)   
5 12/196 (6.1)  16/135 (11.9)   
≥6 11/196 (5.6)  12/135 (8.9) 0/135 0.078 
Max per day (n)  0/196    
1-4 24/196 (12.2)  19/135 (14.1)   
5 86/196 (43.9)  58/135 (43.0)   
≥6 86/196 (43.9)  58/135 (43.0) 0/135 0.888 
      
Vomiting 182/196 (92.9) 0/196 119/135(88.2) 0/135 0.143 
      
Duration (days)  0/182    
1 23 (12.6)  13/119 (10.9)   
2 59 (32.4)  35/119 (29.4)   
≥3 100 (55.0)  71/119 (59.7) 0/119 0.717 
Max per day (n)  0/182    
<5 123 (67.6)  86/119 (72.3)   
≥5 59 (32.4)  33/119 (27.7) 0/119 0.388 
      
HIV      
Exposed  (%) 25/196 (12.8) 0/196 19/133 (14.3) 2/135 0.689 
Infected  (%) 2/58 (3.5) 138/196* 4/45 (8.9) 90/135 0.242 
RV1  (%)      
Vaccinated  
(2 doses) 
195/196 (99.0) 0/197 123/135(91.1) 0/135  
Vaccinated  
(1 dose) 
0/196 (0.0) 0/197 4/135 (3.0) 0/135  
Unvaccinated  
(0 dose) 
2/196 (1.0) 0/197 8/135 (5.9) 0/135 0.002 
Admitted  (%)      
Yes 111/196 (56.6) 0/196 110/135(81.5) 0/135 0.000 
Disease severity (%)      
(Median & IQR) 14/196 (12,16) 3/196 15 (13,16) 0/135 0.186 
Dehydration (%)      
None 26/196 (13.3)  9/135 (6.7)   
Some (5%) 125/196 (63.3)  89/135 (65.9)   
Severe (10%) 46/196 (23.5) 1/196 37/135 (27.4) 0/135 0.144 
IV fluids (%)      
Yes 58/196(29.6%) 0/196 45/135 (33.3) 1/135 0.470 
Oral fluids (%)      
Yes 185/196 (94.4) 0/196 130/135(96.0) 0/135 0.426 
Outcome (%)      
Home 193/195 (99.0)  131/135(97.0)   
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Died 2/195 (1.0) 1/196 4/164 (3.0) 0/135 0.195 
Anthropometry  
(Mean and SD) 
     
WHZ -0.59(1.61) 1/196 -1.00(1.73) 3/135 0.037* 
WAZ -0.47 (1.6) 3/196 -0.78(1.40) 0/135 0.031* 
HAZ -0.05(2.47) 7/196 -0.133(2.46) 7/135 0.762* 
MUAC 13.48 (1.28) 1/196 13.18(1.41) 0/135 0.049* 
SAM 23/193 (11.9) 3/196 27/135 (20.0) 0/135 0.045 
Household size      
≤5 136/196 (69.4)  102 (75.6)   
>5 60 (30.6) 0/196 33 (24.4) 0/135 0.220 
Previous diarrhoeal 
admission (%) 
15/196 (7.7) 0/196 9/135 (6.7) 0/135 0.734 
Previous diarrhoeal 
presentation (%)  
91/196 (46.4) 0/196 85/135 (62.9) 0/135 0.003 
Premature (%) 6/196 (3.1) 0/196 3/134 (2.2) 1/135 0.652 
Birth weight 
(Mean and SD) 
2.98 (0.60) 13/196 2.96(0.52) 11/135 0.808* 
Ever Breastfed (%) 195/196 (99.5) 0/196 134/135(99.3) 0/135 0.790 
Other food (%) 190/196 (97.0) 0/196 127/135(94.1) 0/135 0.203 
Additional child <1 year 
(%)  
     
0 187/192 (97.4)  129/134(96.3)   
1 5/192 (2.6) 4/196 5/134 (3.7) 1/135 0.561 
Additional children < 5 
years (%)  
     
0 126 (65.0)  114/135(68.9)   
1 62 (32.0)  44/135 (26.7)   
2 5 (2.6)  5/135 (3.7)   
3 0 (0)  1/135 (0.7)   
4 1 (0.5) 2/196 0/135 (0) 0/135 0.493 
Electricity at home (%)      
Yes 89/196 (45.4) 0/196 58/135 (43.0) 0/135 0.660 
Shared toilet (%)      
Yes 148/196 (75.5) 0/196 104/135(77.0) 0/135 0.749 
How long for household to 
access water (%) 
     
0-5 mins 34/196 (17.4)  23/134 (17.2)   
5-30mins 94/196 (48.0)  55/134 (41.0)   
>30 mins 68/196 (24.7) 0/196 56/134 (41.8) 1/135 0.385 
      
Water source (%)      
Well 16/195 (8.2)  6/132 (4.6)   
Borehole 35/195 (18.0)  23/132 (17.4)   
Shared tap 
village/compound 
115/195 (59.0)  86/132 (65.2)   
Tap to house 29/195  (15.0) 1/196 17/132 (12.9) 3/135 0.514 
How many people have a 
regular salary (%) 
     
0 68/195 (34.9)  55/135 (40.7)   
≥1 127/195 (65.1) 1/196 80/135 (59.3) 0/135 0.278 
      
Problems getting food in 
the past month (%) 
     
No 136/196 (69.4)  88/135 (65.2)   
Sometimes/often 60/196 (30.6) 0/196 47/135 (34.8) 0/135 0.422 
      
268 
 
Has an adult skipped a 
meal in the past 2 weeks? 
     
Yes 45/196 (23.0) 0/196 99/135 (73.3) 0/135 0.441 
Wealth  
(Mean and SD) 
2.38 (0.57) 5/196 2.37(0.50) 2/135 0.918* 
Time of recruitment      
Quarter of year (%)       
Jan-Mar 43/196 (22.0)  39/135 (28.9)   
Apr-Jun 58/196 (29.6)  48/135 (35.6)   
Jul-Sept 56/196 (28.6)  29/135 (21.5)   
Oct-Dec 39/196 (19.9) 0/196 19/135 (14.1) 0/135 0.135 
Season (%)       
In season 114/196 (58.2)  77/135 (57.0)   
Out of season 82/196 (41.8) 0/196 58/135 (43.0) 0/135 0.838 
ϮP values are X2 p values for differences in proportions between case children and 
control children unless otherwise specified. *2 sided independent ttest **rank sum test.  
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Table A6. Comparison of Anthropometric measurements from the RotaRITE 
transmission epidemiology study, and values from the 2010 Blantyre 
Demographic and Health (DHS) Survey 
 RRTE Values Blantyre (DHS 2010) Standard deviation  
 Mean 
value 
%<-
2sd 
%< -3 
sd 
Mean 
value 
%<-
2sd 
%< -3 
sd 
RRTE WHO* 
HAZ -0.04 19.4 9.42 -1.6 41.6 20.5 2.46 1.35-
1.95 
WHZ -0.59 17.9 5.10 0.4 2.2 0.0 1.61 1.08-
1.50 
WAZ -0.46 10.2 2.04 -0.7 12.7 2.5 1.61 1.17-
1.46 
Where HAZ represents height for age Z score, WHZ weight for height Z score, and WAZ weight for 
age Z score. *Range for standard deviation given as acceptable by WHO(355) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
270 
 
REFERENCES 
1.  Bishop R, Davidson GP, Holmes IH, et al. Virus Particles In Epithelial Cells Of Duodenal 
Mucosa From Children With Acute Non-Bacterial Gastroenteritis. Lancet. 
1973;302(7841):1281–1283.  
2.  Dennehy PH. Rotavirus vaccines: an overview. Clin Microbiol Rev. 2008;21(1):198–208.  
3.  Hu L, Crawford SE, Hyser JM, et al. Rotavirus non-structural proteins : Structure and 
Function. Curr. Opin. Virol. 2013;2(4):380–388.  
4.  Desselberger U. Rotaviruses. Virus Res. 2014;190:75–96.  
5.  World Health Organisation, 2008 WHO. Generic protocol for monitoring impact of 
rotavirus vaccination on gastroenteritis disease burden and viral strains. Geneva, 
Switzerland: 2008. 
6.  Jayaram H, Estes MK, Prasad BVV. Emerging themes in rotavirus cell entry, genome 
organization, transcription and replication. Virus Res. 2004;101(1):67–81.  
7.  Brandt C, Kim H, Rodriguez W. Comparison of direct electron microscopy, immune 
electron microscopy, and rotavirus enzyme-linked immunosorbent assay for detection of 
gastroenteritis. J. Clin. Microbiol. 1981;13(5):976–981.  
8.  Rubenstein AS, Miller MF. Comparison of an enzyme immunoassay with electron 
microscopic procedures for detecting rotavirus. J. Clin. Microbiol. 1982;15(5):938–944.  
9.  Dennehy PH, Gauntlett DR, Spangenberger SE. Choice of reference assay for the 
detection of rotavirus in fecal specimens: Electron microscopy versus enzyme 
immunoassay. J. Clin. Microbiol. 1990;28(6):1280–1283.  
10.  World Health Organisation. Manual of rotavirus detection and characterization methods. 
2009. 
11.  Dennehy PH, Gauntlett DR, Tente WE. Comparison of nine commercial immunoassays for 
the detection of rotavirus in fecal specimens. J. Clin. Microbiol. 1988;26(9):1630–1634.  
12.  Wilhelmi I, Colomina J, Martín-Rodrigo D, et al. New immunochromatographic method 
for rapid detection of rotaviruses in stool samples compared with standard enzyme 
immunoassay and latex agglutination techniques. Eur. J. Clin. Microbiol. Infect. Dis. 
2001;20(10):741–3.  
13.  Park KS, Baek KA, Kim DU, et al. Evaluation of a new immunochromatographic assay kit 
for the rapid detection of norovirus in fecal specimens. Ann Lab Med. 2012;32(1):79–81.  
14.  Theron EMC, Nyaga MM, Dewar JB. Sabinet - Ratification of rapid rotavirus diagnostic test 
strips : opinion paper. South African J. Infect. Dis. 2014;29(2):91–94.  
15.  Gray J, Iturriza-Gómara M. Rotaviruses. Methods Mol Biol. 2011;665:325–355.  
16.  Herring AJ, Inglis NF, Ojeh CK, et al. Rapid diagnosis of rotavirus infection by direct 
detection of viral nucleic acid in silver-stained polyacrylamide gels. J. Clin. Microbiol. 
1982;16(3):473–477.  
17.  Kasempimolporn S, Louisirirotchanakul S, Sinarachatanant P, et al. Polyacrylamide gel 
electrophoresis and silver staining for detection of rotavirus in stools from diarrheic 
patients in Thailand. J. Clin. Microbiol. 1988;26(1):158–160.  
18.  Wilde J, Yolken R, Willoughby R, et al. Improved detection of rotavirus shedding by 
polymerase chain reaction. Lancet. 1991;337(8737):323–326.  
19.  Phillips G, Lopman B, Rodrigues LC, et al. Asymptomatic rotavirus infections in England: 
prevalence, characteristics, and risk factors. Am J Epidemiol. 2010;171(9):1023–1030.  
271 
 
20.  Bennett A, Bar-Zeev N, Jere KC, et al. Determination of a viral load threshold to 
distinguish symptomatic versus asymptomatic rotavirus infection in a high-disease-
Burden African population. J. Clin. Microbiol. 2015;53(6):1951–1954.  
21.  Fischer TK, Gentsch JR. Rotavirus typing methods and algorithms. Rev. Med. Virol. 
2004;14(2):71–82.  
22.  Gentsch JR, Glass RI, Woods P, et al. Identification of group A rotavirus gene 4 types by 
polymerase chain reaction. J. Clin. Microbiol. 1992;30(6):1365–1373.  
23.  Iturriza-Gómara M, Kang G, Gray J, et al. Rotavirus genotyping: Keeping up with an 
evolving population of human rotaviruses. J. Clin. Virol. 2004;31(4):259–265.  
24.  Simmonds MK, Armah G, Asmah R, et al. New oligonucleotide primers for P-typing of 
rotavirus strains: Strategies for typing previously untypeable strains. J. Clin. Virol. 
2008;42(4):368–373.  
25.  Parashar UD, Nelson EA, Kang G. Diagnosis, management, and prevention of rotavirus 
gastroenteritis in children. BMJ. 2013;347.  
26.  Pardo-Seco J, Cebey-López M, Martinón-Torres N, et al. Impact of Rotavirus Vaccination 
on Childhood Hospitalization for Seizures. Pediatr. Infect. Dis. J. 2015;34(7):769–773.  
27.  Lynch M, Lee B, Azimi P, et al. Rotavirus and Central Nervous System Symptoms: Cause or 
Contaminant? Case Reports and Review. Clin. Infect. Dis. 2001;33(7):932–938.  
28.  Nishimura S, Ushijima H, Nishimura S, et al. Detection of rotavirus in cerebrospinal fluid 
and blood of patients with convulsions and gastroenteritis by means of the reverse 
transcription polymerase chain reaction. Brain Dev. 1993;15(6):457–9.  
29.  Zhaori GT, Fu LT, Xu YH, et al. Detection of rotavirus antigen in tracheal aspirates of 
infants and children with pneumonia. Chin. Med. J. (Engl). 1991;104(10):830–3.  
30.  Taboada B, Espinoza M a, Isa P, et al. Is there still room for novel viral pathogens in 
pediatric respiratory tract infections? PLoS One. 2014;9(11):e113570.  
31.  Hemming M, Huhti L, Rasanen S, et al. Rotavirus antigenemia in children is associated 
with more severe clinical manifestations of acute gastroenteritis. Pediatr Infect Dis J. 
2014;33(4):366–371.  
32.  Blutt SE, Matson DO, Crawford SE, et al. Rotavirus antigenemia in children is associated 
with viremia. PLoS Med. 2007;4(4):e121.  
33.  Sugata K, Taniguchi K, Yui A, et al. Analysis of rotavirus antigenemia and extraintestinal 
manifestations in children with rotavirus gastroenteritis. Pediatrics. 2008;122(2):392–7.  
34.  Cunliffe NA, Ngwira BM, Dove W, et al. Epidemiology of Rotavirus Infection in Children in 
Blantyre , Malawi , 1997 – 2007. J. Infect. Dis. 2010;202(Suppl 1):S168–S174.  
35.  Mwenda JM, Ntoto KM, Abebe A, et al. Burden and epidemiology of rotavirus diarrhea in 
selected African countries: preliminary results from the African Rotavirus Surveillance 
Network. J Infect Dis. 2010;202 Suppl:S5–S11.  
36.  Greenberg HB, Estes MK. Rotaviruses: From Pathogenesis to Vaccination. 
Gastroenterology. 2009;136(6):1939–1951.  
37.  Velazquez FR. Protective effects of natural rotavirus infection. Pediatr Infect Dis J. 
2009;28(3 Suppl):S54-6.  
38.  Gladstone BP, Ramani S, Mukhopadhya I, et al. Protective effect of natural rotavirus 
infection in an Indian birth cohort. N Engl J Med. 2011;365(4):337–346.  
39.  Ward RL, Bernstein DI, Young EC, et al. Human rotavirus studies in volunteers: 
272 
 
determination of infectious dose and serological response to infection. J Infect Dis. 
1986;154(5):871–880.  
40.  Hyser JM, Estes MK. Rotavirus vaccines and pathogenesis: 2008. Curr. Opin. 
Gastroenterol. 2009;25(1):36–43.  
41.  Widdowson M-A, Bresee JS, Gentsch JR, et al. Rotavirus disease and its prevention. Curr. 
Opin. Gastroenterol. 2005;21(1):26–31.  
42.  Hahn S, Kim S, Garner P. Reduced osmolarity oral rehydration solution for treating 
dehydration caused by acute diarrhoea in children. Cochrane Database Syst. Rev. 
2002;(1):CD002847.  
43.  World Health Organisation. The Treatment of Diarrhoea. A manual for physicians and 
other senior health workers. 2005 1-50 p. 
44.  World Health Organisation. WHO Pocket Book of Hospital Care for Children. WHO Press. 
Switzerland.; 2005. 
45.  Lazzerini M WH. Oral zinc for treating diarrhoea in children Commentary : Oral zinc for 
treating diarrhoea in children. Cochrane Database Syst. Rev. 2016;(12):938–940.  
46.  Lamberti LM, Fischer Walker CL, Noiman A, et al. Breastfeeding and the risk for diarrhea 
morbidity and mortality. BMC Public Health. 2011;11 Suppl 3(Suppl 3):1.  
47.  Dennehy PH. Transmission of rotavirus and other enteric pathogens in the home. Pediatr 
Infect Dis J. 2000;19(10 Suppl):S103-5.  
48.  Prince DS, Astry C, Vonderfecht S, et al. Aerosol transmission of experimental rotavirus 
infection. Pediatr. Infect. Dis. 5(2):218–22.  
49.  Ye Q, Fu J-F, Mao J-H, et al. Haze is an important medium for the spread of rotavirus. 
Environ. Pollut. 2016;216:324–31.  
50.  Sattar S a, Lloyd-Evans N, Springthorpe VS, et al. Institutional outbreaks of rotavirus 
diarrhoea: potential role of fomites and environmental surfaces as vehicles for virus 
transmission. J. Hyg. (Lond). 1986;96(2):277–289.  
51.  Keswick BH, Pickering LK, DuPont HL, et al. Survival and detection of rotaviruses on 
environmental surfaces in day care centers. Appl. Environ. Microbiol. 1983;46(4):813–
816.  
52.  Samadi A, Huq M, Ahmed Q. SHORT REPORTS Detection of rotavirus in handwashings of 
attendants of children with diarrhoea. Br. Med. J. 1983;286(January):1983.  
53.  Ansari SA, Springthorpe VS, Sattar SA. Survival and vehicular spread of human 
rotaviruses: possible relation to seasonality of outbreaks. Rev. Infect. Dis. 
1991;13(3):448–461.  
54.  Ansari SA, Sattar SA, Springthorpe VS, et al. Rotavirus survival on human hands and 
transfer of infectious virus to animate and nonporous inanimate surfaces. J. Clin. 
Microbiol. 1988;26(8):1513–1518.  
55.  Ansari SA, Sattar SA, Springthorpe VS, et al. In vivo protocol for testing efficacy of hand-
washing agents against viruses and bacteria: Experiments with rotavirus and Escherichia 
coli. Appl. Environ. Microbiol. 1989;55(12):3113–3118.  
56.  Raphael RA, Sattar SA, Springthorpe VS. Long-term survival of human rotavirus in raw and 
treated river water. Can. J. Microbiol. 1985;31(2):124–8.  
57.  Xue B, Jin M, Yang D, et al. Effects of chlorine and chlorine dioxide on human rotavirus 
infectivity and genome stability. Water Res. 2013;47(10):3329–3338.  
273 
 
58.  Tate JE, Burton AH, Boschi-Pinto C, et al. Global, Regional, and National Estimates of 
Rotavirus Mortality in Children less than 5 Years of Age, 2000–2013. Clin. Infect. Dis. 
2016;62(suppl 2):S96–S105.  
59.  Parashar UD, Burton A, Lanata C, et al. Global mortality associated with rotavirus disease 
among children in 2004. J Infect Dis. 2009;200 Suppl:S9–S15.  
60.  Villa S, Guiscafré H, Martinez H, et al. Seasonal diarrhoeal mortality among Mexican 
children. Bull. World Health Organ. 1999;77(5):375–380.  
61.  Lewis KD, Dallas MJ, Victor JC, et al. Comparison of two clinical severity scoring systems in 
two multi-center, developing country rotavirus vaccine trials in Africa and Asia. Vaccine. 
2012;30 Suppl 1:A159-66.  
62.  Velazquez FR, Matson DO, Calva JJ, et al. Rotavirus infections in infants as protection 
against subsequent infections. N Engl J Med. 1996;335(14):1022–1028.  
63.  Velazquez FR, Matson DO, Guerrero ML, et al. Serum antibody as a marker of protection 
against natural rotavirus infection and disease. J Infect Dis. 2000;182(6):1602–1609.  
64.  Premkumar P, Lopman B, Ramani S, et al. Association of serum antibodies with protection 
against rotavirus infection and disease in South Indian children. Vaccine. 2014;32 Suppl 
1:A55-61.  
65.  Desselberger U, Huppertz HI. Immune responses to rotavirus infection and vaccination 
and associated correlates of protection. J Infect Dis. 2011;203(2):188–195.  
66.  Franco MA, Angel J, Greenberg HB. Immunity and correlates of protection for rotavirus 
vaccines. Vaccine. 2006;24(15):2718–2731.  
67.  Blutt SE, Miller AD, Salmon SL, et al. IgA is important for clearance and critical for 
protection from rotavirus infection. Mucosal Immunol. 2012;5(6):712–719.  
68.  World Health Organisation. Report of the meeting on future directions for rotavirus 
vaccine research in developing. Geneva, Switzerland: 2000. 
69.  Widdowson M-A, Steele D, Vojdani J, et al. Global rotavirus surveillance: determining the 
need and measuring the impact of rotavirus vaccines. J. Infect. Dis. 2009;200 Suppl:S1-8.  
70.  World Health Organisation. Generic protocols for (i) hospital-based surveillance to 
estimate the burden of rotavirus gastroenteritis in children and (ii) a community-based 
survey on utilization of health care services for gastroenteritis in children. 2002. 
71.  Agócs MM, Serhan F, Yen C, et al. WHO global rotavirus surveillance network: a strategic 
review of the first 5 years, 2008-2012. MMWR. Morb. Mortal. Wkly. Rep. 
2014;63(29):634–7.  
72.  Monto AS, Koopman JS, Longini IM, et al. The Tecumseh study. XII. Enteric agents in the 
community, 1976-1981. J Infect Dis. 1983;148(2):284–291.  
73.  Koopman JS, Monto AS. The Tecumseh Study. XV: Rotavirus infection and pathogenicity. 
Am J Epidemiol. 1989;130(4):750–759.  
74.  Ferson MJ, Stringfellow S, McPhie K, et al. Longitudinal study of rotavirus infection in 
child-care centres. J Paediatr Child Heal. 1997;33(2):157–160.  
75.  Bartlett A V, Reves RR, Pickering LK. Rotavirus in infant-toddler day care centers: 
epidemiology relevant to disease control strategies. J Pediatr. 1988;113(3):435–441.  
76.  Rodriguez WJ, Kim HW, Brandt CD, et al. Longitudinal study of rotavirus infection and 
gastroenteritis in families served by a pediatric medical practice: clinical and 
epidemiologic observations. Pediatr. Infect. Dis. J. 1987;6(2):170–176.  
274 
 
77.  Cunliffe N, Zaman K, Rodrigo C, et al. Early exposure of infants to natural rotavirus 
infection: a review of studies with human rotavirus vaccine RIX4414. BMC Pediatr. 
2014;14(1):295.  
78.  The Pediatric ROTavirus European CommiTee. The paediatric burden of rotavirus disease 
in Europe. Epidemiol. Infect. 2006;134(5):908–916.  
79.  Williams CJ, Lobanov A, Pebody RG. Estimated mortality and hospital admission due to 
rotavirus infection in the WHO European region. Epidemiol. Infect. 2009;137(5):607–616.  
80.  Van Damme P, Giaquinto C, Huet F, et al. Multicenter prospective study of the burden of 
rotavirus acute gastroenteritis in Europe, 2004-2005: the REVEAL study. J. Infect. Dis. 
2007;195 Suppl:S4–S16.  
81.  Giaquinto C, Van Damme P, Huet F, et al. Clinical Consequences of Rotavirus Acute 
Gastroenteritis in Europe, 2004–2005: The REVEAL Study. J. Infect. Dis. 2007;195(s1):S26–
S35.  
82.  Van der Wielen M, Giaquinto C, Gothefors L, et al. Impact of community-acquired 
paediatric rotavirus gastroenteritis on family life: data from the REVEAL study. BMC Fam. 
Pract. 2010;11(1):22.  
83.  Glass RI, Kilgore PE, Holman RC, et al. The epidemiology of rotavirus diarrhea in the 
United States: surveillance and estimates of disease burden. J. Infect. Dis. 1996;174 
Suppl(October):S5–S11.  
84.  Desai R, Curns AT, Steiner CA, et al. All-cause gastroenteritis and rotavirus-coded 
hospitalizations among US Children, 2000-2009. Clin. Infect. Dis. 2012;55(4):28–34.  
85.  Fischer TK, Viboud C, Parashar U, et al. Hospitalizations and deaths from diarrhea and 
rotavirus among children <5 years of age in the United States, 1993-2003. J. Infect. Dis. 
2007;195(8):1117–25.  
86.  Galati JC, Harsley S, Richmond P, et al. The burden of rotavirus-related illness among 
young children on the Australian health care system. Aust. N. Z. J. Public Health. 
2006;30(5):416–21.  
87.  Ferson MJ. Hospitalisations for rotavirus gastroenteritis among children under five years 
of age in New South Wales. Med. J. Aust. 1996;164(5):273–6.  
88.  Grimwood K, Huang QS, Cohet C, et al. Rotavirus hospitalisation in New Zealand children 
under 3 years of age. J. Paediatr. Child Health. 2006;42(4):196–203.  
89.  White LJ, Buttery J, Cooper B, et al. Rotavirus within day care centres in Oxfordshire, UK: 
characterization of partial immunity. J R Soc Interface. 2008;5(29):1481–1490.  
90.  Van Damme P, Giaquinto C, Maxwell M, et al. Distribution of rotavirus genotypes in 
Europe, 2004-2005: the REVEAL Study. J. Infect. Dis. 2007;195 Suppl:S17–S25.  
91.  Iturriza-Gómara M, Dallman T, Bányai K, et al. Rotavirus genotypes co-circulating in 
Europe between 2006 and 2009 as determined by EuroRotaNet, a pan-European 
collaborative strain surveillance network. Epidemiol. Infect. 2011;139(6):895–909.  
92.  Gentsch JR, Hull JJ, Teel EN, et al. G and P Types of Circulating Rotavirus Strains in the 
United States during 1996 – 2005 : Nine Years of Prevaccine Data. 2009;200(Suppl 1):99–
105.  
93.  Banyai K, Laszlo B, Duque J, et al. Systematic review of regional and temporal trends in 
global rotavirus strain diversity in the pre rotavirus vaccine era: insights for understanding 
the impact of rotavirus vaccination programs. Vaccine. 2012;30 Suppl 1:A122-30.  
94.  Grinstein S, Gómez JA, Bercovich JA, et al. Epidemiology of rotavirus infection and 
gastroenteritis in prospectively monitored Argentine families with young children. Am J 
275 
 
Epidemiol. 1989;130(2):300–308.  
95.  Fischer TK, Valentiner-Branth P, Steinsland H, et al. Protective immunity after natural 
rotavirus infection: a community cohort study of newborn children in Guinea-Bissau, west 
Africa. J Infect Dis. 2002;186(5):593–597.  
96.  Angel J, Franco MA, Greenberg HB. Rotavirus immune responses and correlates of 
protection. Curr Opin Virol. 2012;2(4):419–425.  
97.  Khoury H, Ogilvie I, El Khoury AC, et al. Burden of rotavirus gastroenteritis in the Middle 
Eastern and North African pediatric population. BMC Infect. Dis. 2011;11(1):9.  
98.  Ogilvie I, Khoury H, El Khoury AC, et al. Burden of rotavirus gastroenteritis in the pediatric 
population in Central and Eastern Europe: serotype distribution and burden of illness. 
Hum. Vaccin. 2011;7(5):523–33.  
99.  de Oliveira LH, Danovaro-Holliday MC, Andrus JK, et al. Sentinel hospital surveillance for 
rotavirus in latin american and Caribbean countries. J. Infect. Dis. 2009;200 Suppl(Suppl 
1):S131–S139.  
100.  Nelson EAS, Bresee JS, Parashar UD, et al. Rotavirus epidemiology: The Asian Rotavirus 
Surveillance Network. Vaccine. 2008;26(26):3192–3196.  
101.  Kawai K, O’Brien MA, Goveia MG, et al. Burden of rotavirus gastroenteritis and 
distribution of rotavirus strains in Asia: A systematic review. Vaccine. 2012;30(7):1244–
1254.  
102.  Cunliffe NA, Kilgore PE, Bresee JS, et al. Epidemiology of rotavirus diarrhoea in Africa: a 
review to assess the need for rotavirus immunization. Bull World Heal. Organ. 
1998;76(5):525–537.  
103.  Sanchez-Padilla E, Grais RF, Guerin PJ, et al. Burden of disease and circulating serotypes 
of rotavirus infection in sub-Saharan Africa: systematic review and meta-analysis. Lancet 
Infect. Dis. 2009;9(9):567–576.  
104.  Waggie Z, Hawkridge A, Hussey GDD. Review of rotavirus studies in Africa: 1976-2006. J 
Infect Dis. 2010;202 Suppl(S1):S23-33.  
105.  Barron-Romero BL, Barreda-Gonzalez J, Doval-Ugalde R, et al. Asymptomatic rotavirus 
infections in day care centers. J. Clin. Microbiol. 1985;22(1):116–118.  
106.  Lopman B, Vicuna Y, Salazar F, et al. Household transmission of rotavirus in a community 
with rotavirus vaccination in Quininde, Ecuador. PLoS One. 2013;8(7):e67763.  
107.  Ouédraogo N, Kaplon J, Bonkoungou IJO, et al. Prevalence and genetic diversity of enteric 
viruses in children with diarrhea in Ouagadougou, Burkina Faso. PLoS One. 2016;11(4):1–
22.  
108.  Platts-Mills JA, Gratz J, Mduma E, et al. Association between stool enteropathogen 
quantity and disease in Tanzanian children using TaqMan Array Cards: A nested case-
control study. Am. J. Trop. Med. Hyg. 2014;90(1):133–138.  
109.  Elfving K, Andersson M, Msellem MI, et al. Real-time PCR threshold cycle cutoffs help to 
identify agents causing acute childhood diarrhea in Zanzibar. J. Clin. Microbiol. 
2014;52(3):916–923.  
110.  Tswana SA, Kapaata RW, Jorgensen PH, et al. The detection of rotavirus antigen in faeces 
of asymptomatic children from two different communities in Zimbabwe. Cent. Afr. J. 
Med. 1990;36(12):319–21.  
111.  Abiodun PO, Ihongbe JC, Ogbimi A. Asymptomatic rotavirus infection in Nigerian day-care 
centres. Ann. Trop. Paediatr. 1985;5(3):163–5.  
276 
 
112.  Omoigberale AI, Ojukwu JO, Abiodun PO. Asymptomatic rotavirus infection within Benin 
City urban community, Nigeria. East Afr. Med. J. 1996;73(10):688–90.  
113.  Castello AA, Arvay ML, Glass RI, et al. Rotavirus strain surveillance in Latin America: a 
review of the last nine years. Pediatr. Infect. Dis. J. 2004;23(10 Suppl):S168-72.  
114.  Todd S, Page NA a, Duncan Steele A, et al. Rotavirus strain types circulating in Africa: 
Review of studies published during 1997-2006. J Infect Dis. 2010;202 Suppl(Suppl 1):S34-
42.  
115.  Seheri M, Nemarude L, Peenze I, et al. Update of rotavirus strains circulating in Africa 
from 2007 through 2011. Pediatr. Infect. Dis. J. 2014;33 Suppl 1(1):S76-84.  
116.  Bar-Zeev N, Jere KC, Bennett A, et al. Population Impact and Effectiveness of Monovalent 
Rotavirus Vaccination in Urban Malawian Children 3 Years after Vaccine Introduction: 
Ecological and Case-Control Analyses. Clin. Infect. Dis. 2016;62(Suppl 2):S213–S219.  
117.  Patel MM, Pitzer VE, Alonso WJ, et al. Global seasonality of rotavirus disease. Pediatr 
Infect Dis J. 2013;32(4):e134-47.  
118.  Pitzer VE, Viboud C, Simonsen L, et al. Demographic variability, vaccination, and the 
spatiotemporal dynamics of rotavirus epidemics. Science (80-. ). 2009;325:290–294.  
119.  Levy K, Hubbard AE, Eisenberg JN. Seasonality of rotavirus disease in the tropics: a 
systematic review and meta-analysis. Int J Epidemiol. 2009;38(6):1487–1496.  
120.  Atchison CJ, Tam CC, Hajat S, et al. Temperature-dependent transmission of rotavirus in 
Great Britain and The Netherlands. Proc. R. Soc. B. 2010;277(November 2009):933–942.  
121.  D’Souza RM, Hall G, Becker NG. Climatic factors associated with hospitalizations for 
rotavirus diarrhoea in children under 5 years of age. Epidemiol Infect. 2008;136(1):56–64.  
122.  Pitzer VE, Viboud C, Lopman BA, et al. Influence of birth rates and transmission rates on 
the global seasonality of rotavirus incidence. J R Soc Interface. 2011;8(64):1584–1593.  
123.  Tate JE, Burton AH, Boschi-Pinto C, et al. 2008 estimate of worldwide rotavirus-associated 
mortality in children younger than 5 years before the introduction of universal rotavirus 
vaccination programmes: a systematic review and meta-analysis. Lancet Infect Dis. 
2012;12(2):136–141.  
124.  Bishop RF, Barnes GL, Cipriani E, et al. Clinical immunity after neonatal rotavirus infection. 
A prospective longitudinal study in young children. N Engl J Med. 1983;309(2):72–76.  
125.  Ramani S, Sowmyanarayanan T V, Gladstone BP, et al. Rotavirus infection in the neonatal 
nurseries of a tertiary care hospital in India. Pediatr. Infect. Dis. J. 2008;27(8):719–23.  
126.  Cunliffe NA, Rogerson S, Dove W, et al. Detection and characterization of rotaviruses in 
hospitalized neonates in Blantyre, Malawi. J. Clin. Microbiol. 2002;40(4):1534–7.  
127.  Haffejee IE. Neonatal Rotavirus Infections. Rev Infect Dis. 1991;13(5):957–62.  
128.  Dunn SJ, Greenberg HB, Ward RL, et al. Serotypic and Genotypic Characterization of 
Human Serotype 10 Rotaviruses from Asymptomatic Neonates. J. Clin. Microbiol. 
1993;31(1):165–169.  
129.  Banerjee I, Primrose Gladstone B, Le Fevre AM, et al. Neonatal Infection with G10P[11] 
Rotavirus Did Not Confer Protection against Subsequent Rotavirus Infection in a 
Community Cohort in Vellore, South India.  
130.  Bhandari N, Rongsen-Chandola T, Bavdekar A, et al. Efficacy of a monovalent human-
bovine (116E) rotavirus vaccine in Indian children in the second year of life. Vaccine. 
2014;32 Suppl 1:A110-6.  
277 
 
131.  Bines JE, Danchin M, Jackson P, et al. Safety and immunogenicity of RV3-BB human 
neonatal rotavirus vaccine administered at birth or in infancy: a randomised, double-
blind, placebo-controlled trial. Lancet Infect. Dis. 2015;15(12):1389–1397.  
132.  Loganathan T, Lee WS, Lee KF, et al. Household catastrophic healthcare expenditure and 
impoverishment due to rotavirus gastroenteritis requiring hospitalization in Malaysia. 
PLoS One. 2015;10(5).  
133.  Bar-Zeev N, Tate JE, Pecenka C, et al. Cost-Effectiveness of Monovalent Rotavirus 
Vaccination of Infants in Malawi: A Postintroduction Analysis Using Individual Patient-
Level Costing Data. Clin. Infect. Dis. 2016;62:S220–S228.  
134.  Yen C, Tate JE, Hyde TB, et al. Rotavirus vaccines. Hum. Vaccin. Immunother. 
2014;10(6):1436–1448.  
135.  Glass RI, Parashar U, Patel M, et al. Rotavirus vaccines: Successes and challenges. J Infect. 
2014;68:S9–S18.  
136.  Bresee JS, Parashar UD, Widdowson MA, et al. Update on rotavirus vaccines. Pediatr 
Infect Dis J. 2005;24(11):947–952.  
137.  Bhandari N, Rongsen-Chandola T, Bavdekar A, et al. Efficacy of a monovalent human-
bovine (116E) rotavirus vaccine in Indian infants: a randomised, double-blind, placebo-
controlled trial. Lancet. 2014; 
138.  Moren A, Valenciano M. Vaccine efficacy, effectiveness, impact. Proposed definitions. 
2013;1–11.  
139.  Vesikari T, Matson DO, Dennehy P, et al. Safety and efficacy of a pentavalent human-
bovine (WC3) reassortant rotavirus vaccine. N Engl J Med. 2006;354(1):23–33.  
140.  Ruiz-Palacios GM, Perez-Schael I, Velazquez FR, et al. Safety and efficacy of an attenuated 
vaccine against severe rotavirus gastroenteritis. N Engl J Med. 2006;354(1):11–22.  
141.  World Health Organization. WHO position paper on rotavirus vaccines. Wkly. Epidemiol. 
Rec. . 2007;82(32):285–296.  
142.  Chan J, Nirwati H, Triasih R, et al. Maternal antibodies to rotavirus: could they interfere 
with live rotavirus vaccines in developing countries? Vaccine. 2011;29(6):1242–1247.  
143.  Appaiahgari MB, Glass R, Singh S, et al. Transplacental rotavirus IgG interferes with 
immune response to live oral rotavirus vaccine ORV-116E in Indian infants. Vaccine. 
2014;32(6):651–656.  
144.  Patel M, Shane AL, Parashar UD, et al. Oral rotavirus vaccines: how well will they work 
where they are needed most? J Infect Dis. 2009;200 Suppl:S39-48.  
145.  Gomes MGM, Gordon SB, Lalloo DG. Clinical trials: The mathematics of falling vaccine 
efficacy with rising disease incidence. Vaccine. 2016;34(27):3007–9.  
146.  Madhi SA, Cunliffe NA, Steele D, et al. Effect of human rotavirus vaccine on severe 
diarrhea in African infants. N Engl J Med. 2010;362(4):289–298.  
147.  Phua KB, Lim FS, Lau YL, et al. Safety and efficacy of human rotavirus vaccine during the 
first 2 years of life in Asian infants: randomised, double-blind, controlled study. Vaccine. 
2009;27(43):5936–5941.  
148.  Phua KBB, Quak SHH, Lee BWW, et al. Evaluation of RIX4414, a live, attenuated rotavirus 
vaccine, in a randomized, double-blind, placebo-controlled phase 2 trial involving 2464 
Singaporean infants. J Infect Dis. 2005;192 Suppl(s1):S6–S16.  
149.  Mast TC, Khawaja S, Espinoza F, et al. Case-control Study of the Effectiveness of 
Vaccination With Pentavalent Rotavirus Vaccine in Nicaragua. Pediatr. Infect. Dis. J. 
278 
 
2011;30(11):e209–e215.  
150.  Li RC, Huang T, Li Y LD. Human rotavirus vaccine (RIX4414) efficacy in the first two years 
of life: a randomized, placebo-controlled trial in China. Hum. Vaccin. Immunother. 
2014;10(1):11–18.  
151.  Kawamura N, Tokoeda Y, Oshima M, et al. Efficacy, safety and immunogenicity of RIX4414 
in Japanese infants during the first two years of life. Vaccine. 2011;29(37):6335–6341.  
152.  Linhares AC, Velazquez FR, Perez-Schael I, et al. Efficacy and safety of an oral live 
attenuated human rotavirus vaccine against rotavirus gastroenteritis during the first 2 
years of life in Latin American infants: a randomised, double-blind, placebo-controlled 
phase III study. Lancet. 2008;371(9619):1181–1189.  
153.  Zaman K, Dang DA, Victor JC, et al. Efficacy of pentavalent rotavirus vaccine against 
severe rotavirus gastroenteritis in infants in developing countries in Asia: a randomised, 
double-blind, placebo-controlled trial. Lancet. 2010;376(9741):615–623.  
154.  Armah GE, Sow SO, Breiman RF, et al. Efficacy of pentavalent rotavirus vaccine against 
severe rotavirus gastroenteritis in infants in developing countries in sub-Saharan Africa: a 
randomised, double-blind, placebo-controlled trial. Lancet. 2010;376(9741):606–614.  
155.  Iwata S, Nakata S, Ukae S, et al. Efficacy and safety of pentavalent rotavirus vaccine in 
Japan: A randomized, double-blind, placebo-controlled, multicenter trial. Hum. Vaccin. 
Immunother. 2013;9(8):1–8.  
156.  Peter G, Aguado T, Bhutta Z a, et al. Detailed Review Paper on Rotavirus Vaccines. 
Submitted WHO Strategic Advisory Group of Experts (SAGE) on Immunization, April 2009. 
2009;(April):1–57.  
157.  World Health Organization. Rotavirus Vaccination. Meeting of the immunization Strategic 
Advisory Group of Experts, April 2009. Wkly. Epidemiol. Rec. 2009;84(23):220–236.  
158.  Karafillakis E, Hassounah S, Atchison C. Effectiveness and impact of rotavirus vaccines in 
Europe , 2006 – 2014. Vaccine. 2015;33(18):2097–2107.  
159.  Giaquinto C, Dominiak-Felden G, Van Damme P, et al. Summary of effectiveness and 
impact of rotavirus vaccination with the oral pentavalent rotavirus vaccine: A systematic 
review of the experience in industrialized countries. Hum. Vaccin. 2011;7(7):734–748.  
160.  Rha B, Tate JE, Payne DC, et al. Effectiveness and impact of rotavirus vaccines in the 
United States - 2006-2012. Expert Rev Vaccines. 2014;13(3):365–376.  
161.  Snelling TL, Schultz R, Graham J, et al. Rotavirus and the indigenous children of the 
Australian outback: monovalent vaccine effective in a high-burden setting. Clin Infect Dis. 
2009;49(3):428–431.  
162.  Snelling TL, Andrews RM, Kirkwood CD, et al. Case-control evaluation of the effectiveness 
of the G1P[8] human rotavirus vaccine during an outbreak of rotavirus G2P[4] infection in 
central Australia. Clin Infect Dis. 2011;52(2):191–199.  
163.  Tate JE, Patel MM, Steele AD, et al. Global impact of rotavirus vaccines. Expert Rev 
Vaccines. 2010;9(4):395–407.  
164.  Yen C, Tate JE, Wenk JD, et al. Diarrhea-Associated Hospitalizations Among US Children 
Over 2 Rotavirus Seasons After Vaccine Introduction. Pediatrics. 2011;127(1):e9–e15.  
165.  Tate JE, Haynes A, Payne DC, et al. Trends in national rotavirus activity before and after 
introduction of rotavirus vaccine into the national immunization program in the United 
States, 2000 to 2012. Pediatr Infect Dis J. 2013;32(7):741–744.  
166.  Tate JE, Panozzo CA, Payne DC, et al. Decline and change in seasonality of US rotavirus 
activity after the introduction of rotavirus vaccine. Pediatrics. 2009;124(2):465–471.  
279 
 
167.  Lambert SB, Faux CE, Hall L, et al. Early evidence for direct and indirect effects of the 
infant rotavirus vaccine program in Queensland. Med J Aust. 2009;191(3):157–160.  
168.  Davey HM, Muscatello DJ, Wood JG, et al. Impact of high coverage of monovalent human 
rotavirus vaccine on Emergency Department presentations for rotavirus gastroenteritis. 
Vaccine. 2015;33(14):1726–1730.  
169.  Pendleton A, Galic M, Clarke C, et al. Impact of rotavirus vaccination in Australian children 
below 5 years of age: a database study. Hum. Vaccin. Immunother. 2013;9(8):1617–25.  
170.  Field EJ, Vally H, Grimwood K, et al. Pentavalent Rotavirus Vaccine and Prevention of 
Gastroenteritis Hospitalizations in Australia. Pediatrics. 2010;126(3):e506–e512.  
171.  Cotes-Cantillo K, Paternina-Caicedo A, Coronell-Rodríguez W, et al. Effectiveness of the 
monovalent rotavirus vaccine in Colombia: A case-control study. Vaccine. 
2014;32(25):3035–3040.  
172.  Ichihara MYT, Rodrigues LC, Teles Santos CAS, et al. Effectiveness of rotavirus vaccine 
against hospitalized rotavirus diarrhea: A case-control study. Vaccine. 2014;32(23):2740–
2747.  
173.  Justino MCA, Linhares AC, Lanzieri TM, et al. Effectiveness of the monovalent G1P[8] 
human rotavirus vaccine against hospitalization for severe G2P[4] rotavirus 
gastroenteritis in Belém, Brazil. Pediatr. Infect. Dis. J. 2011;30(5):396–401.  
174.  Correia JB, Patel MM, Nakagomi O, et al. Effectiveness of monovalent rotavirus vaccine 
(Rotarix) against severe diarrhea caused by serotypically unrelated G2P[4] strains in 
Brazil. J Infect Dis. 2010;201(3):363–369.  
175.  Patel M, Pedreira C, De Oliveira LH, et al. Effectiveness of Pentavalent Rotavirus Vaccine 
Against a Diverse Range of Circulating Strains in Nicaragua. Clin. Infect. Dis. 2016;62(Suppl 
2):S127–S132.  
176.  Patel M, Oliveira LH De, Tate J, et al. Association between pentavalent rotavirus vaccine 
and severe rotavirus diarrhea among children in Nicaragua. JAMA. 2017;301(21):2243.  
177.  Gastañaduy PA, Contreras-Roldán I, Bernart C, et al. Effectiveness of Monovalent and 
Pentavalent Rotavirus Vaccines in Guatemala. Clin. Infect. Dis. 2016;62 Suppl 2(suppl 
2):S121-6.  
178.  Pringle KD, Patzi M, Tate JE, et al. Sustained Effectiveness of Rotavirus Vaccine Against 
Very Severe Rotavirus Disease Through the Second Year of Life, Bolivia 2013-2014. Clin. 
Infect. Dis. 2016;62(Suppl 2):S115–S120.  
179.  Patel MM, Patzi M, Pastor D, et al. Effectiveness of monovalent rotavirus vaccine in 
Bolivia: case-control study. BMJ. 2013;346(June):f3726.  
180.  de Palma O, Cruz L, Ramos H, et al. Effectiveness of rotavirus vaccination against 
childhood diarrhoea in El Salvador: case-control study. BMJ. 2010;340(October):c2825.  
181.  Gheorghita S, Birca L, Donos A, et al. Impact of Rotavirus Vaccine Introduction and 
Vaccine Effectiveness in the Republic of Moldova. Clin. Infect. Dis. 2016;62(Suppl 2):S140–
S146.  
182.  Sahakyan G, Grigoryan S, Wasley A, et al. Impact and Effectiveness of Monovalent 
Rotavirus Vaccine in Armenian Children. Clin. Infect. Dis. 2016;62(Suppl 2):S147–S154.  
183.  Gastañaduy PA, Steenhoff AP, Mokomane M, et al. Effectiveness of Monovalent Rotavirus 
Vaccine after Programmatic Implementation in Botswana: A Multisite Prospective Case-
Control Study. Clin. Infect. Dis. 2016;62(Suppl 2):S161–S167.  
184.  Groome MJ, Page N, Cortese MM, et al. Effectiveness of monovalent human rotavirus 
vaccine against admission to hospital for acute rotavirus diarrhoea in South African 
280 
 
children: a case-control study. Lancet Infect Dis. 2014;14(11):1096–1104.  
185.  Armah G, Pringle K, Enweronu-Laryea CC, et al. Impact and Effectiveness of Monovalent 
Rotavirus Vaccine Against Severe Rotavirus Diarrhea in Ghana. Clin. Infect. Dis. 
2016;62(suppl 2):S200–S207.  
186.  Bar-Zeev N, Kapanda L, Tate JE, et al. Effectiveness of a monovalent rotavirus vaccine in 
infants in Malawi after programmatic roll-out: an observational and case-control study. 
Lancet Infect Dis. 2015;15(4):422–428.  
187.  Tate JE, Ngabo F, Donnen P, et al. Effectiveness of Pentavalent Rotavirus Vaccine under 
Conditions of Routine Use in Rwanda. Clin. Infect. Dis. 2016;62(Suppl 2):S208–S212.  
188.  Beres LK, Tate JE, Njobvu L, et al. A Preliminary Assessment of Rotavirus Vaccine 
Effectiveness in Zambia. Clin. Infect. Dis. 2016;62(Suppl 2):S175–S182.  
189.  De Oliveira LHH, Giglio N, Ciapponi A, et al. Temporal trends in diarrhea-related 
hospitalizations and deaths in children under age 5 before and after the introduction of 
the rotavirus vaccine in four Latin American countries. Vaccine. 2013;31(SUPPL.3):99–
108.  
190.  Yen C, Armero Guardado JA, Alberto P, et al. Decline in rotavirus hospitalizations and 
health care visits for childhood diarrhea following rotavirus vaccination in El Salvador. 
Pediatr Infect Dis J. 2011;30(1 Suppl):S6–S10.  
191.  Becker-Dreps S, Melendez M, Liu L, et al. Community Diarrhea Incidence Before and After 
Rotavirus Vaccine Introduction in Nicaragua. Am. J. Trop. Med. Hyg. 2013;89(2):246–250.  
192.  Quintanar-Solares M, Yen C, Richardson V, et al. Impact of rotavirus vaccination on 
diarrhea-related hospitalizations among children < 5 years of age in Mexico. Pediatr. 
Infect. Dis. J. 2011;30(1 Suppl):S11–S15.  
193.  Bayard V, DeAntonio R, Contreras R, et al. Impact of rotavirus vaccination on childhood 
gastroenteritis-related mortality and hospital discharges in Panama. Int. J. Infect. Dis. 
2012;16(2):94–98.  
194.  Molto Y, Cortes JE, De Oliveira LH, et al. Reduction of diarrhea-associated hospitalizations 
among children aged < 5 Years in Panama following the introduction of rotavirus vaccine. 
Pediatr Infect Dis J. 2011;30(1 Suppl):S16-20.  
195.  Gurgel RQ, Ilozue C, Correia JB, et al. Impact of rotavirus vaccination on diarrhoea 
mortality and hospital admissions in Brazil. Trop. Med. Int. Heal. 2011;16(9):1180–1184.  
196.  Richardson V, Hernandez-Pichardo J, Quintanar-Solares M, et al. Effect of rotavirus 
vaccination on death from childhood diarrhea in Mexico. N Engl J Med. 2010;362(4):299–
305.  
197.  Richardson V, Parashar U, Patel M. Childhood diarrhea deaths after rotavirus vaccination 
in Mexico. N Engl J Med. 2011;365(8):772–773.  
198.  Paternina-Caicedo A, Parashar UD, Alvis-Guzmán N, et al. Effect of rotavirus vaccine on 
childhood diarrhea mortality in five Latin American countries. Vaccine. 2015;33(32):3923–
3928.  
199.  do Carmo GM, Yen C, Cortes J, et al. Decline in diarrhea mortality and admissions after 
routine childhood rotavirus immunization in Brazil: a time-series analysis. PLoS Med. 
2011;8(4):e1001024.  
200.  Tsolenyanu E, Mwenda JM, Dagnra A, et al. Early Evidence of Impact of Monovalent 
Rotavirus Vaccine in Togo. Clin. Infect. Dis. 2016;62(suppl 2):S196–S199.  
201.  Msimang VM, Page N, Groome MJ, et al. Impact of Rotavirus Vaccine on Childhood 
Diarrheal Hospitalization Following Introduction into the South African Public 
281 
 
Immunization Program. Pediatr Infect Dis J. 2013; 
202.  Ngabo F, Tate JE, Gatera M, et al. Effect of pentavalent rotavirus vaccine introduction on 
hospital admissions for diarrhoea and rotavirus in children in Rwanda: A time-series 
analysis. Lancet Glob. Heal. 2016;4(2):e129–e136.  
203.  Mpabalwani EM, Simwaka CJ, Mwenda JM, et al. Impact of Rotavirus Vaccination on 
Diarrheal Hospitalizations in Children Aged less than 5 Years in Lusaka, Zambia. Clin. 
Infect. Dis. 2016;62(suppl 2):S183–S187.  
204.  Enweronu-Laryea CC, Boamah I, Sifah E, et al. Decline in severe diarrhea hospitalizations 
after the introduction of rotavirus vaccination in Ghana: a prevalence study. BMC Infect. 
Dis. 2014;14(1):431.  
205.  Abeid KA, Jani B, Cortese MM, et al. Monovalent Rotavirus Vaccine Effectiveness and 
Impact on Rotavirus Hospitalizations in Zanzibar, Tanzania: Data From the First 3 Years 
After Introduction. J. Infect. Dis. 2016;jiw524.  
206.  Mujuru HA, Yen C, Nathoo KJ, et al. Reduction in Diarrhea and Rotavirus-related 
Healthcare Visits among Children <5 Years of Age after National Rotavirus Vaccine 
Introduction in Zimbabwe. Pediatr. Infect. Dis. J. 2017;36(10):995–999.  
207.  Enane LA, Gastañaduy PA, Goldfarb DM, et al. Impact of Rotavirus Vaccination on 
Hospitalizations and Deaths from Childhood Gastroenteritis in Botswana. Clin. Infect. Dis. 
2016;62(Suppl 2):S168–S174.  
208.  Gastañaduy P a, Sánchez-Uribe E, Esparza-Aguilar M, et al. Effect of rotavirus vaccine on 
diarrhea mortality in different socioeconomic regions of Mexico. Pediatrics. 
2013;131(4):e1115-20.  
209.  El Khoury AC, Mast TC, Ciarlet M, et al. Projecting the effectiveness of RotaTeq against 
rotavirus-related hospitalisations and deaths in six Asian countries. Hum. Vaccin. 
2011;106(5):541–545.  
210.  Pitzer VE, Viboud C, Lopman BA, et al. Influence of birth rates and transmission rates on 
the global seasonality of rotavirus incidence. J. R. Soc. Interface. 2011;8(64):1584–1593.  
211.  Halloran ME, Haber M, Longini  Jr. IM, et al. Direct and indirect effects in vaccine efficacy 
and effectiveness. Am J Epidemiol. 1991;133(4):323–331.  
212.  Halloran ME, Longini IM, Struchiner CJ. Design and Analysis of Vaccine Studies. New York, 
NY: Springer New York; 2010. 
213.  Paul Y. Herd immunity and herd protection. Vaccine. 2004;22(3–4):301–302.  
214.  Vanderweele TJ, Halloran ME. Components of the indirect effect in vaccine trials: 
identification of contagion and infectiousness effects. Epidemiology. 2012;23(5):751–761.  
215.  Bennett A, Bar-Zeev N, Cunliffe NA. Measuring indirect effects of rotavirus vaccine in low 
income countries. Vaccine. 2016;34(37):4351–4353.  
216.  Tate JE, Mutuc JD, Panozzo CA, et al. Sustained decline in rotavirus detections in the 
United States following the introduction of rotavirus vaccine in 2006. Pediatr Infect Dis J. 
2011;30(1 Suppl):S30-4.  
217.  Mast TC, Wang FT, Su S, et al. Evidence of herd immunity and sustained impact of 
rotavirus vaccination on the reduction of rotavirus-related medical encounters among 
infants from 2006 through 2011 in the United States. Pediatr Infect Dis J. 2015;34(6):615–
620.  
218.  Leshem E, Moritz RE, Curns AT, et al. Rotavirus vaccines and health care utilization for 
diarrhea in the United States (2007-2011). Pediatrics. 2014;134(1):15–23.  
282 
 
219.  Payne DC, Staat MA, Edwards KM, et al. Direct and indirect effects of rotavirus 
vaccination upon childhood hospitalizations in 3 US Counties, 2006-2009. Clin Infect Dis. 
2011;53(3):245–253.  
220.  Cortes JE, Curns AT, Tate JE, et al. Rotavirus Vaccine and Health Care Utilization for 
Diarrhea in U.S. Children. N Engl J Med. 2011;365:1108–17.  
221.  Tate JE, Cortese MM, Payne DC, et al. Uptake, impact, and effectiveness of rotavirus 
vaccination in the United States: review of the first 3 years of postlicensure data. Pediatr 
Infect Dis J. 2011;30(1 Suppl):S56-60.  
222.  Lopman BA, Curns AT, Yen C, et al. Infant rotavirus vaccination may provide indirect 
protection to older children and adults in the United States. J Infect Dis. 2011;204(7):980–
986.  
223.  Gastanaduy PA, Curns AT, Parashar UD, et al. Gastroenteritis hospitalizations in older 
children and adults in the United States before and after implementation of infant 
rotavirus vaccination. JAMA. 2013;310(8):851–853.  
224.  Anderson EJ, Shippee DB, Weinrobe MH, et al. Indirect Protection of Adults From 
Rotavirus by Pediatric Rotavirus Vaccination. Clin Infect Dis. 2013;56(6):755–760.  
225.  Cortese MM, Dahl RM, Curns AT, et al. Protection against gastroenteritis in US 
households with children who received rotavirus vaccine. J. Infect. Dis. 2015;211(4):558–
562.  
226.  Panozzo CA, Becker-Dreps S, Pate V, et al. Direct, indirect, total, and overall effectiveness 
of the rotavirus vaccines for the prevention of gastroenteritis hospitalizations in privately 
insured us children, 2007-2010. Am. J. Epidemiol. 2014;179(7):895–909.  
227.  Clarke MF, Davidson GP, Gold MS, et al. Direct and indirect impact on rotavirus positive 
and all-cause gastroenteritis hospitalisations in South Australian children following the 
introduction of rotavirus vaccination. Vaccine. 2011;29(29–30):4663–4667.  
228.  Buttery JP, Lambert SB, Grimwood K, et al. Reduction in rotavirus-associated acute 
gastroenteritis following introduction of rotavirus vaccine into Australia’s National 
Childhood vaccine schedule. Pediatr Infect Dis J. 2011;30(1 Suppl):S25-9.  
229.  Reyes JFF, Wood JGG, Beutels P, et al. Beyond expectations: Post-implementation data 
shows rotavirus vaccination is likely cost-saving in Australia. Vaccine. 2017;35(2):345–
352.  
230.  Paulke-Korinek M, Kundi M, Rendi-Wagner P, et al. Herd immunity after two years of the 
universal mass vaccination program against rotavirus gastroenteritis in Austria. Vaccine. 
2011;29(15):2791–2796.  
231.  Marlow R, Muir P, Vipond B, et al. Assessing the impacts of the first year of rotavirus 
vaccination in the United Kingdom. Eurosurveillance. 2015;20(48).  
232.  Thomas SL, Walker JL, Fenty J, et al. Impact of the national rotavirus vaccination 
programme on acute gastroenteritis in England and associated costs averted. Vaccine. 
2017;35(4):680–686.  
233.  Sabbe M, Berger N, Blommaert A, et al. Sustained low rotavirus activity and 
hospitalisation rates in the post-vaccination era in Belgium, 2007 to 2014. 
Eurosurveillance. 2016;21(27).  
234.  Standaert B, Strens D, Alwan A, et al. Medium- to Long-Term Impact of Rotavirus 
Vaccination on Hospital Care in Belgium : A 7-Year Follow-Up of the Rotavirus Belgium 
Impact Study ( RotaBIS ). Infect. Dis. Ther. 2016;5(1):31–44.  
235.  Inns T, Trindall A, Dunling-Hall S, et al. Introduction of a new Rotavirus vaccine: Initial 
283 
 
results of uptake and impact on laboratory confirmed cases in Anglia and Essex, United 
Kingdom, July 2015. Hum. Vaccin. Immunother. 2016;12.  
236.  Prelog M, Gorth P, Zwazl I, et al. Universal Mass Vaccination Against Rotavirus : Indirect 
Effects on Rotavirus Infections in Neonates and Unvaccinated Young Infants Not Eligible 
for Vaccination. J. Infect. Dis. 2016;214(4):546–555.  
237.  Pitzer VE, Atkins KE, de Blasio BF, et al. Direct and indirect effects of rotavirus vaccination: 
comparing predictions from transmission dynamic models. PLoS One. 2012;7(8):e42320.  
238.  Standaert B, Gomez JA, Raes M, et al. Impact of Rotavirus Vaccination on Hospitalisations 
in Belgium: Comparing Model Predictions with Observed Data. PLoS One. 2013;8(1).  
239.  Van Effelterre T, Soriano-Gabarro M, Debrus S, et al. A mathematical model of the 
indirect effects of rotavirus vaccination. Epidemiol Infect. 2010;138(6):884–897.  
240.  Pollard SL, Malpica-Llanos T, Friberg IK, et al. Estimating the herd immunity effect of 
rotavirus vaccine. Vaccine. 2015;33(32):3795–3800.  
241.  Costa I, Linhares AC, Cunha MH, et al. Sustained Decrease in Gastroenteritis-related 
Deaths and Hospitalizations in Children Less Than 5 Years of Age After the Introduction of 
Rotavirus Vaccination: A Time-Trend Analysis in Brazil (2001-2010). Pediatr. Infect. Dis. J. 
2016;35(6):e180-90.  
242.  Tharmaphornpilas P, Jiamsiri S, Boonchaiya S, et al. Evaluating the first introduction of 
rotavirus vaccine in Thailand: Moving from evidence to policy. Vaccine. 2017;35(5):796–
801.  
243.  Anderson EJ. Rotavirus vaccines: viral shedding and risk of transmission. Lancet Infect Dis. 
2008;8(10):642–649.  
244.  Rivera L, Pena LM, Stainier I, et al. Horizontal transmission of a human rotavirus vaccine 
strain--a randomized, placebo-controlled study in twins. Vaccine. 2011;29(51):9508–
9513.  
245.  Koopman JS, Monto AS, Longini  Jr. IM. The Tecumseh Study. XVI: Family and community 
sources of rotavirus infection. Am J Epidemiol. 1989;130(4):760–768.  
246.  Ali M, Emch M, Von Seidlein L, et al. Herd immunity conferred by killed oral cholera 
vaccines in Bangladesh: A reanalysis. Lancet. 2005;366(9479):44–49.  
247.  Jeuland M, Cook J, Poulos C, et al. Cost-effectiveness of new-generation oral cholera 
vaccines: A multisite analysis. Value Heal. 2009;12(6):899–908.  
248.  Frost WH. The Familial Aggregation of Infectious Diseases. Am. J. Public Health Nations. 
Health. 1938;28(1):7–13.  
249.  de Blasio BF, Kasymbekova K, Flem E. Dynamic model of rotavirus transmission and the 
impact of rotavirus vaccination in Kyrgyzstan. Vaccine. 2010;28(50):7923–7932.  
250.  Lee RM, Lessler J, Lee RA, et al. Incubation periods of viral gastroenteritis: a systematic 
review. BMC Infect. Dis. 2013;13(1):446.  
251.  Grimwood K, Abbott GD, Fergusson DM, et al. Spread of rotavirus within families: a 
community based study. Br Med J (Clin Res Ed). 1983;287(6392):575–577.  
252.  Vynnycky E, White RG. An introduction to infectious disease modelling. Oxford University 
Press; 2010 370 p. 
253.  Pickering LK, Bartlett 3rd A V, Reves RR, et al. Asymptomatic excretion of rotavirus before 
and after rotavirus diarrhea in children in day care centers. J Pediatr. 1988;112(3):361–
365.  
284 
 
254.  Richardson S, Grimwood K, Gorrell R, et al. Extended excretion of rotavirus after severe 
diarrhoea in young children. Lancet. 1998;351(9119):1844–1848.  
255.  Mukhopadhya I, Sarkar R, Menon VK, et al. Rotavirus shedding in symptomatic and 
asymptomatic children using reverse transcription-quantitative PCR. J Med Virol. 
2013;85(9):1661–1668.  
256.  Stals F, Walther FJ, Bruggeman CA. Faecal and pharyngeal shedding of rotavirus and 
rotavirus IgA in children with diarrhoea. J Med Virol. 1984;14(4):333–339.  
257.  Phillips G, Lopman B, Tam CC, et al. Diagnosing norovirus-associated infectious intestinal 
disease using viral load. BMC Infect Dis. 2009;9:63.  
258.  Ramani S, Sankaran P, Arumugam R, et al. Comparison of viral load and duration of virus 
shedding in symptomatic and asymptomatic neonatal rotavirus infections. J Med Virol. 
2010;82(10):1803–1807.  
259.  Kang G, Iturriza-Gomara M, Wheeler JG, et al. Quantitation of group A rotavirus by real-
time reverse-transcription-polymerase chain reaction: correlation with clinical severity in 
children in South India. J Med Virol. 2004;73(1):118–122.  
260.  Cunliffe NA, Gondwe JS, Kirkwood CD, et al. Effect of concomitant HIV infection on 
presentation and outcome of rotavirus gastroenteritis in Malawian children. Lancet. 
2001;358(9281):550–555.  
261.  Galil A, Antverg R, Katzir G, et al. Involvement of infants, children, and adults in a 
rotavirus gastroenteritis outbreak in a kibbutz in southern Israel. J Med Virol. 
1986;18(4):317–326.  
262.  Engleberg NC, Holburt EN, Barrett TJ, et al. Epidemiology of diarrhea due to rotavirus on 
an indian reservation:Risk factors in the home environment. J. Infect. Dis. 
1982;145(6):894–898.  
263.  Holdaway MD, Kalmakoff J, Todd BA, et al. Rotavirus infection in a small community. J 
Med Virol. 1985;15(4):389–398.  
264.  Wyn-Jones AP, Lillington AW, Alzaka A. An investigation into the possible role of the 
family unit in the transmission of rotavirus infections of children. Public Health. 
1978;92(6):291–293.  
265.  Haug KW, Orstavik I, Kvelstad G. Rotavirus infections in families. A clinical and virological 
study. Scand J Infect Dis. 1978;10(4):265–9.  
266.  Rodriguez WJ, Kim HW, Brandt CD, et al. Common exposure outbreak of gastroenteritis 
due to type 2 rotavirus with high secondary attack rate within families. J Infect Dis. 
1979;140(3):353–357.  
267.  Wenman WM, Hinde D, Feltham S, et al. Rota Virus Infection in Adults. N. Engl. J. Med. 
1979;301(6):303–306.  
268.  Banerjee I, Primrose Gladstone B, Iturriza-Gomara M, et al. Evidence of intrafamilial 
transmission of rotavirus in a birth cohort in South India. J Med Virol. 2008;80(10):1858–
1863.  
269.  Henry FJ, Bartholomew RK. Epidemiology and transmission of rotavirus infections and 
diarrhoea in St. Lucia, West Indies. West Indian Med J. 1990;39(4):205–212.  
270.  Martinez PP, King AA, Yunus M, et al. Differential and enhanced response to climate 
forcing in diarrheal disease due to rotavirus across a megacity of the developing world. 
Proc. Natl. Acad. Sci. U. S. A. 2016;113(15).  
271.  Jones FK, Ko AI, Becha C, et al. Increased rotavirus prevalence in diarrheal outbreak 
precipitated by localized flooding, Solomon Islands, 2014. Emerg. Infect. Dis. 
285 
 
2016;22(5):875–879.  
272.  Kanyuka M, Ndawala J, Mleme T, et al. Malawi and Millennium Development Goal 4: A 
Countdown to 2015 country case study. Lancet Glob. Heal. 2016;4(3):e201–e214.  
273.  Human Development Report 2015 Work for human development Briefing note for 
countries on the 2015 Human Development Report.  
274.  The World Bank. GDP per capita, PPP (current international $) | Data. 
(http://data.worldbank.org/indicator/NY.GDP.PCAP.PP.CD?locations=MW). (Accessed 
January 6, 2017) 
275.  UNICEF. CME Info - Child Mortality Estimates. 2014; 
276.  Molyneux M, Molyneux E. Reaching Millennium Development Goal 4. Lancet Glob. Heal. 
2016;4(3):e146–e147.  
277.  Population Projections Malawi. 2008. 
278.  Ministry of Health. 2014 Clinical Management of HIV In Children and Adults. 2014;100.  
279.  Iturriza Gomara M, Wong C, Blome S, et al. Molecular characterization of VP6 genes of 
human rotavirus isolates: correlation of genogroups with subgroups and evidence of 
independent segregation. J Virol. 2002;76(13):6596–6601.  
280.  Freeman MM, Kerin T, Hull J, et al. Enhancement of detection and quantification of 
rotavirus in stool using a modified real-time RT-PCR assay. J Med Virol. 2008;80(8):1489–
1496.  
281.  Ward P, Poitras E, Leblanc D, et al. Comparison of different RT-qPCR assays for the 
detection of human and bovine group A rotaviruses and characterization by sequences 
analysis of genes encoding VP4 and VP7 capsid proteins. J. Appl. Microbiol. 
2013;114(5):1435–1448.  
282.  Gautam R, Esona MD, Mijatovic-Rustempasic S, et al. Real-time RT-PCR assays to 
differentiate wild-type group a rotavirus strains from Rotarix® and RotaTeq® vaccine 
strains in stool samples. Hum. Vaccines Immunother. 2014;10(3):767–777.  
283.  Eurorota.net: European Rotavirus network. Rotavirus Detection and Typing. Nucleic acid 
extraction and reverse transcription Virus Detection by PCR. Rotavirus VP7, VP4, VP6 and 
NSP4 genotyping. 2015(15th February 2015). (http://www.eurorota.net/docs.php) 
284.  Bernstein DI, Sack DA, Rothstein E, et al. Efficacy of live, attenuated, human rotavirus 
vaccine 89-12 in infants: a randomised placebo-controlled trial. Lancet. 
1999;354(9175):287–290.  
285.  Glass RI, Parashar UD, Bresee JS, et al. Rotavirus vaccines: current prospects and future 
challenges. Lancet. 2006;368(9532):323–332.  
286.  Kosek M, Bern C, Guerrant RL. The global burden of diarrhoeal disease, as estimated from 
studies published between 1992 and 2000. Bull World Heal. Organ. 2003;81(3):197–204.  
287.  Liu L, Johnson HL, Cousens S, et al. Global, regional, and national causes of child 
mortality: an updated systematic analysis for 2010 with time trends since 2000. Lancet. 
2012;379:2151–2161.  
288.  Lanata CF, Fischer-Walker CL, Olascoaga AC, et al. Global causes of diarrheal disease 
mortality in children <5 years of age: a systematic review. PLoS One. 2013;8(9):e72788.  
289.  Rotavirus vaccine support - Gavi, the Vaccine Alliance. 
(http://www.gavi.org/support/nvs/rotavirus/). (Accessed February 23, 2017) 
290.  Moon S-S, Groome MJ, Velasquez DE, et al. Prevaccination Rotavirus Serum IgG and IgA 
286 
 
Are Associated With Lower Immunogenicity of Live, Oral Human Rotavirus Vaccine in 
South African Infants. Clin. Infect. Dis. 2016;62(2):157–165.  
291.  Nguyen T V, Yuan L, Azevedo MS, et al. High titers of circulating maternal antibodies 
suppress effector and memory B-cell responses induced by an attenuated rotavirus 
priming and rotavirus-like particle-immunostimulating complex boosting vaccine 
regimen. Clin Vaccine Immunol. 2006;13(4):475–485.  
292.  Moon S-S, Wang Y, Shane AL, et al. Inhibitory effect of breast milk on infectivity of live 
oral rotavirus vaccines. Pediatr. Infect. Dis. J. 2010;29(10):919–23.  
293.  Trang N V, Braeckman T, Lernout T, et al. Prevalence of rotavirus antibodies in breast milk 
and inhibitory effects to rotavirus vaccines. Hum. Vaccin. Immunother. 
2014;10(12):3681–3687.  
294.  Cunliffe NA, Kang G. Can Changes to Scheduling Enhance the Performance of Rotavirus 
Vaccines in Low-Income Countries? J. Infect. Dis. 2016;213(11):1673–1675.  
295.  Fischer TK, Valentiner-branth P, Steinsland H, et al. Protective Immunity after Natural 
Rotavirus Infection : A Community Cohort Study of Newborn Children in Guinea-Bissau , 
West Africa. 1998;(April):593–597.  
296.  Hjelt K, Grauballe PC, Schiotz PO, et al. Intestinal and serum immune response to a 
naturally acquired rotavirus gastroenteritis in children. J Pediatr Gastroenterol Nutr. 
1985;4(1):60–66.  
297.  Hjelt K, Grauballe PC, Paerregaard A, et al. Protective effect of preexisting rotavirus-
specific immunoglobulin A against naturally acquired rotavirus infection in children. J 
Med Virol. 1987;21(1):39–47.  
298.  Patel M, Glass RI, Jiang B, et al. A systematic review of anti-rotavirus serum IgA antibody 
titer as a potential correlate of rotavirus vaccine efficacy. J. Infect. Dis. 2013;208(2):284–
294.  
299.  Beyer WE., Palache A., Lüchters G, et al. Seroprotection rate, mean fold increase, 
seroconversion rate: which parameter adequately expresses seroresponse to influenza 
vaccination? Virus Res. 2004;103(1–2):125–132.  
300.  Vink M, van de Kassteele J, Wallinga J, et al. Estimating Seroprevalence of Human 
Papillomavirus Type 16 Using a Mixture Model with Smoothed Age-dependent Mixing 
Proportions. Epidemiology. 2015;26(1):8–16.  
301.  Global Climate Normals (1961-1990) | National Centers for Environmental Information 
(NCEI) formerly known as National Climatic Data Center (NCDC). 
(https://www.ncdc.noaa.gov/wdcmet/data-access-search-viewer-tools/global-climate-
normals-1961-1990). (Accessed February 23, 2017) 
302.  Crampin AC, Dube A, Mboma S, et al. Profile: the Karonga Health and Demographic 
Surveillance System. Int J Epidemiol. 2012;41(3):676–685.  
303.  Heinsbroek E, Tafatatha T, Chisambo C, et al. Pneumococcal Acquisition Among Infants 
Exposed to HIV in Rural Malawi: A Longitudinal Household Study. Am. J. Epidemiol. 
2016;183(1):70–78.  
304.  Bernstein DI, Smith VE, Sherwood JR, et al. Safety and immunogenicity of live, attenuated 
human rotavirus vaccine 89-12. Vaccine. 1998;16(4):381–387.  
305.  Teunis P, Eijkeren J, Ang C, et al. Biomarker dynamics: estimating infection rates from 
serological data. Stat. Med. 2012;31(20):2240–2248.  
306.  Muench H. Catalytic Models in Epidemiology. Harvard University Press; 1958 124 p. 
307.  Baker KK, O’Reilly CE, Levine MM, et al. Sanitation and Hygiene-Specific Risk Factors for 
287 
 
Moderate-to-Severe Diarrhea in Young Children in the Global Enteric Multicenter Study, 
2007–2011: Case-Control Study. PLOS Med. 2016;13(5):e1002010.  
308.  Cook SM, Glass RI, LeBaron CW, et al. Global seasonality of rotavirus infections. Bull 
World Heal. Organ. 1990;68(2):171–177.  
309.  Gladstone BP, Muliyil JP, Jaffar S, et al. Infant morbidity in an Indian slum birth cohort. 
Arch. Dis. Child. 2008;93(6):479–484.  
310.  Armah G, Lewis KDC, Cortese MM, et al. A Randomized, Controlled Trial of the Impact of 
Alternative Dosing Schedules on the Immune Response to Human Rotavirus Vaccine in 
Rural Ghanaian Infants. J. Infect. Dis. 2016;213(11):1678–1685.  
311.  Armah GE, Kapikian AZ, Vesikari T, et al. Efficacy, Immunogenicity, and Safety of Two 
Doses of a Tetravalent Rotavirus Vaccine RRV-TV in Ghana With the First Dose 
Administered During the Neonatal Period. J Infect Dis. 2013; 
312.  Bernstein DI, McNeal MM, Schiff GM, et al. Induction and persistence of local rotavirus 
antibodies in relation to serum antibodies. J. Med. Virol. 1989;28(2):90–5.  
313.  Steele AD, Madhi SA, Louw CE, et al. Safety, Reactogenicity, and Immunogenicity of 
Human Rotavirus Vaccine RIX4414 in Human Immunodeficiency Virus-positive Infants in 
South Africa. Pediatr. Infect. Dis. J. 2011;30(2):125–30.  
314.  Steele AD, Cunliffe N, Tumbo J, et al. A review of rotavirus infection in and vaccination of 
human immunodeficiency virus-infected children. J Infect Dis. 2009;200 Suppl:S57-62.  
315.  Lopman BA, Payne DC, Tate JE, et al. Post-licensure experience with rotavirus vaccination 
in high and middle income countries; 2006 to 2011. Curr Opin Virol. 2012;2(4):434–442.  
316.  Halloran ME, Struchiner CJ. Study Designs for Dependent Happenings. Epidemiology. 
1991;2(5):331–338.  
317.  Halloran ME, Struchiner CJ, Longini  Jr. IM. Study designs for evaluating different efficacy 
and effectiveness aspects of vaccines. Am J Epidemiol. 1997;146(10):789–803.  
318.  Adegbola RA, Secka O, Lahai G, et al. Elimination of Haemophilus influenzae type b (Hib) 
disease from The Gambia after the introduction of routine immunisation with a Hib 
conjugate vaccine: a prospective study. Lancet. 2005;366(9480):144–150.  
319.  Hennessy TW, Singleton RJ, Bulkow LR, et al. Impact of heptavalent pneumococcal 
conjugate vaccine on invasive disease, antimicrobial resistance and colonization in Alaska 
Natives: progress towards elimination of a health disparity. Vaccine. 2005;23(48–
49):5464–5473.  
320.  Karmann A, Jurack A, Lukas D. Recommendation of rotavirus vaccination and herd effect: 
a budget impact analysis based on German health insurance data. Eur. J. Health Econ. 
2015;16(7):719–31.  
321.  Clemens J, Shin S, Ali M. New approaches to the assessment of vaccine herd protection in 
clinical trials. Lancet Infect Dis. 2011;11(6):482–487.  
322.  Halloran ME. The Minicommunity Design to Assess Indirect Effects of Vaccination. 
Epidemiol Method. 2012;1(1):83–105.  
323.  Piszczek J, Partlow E. Stepped-wedge trial design to evaluate Ebola treatments. Lancet. 
Infect. Dis. 2015;15(7):762–3.  
324.  Ruuska T, Vesikari T. Rotavirus disease in Finnish children: use of numerical scores for 
clinical severity of diarrhoeal episodes. Scand J Infect Dis. 1990;22(3):259–267.  
325.  World Health Organisation. WHO child growth standards and the identification of severe 
acute malnutrition in infants and children. WHO/UNICEF joint statement. 2009. 
288 
 
326.  Zou G. A Modified Poisson Regression Approach to Prospective Studies with Binary Data. 
Am. J. Epidemiol. 2004;159(7):702–706.  
327.  Cunliffe NA, Witte D, Ngwira BM, et al. Efficacy of human rotavirus vaccine against severe 
gastroenteritis in Malawian children in the first two years of life: a randomized, double-
blind, placebo controlled trial. Vaccine. 2012;30 Suppl 1:A36-43.  
328.  Patel MM, Tate J, Cortese M, et al. The impact of indirect benefits of vaccination on 
postlicensure vaccine effectiveness estimates: A scenario analysis. Vaccine. 
2010;28(50):7987–7992.  
329.  Platts-Mills JA, Amour C, Gratz J, et al. Impact of Rotavirus Vaccine Introduction and 
Postintroduction Etiology of Diarrhea Requiring Hospital Admission in Haydom, Tanzania, 
a Rural African Setting. Clin. Infect. Dis. 2017;62:S213-9.  
330.  Pitzer VE, Patel MM, Lopman BA, et al. Modeling rotavirus strain dynamics in developed 
countries to understand the potential impact of vaccination on genotype distributions. 
Proc Natl Acad Sci U S A. 2011;108(48):19353–19358.  
331.  National Statistical Office. Malawi Demographic and Health Survey. 2015. 
332.  Preziosi MP, Halloran ME. Effects of pertussis vaccination on transmission: vaccine 
efficacy for infectiousness. Vaccine. 2003;21(17–18):1853–1861.  
333.  Dean NE, Halloran ME, Yang Y, et al. Transmissibility and pathogenicity of Ebola virus: A 
systematic review and meta-analysis of household secondary attack rate and 
asymptomatic infection. Clin. Infect. Dis. 2016;62(10):1277–1286.  
334.  Longini  Jr. IM, Koopman JS, Monto AS, et al. Estimating household and community 
transmission parameters for influenza. Am J Epidemiol. 1982;115(5):736–751.  
335.  Klick B, Leung GM, Cowling BJ, et al. Optimal design of studies of influenza transmission in 
households. I: case-ascertained studies. Epidemiol Infect. 2012;140(1):106–114.  
336.  Sugimoto JD, Koepke AA, Kenah EE, et al. Household Transmission of Vibrio cholerae in 
Bangladesh. PLoS Negl Trop Dis. 2014;8(11):e3314.  
337.  McCaw JM, Howard PF, Richmond PC, et al. Household transmission of respiratory viruses 
- assessment of viral, individual and household characteristics in a population study of 
healthy Australian adults. BMC Infect Dis. 2012;12:345.  
338.  Chen HN, Dennehy PH, Oh W, et al. Outbreak and control of a rotaviral infection in a 
nursery. J Formos Med Assoc. 1997;96(11):884–889.  
339.  Pickering LK, Woodward WE. Diarrhea in day care centers. Pediatr. Infect. Dis. 1(1):47–52.  
340.  Payongayong E, Benson T, Ahmed A, Kanyanda C, Mwanza P, Chilopa K, Banda N MA. 
Simple household poverty assesment models for Malawi: Proxy Means Test from the 
1997–98 Malawi Integrated Household Survey. 2006; 
341.  Ajjampur SS, Rajendran P, Ramani S, et al. Closing the diarrhoea diagnostic gap in Indian 
children by the application of molecular techniques. J Med Microbiol. 2008;57(Pt 
11):1364–1368.  
342.  Cunliffe NA, Gondwe JS, Graham SM, et al. Rotavirus strain diversity in Blantyre, Malawi, 
from 1997 to 1999. J Clin Microbiol. 2001;39(3):836–843.  
343.  Iturriza-gómara M, Isherwood B, Gray J, et al. Reassortment In Vivo : Driving Force for 
Diversity of Human Rotavirus Strains Isolated in the United Kingdom between 1995 and 
1999. J. Virol. 2001;75(8):3696–3705.  
344.  Cunliffe NA, Bresee JS, Gentsch JR, et al. The expanding diversity of rotaviruses. Lancet. 
2002;359(9307):640–641.  
289 
 
345.  Ferdous F, Das SK, Ahmed S, et al. Severity of diarrhea and malnutrition among under 
five-year-old children in rural Bangladesh. Am. J. Trop. Med. Hyg. 2013;89(2):223–8.  
346.  Lewnard JA, Lopman BA, Parashar UD, et al. Naturally Acquired Immunity Against 
Rotavirus Infection and Gastroenteritis in Children: Paired Reanalyses of Birth Cohort 
Studies. J. Infect. Dis. 2017;216(3):317–326.  
347.  Pitzer VE, Bilcke J, Heylen E, et al. Did Large-Scale Vaccination Drive Changes in the 
Circulating Rotavirus Population in Belgium? Sci. Rep. 2015;5:18585.  
348.  Pitzer VE, Basta NE. Linking data and models: the importance of statistical analyses to 
inform models for the transmission dynamics of infections. Epidemiology. 
2012;23(4):520–522.  
349.  Scherer A, Mclean A. Mathematical models of vaccination. Br. Med. Bull. 2002;62:187–
199.  
350.  Smith DL, McKenzie FE, Snow RW, et al. Revisiting the basic reproductive number for 
malaria and its implications for malaria control. PLoS Biol. 2007;5(3):0531–0542.  
351.  Vesikari T, Uhari M, Renko M, et al. Impact and Effectiveness of Rotateq(R) Vaccine Based 
on Three Years of Surveillance Following Introduction of a Rotavirus Immunization 
Program in Finland. Pediatr Infect Dis J. 2013; 
352.  Nagayoshi, S; Yamaguchi, H; Ichikawa, T ; Miyazu, L; Morishima,T; Ozaki, T; Isomura; S, 
Suzuki, S; Hoshino M., Nagayoshi S, Yamaguchi H, et al. Changes of the Rotavirus 
Concentration in Faeces During the Course of Acute Gastroenteritis as Determined by the 
Immune Adherence Hemagglutination Test. Eur. J. Pediatr. 1980;134(2):99–102.  
353.  Schwarz B-A, Bange R, Vahlenkamp TW, et al. Detection and quantitation of group A 
rotaviruses by competitive and real-time reverse transcription-polymerase chain 
reaction. J. Virol. Methods. 2002;105(2):277–85.  
354.  Phillips G, Lopman B, Tam CC, et al. Diagnosing rotavirus A associated IID: Using ELISA to 
identify a cut-off for real time RT-PCR. J Clin Virol. 2009;44(3):242–245.  
355.  Mei Z, Grummer-strawn LM. Standard deviation of anthropometric Z-scores as a data 
quality assessment tool using the 2006 WHO growth standards: a cross country analysis. 
Bull. World Health Organ. 2013;85(6):1–7.  
356.  National Statistical Office. Malawi - Demographic and Health Survey. 2010. 
357.  Subramanian S, Huq S, Yatsunenko T, et al. Persistent gut microbiota immaturity in 
malnourished Bangladeshi children. Nature. 2014;510(7505):417–421.  
358.  Kane A V, Dinh DM, Ward HD. Childhood malnutrition and the intestinal microbiome. 
Pediatr. Res. 2015;77(1–2):256–62.  
359.  Mondal D, Minak J, Alam M, et al. Contribution of enteric infection, altered intestinal 
barrier function, and maternal malnutrition to infant malnutrition in Bangladesh. Clin. 
Infect. Dis. 2012;54(2):185–192.  
360.  Fine P, Eames K, Heymann DL. “Herd immunity”: a rough guide. Clin Infect Dis. 
2011;52(7):911–916.  
361.  Victora, Cesar Huttly, Sharon Fuchs, Olinto M. The Role of Conceptual Frameworks in 
Epidemiological Analysis:A Heirarchical Approach. Internional J. Epidemiol. 1997;26(1).  
362.  Yelland LN, Salter AB, Ryan P. Practice of Epidemiology Performance of the Modified 
Poisson Regression Approach for Estimating Relative Risks From Clustered Prospective 
Data. Am. J. Epidemiol. 2011;174(8).  
363.  Verkerke H, Sobuz S, Ma JZ, et al. Malnutrition is associated with protection from 
290 
 
rotavirus diarrhea: Evidence from a longitudinal birth cohort study in Bangladesh. J. Clin. 
Microbiol. 2016;54(10):2568–2574.  
364.  Rytter MJ ohanne H, Kolte L, Briend A, et al. The immune system in children with 
malnutrition--a systematic review. PLoS One. 2014;9(8):e105017.  
365.  Vittinghoff E, Mcculloch CE. Relaxing the Rule of Ten Events per Variable in Logistic and 
Cox Regression. Am. J. Epidemiol. 2006;165(6):710–718.  
366.  Fine PE, Carneiro IA. Transmissibility and persistence of oral polio vaccine viruses: 
implications for the global poliomyelitis eradication initiative. Am J Epidemiol. 
1999;150(10):1001–1021.  
367.  Payne DC, Edwards KM, Bowen MD, et al. Sibling transmission of vaccine-derived 
rotavirus (RotaTeq) associated with rotavirus gastroenteritis. Pediatrics. 
2010;125(2):e438-41.  
368.  Miura H, Kawamura Y, Sugata K, et al. Rotavirus vaccine strain transmission by vaccinated 
infants in the foster home. J. Med. Virol. 2017;89(1):79–84.  
369.  Hsieh Y-CC, Wu F-TT, Hsiung CA, et al. Comparison of virus shedding after lived 
attenuated and pentavalent reassortant rotavirus vaccine. Vaccine. 2014;32(10):1199–
1204.  
370.  Cowley D, Boniface K, Bogdanovic-Sakran N, et al. Rotavirus shedding following 
administration of RV3-BB human neonatal rotavirus vaccine. Hum. Vaccin. Immunother. 
2017;00–00.  
371.  Vesikari T, Karvonen A, Korhonen T, et al. Safety and immunogenicity of RIX4414 live 
attenuated human rotavirus vaccine in adults, toddlers and previously uninfected infants. 
Vaccine. 2004;22(21–22):2836–2842.  
372.  Patel M, Steele AD, Parashar UD. Influence of oral polio vaccines on performance of the 
monovalent and pentavalent rotavirus vaccines. Vaccine. 2012;30:A30–A35.  
373.  Kahn J-E, Grandpeix-Guyodo C, Marroun I, et al. Persistent rotavirus vaccine shedding in a 
new case of severe combined immunodeficiency: A reason to screen. J. Allergy Clin. 
Immunol. 125:270–271.  
374.  Choko AT, Desmond N, Webb EL, et al. The uptake and accuracy of oral kits for HIV self-
testing in high HIV prevalence setting: A cross-sectional feasibility study in Blantyre, 
Malawi. PLoS Med. 2011;8(10).  
375.  Zaman K, Fleming JA, Victor JC, et al. Noninterference of rotavirus vaccine with measles-
rubella vaccine at 9 months of age and improvements in antirotavirus immunity: A 
randomized trial. J. Infect. Dis. 2016;213(11):1686–1693.  
 
 
 
 
 
 
 
 
291 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                          
